{"5bc844fc-e852-4270-bfaf-36ea9eface3d": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01928186", "Secondary_id": "NCT00684983", "Statement": "Not all participants in the primary trial receive oral capecitabine, oral lapatinib ditosylate or cixutumumab IV in the conrast all subjects in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "86b7cb3d-6186-4a04-9aa6-b174ab764eed": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00662129", "Statement": "Patients with platelet counts greater than 100,000 per millilitre, ANC < 1700 per millilitre, and hemoglobin counts between 4 and 5 grams per decilitre are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [18, 22, 23, 24]}, "dbed5471-c2fc-45b5-b26f-430c9fa37a37": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093145", "Secondary_id": "NCT00703326", "Statement": "In both the primary and secondary trials, heart-related adverse events were recorded.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 7, 8, 9, 10]}, "20c35c89-8d23-4be3-b603-ac0ee0f3b4de": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01097642", "Statement": "Adult patients with histological confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3, 4, 5]}, "f17cb242-419d-4f5d-bfa4-41494ed5ac0e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00852930", "Secondary_id": "NCT02308020", "Statement": "Laser Therapy is in each cohort of the primary and secondary trials, as well as neoadjuvant chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "fc5c4554-7ce9-4c16-b374-a3cd9d15b021": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00971945", "Secondary_id": "NCT01027416", "Statement": "Patients must have already participated in a specific clinical trial to participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "96b77cdd-aa9f-4770-8447-8a04d9ca5da7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00633750", "Statement": "Patients with clinical stage II invasive breast carcinoma (T2 N1) are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 4, 10]}, "c73faed2-371b-4238-bf7d-293fae380203": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00003404", "Secondary_id": "NCT00711529", "Statement": "The primary and secondary trials have hypnotherapy-based interventions, the secondary trials also used pain medications in their intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8765009d-ffc4-4395-ab7a-11ecdfd43a40": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00201773", "Statement": "\u2022 Adele is an 85-year-old woman with histologically confirmed ER+ breast cancer at stage II with an ECOG of 0, she is eligible for the primary trial", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 6]}, "0ad7293d-df35-42e8-881d-f2afc3f7d3fd": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02606708", "Secondary_id": "NCT02504424", "Statement": "Only patients in the primary trial receive 40.5 Gy brachytherapy, patients in the secondary trial receive no radiation therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "2bc1e094-41a1-46d9-9b0c-b5a47f23323d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00895414", "Statement": "Some drinks are prohibited for patients who undertake the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "83b83400-1439-462d-bba3-42817b5b1fa1": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00777049", "Statement": "Most cases of CHF in the primary trial were in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 14, 20]}, "c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00058058", "Statement": "\u2022 Applicants for the primary trial must have a life expectancy of more than 6 months.", "Label": "Contradiction", "Primary_evidence_index": [19, 9]}, "17a821f8-5e68-4bf7-ac01-3f96ddfc5187": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02964234", "Statement": "Patients eligible for the primary trial must live in the United States.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "d76d6c7f-ba39-483c-a89e-152af5ae2878": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02525718", "Secondary_id": "NCT02606708", "Statement": "Patients in group 1 of the secondary and primary trials do not receive the same dose of AIMRT.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "65f3e755-3e23-4e84-a218-87922759094d": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01669343", "Secondary_id": "NCT00146172", "Statement": "The primary trial administers letrozole for 28 days, while the secondary trial administers a 4-cycle 21-day intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "d3590771-806b-4754-a455-38113bfedfca": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00952692", "Statement": "\u2022 Applicants for the primary trial should have adequate colon and liver function and should not currently receive amiodarone or amiodarone in the last 28 days. Renal function is not relevant for inclusion.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61]}, "941b960f-8d57-4830-9d4c-8e96765ba76c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00994279", "Secondary_id": "NCT00545077", "Statement": "The primary and secondary trials administer Bevacizumab to each HER2+ patient.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f79a9011-0a68-4255-a40f-5d73af412bf0": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01425268", "Secondary_id": "NCT01373671", "Statement": "The CO2 is used as part of the intervention in only one of the primary test study groups and is not used in any of the secondary test study groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00777101", "Secondary_id": "NCT00559845", "Statement": "There was no complete suicide in the primary or secondary trial, but there was an attempt in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "57f3a264-9119-4931-9f9c-9cb20e945973": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00075270", "Secondary_id": "NCT01781299", "Statement": "The primary trial is to test a chemotherapeutic treatment while the secondary trial is to test a physiotherapy course.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "589e2f5b-9286-465b-8162-bb1549cd5ece": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00305448", "Statement": "At least 4 patients in both cohorts of the primary trial received a complete (CR) or partial (PR) response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "8275f846-59b6-404d-a6d8-e01335279f1a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03066947", "Statement": "Less than 1/4 of patients in the primary trial experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01390064", "Statement": "Both cohorts in the primary trial are treated subcutaneously.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "18d9991c-ca96-4bab-93af-77654857a07f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01142661", "Statement": "The primary trial does not accept patients with grade 1 alopecia.", "Label": "Entailment", "Primary_evidence_index": [17, 19]}, "6fb9056d-277c-4dc2-9b45-d7661bb41831": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01925170", "Secondary_id": "NCT00324259", "Statement": "Participants in cohort 1 of the primary trial undergo mammography, while patients in cohort 1 of the secondary trial receive 6 mg estradiol in addition to mammography.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "52b23601-2276-4634-96c7-8b6e55596085": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129376", "Statement": "Only one patient in the primary trial experienced clinically significant inflammation of the back of the throat.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "95e05332-4926-4381-90a4-87941269e7bf": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00431067", "Statement": "More than 5% of primary test participants received a partial response (PR).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "20d51467-b059-4f39-b636-d32f2dc692da": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00054028", "Secondary_id": "NCT02162719", "Statement": "The primary and secondary trials administer at least partially their oral interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "15c83d26-f9ba-44cc-a920-6941781cdd8b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01427933", "Statement": "Neutropenia affected the majority of patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "e100212f-5bef-4f84-a3c1-d18a6b3e8355": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01648322", "Secondary_id": "NCT00436566", "Statement": "The primary test is shorter than the secondary test, and both studies use the same units of measurement in their evaluation.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 10], "Secondary_evidence_index": [0, 1, 2, 3, 9]}, "56d2a387-49dd-49b9-93bb-bcb092bf2714": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02286843", "Statement": "The primary test consists of testing a new radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "2485a3e1-7520-47d2-b941-32ebf91e5b65": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00300781", "Statement": "The primary trial participants receive an intervention based on their previous treatments.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b97d9465-db14-43af-9451-4b824e67abb8": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00899574", "Secondary_id": "NCT01007942", "Statement": "The primary and secondary trials use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not for the other.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "798c0983-5265-47ea-bfcd-735738793482": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02010021", "Statement": "One patient recently received Tamoxifene to treat breast cancer, they are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 11]}, "127e9179-6781-4b9a-abe9-080d2ffad591": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02176083", "Secondary_id": "NCT03061175", "Statement": "Neither the primary trial nor the NCT0306117 use chemotherapy or radiotherapy in their intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00089479", "Secondary_id": "NCT02964234", "Statement": "Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, without evidence of metastatic disease. She is eligible for the primary trial but not for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "16dc5a77-5758-4d19-9801-6e9932d9fbc9": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01401166", "Statement": "Several patients in cohort 1 of the primary trial prefer oral tablets as a method of drug administration.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2ed770a0-fe98-4029-9511-ad04a94a1a69": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00190671", "Secondary_id": "NCT00455533", "Statement": "In cohort 2 of the primary trial, the number of patients with leukopenia was higher than in cohort 1, while in cohort 1 of the secondary trial, the number of patients with leukopenia was higher than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 14, 19], "Secondary_evidence_index": [0, 3, 12, 15]}, "b4c97206-66fd-468b-8388-fac076222c10": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00863655", "Statement": "There were 7 other cases of anaemia and 1 other cases of intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 12, 13, 14, 15]}, "6e22d118-af77-41bd-bd47-9385779f33aa": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00450723", "Statement": "There are several types of surgical and therapeutic treatments that are prohibited for patients who want to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [19, 20, 21, 22, 23, 24]}, "ccc5362a-33d0-4f1b-be46-d31729ba9194": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01945775", "Statement": "The shortest PFS in the Talazoparib group in the primary trial was more than a month shorter than the median PFS for this group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "fa530b28-9142-49f2-aa80-4d04fa532910": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03765996", "Statement": "The primary trial group 2 participants are registered in anastomosis regions, but no complex physiotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00063570", "Statement": "None of the patients in cohort 1 of the primary trial had platelet deficiency, and none of the patients in cohort 2 had pyrexia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "41cf791e-ed7a-48e5-af84-eefc9fa41ba7": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00503906", "Secondary_id": "NCT01142661", "Statement": "The adverse reactions of the primary trial where all are also common, while in the secondary trial alcohol intoxication was reported as the most common event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d417aa7b-6d2c-46f8-812c-426ea60e0328": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00894504", "Statement": "There were only 3 adverse events in the primary trial that occurred more than twice.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "2744cc0a-86e9-4764-ae1c-f10f635dc283": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171704", "Statement": "Most patients in the Letrozole group in the primary trial experienced a decrease in bone mineral density of the lumbar spine after 24 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2e4717fd-b349-48a3-b751-88674dfaaa18": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02392611", "Statement": "In the primary trial, cohort 1 patients must have failed or become intolerant to the standard treatment, or have no standard treatment available, and cohort 2 patients must respond well to the standard treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b0c65cd7-8cad-404d-8704-ee074e480f57": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01237327", "Secondary_id": "NCT00030823", "Statement": "The primary and secondary trials do not have overlapping inclusion criteria, with the exception of the age limit of 18 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 51, 54, 55, 56, 51, 58, 59]}, "28e20650-e100-4e30-a319-5eceb69a979d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00509769", "Statement": "One patient in the primary trial had toxic hepatitis.", "Label": "Entailment", "Primary_evidence_index": [0, 9]}, "8cf0c320-9486-4531-9212-bb3284b734f1": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02336737", "Secondary_id": "NCT01432886", "Statement": "The secondary test consists of testing the DLT for its interventions, while the primary test evaluates the effectiveness of lymph node detection using SentiMag and SiennaXP.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "34a75478-e7cc-495e-86c3-d0accdaf1ddd": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317603", "Statement": "The primary trial participants must be over 18 years of age, have histologically confirmed stage 4 breast cancer, an ECOG < 2 and a life expectancy greater than 6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 6, 7, 8]}, "47780450-1202-4934-8e50-b29416b124f5": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00332709", "Secondary_id": "NCT00659373", "Statement": "All participants in the primary trial receive the same dose of Letrozole and all patients in the secondary trial receive the same dose of Tamoxifen.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00179309", "Statement": "There were 2 cases of severe back pain observed during the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "c5e6497a-2e2f-4663-97fd-e73ba8904b0c": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01856543", "Secondary_id": "NCT00365599", "Statement": "In all secondary and primary trial cohorts, there was only one recorded case of myocarditis and thrombosis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "c4dd814d-f525-465f-abe1-a7975771d57e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01105650", "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less than IL-2 than participants over 45 kg, but all participants will receive methylprednisolone 3 times a week for 6 doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "cfd93077-87c5-458b-8712-e1896929309d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00924352", "Statement": "One primary test patient had abnormally low red blood cells, white blood cells, and platelets.", "Label": "Entailment", "Primary_evidence_index": [4]}, "a3faaf85-62c6-430f-acf2-9c5992ee5221": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00503906", "Secondary_id": "NCT01142661", "Statement": "\u2022 Adverse reactions in the primary trial where all were also common, while in the secondary trial disease progression was reported as the most common event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01931163", "Secondary_id": "NCT00274469", "Statement": "Less than 5% of patients in cohort 1 of the primary trial had high blood sugar levels, with 0% of patients in the secondary trial having high blood sugar levels.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "335936e4-9eaa-43b3-84fe-6f112c0d0226": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00574145", "Secondary_id": "NCT03167359", "Statement": "Radiotherapy and tactile curative therapy are used in all cohorts of the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "19921113-538e-4fd2-81a6-6053f2dd6459": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02622074", "Statement": "In cohort 2 of the primary trial, patients with DLT were 38% more likely than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "6a013bb4-0688-4f02-96c5-062f3ca67ae1": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448279", "Statement": "In total, there were 5 times more adverse reactions in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "c103a786-0b1d-4124-aa5d-4945ded2c384": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01106040", "Secondary_id": "NCT01441596", "Statement": "The primary and secondary tests do not study PFS, PBR or DLT.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "2746a75c-7f01-4dc3-a05e-5c7499e75555": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00274768", "Secondary_id": "NCT00654836", "Statement": "Patients with no more than one stage 3 cancer are eligible for the secondary trial and the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61]}, "df64a4c5-08f3-40c7-a4e7-2a6271bc9e53": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00416572", "Statement": "Patients with anterior skin cancer malignancies are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [12, 13]}, "682f5e80-75c4-4a36-9bc1-b389a98ad160": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193037", "Statement": "None of the patients in cohort 1 of the primary trial had hypotension.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02673918", "Secondary_id": "NCT01042938", "Statement": "Only white and Asian patients are eligible for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 4]}, "348c9273-6aa1-43a8-840d-3cf080874669": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00934856", "Statement": "In total, in both cohorts of the primary trial, there were at least 2 patients with fever.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "dfe6228e-6bfb-49d3-b0b4-397aab177bea": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00068588", "Statement": "The results between the two arms of the primary trial cannot be compared because there were no patients in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9f424ebb-63b8-4930-b2c1-cd46fff4d706": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01302379", "Statement": "Only one cohort of patients in the primary trial showed a positive median change in insulin from baseline.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "c1f8c7fb-22de-4501-af86-d9eb59542ae3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00324259", "Statement": "The cohort 2 of the primary trial had one more patient with a stable disease than the cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6630047b-7ebc-4435-8203-cf6bbe6b6ee7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00331630", "Statement": "A left ventricular ejection fraction > 50% is required to participate in the primary test.", "Label": "Entailment", "Primary_evidence_index": [18]}, "039c3fc2-f798-4d97-b904-9aa7d363eeef": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00903162", "Secondary_id": "NCT01674062", "Statement": "Patients with in situ cervical cancer are eligible for the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [10, 12], "Secondary_evidence_index": [6, 10]}, "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121134", "Statement": "The primary test requires participants to have undergone a PTR.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "f8028143-35d1-4cc3-895a-acb577db4715": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00537771", "Secondary_id": "NCT00354640", "Statement": "The cohort 1 participants in the primary trial and all participants in the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 5]}, "907f7e56-b6ec-4a43-bf3a-14f93c644bc1": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00193180", "Statement": "A patient over 18 years of age with chronic viral hepatitis would be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 8, 16]}, "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00853996", "Statement": "Women classified as at high risk of developing breast cancer over the next five years and over their lifetime by the Gail model are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "a41bf7b0-9a09-4ce0-8832-f13758581f20": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01572727", "Statement": "The primary trial cohort 1 recorded more optical adversity events than the cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5f2d2015-eaf9-45a8-9583-fddbc9807287": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00130533", "Statement": "Less than 0.25 % of patients in cohort 1 of the primary trial had hyperbilirrubinemia.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "609ddd08-ebd5-4661-be43-874b65dbfe52": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03273426", "Secondary_id": "NCT01091168", "Statement": "Patients with dementia or schizophrenia may be eligible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [4]}, "b6ac985d-87ae-4e0f-83e1-38033c1db5cc": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00322348", "Secondary_id": "NCT00429572", "Statement": "The primary and secondary trials use ECOG to assess the performance of potential candidates.", "Label": "Contradiction", "Primary_evidence_index": [2], "Secondary_evidence_index": [2]}, "43ff9425-5e6e-4a85-a8ca-0c0c67a96623": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00431067", "Statement": "More than 5% of primary test participants met the response target (OR).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "b3ccde30-cdfc-4e18-aee0-8b3a921dde39": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470301", "Statement": "Each primary trial patient receives tipifarnib PO, as well as paclitaxel, doxorubicin hydrochloride, and acyclophosphamide IV, but only one subgroup of participants undergoes dissection of axillary lymph nodes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "8697a59e-0f1c-452a-b15a-6d24e2df387f": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00191815", "Secondary_id": "NCT01301729", "Statement": "None of the patients in the primary or secondary trial committed suicide.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4ab74186-5f4e-4139-af05-d4a9871a251d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02721147", "Statement": "Stephanie has been living with her husband for 31 years, she is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6]}, "082ee581-f420-4892-b098-ce82c6ad0210": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00432172", "Statement": "All adverse events recorded in the primary trial were heart-related.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "7bf084eb-873a-4011-9b98-3a899ee582ee": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00982319", "Statement": "Pre- and post-menopausal women may enter the primary trial as long as they do not have prior hormone replacement therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01575522", "Secondary_id": "NCT00181363", "Statement": "The primary and secondary trials test completely different methods of intervention, but use the same 21-day cycle.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00741260", "Statement": "Patients with positive ERBB2 tumours are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "f6c85ce8-e0fc-4186-a961-6207dd4cacd2": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01268150", "Statement": "Most primary trial patients treated with Eribilin Mesylate did not obtain a complete (CR) or partial (PR) response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5bdd61d9-aadf-4944-afe3-a04242d9c2b2": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02321527", "Statement": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2]}, "b8ce7d6a-d707-48e0-816c-de7ac3a63823": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01252277", "Statement": "The 34-year-old sister of Fiona has been diagnosed with channel carcinoma, so fiona may be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "53d88010-e7d7-41c7-b20d-6328c8e507d1": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01498458", "Statement": "For some types of adverse events in the primary trial, there have been no recorded cases.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8257bf5c-fae6-44c0-a86d-293746fdc468": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01416389", "Statement": "In the primary trial cohort 1 there were more cases of hepatic encephalopathy and pneumonia than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00372424", "Secondary_id": "NCT00041067", "Statement": "Patients with positive HER2 breast tumours are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [3]}, "974225b7-9089-499c-9550-0a7207fd28b2": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03346161", "Secondary_id": "NCT01000662", "Statement": "The primary trial procedure does not require that patients undergo medical treatment during the study, while in the secondary trial all patients receive radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6f533f52-c8e4-4983-8968-69af03a9e34a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01506609", "Statement": "Patients with cytologically confirmed breast cancer who have a local recurrent disease are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "690b8562-7d68-4642-bacb-601f227bb763": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00591864", "Statement": "The primary test does not have an intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "75f94edd-dbde-4a19-be18-e67c767f6d8f": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03618017", "Statement": "The intervention section of the primary trial does not describe the dose, frequency or duration of the intervention for cohort 2, but cohort 1 receives placebo twice daily for two months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00687440", "Secondary_id": "NCT01307891", "Statement": "The primary trial had a higher percentage of patients with at least partial response than either cohort in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "34ee4f66-e6f7-458c-964c-12fa730a9d56": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02556632", "Statement": "The two cohorts in the primary trial apply the topical intervention for approximately every 4-6 hours per day during one week of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "9b0451fe-f760-46d3-b555-0a9b83546e73": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00087152", "Secondary_id": "NCT00203502", "Statement": "The primary trial recorded half of the number of patients who vomited like the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5]}, "b9304415-073d-476e-a056-cb2a747d56fa": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00021255", "Statement": "The primary trial cohort 2 was for doxorubicin only during Cycles 1 to 4, followed by doxorubicin, cyclophosphamide, herceptin, and docetaxel during Cycle 5 of the study.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5]}, "6e365e33-16b8-43e1-99b5-49dfed6f7b13": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00316199", "Statement": "Only Chinese women with breast cancer in stage 4 or non-resectable and local repeaters are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01306942", "Statement": "Participants in cohort 1 of the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "27acc6d7-c12d-4a38-9133-a5c8429dd264": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00656669", "Statement": "The primary trial recorded 23 adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "5919a080-2f0d-4c3b-9b03-10df80b2e680": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01007942", "Statement": "There were no adverse events in the primary trial that affected more than 10% of a given cohort of patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "91f6e62a-97e7-49fa-8509-7ff8c1f0155e": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00671918", "Secondary_id": "NCT00571987", "Statement": "Patients with pure in situ ductal carcinoma (DCIS) or melanoma are eligible for both the secondary and primary trials, and may participate in these trials in conjunction with other clinical trials, up to a maximum of 3.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 12], "Secondary_evidence_index": [0, 9]}, "b351a091-d5fb-49f9-a864-5c89c6316b1b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01688609", "Statement": "Patients should have histologically or cytologically confirmed invasive PR+ breast cancer with a primary tumour > 2 cm in diameter TO PARTICIPATE in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "d5ca2086-8404-42d1-bf45-5370f3d4e8e8": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02139358", "Secondary_id": "NCT02574455", "Statement": "There were 16.67% more bleeding cases in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "4c038972-20a9-4031-a1cd-ba00e9dd0908": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00410813", "Secondary_id": "NCT00617539", "Statement": "In the primary trial, Dasatinib, 70 mg, twice daily, gives a median PFS better than Dasatinib, 100 mg, daily. The opposite was true in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "82d6275a-97e6-4d13-84eb-5f7c2585db8b": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02132949", "Secondary_id": "NCT01111825", "Statement": "Between the primary trial cohort and the secondary trial, there was only one patient with heart failure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "286e74e5-74ed-4d42-b32d-f1398c514d37": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01125566", "Statement": "At least one primary trial participant receiving oral treatment of the afatitinib film-coated tablet at an initial dose of 40 milligrams (mg) once daily and a 10-minute weekly intravenous injection of Vinorelbine 25 mg/metre^2 (metre=m) experienced PFS over a 9-month period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "634642da-db6d-49cc-a999-67f46e91dbca": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01237327", "Secondary_id": "NCT00030823", "Statement": "The primary and secondary trials do not have overlapping inclusion or exclusion criteria.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 51, 54, 55, 56, 51, 58, 59]}, "a529e364-2da7-4067-acb6-9fb2f0adf08b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01401062", "Statement": "A patient who has undergone T-cell transfer treatment in the last 2 weeks would be excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 8]}, "317e00ae-9d17-4f85-8787-602cc2548fdb": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00004092", "Statement": "\u2022 Cancer patients who have spread a breast tumour to their bone marrow are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4]}, "de955acc-ce0e-4416-9884-644a06971603": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00195013", "Secondary_id": "NCT00620373", "Statement": "The Primary Trial Cohort 2 and the Secondary Trial are test groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4956f0d0-4df4-4de3-9a46-6073927485c3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01017549", "Secondary_id": "NCT01390064", "Statement": "The secondary trial has more cohorts of patients than the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9ca0cc75-58b3-451d-abcc-378526744ca4": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01985971", "Secondary_id": "NCT03273426", "Statement": "Patients will have to undergo MRI prior to entry for the secondary and primary trials, as patients in the primary trials will also have to have MR and PET imaging after entry into the study.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 2], "Secondary_evidence_index": [0, 6]}, "6efb001b-5ed3-470b-a206-7768a1adf597": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01581619", "Statement": "Invasive canal breast cancer confirmed histologically would result in the exclusion from the primary trial, but not from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [4, 10]}, "70dd1a42-6e40-4880-80a8-45dfd4941ce4": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00089973", "Statement": "The primary test uses a 3-week cycle for the administration of SB-715992.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "85f43677-b680-4127-b1da-7e1cc966e4b2": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01943916", "Secondary_id": "NCT01653964", "Statement": "Not all subjects in the primary and secondary trials will be administered 4-8 mCi Tc-99m sestamibi.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "4cccea8a-22ae-4813-96df-b902850f4991": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01783444", "Secondary_id": "NCT03136367", "Statement": "Women of any age may participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "8574ecd7-4da7-49b0-a273-de495bc1fee7": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00951665", "Statement": "Both nausea and death are the most common adverse events in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "01b82c51-dd3d-430b-9523-0e93a9eb9c1a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00950300", "Secondary_id": "NCT00615901", "Statement": "The primary trial recorded a multitude of patients suffering from chest pain, whereas the secondary trial observed only one patient suffering from abdominal pain.", "Label": "Contradiction", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 3]}, "93149dfc-667b-48d3-a46d-ad48b15e701f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00451555", "Statement": "Cohorts 1 and 2 of the primary trial recorded exactly the same number of each type of adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "d080eec7-412f-4a44-8c56-91e0ec459acc": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01422408", "Statement": "The primary trial is a Phase II trial in which all participants will receive 0.05% topical fluoconide cream to apply to their genitals twice daily for two weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "fd18a599-f94a-478a-975f-854a4210ccad": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00659373", "Secondary_id": "NCT02202252", "Statement": "The primary trial has a duration of intervention of 5 years, the duration of the secondary trial is only one day after the drains have been removed.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "ac9ca070-80b2-4913-97d8-06d1b90fcfce": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01797120", "Secondary_id": "NCT02005887", "Statement": "Both the secondary and primary trials have a placebo arm and a test arm.", "Label": "Contradiction", "Primary_evidence_index": [7, 8, 9, 3, 4, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00082810", "Statement": "During the entire duration of the primary trial, paritiquants receive increasing doses of Fulvestrant.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "009d23bb-2179-4ce3-927d-4dedca6b32a8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00479674", "Statement": "Patients who have already been treated with bevacizumab are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [22, 24]}, "5152d810-7669-4fb2-a66b-a0a1d6026af5": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00577122", "Secondary_id": "NCT01923168", "Statement": "The secondary and primary trials use both the complete pathological response (CTR) as a measure of the results and a 6-month delay.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "e8f4a600-0296-47d4-903b-2fa840ebcf28": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02005549", "Statement": "Patients with stage 3 cervical carcinoma are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "3fa8b747-b48d-4fb4-995d-38a23c64ccb3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02069093", "Statement": "In the primary trial, 2 of the patients were either symptomatic but were able to swallow a modified diet; symptomatic and unable to feed or hydrate orally or had symptoms associated with potentially fatal consequences.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b9c294c3-93b7-4681-be02-285f9e5cd867": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03167359", "Secondary_id": "NCT01385137", "Statement": "Between all primary and secondary trial cohorts, omega-3 fatty acids are only used in one cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "9df90d78-d857-4e1d-a650-e47f7b6b68d6": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00322374", "Statement": "The primary trial cohort 2 receives a higher dose of Ixabepilone at a higher frequency than cohort 1,", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03098550", "Statement": "The results section indicates that there were no patients in the primary trial with 0 adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "92ac6e0c-8427-454d-9218-36eda1c580a7": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01653964", "Secondary_id": "NCT02660788", "Statement": "The interventions in the primary and secondary trials are so different that it is not possible or useful to compare them.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "f0aff1fc-4a67-4b28-a974-a4a67a5c930f": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00733408", "Statement": "There were more than 14 weeks of difference in progression-free survival between minimum and maximum PFS in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00121836", "Secondary_id": "NCT00256243", "Statement": "Patients who are not willing to sign and give written informed consent to participate in the primary or secondary trial will not be invited to participate.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [11]}, "96ab702d-cfe1-48fb-b348-a7c7b8db3f16": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00684983", "Statement": "The median duration during which a patient in the A arm of the primary trial survived after receiving a TBBC diagnosis was 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6224d2de-c62b-4b43-8517-475eaa565491": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00811135", "Statement": "The majority of patients in the primary trial had at least one adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "95154c62-9f79-4d80-90fd-2f61612285b0": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01095003", "Secondary_id": "NCT01702571", "Statement": "In total, more than 5 patients in the primary and secondary trials suffered from Earache.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "2f6243a9-af40-426d-9a6a-a5c5708cf1b4": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00721630", "Secondary_id": "NCT00364611", "Statement": "The primary and secondary tests recorded exactly the same number of cases of nausea.", "Label": "Entailment", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 7]}, "837f0588-22fc-4069-b2bc-297b3f6aabf7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00058058", "Statement": "\u2022 Applicants for the primary test do not need to meet a specific life expectancy criterion.", "Label": "Entailment", "Primary_evidence_index": [19, 9]}, "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00572728", "Secondary_id": "NCT02472964", "Statement": "Patients in the primary trial will not be required to take Herceptin?\u00a9 (trastuzumab) or paclitaxel intravenously as in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03511378", "Statement": "Patients must have a life expectancy of more than half a year to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02630693", "Statement": "One 30% of patients in the primary trial had a life-threatening reaction to infection.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d72ecaae-c132-480c-af5e-87c58dd26082": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00679341", "Secondary_id": "NCT00201851", "Statement": "The only adverse reaction observed in patients in the secondary and primary trials was endocervical cancer.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "80245791-4a95-4682-bd5f-856694c9f52f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00721409", "Secondary_id": "NCT02413320", "Statement": "Patients with negative HER2 tumours are eligible for the primary trial, but not for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01325428", "Secondary_id": "NCT00073073", "Statement": "The secondary trial and the primary trial do not require participants to be of a particular ethnic group, to be able to speak a particular language, or to be above a certain threshold.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "f0da58e6-e937-41ac-b53a-d46ec8a28d11": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01923168", "Statement": "Intervention 1 of the primary trial requires participants to take 300 mg of alpelisib once daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "5a74a63a-3912-44f0-9e83-4e6b678cbe90": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02685566", "Secondary_id": "NCT03076190", "Statement": "The primary and secondary trials have the same number of study groups and test the effectiveness of digital mammography in the field.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "43f03ba4-ef03-4f57-b059-3d9267f0dcf8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00325234", "Statement": "Patients under the age of 18 who wish to participate in the primary trial should discontinue any anti-tumour hormone therapy prior to entry into the study and have a life expectancy of more than 3 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 8, 13]}, "6e106caf-2522-4022-898d-64b82093d77a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02413320", "Statement": "Women over 20 years of age without prior chemotherapy with therapeutic intent for current cancer are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5]}, "7f8a918c-fab8-4129-8178-0cda7d0441e1": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00021255", "Statement": "Cohort 2 of the primary trial with Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the study cycles.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5]}, "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01125566", "Statement": "At least 400 primary trial participants receiving oral treatment of the afatitinib film-coated tablet at an initial dose of 40 milligrams (mg) once daily and a 10-minute weekly intravenous injection of Vinorelbine 25 mg/metre^2 (metre=m) experienced PFS for 9 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02018458", "Secondary_id": "NCT00895414", "Statement": "Patients with unexplained fever below 38 degrees Celsius may be included in the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [25, 28], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "0290bc2d-9cd3-44ab-9b04-385f19527c42": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02550210", "Statement": "Patients should have a channel carcinoma, which may be felt by contact to be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "505afbf8-b2b4-4b12-99c5-e0feef473248": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00577122", "Secondary_id": "NCT01923168", "Statement": "Both the secondary and primary trials do not use the rate of clinical benefit as a measure of their results, and they do not use the same time frame.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01816594", "Secondary_id": "NCT02222337", "Statement": "Patients with newly diagnosed stage 0 bilateral breast cancer may not participate in the primary trial, but may still be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2e540abd-06e3-483d-bd69-6eb5d2275e9e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01830933", "Secondary_id": "NCT01224678", "Statement": "Patients in the primary and secondary trials are treated daily orally.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [5]}, "d905f4cb-32aa-41b8-8f61-40578d8ea9ae": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274469", "Statement": "No less than 2 patients in either cohort of the primary trial felt sick.", "Label": "Contradiction", "Primary_evidence_index": [0, 12, 13, 25]}, "45510043-7931-493b-8251-41b0be9aabbd": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00232505", "Statement": "There were 2 cases of patients with ear tachycardia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e7037f34-bd2e-402e-a19c-48073781885a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193037", "Statement": "Ten of the patients in cohort 1 of the primary trial had hypotension.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "5275a332-46c1-4941-8850-26a8033012e3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981305", "Statement": "Only those who have already been diagnosed with cancer and have no signs of cancer after completion of treatment are elected for the primary trial, as long as they are over 20 years of age.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01129622", "Secondary_id": "NCT01156987", "Statement": "Both the secondary and primary trials used MRI and Letrozole for their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "b02f43d7-44bb-4219-9a08-fd70e7cc9b87": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01004744", "Statement": "Patients should have a confirmed postmenopausal status, defined as a lack of period for more than one year, if they are to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2]}, "1a6661e0-343f-4056-b568-611e7cc7750c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01827163", "Statement": "All breast cancer patients above the stage who are currently receiving radiotherapy or biotherapy are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [13, 14]}, "ec97c90e-f904-4cf2-9567-8525edf747cf": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03196635", "Secondary_id": "NCT01943916", "Statement": "Both the primary and secondary trials evaluate patient-assisted imaging interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "7a129a1e-20d9-4f5a-a921-d30957460e27": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00820222", "Secondary_id": "NCT01819233", "Statement": "The secondary and primary trials do not test the same treatment methods for cancer.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01566721", "Statement": "The percentage difference for participants with at least one adverse event (AE) during the treatment period in both cohorts of the primary trial is less than 1%.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a1c99d5b-d53a-4195-ad5f-5e1b48c22078": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03176238", "Secondary_id": "NCT01498458", "Statement": "While there is a much higher percentage of thrombocytopenia patients in the secondary trial than in cohort 1 of the primary trial, no solid comparison can be made due to significant differences in cohort size.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "0203435e-03a0-4c41-afdf-6c497d8908c1": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00331630", "Statement": "Men with a left ventricular ejection fraction > 50% are excluded from the primary test.", "Label": "Contradiction", "Primary_evidence_index": [18, 9]}, "e6388dc2-b096-467d-8b70-fd5346dd581a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00083174", "Secondary_id": "NCT00190671", "Statement": "The highest number of occurrences for any adverse event during the primary and secondary trials was 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "93511e52-1c12-4dee-858e-13b10793e2a6": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429182", "Secondary_id": "NCT00429507", "Statement": "The secondary trial uses radiotherapy exclusively in its intervention, while the primary trial gives its cohorts stem cell transplants on the first day of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "cb932dbf-4c98-4488-b189-1286442968b6": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02005549", "Statement": "Patients with cervical carcinoma in situ are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "0b9aa7e8-5912-44db-b9b0-6a84df769e19": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00545688", "Statement": "There were no patients with paranasal sinus reactions in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "570ab6bb-b23c-4955-b6b0-d756d1b69c0e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00756717", "Statement": "Patients with cytologically confirmed metastatic invasive breast cancer at an early stage with an Allred score of 3 are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "daf105f8-58e8-47d7-b0a2-5949620b0a2b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00296036", "Statement": "The primary trial administers placebo and urea/lactic acid cream at the same frequency and over the same areas of the skin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c4b671ae-4701-43a3-ada1-659c265d1f3a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01582971", "Statement": "To participate in the primary trial, participants need to know where they are and what day they are.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "0a17a404-ed1d-4c31-a192-509b68198ea8": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00717405", "Statement": "There was a dental adverse event in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02699983", "Secondary_id": "NCT00994279", "Statement": "Neither the primary test nor the secondary trial requires participants to practice yoga while wearing a Fitbit activity monitoring device.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e8b86ef4-3ce8-4d81-a632-f30672c80ff5": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02115607", "Secondary_id": "NCT01823107", "Statement": "In the primary trial, patients receive infusions of Perflutren lipid microspheres, whereas in the secondary trial, subjects are implanted with a Meso BioMatrix Acellular peritoneic matrix.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "879f2f14-38a8-419a-bae0-e62ed81eb9dd": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00146172", "Statement": "The primary trial cohort 1 is less than 60% of the LA-EP2006 dose in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2ec46285-dd0c-4420-b9f6-e44a1ac74f20": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01752907", "Secondary_id": "NCT01940497", "Statement": "There were 0 cases of fractures of Tibia or Fibula during the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "f8afffdc-649b-4921-942a-66b804a3717f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121992", "Statement": "To be eligible for the primary trial, patients must not have prior radiation therapy, systemic anthracycline or anticancer, and must have bilateral breast cancer T1-4, N1 and M1.", "Label": "Contradiction", "Primary_evidence_index": [12, 13, 14, 15, 19]}, "65f22210-47dd-4865-99e2-ddd414dddb08": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01806259", "Statement": "More than 82% of patients in the primary trial achieve non-recurrence survival after 5 years.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00915603", "Secondary_id": "NCT02511730", "Statement": "The INR of 1.35 is sufficient to participate in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 24], "Secondary_evidence_index": [0, 1, 2, 3]}, "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00917735", "Statement": "A patient in cohort 2 of the primary trial crashed his motorcycle.", "Label": "Entailment", "Primary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "0aa3c085-b9c6-4918-a5d0-eabc55bdd177": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01560416", "Statement": "There were more than 10 more adverse events in cohort 2 than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 12, 13]}, "333c2723-e2e8-4c68-9591-36b7f169ff26": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00828074", "Statement": "A higher percentage of cohort 1 in the primary trial showed signs of fever compared to cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 13, 18]}, "1fa01b9a-1288-404c-ad58-8dcf3db3264c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00477464", "Statement": "59% of the primary A arm received a better overall response, classified as a complete or partial (confirmed) tumour response or stable disease for at least 6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ed272c3f-37a1-4db7-8990-bf226f8c9822": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02049957", "Secondary_id": "NCT01506609", "Statement": "There are the same number of cases of Diplopie in the primary trial as anemia in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "b1497cf4-6b06-4227-b679-19e2ac5fb5c3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01421017", "Statement": "The primary studies focus on the effects of CTX/IMQ/RT and Epothilone on central nervous system (CNS) progression-free survival 9 weeks after initiation of treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "186d5a67-1309-4abc-b31a-de026c5b8bda": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00405938", "Statement": "Patients diagnosed with intradural tumours are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 10]}, "6b86f306-f989-4676-8f5e-c4c8a6aa4258": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470847", "Statement": "The primary trial participants will receive either Lapatinib, WBRT or Herceptin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "0e8e4a92-b104-4192-ad36-33b683f94216": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02463032", "Statement": "There was less than 5% difference in the 9 mg and 18 mg results in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00438659", "Secondary_id": "NCT01271725", "Statement": "The primary trial has a topical intervention, while the secondary trial has oral interventions and IV.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "03a8a787-2bf3-43e5-9c9e-7bd9c3278751": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171704", "Statement": "All patients in the Letrozole group in the primary trial experienced a decrease in bone mineral density of the lumbar spine after 3 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "7d7a9a69-533a-4480-b2e7-aa59eb8a738b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02260531", "Statement": "The percentage of participants with a complete (CR) or partial (PR) response was 6 times higher in the HER2-positive group in the primary trial than in the ER+ and/or PR+ group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "c6fc8336-7c74-443e-9548-3bbafe21fc37": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00036270", "Statement": "In total, less than 10% of patients in the primary trial experienced a relapse or died.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9035000f-d87b-439f-882a-e6e30694e391": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01351376", "Statement": "Currently prescribed patients Diuretics are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 18]}, "522ca0ec-aeb0-4083-a274-ab58c2cddb8a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03210220", "Secondary_id": "NCT00290745", "Statement": "Unlike the primary test, the secondary test does not test hormonal analogues or gonadotrophin medical devices.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "46d65581-7a0a-423b-907e-662c1f5843cc": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01127763", "Statement": "There were 4% more cases (1 more) of Dyspnea than of Dehydration in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 6]}, "f4ea6e98-75e1-43a0-8202-548bb7ceb66c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02413008", "Secondary_id": "NCT02725801", "Statement": "The primary trial procedure requires patients to receive multiple treatment applications over a period of several weeks, while the secondary trial procedures are applied only once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00534417", "Statement": "The median TTP for patients in cohort one of the primary trials is NA.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "932728c5-2e7f-401f-be64-e90597ff2ce2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129935", "Statement": "There were more cases of embolism in cohort 2 of the primary trial than in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "54ad9406-852c-40fc-bd0e-8e7e81eacc71": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00291577", "Statement": "It is not possible for a primary trial participant to have time to reach a maximum plasma concentration of 16, 17 or 20 hours.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "7021a4a9-b474-4568-a3b8-015a50c9d9cc": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00201760", "Secondary_id": "NCT00127933", "Statement": "Patients should have a triple negative breast carcinoma to participate in the secondary or primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 3]}, "24eced44-40b2-4365-abd3-42eb13220cf0": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00290745", "Statement": "There is no radiation therapy or educational part of the intervention used in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "3e2dda3a-815f-4681-a470-009d9f9b30d6": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01448447", "Secondary_id": "NCT03252145", "Statement": "The primary test consists of testing a radiotherapy intervention while the secondary test consists of testing a new portable medical device.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "1a293e7c-691f-4f93-bab8-6bf5d9b3f904": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01653964", "Secondary_id": "NCT02660788", "Statement": "The interventions in the primary and secondary trials are similar because they test the same drug, but they do not use the same doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "a87e6e20-c7d0-4941-9933-204fab99b299": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00444535", "Statement": "Less than one-third of participants in the primary trial treated with Lapatinib achieved progression-free survival after 6 months of study treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "6c3427a8-27a1-459c-9fbc-175649210868": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01940497", "Statement": "In the primary trial cohort 1 there were more allergic reactions than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "883bec6a-bce2-4e60-9304-49a056e66df7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00101400", "Statement": "One female with hemoglobin > 10.0 g/dl, the absolute number of neutrophils 1.733 mm3, the number of platelets = 100,000/\u00ac\u00ac\u03bcl and total bilirubin < 1.2 x ULN are eligilbic for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [9, 10, 11, 12]}, "8720143a-2611-4502-a5ee-da4e641df918": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02402764", "Secondary_id": "NCT00490646", "Statement": "There have been no cases of extravasation in either the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "0fdda7a2-4119-40a7-84f3-6c5c6077df49": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02186015", "Statement": "Women in cohort A and B of the primary trial with a serum level of 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly additions of cholecalciferol.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e7eae332-6b6a-41e0-aa31-86a781fd373f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01273896", "Statement": "There were twice as many cardiac adverse events as the cases of Dyspnea in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 8]}, "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01439945", "Statement": "In the primary test, low dose magnesium oxide is 400 mg/day lower than the high dose of magnesium oxide.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "c09b9f7c-2d22-4c44-a79d-32929530dd9e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01735175", "Secondary_id": "NCT01216319", "Statement": "Both the secondary and primary trials are biodesign interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "6f143256-52e4-40b7-950c-5c892f8632b9": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00003199", "Statement": "The group of patients with the highest percentage of PFS at 5 months in the primary trial was in stage IIIB patients, and the worst was in stage IV patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "d2718f05-1d35-4c84-a054-06a3fe4a0a9c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00217399", "Statement": "To be included in the primary trial, patients must have at least one measurable one-dimensional lesion and must meet certain specific size conditions.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5, 8]}, "7f49cafd-3a27-4fc8-872d-914b9176442e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01427933", "Statement": "Neutropenia was the most common adverse event in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01998906", "Statement": "The same number of cases of Neutropenia and Pancytopenia is observed in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 4]}, "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00428922", "Secondary_id": "NCT00499083", "Statement": "Patients who received pre-stage 4 radiation therapy more than 5 years ago are not eligible for the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [26]}, "4ab00376-83a4-467e-8a1e-6b8b1643a8f0": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365599", "Secondary_id": "NCT01771666", "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no history of blood clots are eligible for the primary test but excluded from the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 10, 12, 15, 25], "Secondary_evidence_index": [0, 6]}, "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01565499", "Secondary_id": "NCT01234402", "Statement": "None of the patients in the primary trial were reported to have heart-related adverse reactions, while many of the patients in the secondary trial had several heart-related problems.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "407369fa-92ba-4994-8a0f-d372995f3241": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02699983", "Secondary_id": "NCT00994279", "Statement": "Neither the primary test nor the secondary trial requires participants to practice yoga.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "05e50a3d-d5b2-4fe6-9709-c884c89c5f71": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01004172", "Secondary_id": "NCT00802945", "Statement": "Both the primary and secondary trials evaluate the response rates, but the primary trials investigate the CNS response, while the secondary trials study the tumour response, and they test different treatments.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "59fd53e4-b38c-4018-bafc-6fd7f7becebe": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00546104", "Statement": "A patient in the primary trial suffered from a blood clot blocking his blood vessels.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c17eaeab-4e99-4cc4-8681-ae6ccddba572": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01926886", "Statement": "There were no cases of cellulitis, nausea or anaemia in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "621d06ac-12dd-42c2-a012-15c1d94a4f0b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00952692", "Statement": "The primary test must have adequate renal and hepatic function and must not currently receive amiodarone or amiodarone in the following 6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 27, 28, 38, 43]}, "021e79d2-ce70-43cf-aac9-fa8d4c8d3770": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193063", "Statement": "In the primary trial cohort, three different types of infections are observed: pneumonia, urinary tract, and athlete's foot.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "06aa0fbc-fe49-4715-88cc-507646f6323f": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00486525", "Statement": "The difference between the two cohorts in the primary trial is that cohort 1 participated in a Hatha yoga, while cohort 2 abstained from yoga.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "21947261-bbef-4d3a-adda-02bb4a91a3ca": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00754325", "Secondary_id": "NCT00399529", "Statement": "Both the secondary and primary trials accept patients with breast progesterone receptor adenocarcinoma (PgR+).", "Label": "Contradiction", "Primary_evidence_index": [1, 2], "Secondary_evidence_index": [0, 1]}, "71daae7c-3ee5-4451-91e2-273d8ff55aae": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00617942", "Secondary_id": "NCT00388726", "Statement": "The secondary trial had a total number of patients with lower adverse reactions than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00203502", "Statement": "Each patient in the primary trial had at least one adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "7d22937b-9823-45fa-a914-261f993e4d64": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01644890", "Statement": "Throughout the primary trial, a patient developed problems with his vision.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "507a4189-4905-4752-8348-d715a5ce3962": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01940497", "Statement": "There were 3 more allergic reactions in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "24001e83-6a8c-4f67-9c24-55dc285c4cc2": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00096356", "Statement": "The results of the primary trials indicate that CoQ10 reduces the level of fatigue experienced by patients compared to placebo.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d179396d-94fe-465f-a4f1-e7c3291a0a9a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00513695", "Statement": "Filgrastim is the only drug in the primary trial administered by subcutaneous injection.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "4b893eeb-80a4-4a83-8df5-b5c668ce55b1": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00796978", "Secondary_id": "NCT01276041", "Statement": "More patients in the secondary trial had oedema in their limbs, compared to patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "44cd16f5-6638-4d82-9121-1941eb8ce4b5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448279", "Statement": "In total, there were more adverse reactions in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "50ac2c53-3b63-4507-8712-41f8c257b4da": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01697345", "Secondary_id": "NCT00513292", "Statement": "fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "14607d45-9aef-458d-89cc-d47c62c23322": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02322814", "Secondary_id": "NCT00356148", "Statement": "A patient with histologically confirmed triple negative breast cancer without known brain metastases and without a history of autoimmune disease or cardiac dysfunction may be eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 22, 15, 33], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d2961e96-bd3b-4994-aa7e-2b310eb6204e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01300351", "Statement": "At least 1 primary test participant showed signs of poor liver function.", "Label": "Entailment", "Primary_evidence_index": [0, 7]}, "8a5d7285-f4be-4e50-9057-19f74bcc410b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03106077", "Statement": "Patients in the primary trial receive no more than 200 mg IMGN853 intravenously every 3 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "512990dd-45d2-4b31-b571-66735ff02308": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00394251", "Statement": "There were 4 different adverse events, for which 0 cases were recorded in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "383db144-4bcd-4ebc-989c-b6ae7d282026": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00471276", "Secondary_id": "NCT00951665", "Statement": "gastrointestinal haemorrhage was more common in patients in cohort 2 of the secondary trial than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00951665", "Statement": "Most patients in cohort 1 of the primary trial died from unknown causes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "228e80ab-84d6-4b60-9960-dcdcbd78c03c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00328783", "Statement": "Patients with a MSV of 80% to 120% are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "b7caad28-5fb2-4eb6-845e-8315cff97318": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00896649", "Statement": "Prior hormonal treatment in the metastatic or adjuvant setting is not necessary for patients in the primary trial, nor is it necessary to have adequate organ function or a particular racial or ethnic origin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "73c37b9c-e7ba-4c90-b26e-23b7a65509c4": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00005957", "Statement": "T2 N1 M0 breast adenocarcinoma are eligible for primary testing.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "d5b81f6c-821a-4db5-8810-9cc47a952913": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02287675", "Statement": "Informed consent is required for entry into the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "cdba382e-894b-4f79-a8e2-ff818746adc5": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01202591", "Statement": "100% of patients in the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0093175a-38cb-4f63-b391-709ac48158b8": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00971737", "Secondary_id": "NCT00392392", "Statement": "Patients with HER-2 overexpressing tumours are eligible for the secondary trial, but not for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 3]}, "19106207-4fa2-4cc4-8e22-6e5330bf05ce": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00846027", "Statement": "None of the adverse events recorded for the primary trial occurred more than once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "a015685e-f744-4bb2-a6d3-893f081d6dcc": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02597452", "Secondary_id": "NCT01929395", "Statement": "Both the primary and secondary trials use 21-day cycles for their interventions up to a maximum of 10 and 4 cycles respectively.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "b9578bae-6640-4ef1-ba2c-899b45c602ee": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01487954", "Statement": "All patients in the primary trial had to drink 4 cups of water, either alkaline water or distilled water, depending on the cohort in which they were located.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "405369ef-d216-4d81-a04f-46f36f466a19": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01416389", "Statement": "In the primary trial cohort 1 there were more cases of urinary infections and lumbar fractures than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 10, 11, 14, 24, 25]}, "e424c65e-7c6f-43a4-95e4-6beb705d9903": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559754", "Secondary_id": "NCT02924883", "Statement": "A higher percentage of patients in cohort 1 of the secondary trial had stomatitis than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01466270", "Statement": "The placebo group in the primary trial had better mean retention than the QD group of dodopezil hydrochloride.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00072293", "Statement": "Patients with non-palpable breast injury and 0 palpable axillary lymph nodes are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 12]}, "6843daf8-8136-4973-9bf2-62a622d5a890": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01156987", "Secondary_id": "NCT02234479", "Statement": "The primary trial participants receive an intervention based on their diagnosis of HIV, whereas in the secondary trial, interventions are attributed to randomity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2, 5, 6, 7]}, "2687b547-c225-4838-bbcd-99212a74d815": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01828021", "Secondary_id": "NCT01326481", "Statement": "Patients in the primary and secondary trials did not have the same adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fadf7710-6e4d-49d6-82fc-4f3137b5e26b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00759785", "Statement": "Only one adverse event was observed in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00074152", "Statement": "All cases of adverse reactions in the primary trial occurred in patients in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "6c0896ac-db42-45b4-a6e2-620a27fd321a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01439945", "Statement": "In the primary test, low-dose magnesium oxide is 5% lower than the high-dose magnesium oxide.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "3a80ba8a-265f-4931-a9a8-b7e00e372599": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00432172", "Statement": "All adverse events recorded in the primary trial occurred in patients in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "df4b98f2-7ca9-4855-8d94-d62407ff8535": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01929395", "Secondary_id": "NCT01857882", "Statement": "The primary trial has only one trial cohort while the secondary trial has a control group and a control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "5d2542fa-5482-4aff-af29-80875a0a9dcc": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01015131", "Secondary_id": "NCT00312208", "Statement": "The primary trial records cases of rectal haemorrhage in its cohort of patients, while the secondary trial records vaginal haemorrhage.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "5deb8ebd-fbd2-4d84-8ad2-a1248426908b": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00880464", "Secondary_id": "NCT00458237", "Statement": "\u2022 Patients infected with HIV+ are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [14, 18], "Secondary_evidence_index": [12, 26]}, "5f4880ac-1ce2-4b89-841b-a9918720b6ea": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365417", "Secondary_id": "NCT00853996", "Statement": "To be eligible for both the secondary and primary trials, patients must meet all of the following conditions: alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and hemoglobin > 10 g/dL.", "Label": "Entailment", "Primary_evidence_index": [11, 13, 14, 9, 10], "Secondary_evidence_index": [17, 18, 20, 23]}, "b3aabfaa-23cb-4a75-8416-761d8574f0a4": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01441596", "Statement": "Patients in cohort 1 of the primary trial may receive a progressive increase in Afatinib monotherapy doses from 40 mg PO to 50 mg PO.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "f697c2d8-e0dd-476e-8ff4-dffe053076f8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00524303", "Statement": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse than the Lapatinib arm, which reached a pCR rate of 45%.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f2c0f753-1775-42af-94f0-b87b20156e65": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02835625", "Secondary_id": "NCT00486525", "Statement": "The primary and secondary trials do not use chemotherapy, radiotherapy or mammography in their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "17b31c1d-db62-4628-b390-02da22512079": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01028352", "Statement": "Patients with musculoskeletal symptoms associated with the aromatase inhibitor, such as grade 1 or higher musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5, 6]}, "2e6e1044-8b4a-41f7-8319-85fc5bba4482": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00574145", "Secondary_id": "NCT03167359", "Statement": "Radiotherapy is used in all cohorts of the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00493649", "Secondary_id": "NCT01201265", "Statement": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "0c0324d2-0672-45cb-b715-e51e48786afb": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03618017", "Statement": "The intervention section of the primary trial does not describe the dose, frequency or duration of the intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "b3bd3522-8731-448a-bade-a5a350697a98": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01421472", "Statement": "More than 9 patients in the primary trial had side effects associated with a small number of white blood cells in the bloodstream.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "8607e8c1-6e99-49be-a63e-e707856c805a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01572038", "Secondary_id": "NCT00826267", "Statement": "Each patient in the primary trial receives 3 different medications, while in the secondary trial, patients receive expressive and supportive group psychotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1c26e1a7-9d77-46ff-b1c6-179ece7c190f": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03252431", "Statement": "On average, patients in both arms of the primary trial experienced Grade 4 Neutropenia during the same period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "0a156ee2-eb90-40d2-9802-27b9b4a42ff3": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191789", "Statement": "In cohorts 2 and 3 of the primary trial, there was only one case of jaundice.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "82895f11-37bf-4d03-8de2-84818d93cce0": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00266110", "Secondary_id": "NCT00879086", "Statement": "The primary and secondary trials have completely different adverse event reports.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "f94643de-7122-4a58-972d-b0bb7e59d441": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00878709", "Secondary_id": "NCT02447003", "Statement": "The primary trial had a total of 3 patients with pancreatic cancer, the secondary trial had 0.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "1485315b-3169-42a3-a672-6f7963d49a51": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01869764", "Secondary_id": "NCT02556632", "Statement": "Each participant in the secondary and primary trials undergoes a laboratory biomarker analysis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b4ef27ca-52b4-4af3-9b60-e9e0285e0e86": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03719677", "Statement": "Potential participants will be considered regardless of the hormonal susceptibility of their breast cancer.", "Label": "Contradiction", "Primary_evidence_index": [7]}, "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03371732", "Statement": "Patients with the Karnofsky Index = 72 are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "426196d8-44ab-4c5c-8f81-5cb12345ad69": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00899574", "Secondary_id": "NCT01007942", "Statement": "The primary trial uses different inclusion criteria for its cohorts, the secondary trial uses only one inclusion criterion for all cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "bcf433b6-4029-4d00-9ccf-d8d94f1722d8": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00365365", "Secondary_id": "NCT00005908", "Statement": "The primary and secondary trials recorded only one type of acute adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "1268edfc-cce2-4f07-9fbb-392341b7f399": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01605396", "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group in the primary trial had a median PFS of more than 5 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "58ccfd13-aa6d-4604-bf3d-c69270fe50d2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01276041", "Statement": "A patient in the primary trial died in a case not associated with a specific term CTCAE.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00182793", "Secondary_id": "NCT00509769", "Statement": "The majority of patients in the primary and secondary trials experienced an adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "8c84c96f-1635-40dc-839b-fc937ed566a2": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01105312", "Statement": "\u2022 Patients with measurable diseases are only eligible for Phase 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5, 6]}, "7b48355e-3b9c-4cca-b7fa-1cbd612d1523": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320710", "Statement": "There were no adverse events in cohort 2 of the primary trial in more than 5% of patients.", "Label": "Entailment", "Primary_evidence_index": [13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "3d188d93-13c6-48f3-b231-dcdeef81080e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00617539", "Statement": "The presence of extracranial metastases is one of the exclusion criteria for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01209195", "Statement": "Lower doses of MM-121 and Paclitaxel are used in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "2206dc2a-93da-4c11-b110-81f9c39af807": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00101400", "Statement": "One female with hemoglobin > 10.0 g/dl, the absolute number of neutrophils 1.733 mm3, the number of platelets = 100,000/\u00ac\u00ac\u03bcl and total bilirubin > 1.6 x ULN are eligilbic for the primary test.", "Label": "Entailment", "Primary_evidence_index": [9, 10, 11, 12]}, "6173faf3-f845-4cf1-94a9-756d1bff48bb": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01419197", "Statement": "There was a patient in the primary trial who suffered from a significant decrease in granulocyte count in his blood.", "Label": "Contradiction", "Primary_evidence_index": [13, 17]}, "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02006979", "Statement": "Only one cohort in the primary trial should receive manual lymphatic drainage prior to each cycle of anthracyclines.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00849472", "Statement": "More than a dozen participants in the primary trial are classified as having a complete pathological response (PTR) in the breast and nodes.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "87987ebb-6799-4d1d-8529-d33c6b7799f8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00548184", "Statement": "64 of primary trial participants receiving lapatinib 1000mg per day and trauzumab 4mg/kg load dose, followed by 2mg/kg per week, had at least one almost complete or better pathological response after 12 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "bf94f208-a29b-4d8f-92a7-3cb8241ce344": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00097721", "Secondary_id": "NCT00896649", "Statement": "Black women may not participate in the secondary trial or in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36], "Secondary_evidence_index": [5, 6, 7, 8, 9, 10]}, "c68f6822-24fa-44b5-bf63-c272a8031fab": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02988986", "Statement": "Patients should have an AST or ALT < 1.5 ULN to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 20]}, "54a459cf-f01a-4abc-a8cf-0efebc01c694": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02019277", "Secondary_id": "NCT00863655", "Statement": "The primary and secondary trials did not record any of the same types of adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "dd4b5a08-c033-4429-81d0-1ad59596edbd": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02683083", "Statement": "People with hyperthyroidism and diabetes mellitus are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [11, 12, 13, 14, 15, 16]}, "d97ebc59-ab4b-462a-9057-12f4fc46df56": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01153672", "Secondary_id": "NCT01432145", "Statement": "In the primary trial, patients receive vorinostat at the same frequency and route of administration as in the secondary trial, 6-Mercaptopurine.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2e4c7d0b-f1a2-4204-bac3-7445852fd916": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01727011", "Secondary_id": "NCT01420146", "Statement": "The primary test and secondary test procedures involve a variety of scans, such as CT, PET, MRI and dosimetry.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01928186", "Secondary_id": "NCT00684983", "Statement": "All participants in the primary trial and in cohort 1 of the secondary trial did not receive oral capecitabine, oral lapatinib ditosylate, or cixutumumab IV, but cohort 2 of the secondary trial received all of these elements.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4546c169-cc5c-4e03-bcce-31d491ed18e0": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01989676", "Statement": "The primary test records only cardiovasuclar adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "1bb3badf-41c6-4741-90f0-367473ce254d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00612560", "Statement": "Children and adults who are illiterate are not able to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 12, 13]}, "87953ba3-3e94-421c-b426-b716562b8b5d": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02806544", "Secondary_id": "NCT00605267", "Statement": "A patient with RA positive breast cancer at stage 2B, confirmed pathologically, is possible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3]}, "847b4dbe-428f-431c-8916-2a9c0c80cce4": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00686127", "Secondary_id": "NCT01129622", "Statement": "The doses are specified in the intervention section of the secondary and primary tests.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "9c00b318-0a3a-43c9-a6cd-2983c07be393": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00232505", "Statement": "There have been no cases of patients with abnormal heart rates in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "cbfe14a5-5169-4de3-b69f-13b489be949a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02597452", "Secondary_id": "NCT01929395", "Statement": "The primary and secondary tests do not use cyclic interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00325598", "Statement": "There is a significant difference in the percentage of participants obtaining a dosimetrically satisfactory treatment plan between cohort 1 and 2 of the primary trial, the increase in the number of Gy has a huge effect.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01332630", "Secondary_id": "NCT00121134", "Statement": "There were more patients with hypotension in cohort 1 of the primary trial than in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "eae76b80-107c-4469-b06f-73d5f7a4c1d5": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02073487", "Secondary_id": "NCT03371732", "Statement": "\u2022 Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary test and the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00347919", "Statement": "Less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive disease at Week 12.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "91ad45ae-6714-4c27-ac1a-d8ff8e89684f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00334542", "Statement": "A patient with a bilateral mastectomy would be excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [6]}, "91cf53f9-7233-49ee-a619-c027f6db67ac": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00605267", "Statement": "Only men may be eligible for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "78894316-fc7d-4d61-a2d4-9ea369bfce20": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02273973", "Statement": "Two times as many patients in cohort 1 of the primary trial had erysipelas as bacterial diarrhea.", "Label": "Entailment", "Primary_evidence_index": [0, 11, 12]}, "889e6622-1614-4f6c-a47c-e7caad6e154f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00879086", "Statement": "While cohorts 1 and 2 in the primary trial had the same number of patients with anaemia and Neutropenia, Cohort 1 had 1 case of Leukopenia more than cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 4, 5, 14, 17, 18, 19]}, "4577d986-d7e5-4b5d-9852-b944a6f7f252": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01740323", "Secondary_id": "NCT00127205", "Statement": "The secondary and primary trials accept patients of the same age group.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16, 17]}, "e83b56ba-d129-4cde-976d-2865e67ef4a3": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02472964", "Secondary_id": "NCT00089661", "Statement": "The primary study studies the response of tumours, while the secondary study studies changes in bone mineral density.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "eee75423-9a61-4a57-8baf-8f91b9562486": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01705691", "Statement": "The majority of patients in the primary trial suffered from kidney stones.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "9e046221-7d4b-4681-a374-96793350927d": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00802945", "Secondary_id": "NCT01231659", "Statement": "Group 1 of the secondary trial has a higher rate of OR than the Everolimus + Letrozole cohort of the primary trial and trastuzumab cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5448c6b8-244c-4a42-bbef-e1a1a2e254e2": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01738438", "Secondary_id": "NCT00331552", "Statement": "- Cyclophosphamide, Doxil and Trastuzumab were used in the secondary test procedure, but not in the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00429572", "Secondary_id": "NCT02455453", "Statement": "Premenopausal patients are excluded from the secondary trial but eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1]}, "8d450d42-4eb1-4edb-be76-b2885964aa90": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01506609", "Secondary_id": "NCT00656019", "Statement": "Patients with cytologically confirmed breast cancer who have a local recurrent disease are not eligible for the secondary trial but are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "2674e194-3113-4a11-b2cc-f089d960d194": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01104584", "Statement": "The primary trial does not use trastuzumab, tamoxifen or exemestane in its intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "a7232387-b266-4bfb-8df8-ca9789188500": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00490646", "Statement": "The primary trial cohort 1 had 25% more patients with adverse reactions than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "2e317381-2704-4d06-a793-1d2b29139969": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01959490", "Statement": "In total, only one primary trial participant did not obtain the complete pathological response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "030316a2-fb48-469d-9c55-04cdc9a37fb6": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00559507", "Statement": "The primary trial participants receive saracatinib PO every day of the duration of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "2c723e02-14d8-4a80-a95f-517e904bbbad": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00338286", "Statement": "No primary trial participants had progression-free survival over 1 year, but several patients had PFS of less than 1 month.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "8befa03f-c3da-4950-8d27-491ea06b51ed": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00885755", "Secondary_id": "NCT01075100", "Statement": "While patients' appetites were not affected in the primary trial, at least one was affected in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "32424458-a3e2-440a-9693-6a2f8d4aaddb": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01307891", "Statement": "The Abraxane + Capecitabine group in the primary trial has 61 additional patients who have either a complete response (RC) disappearance of all target lesions; Partial Response (PR) decrease by at least 30% in the sum of the longest diameter of target lesions compared to the Abraxane Alone group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a2b25229-c003-49c3-8b0b-94b68f756d3c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00468585", "Statement": "The primary trial did not record skin infections in their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "728721c4-6376-4ab8-9e4a-af8596bd1ab3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00852930", "Secondary_id": "NCT02308020", "Statement": "The Laser Therapy is only used in cohort 1 of the primary trial, and none of the cohorts in the secondary trial use it.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "c7151ad6-bcac-48e1-ba1e-e6f56a043804": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01086605", "Secondary_id": "NCT00570921", "Statement": "Both Cholecystitis cases are recorded in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "4f71e33c-4f0f-4952-bb03-52402be5f9f4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02015676", "Statement": "There is 1 case (1.45%) of thrombocytopenia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "ef675459-a7d9-4ea1-8963-c95682c38d15": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03004534", "Statement": "Participants with a T4 N1 M0 breast carcinoma are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5, 6, 7, 8]}, "f9df9e45-eb68-4257-801e-b086a89374b8": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02658734", "Secondary_id": "NCT02073487", "Statement": "Women Patients with FEVL > 50% who have already been treated with one of the following medicines; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]}, "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00319254", "Statement": "The primary trial did not use the overall response rate, tumour response rate, or progression-free survival rate as a measure of the results.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "958721dc-e374-4fd1-abb9-071add70bde3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00820170", "Statement": "Based on the results of the primary test, the DMT for paclitaxel is approximately 120 mg.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "19c0b2c7-e45c-4740-b25d-f6e738b59893": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01764022", "Statement": "The primary trial cohort 2 recorded 1 thrombocytopenia incident.", "Label": "Entailment", "Primary_evidence_index": [10, 13]}, "7bcfca9e-1b09-45d4-8165-cb6ac96b8815": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02896855", "Secondary_id": "NCT00171314", "Statement": "The secondary trial recorded more gastrointestinal adverse events than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e3a8be03-20e4-460d-9ebc-f958a515ac45": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01095003", "Statement": "Less than 5 patients in the primary trial had Earache.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "f1096271-3160-4483-9246-ba0d96735efb": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01118624", "Statement": "Less than 5% of primary test participants achieved either RC or PR.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "329b6871-2edc-4142-a4af-e7f8cef118ee": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00004888", "Statement": "The primary test participants suffered more from first-year cardiotoxicity events after Cycle 8 than from third-year events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "67522762-9423-4e3d-bf75-247f84ba7f05": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365417", "Secondary_id": "NCT00853996", "Statement": "To be eligible for both the secondary and primary trials, patients must meet all of the following conditions: alkaline phosphatase < 2.5 x ULN, aspartate aminotransferase <= 1.5 x ULN and hemoglobin > 10 g/dL.", "Label": "Contradiction", "Primary_evidence_index": [11, 13, 14, 9, 10], "Secondary_evidence_index": [17, 18, 20, 23]}, "efd37946-54f3-4813-b63d-6d7df6123677": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02630693", "Statement": "A total of 3 patients in the primary trial experienced a life-threatening reaction to infection.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "dcf62f43-04b7-4acb-b444-2d805238a8b1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02162667", "Statement": "In the primary trial, the Herceptin group had a higher percentage of patients with partial pathological response than the CT-P6 and ZA groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "83dc7b9a-b863-4f81-88fb-763afc3b79e8": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03252145", "Secondary_id": "NCT00904033", "Statement": "None of the subjects in the primary trial are required to inject pills, and half of the subjects in the secondary trial should take one tablet weekly.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "d446920a-2b8e-4452-b9f2-17d2771dbb07": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00075764", "Statement": "The most common adverse event in cohort 1 of the primary trial is Neutropenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "aa710138-bf2a-4a7f-8014-4513fa1f448b": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01269346", "Secondary_id": "NCT01597193", "Statement": "Both cohort 1 of the primary trial and cohort 1 of the secondary trial have less than 30% adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01340300", "Secondary_id": "NCT00671918", "Statement": "While patients must take less than 2 hours of physical exercise per week to participate in the primary trial, this is not a requirement for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "6a71c114-2e38-4d57-8f8b-8252d9c62cbe": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01491737", "Statement": "There were 4 cases of febrile neutropenia in cohort 1 of the primary trial and 0 cases of heart failure.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 5]}, "4333aaa3-dbe4-4275-a982-881fe25c96c0": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00407888", "Statement": "The arm 2 of the primary trial receives high-dose chemotherapy over a 21-day cycle up to 3 times in the absence of disease progression or unacceptable toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "d605b820-2915-4b19-b9cd-ca7850645f83": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00357110", "Statement": "Only 6 patients in cohort 1 of the primary trial had varicose veins.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "d6de70df-d113-4bc8-9d3b-b71f31937ebe": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01525589", "Statement": "People who inherit harmful variants of the BREast Cancer 1 or 2 gene are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 13]}, "9f897b29-7cfa-414c-8cf6-212a68ec2216": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03346161", "Secondary_id": "NCT01000662", "Statement": "Neither the secondary trial nor the primary trial requires patients to undergo any medical treatment during their procedures, but they only test the effectiveness of the consultations.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00676663", "Statement": "The placebo group in the primary trial was much more effective than the test group, as a lower PFS is ideal.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "4606f64f-64cc-4d73-a8be-75701c97008d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00024102", "Statement": "One patient in cohort 2 of the primary trial received plasma transfusion.", "Label": "Contradiction", "Primary_evidence_index": [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "40bef815-18ed-4db5-8108-9a1cdbdd0a13": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00478257", "Statement": "There is no need for adequate haematological, hepatic and renal function to participate in the primary trial. However, being pregnant is necessary.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "5c676007-9ea4-4f80-82dd-89293237cb07": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00319254", "Statement": "The primary test did not use the overall response rate, the tumour response rate, or the preference score as a measure of the results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "a6682883-ace7-4d83-a35c-956928fdc75a": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01325428", "Secondary_id": "NCT00073073", "Statement": "The secondary trial and the primary trial do not require participants to be ethnic, gender, size or speak a particular language.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "1a271e29-477b-4819-a472-5c7c7df99e70": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00265759", "Secondary_id": "NCT00866905", "Statement": "Two cases of haematolysis were recorded in the primary trial, none in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "060e833e-384f-48f0-8e56-ebd95f55f221": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01926886", "Statement": "There were no cases of cellulite, vertigo or anaemia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "ac193d32-156e-48bf-bc6b-d613691f869c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01166763", "Statement": "Only three types of adverse reactions were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "d79173da-5e59-4150-99bd-f1c20118dddc": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00503750", "Statement": "All participants in the primary trial must have recently undergone either an echocardiography.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "50559f15-636d-4265-8f8c-4aad016c6c50": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01176916", "Secondary_id": "NCT00186121", "Statement": "\u2022 Postmenopausal women are eligible for the primary trial, and premenopausal women are eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2]}, "a5af6d2b-4cea-40aa-acdc-59fab5362b3e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00635050", "Statement": "\u2022 Patients with breast cancer who have estrogen receptors are included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "7e89b190-b8f7-4281-b0f1-0e65dcebf402": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00941330", "Statement": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as patients in cohort 2 receive Cytoxan.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "6036d341-9c6a-49fc-a2f4-19c0e2399f4c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01565083", "Statement": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [12, 22, 23]}, "a84afa25-2741-4a08-9e6c-4049f5feca48": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01790932", "Statement": "Patients with phosphoinositide 3-kinase inhibitor treatment are eligible for primary testing if this treatment has been completed more than 5 years previously.", "Label": "Contradiction", "Primary_evidence_index": [5, 6]}, "09e4c746-642a-4a5d-a267-25258a3f2ec0": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01669343", "Secondary_id": "NCT00146172", "Statement": "The primary and secondary trials do not have the same duration of intervention administration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "99855d11-e2e4-4a0e-b40e-2264ff128ac5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02502864", "Statement": "The primary test recorded the same number of occurrences for each type of adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "54fe69c7-5a67-49b1-8bc5-c975133e2bb7": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00712985", "Secondary_id": "NCT02038010", "Statement": "Patients in the primary trial receive a lower dose of Zometa IV than patients in the secondary trial receiving ado-trastuzumab emtansine.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "76362fd3-3a07-4aa3-a072-b9075d2ea791": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00436566", "Statement": "No patients in the primary trial had congestive heart failure (during active therapy).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "064b39e9-e9d8-4c51-a76a-ad150bb127f1": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00878709", "Secondary_id": "NCT02447003", "Statement": "The primary study involved a total of 3 patients with pancreatic-related adverse reactions, the secondary study was 0.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "67a628d7-d883-44b9-b351-901f20fd5d0a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429182", "Secondary_id": "NCT00429507", "Statement": "The secondary and primary trials give their patient cohorts stem cell transplants on the first day of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "78c60212-28f7-4306-9f63-549be04687b2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448591", "Statement": "Only two types of adverse reactions, leukopenia and anaemia, occurred in more than 1% of patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "a72e1259-50be-48e5-bdf8-296040cbf7ce": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01593020", "Secondary_id": "NCT00834678", "Statement": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from the secondary trial but eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [13, 18], "Secondary_evidence_index": [23]}, "19cfd511-8582-4116-8d51-7ec4a6221022": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03366428", "Statement": "0/49 Primary Trial Participants with metastatic and/or non-resectable breast cancer with HER2 showed a maximum change from the initial QTcF trial of less than 60ms.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "3f012bd3-bb89-414b-9dd9-35cef524a69a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00820170", "Statement": "Based on primary test results, dasatinib DMT in combination with paclitaxel weekly is approximately 120 mg.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "5eafb3a1-473a-4270-848d-173e5dca9466": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02600923", "Statement": "Patients with leukaemia, hepatitis or cataract cannot be included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "ed956644-5228-4915-b706-1cedb0462577": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00711529", "Secondary_id": "NCT02835625", "Statement": "The primary test participants are treated with hypnosis, which is not used at all in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "02158762-9490-46a1-b494-0589885fd4ce": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00281697", "Statement": "The primary trial does not record any cardiac adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00217672", "Secondary_id": "NCT00110084", "Statement": "The rate of occurrence of enterovedic fistula was higher in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "7ec286e9-f519-41da-848d-a0bc5a50c0ee": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00686127", "Secondary_id": "NCT01129622", "Statement": "The doses are specified in the intervention section of the secondary test, whereas for the primary test they are not clearly specified.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "d0af59a9-04ae-4922-97eb-dc29f5bc44e3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00256698", "Secondary_id": "NCT03573804", "Statement": "Both primary and secondary trials use completely different drugs and techniques for their interventions, but both require locally trained radiologists for evaluation.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "5d4cbb15-ea50-4394-b1b9-ab4553b5b275": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00509587", "Statement": "Patients in the primary trial receive oral pazopanib once daily until disease progression or unacceptable toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00777049", "Statement": "The 4 cases of FHC in the primary trial were in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 14, 20]}, "78a5162d-140a-4631-b776-5c284446b5ec": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02366130", "Secondary_id": "NCT01262027", "Statement": "The primary and secondary trials have completely different adverse reaction profiles.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3]}, "633ef768-9e9b-4336-9142-8d4ce7ee2342": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01026142", "Secondary_id": "NCT00846027", "Statement": "There were 10 times more patients with left ventricular systolic dysfunction in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 12, 19], "Secondary_evidence_index": [0, 4]}, "7c5b29bc-ac37-48bb-abb1-a102174f79ef": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00826267", "Statement": "Cohorts 1 and 2 in the primary trial receive 50 mg of various medications administered orally from day 1 to day 21.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00708214", "Statement": "All free progression participants (after 16 weeks of treatment) in the primary trial were in the Afatinib 50 mg group with Letrozole.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00615901", "Secondary_id": "NCT00829166", "Statement": "The primary trial had much more seizures than the secondary trial, although it had less than one-tenth of the total number of patients in its cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e852619c-312a-470f-8b77-149e79f69a3f": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00390455", "Secondary_id": "NCT00558103", "Statement": "In the secondary and primary trials, the test cohorts produced better results than the control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "27160f45-e4cb-48be-8cf2-c23ced4578c0": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003830", "Statement": "The most common adverse reaction in both cohorts of the primary trial was anaphylaxis, which affected more than 10 patients in total.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "e4b65e9f-10f6-4424-95d2-837e29587a63": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00754325", "Secondary_id": "NCT00399529", "Statement": "Both the secondary and primary trials accept patients with HER-2/neu-overpressant adenocarcinoma.", "Label": "Entailment", "Primary_evidence_index": [1, 2], "Secondary_evidence_index": [0, 1]}, "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01127373", "Statement": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumours are eligrbs for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "7796fe1b-1952-4339-90f3-47b051ebe927": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01432886", "Statement": "One of the patients in cohort 2 of the primary trial had persistent neutropenia for more than 7 days.", "Label": "Contradiction", "Primary_evidence_index": [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c7df7b38-068b-48a8-b805-b8ebb3e854e6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01086605", "Secondary_id": "NCT00570921", "Statement": "The primary and secondary tests do not record any of the same adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "39227bbb-0e26-4ba0-94a7-762376541889": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00945061", "Statement": "Patients with multifocal breast cancer cannot be accepted for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03283553", "Secondary_id": "NCT02679755", "Statement": "The primary and secondary trials have a different number of cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "fd15ddaf-1abc-4551-a5b3-08217b975e36": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02321527", "Statement": "Patients with invasive breast cancer greater than 70 mm in diameter are included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2]}, "067f4671-0720-4980-a0fa-8d01d31daa9a": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00054132", "Secondary_id": "NCT01421017", "Statement": "Because the primary and secondary tests use very similar result parameters, we can easily compare and contrast their results.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "026e7eb7-37fd-4aae-b74f-dacf905db262": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02366130", "Secondary_id": "NCT01262027", "Statement": "The primary trial reported more than 10 times the number of patients with adverse reactions such as the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3]}, "a79fc503-215f-40d4-9cc1-e101cec3a9c9": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02878057", "Statement": "Patients who are fully active and able to pursue all pre-disease performance without restriction are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191269", "Statement": "The primary trial measured the number of participants with disease progression (PD) or death to assess the performance of its interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00574587", "Secondary_id": "NCT00777049", "Statement": "There were no cases of heart padding in the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "ccb703ea-df18-451b-8db8-ed0e510a4c0f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03592121", "Secondary_id": "NCT01439711", "Statement": "Unlike the secondary test, the primary test does not specify the dose or frequency of its intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "56cd4492-3884-4b2a-a000-7c859d86f6f5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00284180", "Statement": "In both cohorts of the primary trial, a total of two patients had low levels of oxygen in their body tissues.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "08b79e0d-5e97-45fb-ac83-0096b56f714b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01492101", "Statement": "Less than 1% of any of the cohorts in the primary trial were affected by pancytopenia or coagulopathy.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5, 11, 15, 16]}, "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01466270", "Statement": "The placebo group in the primary trial had mean retention greater than 10% higher than the QD PO group of dodopezil hydrochloride.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6d549a9b-47bf-4369-962b-2759cfd7051e": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00798135", "Secondary_id": "NCT01209195", "Statement": "Both the primary and secondary trials focus on the pharmacokinetics of Itraconazole 500mg QD.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3]}, "596f20cf-299d-40a3-881a-cdd49bcb21f6": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00703326", "Secondary_id": "NCT00274768", "Statement": "Participants with primary HER2- breast tumours, confirmed by in situ fluorescence hybridization, are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 5], "Secondary_evidence_index": [0, 1, 7, 8]}, "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03066947", "Statement": "At least one patient in the primary trial had gastroesophageal reflux.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00418028", "Secondary_id": "NCT00293540", "Statement": "Sam has recently received a liver transplant, is not eligible for the primary trial, but is eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [7, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "d4b2d877-34af-4944-84f7-046e22c2854e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01781299", "Statement": "All subjects in the primary trial must undergo minor surgery.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "d3ca3729-2795-4cd5-9968-666781d17fac": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00119262", "Statement": "Cohorts 1 and 2 of the primary trial had a different number of patients with congestive heart failure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01752907", "Statement": "In the primary trial, there were 0 cases of Tibia or Fibula fractures.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "b98c7a50-ed79-41ff-9733-fff143f630be": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01901146", "Secondary_id": "NCT00209092", "Statement": "The primary trial cohort 1 recorded the same number of neutropenic fever cases as cohort 1 in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 4]}, "47aa5686-75af-4ed8-b4ff-715b458ce40a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02203565", "Secondary_id": "NCT00194779", "Statement": "The analysis of laboratory biomarkers is used in the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "e89fdc93-d624-4ba7-aa64-574a278e982b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00077376", "Secondary_id": "NCT01256008", "Statement": "The primary trial is studying a new chemotherapy treatment, while the secondary trial is testing a type of psychological therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1739541a-2d3f-4a13-b956-769a1cbed4d7": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00871858", "Statement": "One patient in cohort 1 of the primary trial was diagnosed with clear cell renal carcinoma.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02187744", "Statement": "One patient in the primary trial suffered sepsis due to the presence of an implanted device.", "Label": "Entailment", "Primary_evidence_index": [0, 7]}, "206fc00c-2c34-42bc-8fca-44be696e03c9": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02312622", "Statement": "The two cohorts in the primary trial receive identical interventions; the pegylated irinotecan administered intravenously (IV) at 145 mg/m\u00ac\u00c2\u00a7 in monotherapy once every 21 days, the differences between cohorts are the type of cancer diagnosed, cohort 1 is the NSCLC, while cohort 2 is the MBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00393939", "Statement": "Median (95% confidence interval) Progression-free survival (PFS) was 1 year higher in Trastuzumab + Sunitinib patients in the primary trial than in the Docetaxel group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "83cef795-d4a8-486c-8ac1-34a9acee9672": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00581256", "Statement": "Patients with breast cancer on the left side and ECOG between 1 and 2 are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 8, 14, 17]}, "b3cee7a6-cec1-4676-974d-7cfb3ccd9919": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00127933", "Secondary_id": "NCT00191789", "Statement": "In the primary trial, one patient had a catheter-related complication, while in the secondary trial, no patients were observed.", "Label": "Entailment", "Primary_evidence_index": [12, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "007de11b-4265-4695-b18e-e0d6909a347a": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00944047", "Secondary_id": "NCT00228943", "Statement": "Patients with HER2 positive tumours are excluded from the primary trial but may be included in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ce621235-b584-439b-bb11-ab2fa04c3195": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01869764", "Secondary_id": "NCT02556632", "Statement": "Each participant in the secondary and primary trials undergoes a laboratory biomarker analysis and completes a questionnaire.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f358f023-2393-44eb-9535-3f0e1851318d": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01646346", "Secondary_id": "NCT03283553", "Statement": "Both secondary and primary tests use irradiation techniques in their studies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0e963b25-0d2b-4fc6-89c6-1eb068bc092e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470301", "Statement": "Each patient in the primary trial receives tipifarnib PO, as well as paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "390b08d3-e147-47f9-82d7-0643b8d5c8ae": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00733408", "Statement": "There was a slightly less than 8 weeks difference in progression-free survival between the minimum PFS and the maximum PFS in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2570cb04-4edd-48c9-b634-9f2e086469de": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00994279", "Secondary_id": "NCT00545077", "Statement": "Between the primary trial and the secondary trial, Bevacizumab is administered only to patients in cohort 2 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f6a7e279-b923-45e3-8ad5-e81e17c0a682": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00270894", "Statement": "60 patients in the primary trial were able to complete at least 85% of the schedule dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3d82851c-f302-4988-bd78-232583e04e96": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02511730", "Secondary_id": "NCT00193206", "Statement": "Patients with prior chemotherapy are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 6]}, "5c9f5916-37d3-4f6f-977b-be70204cf57c": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01819233", "Statement": "All participants in the primary trial have the same number of calories in their diet throughout the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "0c5f2498-4c10-4e51-8915-d86b37b08156": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01156987", "Secondary_id": "NCT02234479", "Statement": "The primary trial participants receive an intervention based on their diagnosis of cancer, while in the secondary trial, interventions are attributed to randomity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2, 5, 6, 7]}, "c54dc963-671a-4384-8b1f-d8058a832131": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00545688", "Statement": "No patients experienced paranasal sinus reactions or left ventricular dysfunction in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02340221", "Statement": "A total of 32 patients in the primary trial experienced diarrhoea.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "91adb350-ab20-41a6-944d-c13b55cf33f2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00014222", "Statement": "Cohort one of the primary trials reported 2,680 patients experiencing eye-related adverse events, while cohort two reported none.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "78949f1f-6738-4220-a233-e7831902e6f3": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02038010", "Secondary_id": "NCT00764322", "Statement": "Neither the primary nor the secondary test measures the dose limit toxicity of BYL719 in combination with T-DM1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3]}, "135311d8-c579-4568-913e-937be00dde7e": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00390455", "Secondary_id": "NCT00558103", "Statement": "In the secondary and primary trials, the test cohorts obtained a better overall response than the control groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0984431d-4997-41dc-9ba4-07134568c3fa": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00258349", "Secondary_id": "NCT01328249", "Statement": "The primary trial cohort 1 does not receive Eribilin Mesylate With Prophylactic Filgrastim, while the two secondary trial cohorts receive it.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "d9dc4a6d-a913-46ac-b0aa-d50823ff2305": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00662129", "Statement": "Patients with platelet counts greater than 100,000 per millilitre, ANC < 1700 per millilitre, and hemoglobin counts between 11 and 18 grams per decilitre are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [18, 22, 23, 24]}, "9d9ab190-cdcf-4320-b69a-12f2dad9dba9": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02435680", "Secondary_id": "NCT01743560", "Statement": "The secondary test and the primary test use non-comparable evaluation parameters and significantly different time frames.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "89fdf182-7474-4e70-baf7-03c8920c4ff3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01385137", "Secondary_id": "NCT00593346", "Statement": "While placebo treatment is used in cohort 2 of the secondary trial, there is only one trial group in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "9f2fd0cc-af87-433d-9d2f-6235591d6cb1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00422903", "Statement": "The percentage of participants who received an objective clinical response (ORC) in the breast, assessed by an independent radiological assessment monitoring committee, was highest in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "90364098-7e9a-47be-ab2e-f66958cfb09d": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02413008", "Secondary_id": "NCT02725801", "Statement": "\u2022 Interventions in the primary and secondary trials are conducted daily for a period of several months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "021c3f62-8067-49e3-9d4b-c7641feb2548": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00331552", "Secondary_id": "NCT01306942", "Statement": "The same dose of trastuzumab was used for interventions in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "6893c9b4-d3a3-47a8-ada9-8aef67de2375": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01702571", "Statement": "Patients with incurable and non-resectable breast cancer are eligible for the primary trial unless they are metastatic.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "b88cde11-ae29-48e8-832b-4b9cb2596c30": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00859651", "Statement": "Helen had stage III ovarian cancer two years earlier, from which she is still recovering, she is excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [13, 14]}, "ebe7078c-fd8b-439a-b1f5-7bd482071ead": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02472964", "Secondary_id": "NCT00089661", "Statement": "The primary studies focus on the evolution of the tumour diameter, while the secondary study focuses on the evolution of the frequency of heart failure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "d0b9c11c-50f2-4803-a96c-fff3ca90cf36": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02312622", "Statement": "The two cohorts in the primary trial receive identical interventions; the pegylated irinotecan administered intravenously (IV) at 145 mg/m\u00ac\u00c2\u00a7 as monotherapy once every 21 days (1 cycle), the difference between cohorts is the type of cancer diagnosed in patients, cohort 1 is NSCLC, while cohort 2 is mBC.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "b620e1c5-69c4-4c30-9006-faa346200b60": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01256008", "Secondary_id": "NCT00300781", "Statement": "The primary trial focuses on cognitive behavioural therapy, a type of psychotherapy, as opposed to secondary studies, Trastuzumab, a type of chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0900325b-6ecd-46f1-b3f1-a2ce1605d151": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00325598", "Statement": "There is no difference in the results or size of the cohort between cohort 1 and 2 of the primary trial, the Gy increase has no significant effect.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6f10e1f3-1197-464e-b574-d697fb49331d": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02419807", "Secondary_id": "NCT00777101", "Statement": "Patients with HER2 + breast cancer are eligible for both the primary and secondary trials. However, only patients with Stage 1-2 breast cancer are eligible for the primary trials, and patients with Stage 3-4 are eligible for the secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "cbf91beb-829b-488f-8e80-3b08b891a181": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03592121", "Secondary_id": "NCT01439711", "Statement": "Both secondary and primary trials require that their patients receive their respective interventions on a daily basis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "985df98b-b397-4dbc-8fad-43ada30927d7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00254592", "Statement": "Patients in need of acute supportive care may participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 9]}, "0d4fdeef-89b2-463b-8252-66fa51d9ce8c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00356811", "Secondary_id": "NCT00296036", "Statement": "The secondary test procedure is applied to the palms and soles twice a day, the primary test participants do not receive any medication on the skin of the hands or feet, but rather on the chest or chest wall.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02595372", "Statement": "27.6% of patients with fatty acid synthase (FSFA) expression in the primary trial treated with Minocycline hydrochloride did not receive a complete pathological response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "494c1f01-5a2d-409e-b614-5871f408fbe6": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00450866", "Statement": "In primary trial group A, the percentage of patients with an increase of more than 25% in the tumour area at 3 months after treatment is higher than in group B.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "17881072-2517-483f-9c03-1edad21a58cf": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01008150", "Secondary_id": "NCT00375427", "Statement": "In total, the secondary test recorded only 3 more cases of pyrexia than the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00093795", "Statement": "Patients with metastatic cancer cells in less than 3 lymph nodes, at least one of which is more than 2 mm, cannot enter the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 8]}, "da6ce3a9-b653-47b2-9271-f831e4de3f19": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00912340", "Statement": "In cohort 2 of the primary trial, fewer patients had an unusual amount of fluid around the lungs than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 8, 15]}, "66979ae5-a709-4adf-9067-287f0f92b9e2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00828074", "Statement": "A higher number of participants in cohort 2 of the primary trial experienced fever compared to cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 13, 18]}, "0af6799b-655f-4b8b-a192-ce8dcbb2fcff": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02692755", "Statement": "Only black women are eligible for the primary trial, provided they do not have uncontrolled or symptomatic brain metastases.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 10, 11, 12]}, "3a3e2387-c4c7-48e6-b3ca-1257de7019c2": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00072293", "Statement": "Patients with palpable breast lesions and axillary lymph nodes are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [3, 12]}, "46ac8a9f-77ab-40cf-9421-64aad4ae6976": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00537771", "Secondary_id": "NCT00354640", "Statement": "\u2022 Cohort 1 participants in the primary trial and all participants in the secondary trial take 1 milligram PO QD anastrozole.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 5]}, "d2b7253b-0654-4bb1-a9a4-b203714d64f9": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00445458", "Secondary_id": "NCT00950742", "Statement": "The primary and secondary tests measure the DLT of their respective interventions using the same time frame.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "9a896e4a-ae6b-468c-a7c0-32c1514c0b48": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00107276", "Secondary_id": "NCT00232505", "Statement": "Less than 5% of patients treated in the primary trial experienced adverse reactions, compared to almost 10% of patients in cohort 1 of the secondary trial experienced adverse reactions, and more than 30% of those in cohort 2 of the secondary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 8, 9]}, "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00356811", "Secondary_id": "NCT00296036", "Statement": "The secondary trial procedure applies to palms and soles twice a day, and no topical drugs are given to primary trial participants.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0931065d-35e4-4f82-8ef6-ac6db900127a": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00290732", "Secondary_id": "NCT02748213", "Statement": "Patients whose breast cancer has spread to the skin and chest wall are eligible for the secondary trial, but not for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2, 8], "Secondary_evidence_index": [0, 1]}, "70912726-ba1b-47ef-9005-9584c8caf559": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00853996", "Statement": "Women classified as low risk of developing breast cancer over the next five years by the Gail model, and no family history of hereditary breast cancer, are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 8]}, "6743f85c-8318-49cc-acba-94aeb1f57130": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00493636", "Statement": "The primary trial cohort 1 had a PFS longer than cohort 2, but the patient with the longest PFS was in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "ddffa26d-2581-477a-955c-ebf0c2ab0f97": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00784849", "Secondary_id": "NCT02104895", "Statement": "The accelerated partial irradiation of the breast is used in one form or another for both cohorts of the secondary trial, but not at all in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "f1a45b47-498d-45c8-b6d9-6c8f035da30b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01201265", "Statement": "One patient in the primary trial was affected by Sepsis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "a5272c37-0e32-42db-a44a-d17df7bd70ff": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00179309", "Statement": "No pain-related adverse reactions were observed in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "4c67a7b4-36fa-4c20-a15a-122609550973": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00201773", "Statement": "Adele is an 85-year-old woman with ER+ breast cancer historically confirmed by an ECG of 0, she has a life expectancy of less than 6 months and a history of thrombotic events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 6]}, "120c6aa7-fcaa-4eaa-b520-6382968a6724": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00620373", "Statement": "The primary trial tests two different modes of dental imaging: mammography and gamma imaging.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00050011", "Statement": "The primary test results show that Upfront Zoledronic acid is a better treatment than retarded zoledronic acid to prevent changes in bone mineral density (BMD) in the lumbar spine (L1-L4).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "ac997ae1-7e48-48e2-af9e-f7e289622250": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00798135", "Secondary_id": "NCT01209195", "Statement": "The primary and secondary tests examine different outcome measures for different interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3]}, "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02915744", "Statement": "The difference in median overall survival (SG) of patients between the two cohorts in the primary trial was less than one month, with the patient with the longest GS in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "441c0760-ca4a-4f1d-864e-a77395fd1f18": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00399802", "Statement": "The Lapatinib group in the primary trial showed a lower percentage change from the reference base in urinary collagen type I N-telopeptide than in the Odanacatib 5 mg group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "fbe60029-8944-4e12-b4b2-3413037a10cc": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00723125", "Statement": "57% of patients in cohort 1 of the primary trial had complete pathological response rates to surgery.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "fe1782aa-a871-4608-a7cb-8f83b7f76d8a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00278109", "Secondary_id": "NCT01881230", "Statement": "- Gemcitabine is not used in the primary trial and is only used in cohort 2 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02364388", "Secondary_id": "NCT01425268", "Statement": "There is no overlap between the treatments used in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00405938", "Statement": "Patients with intracranial metastases may be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [9, 10]}, "4dc22366-3ff3-41c8-aa4c-7342d7b7085d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00263588", "Statement": "The majority of subjects in the primary trial had a progressive disease or objective CNS response rate that was unknown.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "196c2132-c735-4b79-bf03-3a830fcaf0fc": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00645333", "Secondary_id": "NCT00006110", "Statement": "The primary trial records several central nervous system-related adverse events in its patients, while the secondary trial does not.", "Label": "Contradiction", "Primary_evidence_index": [7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "72619b0a-57c2-465c-8428-72019b59f8ae": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02924883", "Statement": "In the primary trial, all cases of Enteritis, Vertigo and heart failure occurred in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "b8663fa7-585a-4cd9-afd2-89e8e1a58b82": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02732119", "Statement": "Mark complained of having had a heart racing twice in the last month and is therefore excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [8, 14]}, "7c92d075-ba9d-45b5-9834-83b09d2753bc": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02536794", "Secondary_id": "NCT00712985", "Statement": "Both the primary and secondary trials administer IV treatments to their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00411788", "Statement": "If Hannah takes ketoconazole to treat the athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday.", "Label": "Contradiction", "Primary_evidence_index": [18, 33]}, "9a346aac-46c2-4a50-8f3a-309b3b7bc295": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00382785", "Secondary_id": "NCT00784849", "Statement": "Neither the primary nor secondary test uses low-dose magnesium oxide, biopsies, or mometasone in their intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "949d79e0-95db-47a2-802a-6280c0255923": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02132949", "Secondary_id": "NCT01111825", "Statement": "Between the two cohorts of patients in the primary and secondary trials, there was only one patient with granulocyte deficiency in the blood.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "6e080a1e-a03e-4547-a7c4-c9d5a80de977": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01325207", "Secondary_id": "NCT02429427", "Statement": "Patients participating in the primary and secondary trials experienced serious eye disorders.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "63218fb2-3f5b-4738-bea8-11fbbc560949": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01730729", "Statement": "Patients with severe malabsorption disorders are not eligible for the primary trial unless they are able to receive an intravenous (IV) diet.", "Label": "Contradiction", "Primary_evidence_index": [24, 31, 30]}, "d7fa4f81-e108-491f-9b08-c147a33863e8": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01953003", "Statement": "Patients receiving intervention 1 of the primary trial will be administered orally and intravenously.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "f24afb09-ea65-457f-9f9b-0db3cc3101ac": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00849472", "Statement": "Two dozen primary test participants are classified as having a complete pathological response (CPR) in the breast and nodes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3cd79df2-e6dd-41dd-b819-4d993b5f7aed": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00403130", "Statement": "No cases of Leukopenia, Epitase or Arrhythmia were observed in patients participating in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "d2d6f646-5881-42a2-b965-0c6f79e89463": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00090857", "Statement": "If the results of this analysis are greater than 2 standard deviations below normal, the study physician may still decide to allow them to participate.", "Label": "Entailment", "Primary_evidence_index": [7, 8]}, "428d5165-560b-4783-8c4b-5fd3a3289cab": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00022672", "Statement": "There were no patients in either cohort of the primary trial with PFS greater than one year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6e7df2e4-11b3-4183-aefc-760f85809515": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02536794", "Secondary_id": "NCT00712985", "Statement": "Both the primary and secondary trials administer Zometa to their patients intravenously, although at different doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "45e6b4b6-ca31-4318-936e-5b27cbca47a2": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01439711", "Statement": "One primary trial patient experienced a decrease of 2.87 cm3 in the total volume of functional MRI tumours (FTV) over a 3-month period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "22a6d10e-55c5-4a8c-8010-3e8252bcb279": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00458237", "Statement": "The patient who has recently undergone external beam radiation therapy is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00593346", "Secondary_id": "NCT00902330", "Statement": "The primary test treatment takes less time than the secondary test treatment, but is given much more frequently.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "50d119f6-a657-4619-918e-7617ac57f052": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03078751", "Statement": "In cohort 1 of the primary trial, one case of AML was reported.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "e436827b-10db-4179-bf8f-07786ee6145b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01009918", "Statement": "There are no racial criteria for entry into the primary trial, but there are gender criteria.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "fcc6708a-b0fc-4215-a45f-02b1e0e2d30a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00631852", "Statement": "Patients with haemophilia are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [12, 19]}, "d63706f1-4fb8-488d-8f86-c1a19df341d4": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00944047", "Secondary_id": "NCT00228943", "Statement": "Patients with HER2-substantiated tumours are excluded from the primary trial but may be included in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ab357056-67a7-4227-966d-8c96eb1640fd": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02694029", "Statement": "The primary test candidates should be able to hold their breath for half a minute.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "0359eef3-6339-485e-95bc-0cb6fa7bcd12": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00635050", "Statement": "\u2022 Patients with breast cancer who have estrogen receptors are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "57ef3c6c-b4e1-4302-b423-aa9faca21200": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00791037", "Secondary_id": "NCT00606931", "Statement": "The primary and secondary trials do not use the same route of administration for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "29d5779b-c228-4b82-9ca8-075beadae879": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00091442", "Statement": "There have been more cases of febrile neutropenia than eukopenia in the primary trial, but fewer cases of febrile neutropenia than Neutropenia.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 3, 4]}, "4e124d90-68d7-40bd-a8b1-27cb49d64c64": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00591864", "Statement": "Patients in the primary trial receive Trametinib, Akt inhibitor GSK2141795 PO QD on days 1 to 28, up to a maximum of 8 cycles.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00291694", "Statement": "The route of administration of the two interventions in the primary trial is topical skin cream.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f4c7dae5-012f-4f05-b5ba-da072fe1359c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01674062", "Statement": "One patient in the primary trial was observed with enteritis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "927bbb75-37da-4b75-9483-252d31a0fd98": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01067976", "Secondary_id": "NCT00941330", "Statement": "In contrast to the secondary test, the primary test does not provide for cycles or doses in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "80a5cdbc-0721-41b6-af1a-28e3f46557ce": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01610284", "Statement": "One patient in the primary trial had a cardiac adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "af710d36-8062-4412-8d11-1c57a14b5e5a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00217672", "Secondary_id": "NCT00110084", "Statement": "The primary test had three times the rate of onset of enterovedic fistula as a secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "c91c7dc1-17b7-4475-9aec-38999a18a306": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00717405", "Statement": "There were several patients who contracted pneumonia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "5357ce66-7f7b-4ffd-926c-f6116f5a2e20": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00243503", "Secondary_id": "NCT00448279", "Statement": "The primary and secondary trials observed a different number of adverse reactions in their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "3c7ecca8-5397-41f5-b72b-84217bf3acd2": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00399529", "Statement": "Women with chronic obstructive pulmonary disease who do not need systemic corticosteroids are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [8]}, "2c53e14a-719c-4994-9090-73f9bddb60ba": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00615901", "Secondary_id": "NCT00829166", "Statement": "The primary trial recorded more seizures than the secondary trial, although it had less than one-tenth of the total number of patients in its cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089999", "Statement": "In total, more primary trial participants had no tumour response, than partial response, and only 3 patients had a complete response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "bfb617c8-51ae-4ab2-be05-6346daad5437": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00820222", "Secondary_id": "NCT01819233", "Statement": "Both the secondary trial and the primary trial interventions require subjects to follow restricted calorie diets or gluten-free diets, while complementing food journals.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "dcc5c3b0-848b-4ef4-afe6-e9c9933e33af": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00404066", "Statement": "\u2022 Abnormal LVEF, pregnancy or breast-feeding automatically eliminates patients from participating in the primary trial, unless they are treated with herbal medicines.", "Label": "Contradiction", "Primary_evidence_index": [17, 22, 28, 29]}, "18fcd396-cb03-4e80-bb2d-ee03c12ba32a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00455533", "Secondary_id": "NCT00767520", "Statement": "During the secondary and primary trials, there was only one case of pregnancy in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "694c5820-ebb6-4271-8685-a0b51c637f7f": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00038103", "Statement": "There is no significant difference in the proportions of subjects with clinical benefit in the Exemestane + Celecoxib cohort and in the Exemestane only cohort of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "b87abb47-13b6-4dbe-9cfd-e63075b676aa": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00662025", "Statement": "At the time of evaluation 0, participants in the primary trial had a confirmed disappearance of all target and non-target lesions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00754845", "Statement": "Patients who received more than 5 years of anastrozole therapy, completed less than a year ago, are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2, 3]}, "23df2cc2-6aae-4251-a8a7-e2f5a65f176a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02149524", "Statement": "None of the adverse events in the primary trial were related to IG.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "1bd51c93-d7a8-4da4-825d-ada625033c34": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00418028", "Secondary_id": "NCT00293540", "Statement": "Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for the primary trial, but is eligible for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [7, 10], "Secondary_evidence_index": [3, 4]}, "58c58b68-fc9a-438c-8a85-9233dde714c9": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01827787", "Statement": "The Triple-Negative breast cancer cohort in the primary trial had a much lower OR than the HR+/HER2- cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "843778c6-a320-49a1-93a0-5dc6239b822a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00965523", "Statement": "The most common adverse reactions in the primary trial where infection and stomatitis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a5486f80-69e5-4a5a-8435-f82f39cddf85": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00080301", "Statement": "There were 2 more cases of gastrointestinal haemorrhage in cohort 2 of the primary trial than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "c2c60b25-f255-48ba-bcb7-2bcd2de4315d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00171314", "Statement": "There are four types of adverse events in the primary trial, for which no events are recorded.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "a8167a90-8ccf-4024-a4cc-8c1b047fd548": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00068601", "Secondary_id": "NCT01684215", "Statement": "The primary and secondary trials do not use the same route of administration for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00106002", "Statement": "The primary trial participants are treated with 600 mg Pemetrexed orally twice a month until a complete response or progression of the disease.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "277f5d17-36cc-44c5-9b94-7e052f2bdb2c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01067976", "Secondary_id": "NCT00941330", "Statement": "In contrast to the secondary trial, the primary trial only provides for the duration of cycles and doses of drugs in the intervention section.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "fcb195de-2143-44d8-8c46-136104554e2d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01492101", "Statement": "There was less than 1% of either cohort in the Pancytopenia primary trial, but slightly more than 5% of patients in cohort 1 had coagulopathy.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5, 11, 15]}, "70337af9-3d4a-44bc-bbfa-0d97ea88553c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317720", "Statement": "Patients must have at least 3 pre-treatments with trastuzumab to be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "9cf89221-5801-4709-a098-de763b6e702e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00334542", "Statement": "A patient with mastectomy would be excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [6]}, "f89883ea-dd60-4d5f-9354-13fbca2aeec8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01031446", "Statement": "Sarah was the victim of epileptic seizures of a brain tumor, which will not prevent her from participating in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5]}, "a289f67c-ff56-44a9-b3da-152fb0d20271": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01301729", "Secondary_id": "NCT02129556", "Statement": "Only one respiratory adverse event was recorded during the duration of the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "10ed1242-c6ab-4ad0-b93c-4738857f543a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02635737", "Statement": "Patients with ICD may be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [6, 7]}, "683b9885-4027-4108-b37e-61255611538a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02692755", "Statement": "Asian, British and white women are eligible for the primary trial, provided they do not have uncontrolled or symptomatic brain metastases.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 10, 11, 12]}, "a47e048a-56aa-49e0-9903-563f53797b6e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00600340", "Statement": "- Cohorts 1 of the primary trial with Bevacizumab patients at a higher frequency and dose than those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "690de5e2-3d7f-407e-8eb9-783adf58841b": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00356148", "Secondary_id": "NCT01856543", "Statement": "Women of all ages can participate in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "f5477a02-dde7-44c8-80b5-2cdb9fa66f23": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01234337", "Secondary_id": "NCT00217672", "Statement": "More than 2 cases of anaphylaxis occurred either in the primary test or in the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "dc184dcb-a22d-4cac-bee1-6c182692e522": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03511378", "Statement": "In order to participate in the primary trial, patients must have a life expectancy greater than one year.", "Label": "Contradiction", "Primary_evidence_index": [0, 8]}, "4dfbdeba-cae0-48b2-a38d-07338512904e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03076190", "Secondary_id": "NCT03196635", "Statement": "- Molecular mammary imaging is not applied in either the primary trial or the secondary trial interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "62489179-bb30-4b96-a904-ea907dd05e23": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01097460", "Secondary_id": "NCT01009918", "Statement": "Each patient in the primary and secondary trials had at least one adverse event that occurred over a 2 year period.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "45891239-bb78-4f83-8306-8edceb8247fe": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01011946", "Statement": "All patients in the primary trial should have a bilateral breast mammography prior to entry into the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00258349", "Secondary_id": "NCT01328249", "Statement": "The primary trial cohort 1 does not receive Eribilin Mesylate or Vorinostat, while the two secondary trial cohorts receive some of the two.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "91f23b55-38b6-41c4-af30-baa15e989aa7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00371254", "Statement": "Patients should have an eceptorsestrogen (ER) receptor -, a progesterone receptor (PR) - and a human epidermal growth factor receptor 2 (HER2) - non-metastatic breast cancer, as well as the absence of Dysphagia.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 8, 12]}, "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00374322", "Statement": "The primary test results showed that participants receiving lapatinib at 1500 milligrams (mg) orally were twice as likely to reach DFS at 5 years of age as patients on placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "a2d489d5-3677-43ef-b03a-33d571c0c3b2": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02650193", "Secondary_id": "NCT00656669", "Statement": "Patients with Class III obesity may not be included in the primary trial, but may be included in the secondary trial, provided they do not have uncontrolled hypertension.", "Label": "Entailment", "Primary_evidence_index": [0, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "943ff737-4edd-4dbd-a3c9-213e3e0234d8": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00423917", "Secondary_id": "NCT00082641", "Statement": "In both the primary and secondary trials, there are instances of confusion in their patient cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 7, 8, 15]}, "be50c45f-ec51-40c8-904f-ffc200d39d9d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01042938", "Statement": "Only patients able to understand English are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 11]}, "f53c8212-6da8-470f-a392-1bb037ed90e8": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04030104", "Secondary_id": "NCT02525718", "Statement": "Intervention 1 for the secondary and primary trials includes either no treatment at all or placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "7b7e6e8b-aa62-4fcd-af1e-c243995243d1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02622074", "Statement": "There were twice as many patients with DLT in cohort 2 of the primary trial as in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "74a53536-bb9d-4c64-9280-679d7b660cdd": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02162719", "Statement": "The primary trial does not examine the effects of its intervention on the patient's PRT.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "6b35c306-a699-44f2-8606-a58d58fc18f3": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00728949", "Statement": "There were 6 categories of adverse reactions for cohort 1 of the primary trial that recorded at least three cases.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "62f50fe5-a83d-4f07-9dc7-8f495254d398": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00784849", "Secondary_id": "NCT02104895", "Statement": "While breast irradiation is used in one form or another for both cohorts of the secondary trial, it is not used in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "edcae553-8a0a-45d2-a0fa-4db68608ef03": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121134", "Statement": "The primary trial requires participants to have a primary tumour > 5cm in the longest dimension.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "a1b3667f-bfa5-426a-975a-20ed350c12c0": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00748553", "Statement": "Patients in the primary study receive 5 doses of azacitidine (Vidaza) per month and 3 doses of Nab-paclitaxel (Abraxane) per month.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "903617fa-7c40-45ac-a03c-498f51879408": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02915744", "Statement": "The difference in median, maximum, and minimum overall survival (MS) of patients between the two cohorts in the primary trial was less than one month.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9436e18a-a055-41c3-980f-bf451b4da7ee": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00171314", "Statement": "There are four types of adverse events in the primary trial, for which an event is recorded.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f57403d9-7278-481e-bcb9-066bf31b6158": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01201265", "Secondary_id": "NCT00932373", "Statement": "One patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688909", "Secondary_id": "NCT00129376", "Statement": "Patients in the primary and secondary trials did not experience any of the same adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "0f0e5a8e-3972-46c2-84dd-7436e82a9787": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00291135", "Secondary_id": "NCT00291694", "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "420e4977-ce75-4fab-99e0-3e7db837d521": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191152", "Statement": "The primary trial lasted more than 21 days in the docetaxel plus capecitabine group, the longest progression time of the disease.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "d07b4a30-e74f-468a-8420-7ade791d372d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00096356", "Statement": "The results of the primary trial indicate that CoQ10 reduces the PFS of breast cancer patients by approximately 8% compared to placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "412b2743-8f76-494a-af97-f7bf9541a890": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02536339", "Secondary_id": "NCT00371345", "Statement": "At least one type of respiratory disease was observed in patients in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 11]}, "fd43feb6-4a55-4de6-b21d-25ff723b0959": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00631852", "Secondary_id": "NCT00193037", "Statement": "Patients may be forced to participate in the secondary and primary trials, even against their consent, provided that this is in their best interests.", "Label": "Contradiction", "Primary_evidence_index": [0, 8], "Secondary_evidence_index": [0, 9]}, "e1fa68ac-42b4-4223-a362-a89c43562e06": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01256567", "Secondary_id": "NCT01926886", "Statement": "The most common adverse reaction in the primary trial was febrile neutropenia (14.29%), while in the secondary trial it was a decrease in ejection fraction (4.95%).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6f5570c0-4114-47ee-9611-b2e4be91cf9a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03165955", "Secondary_id": "NCT00912340", "Statement": "2 patients in the primary trial suffer from DVT, 0 in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01224678", "Statement": "Intervention 2 of the primary test resulted in a percentage change in tumour diameter lower than intervention 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "6495c223-f7d9-459f-8c57-66a2caac5ee4": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02581839", "Statement": "All participants in the primary trial had a progression-free survival of the central nervous system (CNS) >= 16 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "eb61fee2-30fc-42f9-80bd-4d73d6af592c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01216319", "Secondary_id": "NCT03346161", "Statement": "The secondary and primary trials evaluate interventions associated with breast reconstruction in patients with mastectomy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "79c698bf-a756-4a73-8075-38c3c5eb7a04": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00091832", "Statement": "The two cohorts in the primary trial in a percentage of negative (average) variation from the creatinine-adjusted urinary N-telopeptide reference base (uNTx/Cr).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f7be0a6e-6c63-473e-af00-df009f3d7d46": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00571987", "Statement": "\u2022 Breast implants and Diffuse microcalcifications will not disqualify a patient from entering the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "6f686de9-f110-4be0-9cd8-1ceb0ce6f073": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01376349", "Secondary_id": "NCT01912612", "Statement": "The primary trial cohort 2 receives 3.25 mg of DHEA vaginal QD gel more than the subjects in cohort 1 of the two secondary trial cohorts only the Duloxetine 30 mg pain-free cohort per day.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01004744", "Statement": "Patients should have a pregnancy confirmed by a positive Hcg test if they are to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2]}, "ffa913b7-9875-458e-8a28-476f9e788bb0": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02463032", "Statement": "There was less than 5% difference in the percentage of participants with an objective response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193206", "Statement": "The primary test has a total of 7 different types of infections.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "d8e47fe7-be41-4f74-881b-a80cd3a1e95f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03456427", "Secondary_id": "NCT02685566", "Statement": "There are no details of the duration or frequency of administration in the intervention sections of the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e77e15a3-d851-4174-80c3-7b5156e7f987": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00236899", "Secondary_id": "NCT01153672", "Statement": "The primary and secondary trials do not use any of the same drugs in their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "c003dd08-af3b-44cc-b31c-6fbdadfa1d83": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01806259", "Statement": "In total, more than 85% of patients in the primary trial achieve non-recidivism survival after 3 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "8ddf49c7-316e-4c7c-b2dd-423182a37612": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00455533", "Secondary_id": "NCT00767520", "Statement": "During the secondary and primary trials, there was only one case of sudden and unexpected death in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d9e41be5-1e37-4dff-b51a-166576f351d0": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01498458", "Statement": "For all types of adverse events in the primary test, at least one case has been recorded.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "ee2287bd-af76-4232-9575-d371fe3257dc": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00544167", "Statement": "Each adverse event in the primary trial occurred once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e5495b51-5f42-4e97-80ec-c215652bd3ab": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00675259", "Secondary_id": "NCT01875367", "Statement": "Patients with an immuno-histoChimistry test result of 3+ are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [15, 18], "Secondary_evidence_index": [0, 15]}, "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00612560", "Statement": "Children and adults who are illiterate may participate in the primary trial, unless they can read and write in Italian.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 12, 13]}, "9ae51f9c-8544-4764-b731-e4efe9ae0ba6": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00452673", "Statement": "1/7 patients in cohort 1 of the primary trial had dose-limiting toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5b1915da-1819-4504-81bd-3f44a83b5e95": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320541", "Statement": "In the primary trial cohort 2 there were three times as many cases of Leukopenia as in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 13, 17]}, "edb1e4c0-7669-4b8c-878b-ea8ca060c350": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00074152", "Statement": "Only 2 cases of adverse events in the primary trial occurred in patients in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "915939cf-7813-43e7-b503-e14a7eb4e568": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00429299", "Statement": "Only one cohort in the primary trial is administered to trastuzumab 600 mg/m^2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "126c1169-b375-4f89-95b2-52e971d19565": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00856492", "Statement": "There were no deaths and no cases of infectious enterocolitis in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "11235250-3627-427e-aae9-099507484456": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00284180", "Statement": "In the three cohorts of the primary trial, a total of two patients had low levels of oxygen in their body tissues.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "8a9f2247-7c51-44be-910b-5091d9abb2ea": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00236899", "Secondary_id": "NCT01153672", "Statement": "Both the primary and secondary trials administer Paclitaxel and Gemcitabine to their patient cohorts, but only the secondary trial uses positron emission tomography.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "7e283897-4d9e-4353-8331-00f8db16cc7e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00038467", "Statement": "The groups of patients in the primary trial each receive different oral medications, either tamoxifen or exemestane.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "54b15068-023b-4e60-bb82-2a22512fda62": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00847171", "Secondary_id": "NCT01764022", "Statement": "Male patients with systemic lupus erythematosus are excluded from the primary trial, but may still be eligible for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [24, 32], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35]}, "78764961-52be-4235-a2b7-e581497d0099": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00900627", "Statement": "Both groups of the primary trial receive the same medication treatment, but different doses.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e09fe98c-ec5c-49cf-9f49-92ba8824e82e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03708393", "Secondary_id": "NCT03456427", "Statement": "The primary and secondary trials require the active involvement of the patient to apply the treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "a83d98c9-e3da-4449-878b-5fa2f3bee8cf": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01277757", "Statement": "The primary trial does not consist of testing a new physiotherapy or radiotherapy procedure.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "41db854e-1565-4eda-8236-550556043b47": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01027416", "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by a nucleus biopsy and a human chorionic gonadotropin urine test.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 8]}, "f559cacb-30e7-47cf-9ac6-5929c1a508f7": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00493649", "Secondary_id": "NCT01201265", "Statement": "There was no MRSA infection in the secondary or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "79362f6d-ef2c-4b93-8719-be361d0b5acc": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03096847", "Secondary_id": "NCT01840163", "Statement": "Women Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a Stage 1 to 2 Ductal Carcinoma in situ and can speak English.", "Label": "Contradiction", "Primary_evidence_index": [9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "54918996-1b4d-48bd-a0ca-13d8e259767b": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02650193", "Secondary_id": "NCT00656669", "Statement": "\u2022 Class III obesity patients cannot be included in the primary trial, but may be included in the secondary trial, even if they have uncontrolled hypertension.", "Label": "Contradiction", "Primary_evidence_index": [0, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00679341", "Secondary_id": "NCT00201851", "Statement": "Patients in the secondary and primary trials did not have the same adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "52c8361f-75dc-45f1-a35c-79180a22b931": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02015676", "Statement": "No cases of thrombocytopenia were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091168", "Statement": "Patients in the primary control group had median overall survival of less than one year, but several patients in the B-arm survived for more than one year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 11, 12, 13, 14, 15, 9, 17]}, "db8ffa86-bf52-47bb-89f7-42e7ae47b84d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01271725", "Statement": "In the primary trial, the percentage of participants with an objective response (OR) for Afatinib monotherapy was 18% lower than that for Afatinib and Paclitaxel or Vinorelbine Combine Therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "5a01d00f-8601-4c17-b814-be87e63b0d8a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02392611", "Statement": "The primary test cohorts are not separated according to the patient's characteristics.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "7577f05f-04e9-44de-9e00-b7411ff4010f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01351376", "Statement": "The laxatives currently prescribed are not excluded from the primary test.", "Label": "Contradiction", "Primary_evidence_index": [5, 18]}, "3b0440e6-cf85-4236-8a1d-2e3572143946": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191451", "Statement": "Patients in the primary trial experienced only one type of oesophageal side effects and several types of cardiac side effects.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6f342205-ef33-482a-b74a-74644537538b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00077857", "Statement": "Patients should be over 18 years of age, female, have one or more target lesions and more than 2 chemotherapy regiments to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 5]}, "5b63fffb-0a75-414f-8744-5fea78395f28": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00950742", "Statement": "100 participants in the Afatinib 20mg + Herceptin group in the primary trial suffer from the limiting dose of toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "9e655973-7d1d-4528-8394-a9cbcf0b978f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02279108", "Secondary_id": "NCT00943670", "Statement": "Adult patients with HER2-infiltrating breast cancer who have had a prior lumpectomy or breast reduction on the same side are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "ea62355f-aab9-4796-8658-746c0b669ca7": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00073073", "Secondary_id": "NCT00054028", "Statement": "There is no placebo or control group in the primary trial, in the secondary trial, Suramin acts as a placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "55eaae8d-611c-4dbb-b162-de664902e059": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454805", "Statement": "In the primary trial, there were more cases of intestinal obstruction in cohort 1 than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 8, 14, 22]}, "c3438bb2-4a49-4f14-ae50-a46fb48d0208": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00485953", "Secondary_id": "NCT00068601", "Statement": "The dose of cyclophosphamide in the secondary test and the dose of Placebo in the primary test are not specified.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "8f505cec-6ad4-4142-a861-1771e3ae5cdd": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00821964", "Statement": "The primary trial participants apply topical imiquimod to skin lesions once a day for a total of 13 days every 28 days of the cycle.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "8f4f9793-041d-448b-9da8-b0c787a875bb": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00478257", "Statement": "In order to participate in the primary trial, adequate haematological, hepatic and renal function is not required.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01735175", "Secondary_id": "NCT01216319", "Statement": "The secondary trial consists of testing a surgical procedure, unlike the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "61d56c2a-089f-4fa3-9e97-3a9007576077": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00376597", "Statement": "The primary trial does not receive any IV, oral or surgical interventions during the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00411788", "Statement": "If Hannah takes ketoconazole to treat the athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for next month.", "Label": "Entailment", "Primary_evidence_index": [18, 33]}, "bad4d3e7-a05a-44fd-937a-c94a23655c03": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01712009", "Secondary_id": "NCT00343382", "Statement": "In the primary trial, cohorted patients 2 receive naproxen at the same frequency and dose as cohort 2 patients in the secondary trial receive Pilocarpine.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [3, 4, 5]}, "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00499122", "Secondary_id": "NCT00454805", "Statement": "There have been several cases of multi-organism failure in cohort 1 of the secondary trial and cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "0c435231-a09c-4424-924a-13840c6b7068": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191789", "Statement": "In the primary trial, there were 1 cases of jaundice.", "Label": "Entailment", "Primary_evidence_index": [0, 12]}, "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01217385", "Secondary_id": "NCT01202591", "Statement": "While prior exposure to exemestane is not permitted for patients in the secondary trial, the primary trial may accept patients despite this.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [6, 7]}, "a29e6a86-65f3-4565-93e2-81f49fa837e4": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01252290", "Secondary_id": "NCT00479674", "Statement": "Unlike the secondary test, the primary test does not record any cases of anaemia, dyspepsia, nausea or depression.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00418457", "Statement": "The reconstruction of the components within 10 days of the start is acceptable for patients entering the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "34bb7f09-3b2b-464f-96df-c8d80b1206fc": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03190083", "Secondary_id": "NCT01805089", "Statement": "All stages of cancer are accepted for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "e9824c27-bb70-4707-9599-ff20281f873e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00357110", "Statement": "Less than 20% of patients in cohort 1 of the primary trial had varicose veins.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "43fcba9b-4edd-433d-86a7-370cbbf56853": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00320385", "Secondary_id": "NCT00075270", "Statement": "The median time between randomization and the first documented sign of disease progression or death due to any cause for all primary trial participants was less than the median time for secondary trial patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02555657", "Statement": "The median time between randomization and death for any cause was higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "27e0b995-b3d1-46a6-900a-d6e513504ff3": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00398567", "Statement": "In the primary trial, 3/4 patients did not experience adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "36a5357f-0c5f-4c64-a56a-a84aab165a16": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01727011", "Secondary_id": "NCT01420146", "Statement": "The primary test and secondary test procedures involve a variety of scans, such as CT, PET and dosimetry.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "c876167f-fe1e-4c3b-9183-dd3c1069ed0b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00024102", "Statement": "One patient in cohort 2 of the primary trial received a transfusion of packaged red blood cells.", "Label": "Entailment", "Primary_evidence_index": [12, 18]}, "d6989b67-ae99-4c2a-a67d-c2285cc57058": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191152", "Statement": "The longest progression time of the disease the primary trial was more than 11 months in the Docetaxel Plus Capecitabine group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00320385", "Secondary_id": "NCT00075270", "Statement": "The two cohorts in the primary trial exceeded cohort 1 of the secondary trial in the median PFS.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "886d3280-bc44-4a58-a5ba-66b018210332": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00076024", "Statement": "The minimum period between the start of treatment of the study and the first documentation of objective tumour progression or cancer death for any patient in the primary trial was just over a year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "03dcb6d9-efae-40ec-87ee-68ef89424498": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00323479", "Secondary_id": "NCT03078751", "Statement": "There have been more cases of mental health deterioration in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "b881b717-1c8a-41b8-9554-6ed9e8ee7c77": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193206", "Statement": "The primary trial has a total of 7 patients with various infections.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "20530faf-addb-47bf-896d-b9666e149223": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01439282", "Statement": "In cohort 1 of the primary trial, adverse events were 20% higher than cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 14, 15]}, "52557c9f-f771-4f31-bb71-01f87f9f5821": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00041067", "Secondary_id": "NCT01273896", "Statement": "Patients with positive ER, RA or HER2 tumours in stage 4 may be eligible for secondary or primary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]}, "11472413-533f-45f9-9aac-c46bca318aab": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00373256", "Statement": "The primary trial cohort 1 included more than 200 patients treated with Sunitinib and Paclitaxel for 18 months or until death, and the median PFS for this group was just under 71\u20442 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00191854", "Statement": "Patients do not need a positive Her2neu tumour or measurable lesion to be included in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "6446f085-c6b0-43ce-82ed-16d6952b549e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00880022", "Secondary_id": "NCT00916578", "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression. However, all patients in the secondary trial are treated with Trunk compression.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01104584", "Statement": "The primary test participants receive either 50mg/m2 of trastuzumab, tamoxifen or exemestane.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "db90c9d8-b289-48e2-a7df-f41620b3feab": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00110084", "Secondary_id": "NCT01961544", "Statement": "Both the primary and secondary trials reported cases of sepsis in their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 12]}, "f2533676-1e72-444e-8aef-1fa826ceb804": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01419197", "Statement": "There are no cases of agranulocytosis in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "c15309b3-eb08-4d46-94ef-e4a504a111db": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03708393", "Secondary_id": "NCT03456427", "Statement": "The intervention in the primary trial is performed either by a doctor, radiograph or sonograph, while one of the interventions in the secondary trial requires the active participation of the patient.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "4885cd77-628c-4b8f-8345-6bce2165938c": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02964234", "Secondary_id": "NCT00246090", "Statement": "Patients eligible for the primary and secondary trials must live in the United States.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "8809cc5e-36d5-4f7e-b06d-b1915a421f71": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00759785", "Statement": "Only one adverse event, a mammary abscess, was observed in patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00908791", "Secondary_id": "NCT00297596", "Statement": "Patients over 60 years of age with histology-confirmed breast cancer and advanced Alzheimer's disease are not eligible for secondary and primary trials unless they have an ECG>2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 21]}, "ca27db58-14c4-4889-95b1-69be9c10a07a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00623233", "Secondary_id": "NCT01525589", "Statement": "More patients with a low platelet count in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5147b171-b5dc-46d6-a153-1a6d9a062ef1": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03190083", "Statement": "All stages of cancer are accepted for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "a5ed3500-1ea1-40b6-b1cb-3d5ae776f713": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00656669", "Statement": "There were no adverse events in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "3c482d5e-bfad-4a46-9e98-ba9967f2d900": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00903162", "Secondary_id": "NCT01674062", "Statement": "Patients with CWB are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [10, 12], "Secondary_evidence_index": [6, 10]}, "48ccd744-abf1-4e98-bc86-8ecd625e6279": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00654836", "Statement": "Patients with a negative metastatic HER-2 adenocarcinoma in the breast may be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 5]}, "dce5d9c8-7da6-4732-b969-c492c876cdca": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01783444", "Statement": "Women of any age can participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "1882de62-2df2-4b73-a3d2-81811f85f661": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01106898", "Statement": "2% of patients in the primary trial were diagnosed with foie gras disease after 3 years of chemotherapy or maintenance therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "161c852e-a42c-47c2-ab6a-2b7bd6a4b934": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00325234", "Statement": "If patients wish to participate in the primary trial, they should discontinue any anti-tumour hormone therapy and have a life expectancy of more than 3 months.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8]}, "eb152d1b-a0d6-428c-8d1d-eb5d862a8147": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01120184", "Statement": "At least one patient in cohort 1 of the primary trial had haemophilia, a rare coagulation disorder.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "0701ac32-45b3-4199-aa20-a71080ce9bf6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00546156", "Secondary_id": "NCT00398567", "Statement": "There are no cases of Vertigo in the primary trial or the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "866876f5-68de-44bd-b58a-e4b590aa4b39": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03573804", "Secondary_id": "NCT02781051", "Statement": "The primary trial participants must undergo at least one MRI during the procedure, the secondary trial patients must use an adjustment device.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "b4304362-1cb4-4606-9de4-03935ad509f1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00370552", "Statement": "There are 55 more participants with the best tumour response of partial response (PR) or complete response (CR) in cohort 2 of the primary trial than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9cddd86a-4340-4918-b000-7e6e593a3f7f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03097653", "Secondary_id": "NCT00662129", "Statement": "Women between the ages of 18 and 25 with stable angina cannot be included in either the secondary trial or the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72]}, "c3f01101-2259-4677-add1-1b1f48a0202b": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00528567", "Secondary_id": "NCT01196052", "Statement": "The total number of patients affected by adverse events in cohort 2 is greater than 1000.", "Label": "Contradiction", "Primary_evidence_index": [11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "33b827a0-ada5-4204-abb8-d5239ea16f0b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00143390", "Statement": "In the primary trial, there was a difference of less than 3 days between the maximum recorded TTP of the Exemestane group and the Anastrozole group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "40f1d3ce-2ff8-4177-9b11-0bf10b7f6591": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00259090", "Statement": "The primary studies focus on the impact of Fulvestrant, Anastrozole, on the H-score estrogen receptor.", "Label": "Entailment", "Primary_evidence_index": [1]}, "22bff413-a1bd-419b-b19b-2157dedc9948": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00802945", "Secondary_id": "NCT01231659", "Statement": "Group 1 of the secondary trial has a higher RRO than the 14-day NKTR-102 cohort in the primary trial and the 21-day NKTR-102 cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "b64d6e41-7ec7-4e62-beda-c28559a6cee7": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00880022", "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2ea80a50-0db3-4ff2-8ca0-71eb048649f7": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01875367", "Statement": "More than 3 patients in the primary trial had a common cold.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "20545360-b2a1-4be9-997a-97040866b239": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00880464", "Secondary_id": "NCT00458237", "Statement": "\u2022 AIDS patients are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [14, 18], "Secondary_evidence_index": [12, 26]}, "3b1bdc19-62cd-4ff1-9e30-424e124342f3": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02425891", "Secondary_id": "NCT00593827", "Statement": "The secondary and primary trials measure the PFS of their patient cohorts and use the same time frame.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "a44cd0d1-92b3-4add-badf-b8dd5a324138": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01466972", "Secondary_id": "NCT01446159", "Statement": "The primary trial recorded one patient with congestive heart failure, and the secondary trial did not.", "Label": "Entailment", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 5, 13, 18]}, "291bb67e-f02f-49d4-b967-29cc9f5098c4": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01738438", "Secondary_id": "NCT00331552", "Statement": "- Cyclophosphamide, cabozantinib, and trastuzumab were used in the secondary test procedure, but not in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "55704a1f-eab2-44ea-a6de-8df508a28066": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00274768", "Secondary_id": "NCT00654836", "Statement": "Patients with stage 4 cancer are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [2], "Secondary_evidence_index": [2]}, "6e1955b8-e6fa-42b2-a498-7ada9e733304": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01593020", "Secondary_id": "NCT00834678", "Statement": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [13, 18], "Secondary_evidence_index": [23]}, "52337e14-7f51-40c1-b965-fb6aba8ae4e7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00821886", "Statement": "Patients prescribed with bisoprolol or labetalol for the treatment of CHF are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [20, 33]}, "8a6397e9-84cd-4a2e-ac6a-b56ee355d862": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00004092", "Statement": "\u2022 Cancer patients who have spread a breast tumour to their CNS are able to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [4]}, "8b5f946c-71d9-42cd-aa9a-1d3a4845c460": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01401959", "Secondary_id": "NCT00852930", "Statement": "The primary trial refers to specific interventions for its patients based on their hormonal status, the A cohort is NTBC patients and the B cohort is ER/PR +HER2- BC patients, unlike the secondary trial attributes random interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "8f0aff7f-0d9e-498b-bcb6-05e6d309724c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01852032", "Secondary_id": "NCT01118624", "Statement": "The secondary trial administers placebo tablets twice the rate of the primary trial, but less than half the dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "b7936bbc-f0c0-444c-a199-2db323c30396": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00313170", "Secondary_id": "NCT00305448", "Statement": "The primary trial patients treated with Fulvestant 250 mg had an objective response rate of 33% higher than those treated with Fulvestant 250 mg + loading dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "6d6625ec-26b7-4157-a38c-87c770201323": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01373671", "Secondary_id": "NCT00686127", "Statement": "The Lidoderm products are used in response arm 1 of the secondary test, and a Siemens product is used in arm 1 of the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01305941", "Statement": "Patients should submit IHC 3+ or FISH amplified results to participate in the primary trial, which means that their cancer is histologically confirmed to be triple positive.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "7e0259a3-073b-45f5-8e08-2cfaceecef0b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00606931", "Statement": "The primary trial tests MRI as a technique to guide biopsies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "c94ad26b-1f5e-4446-a4fe-bb949c5dc561": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00438100", "Secondary_id": "NCT00662025", "Statement": "Patients should have a BUN < 20 mg/dL, platelet count < 90,000/mm3, leukocyte count from 5,000/mm3 to 8,000/mm3 to be eligible for primary or secondary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00244881", "Statement": "30% of primary trial participants had increased CEC levels after 42 days of treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5c00f992-5066-42f2-88d7-566b8b9104b5": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089661", "Statement": "On average, cohort 1 participants in the primary trial had an increased rate of acute toxicity, whereas cohort 2 participants had no acute toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "4c0ffc50-5cb2-4574-b954-335d142edbe4": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01527487", "Statement": "Patients who have prescribed citalopram as a continuous treatment for depression are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [32, 49]}, "4e3379b9-f971-4ab6-8846-c395f1162bf2": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00810797", "Secondary_id": "NCT00828074", "Statement": "Skin infections were more common in patients in cohort 1 of the secondary trial than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 8]}, "9872394c-18b7-4f88-849e-0e2831e6ebf0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00579826", "Statement": "The primary trial cannot currently receive treatment for rheumatoid arthritis, experience poorly controlled migraines, receive hormone replacement therapy, or have a history of invasive breast cancer in the past three years.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 6, 8, 10, 11]}, "adf3bb50-ec36-467a-987a-f33c10380c60": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01771666", "Secondary_id": "NCT01256567", "Statement": "Japanese participants with an ECOG of 2 are eligible for the secondary and primary tests.", "Label": "Contradiction", "Primary_evidence_index": [0, 7], "Secondary_evidence_index": [0, 1, 2]}, "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01875367", "Statement": "One patient in the primary trial had a cerebral infarction.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "03cb39e4-1d21-47e5-9b09-ebe508eb2a17": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00477464", "Statement": "59 patients in the primary A arm received a better overall response, classified as a complete or partial (confirmed) tumour response or stable disease for at least 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "dca6ba74-441e-482f-b667-6c45800ed8c1": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425672", "Statement": "Patients receiving Intervention 1 of the primary trial must undergo a 21-day treatment cycle for a total of 6 courses, except for deaths.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "aeecc244-13a9-4944-858e-27ef49585e90": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01702571", "Statement": "Patients with locally advanced incurable and non-resectable breast cancer are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "741ca5eb-4737-4a35-a9fd-4235d6552b4f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01256008", "Secondary_id": "NCT00300781", "Statement": "The primary trial involves cognitive behavioural therapy, a type of psychotherapy, unlike secondary studies Neratinib, a type of chemotherapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b8e0458c-b834-42b5-b5fd-8791f89b0853": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01881230", "Statement": "The Gemcitabine group in the primary trial had a median Kaplan-Meier estimate of progression-free survival more than 2 months less than the Carboplatin group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1a112ed3-8318-493b-8973-10de01794892": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00382018", "Secondary_id": "NCT03012477", "Statement": "Between primary and secondary trial patients, only one patient had sepsis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [5]}, "6044590d-0f89-4a6e-8be7-54ca0c0327d9": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00003404", "Secondary_id": "NCT00711529", "Statement": "The primary trial does not have a hypnotherapy-based intervention, and the secondary trial does not have a radiotherapy intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8d3378f7-caaf-4654-b12a-382a0e911eb1": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02429427", "Statement": "Patients with a platelet count of 50 x 109/l are not eligible for primary testing", "Label": "Entailment", "Primary_evidence_index": [0, 7]}, "f701473d-e034-4a06-9829-d20cc483162c": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01516736", "Secondary_id": "NCT00733408", "Statement": "The results of the primary and secondary trials are not comparable, as the different size of the cohort is too large.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "3889cecd-aa2d-4f58-857e-11d7209f9cf4": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00450866", "Statement": "In the primary trial, a cohort 1 has a higher percentage of patients with progression-free survival at 3 months after treatment than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00338286", "Statement": "No primary test participant had progression-free survival for more than one year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "cb023dbc-3e99-4c32-a857-7f8d49ef5a96": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00789581", "Secondary_id": "NCT02445586", "Statement": "The secondary trial reported more cases of haematemesis, but the primary trial revealed more cases of DIASTOLIC DYSFUNCTION in both cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "1d0ce237-70eb-45b4-9c77-f0b70d410387": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00193180", "Statement": "A patient over 18 years of age with cirrhosis cannot participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 8, 16]}, "93290529-38b1-444b-9ac8-fa32b98821c5": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00256243", "Secondary_id": "NCT00721630", "Statement": "Patients who wish to participate in the secondary trial should be in a specific location, which is not necessary for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "dad5ecc6-afcf-496c-8193-778a100c0318": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00436917", "Statement": "- Patients with scoliosis with a Cobb angle greater than 20 degrees at the lumbar spine or with surgery prior to the lumbosacral spine are excluded from the primary trial as they are contraindications to X-ray (DXA) dual-energy absorptiometry.", "Label": "Entailment", "Primary_evidence_index": [39, 40, 41]}, "d0efe29c-1d76-4129-9cf5-2955564d1370": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00976989", "Statement": "Patients with a LEVF greater than or equal to 60% are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "63ec91be-7e12-431e-84b0-ca401bfb157b": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01048099", "Secondary_id": "NCT02502864", "Statement": "The primary test recorded 2.38% more adverse reactions than the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "fd5af11f-7270-49d5-924a-755ff399c463": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00373256", "Statement": "The primary trial cohort 1 included 250 patients treated with Sunitinib and Paclitaxel for 18 months or until their death, and the mean PFS for this group was just under 7 and a half months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 7, 8, 9]}, "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02186015", "Statement": "Women in the B cohort of the primary trial with a serum level of 25 (OH)D greater than or equal to 30 ng/ml did not receive a weekly supplement of cholecalciferol.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6a5ee728-7db9-4ec0-b98c-0500e9a6187e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00924352", "Statement": "One primary trial patient had abnormally low levels of AST, ALT and ANC.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "a495df61-260d-479c-8d5f-d586f295c672": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02297412", "Secondary_id": "NCT02667626", "Statement": "The secondary trial cohort 2 and the primary trial are control groups, receiving a placebo PO BID tablet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "917afeec-5152-4424-89e3-7f3ffad6378f": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01105650", "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m2 less than IL-2 than participants weighing more than 45 kg, but all participants will receive IL-2 3 times a week for 6 doses.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01617668", "Statement": "Patients should have healthy kidneys, liver and bone marrow to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8, 9, 10]}, "f5aa1aa3-7be3-4518-8cc5-df2394e70e96": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02244580", "Secondary_id": "NCT01901146", "Statement": "Patients with indeterminate estrogen receptor status may be accepted both in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5, 7]}, "45338f7c-5aaa-40fb-8503-7c943e1f3a29": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03584009", "Statement": "Participants in the primary trial administered with Fulvestant 500mg intramuscular injection received a higher percentage of clinical benefits than participants who received an additional 800mg of Venetoclax orally.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0964be32-f9e7-49ec-ad22-b030d483702a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429507", "Secondary_id": "NCT00038467", "Statement": "Unlike the secondary trial, the primary trial does not administer any oral drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "73cfc4ea-afc0-465b-a403-c1bd771ded33": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01527487", "Statement": "Patients who have prescribed citalopram as a continuous treatment for depression are not eligible for the primary trial because psychological diseases are not permitted.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]}, "75b67d63-9727-418d-afd5-c0fb867417b5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00876395", "Statement": "Patients with ulcerative colitis are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 15]}, "94cd9451-35a4-4035-a7de-2d385f771607": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01671319", "Statement": "1/42 patients in cohort 2 of the primary trial passed out.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "18310f83-54ca-4530-92f1-7c41419ab69e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00068341", "Statement": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "4fa6b99e-0e70-465d-8b24-b728979b3689": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00567190", "Statement": "There was the same number of anemic skates in both cohorts of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 12, 14]}, "e0fac0a4-a5ab-4089-8986-f601586506af": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00627978", "Statement": "Women with leptomenenic metastases are unfortunately excluded from the primary trial, as this would prevent them from giving their informed consent to enter the study.", "Label": "Contradiction", "Primary_evidence_index": [18, 19]}, "85210693-996a-4ab9-92f4-62060571da21": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01847001", "Statement": "Spanish women with a heart rate of not more than 50 beats per minute are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00148668", "Statement": "Cohorts 1 and 2 in the primary trial recorded the same number of patients with Neutropenia.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6a37e999-4b7e-4654-b9ac-7776a0720040": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01310231", "Secondary_id": "NCT00093808", "Statement": "One patient in the secondary trial developed a eating disorder, and there were no cases of this in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "a625ff4b-9c91-4ab8-a78b-df833d15759a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00423917", "Secondary_id": "NCT00082641", "Statement": "In both the primary and secondary trials, there are cases of confusion in all of their patient cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 7, 8, 15]}, "b25e7c40-a1db-4ae7-9613-0f65ddb4c040": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00082641", "Statement": "At least one patient in the primary trial suffered a life-threatening bone fracture.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00856492", "Statement": "There were no deaths and no cases of anaemia in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "c0ddffa9-4a88-4ee1-8525-a77e887c3d85": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01268150", "Statement": "The Eribilin Mesylate group in the primary trial had a higher proportion of patients with a complete (CR) or partial (PR) response than the control group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "64ea58e5-e28f-42bc-818e-31bbf347080c": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00129389", "Secondary_id": "NCT00304096", "Statement": "Patients with permanent sensory loss who interfere with daily activities are excluded from the primary trial but may still be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [22, 30], "Secondary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]}, "7a0f4365-9775-4f1d-a1c7-4630b41b43ea": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01905592", "Statement": "The primary trial only defines the intervention dose for cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "64dcb690-ef14-4cf2-85e5-670eb0645d7f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01073865", "Statement": "Women over 18 years of age, whose last period was 2 weeks before, are entitled to the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "cacd1b1b-510e-421b-9adb-c5715f281794": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01566721", "Statement": "A greater number of patients in cohort 2 of the primary trial had at least one adverse event (AE) during the treatment period than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02502864", "Statement": "The maximum number of occurrences for an adverse event in the primary trial was 3.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "7926bfa3-cf49-4589-8143-0a0826336b67": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01401166", "Statement": "All patients in cohort 1 of the primary trial had a preferred method of drug administration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00975676", "Secondary_id": "NCT00632489", "Statement": "The primary trial does not explicitly indicate the dose of Triptoreline for any of its patient cohorts, nor does the secondary trial provide details of the doses used for LBH589, capecitabine and lapatinib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00887575", "Secondary_id": "NCT01610284", "Statement": "The cohort 1 of the secondary trial had more than 50 times the number of patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01269346", "Secondary_id": "NCT01597193", "Statement": "The Primary Trial Cohort 1 and Secondary Trial Cohort 1 have the same total number of adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "1aee22c7-96f2-4ea6-909a-48741f87ba07": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01111825", "Statement": "No cases of Constipation, Diarrhoea, Nausea or febrile neutropenia were observed in cohorts 1 and 2 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "d677707e-9ca9-4801-8fcd-7960a9f4f30a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00513695", "Statement": "Paclitaxel is the only medicine in the primary IV trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "5335a9c9-bae1-42e9-9428-eb0eded62d7f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03252145", "Secondary_id": "NCT00904033", "Statement": "None of the subjects in the primary trial are required to inject pills, while both cohorts in the secondary trial are required to take one tablet weekly.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "e6c0f7af-b549-4aad-8f3c-15f367a04a50": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01307891", "Statement": "The Abraxane + Tigatuzumab group in the primary trial has 10% more patients with either the complete response (RC) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions compared to the Abraxane Alone group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1fc3aeac-3bc0-4a47-8222-ea267a822804": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00929240", "Statement": "There are no cases of febrile bone marrow aplasia in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "9e664bcb-38cc-4ca6-9738-28d96248b7f2": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00320411", "Statement": "The primary trial participants should take 6 tablets of Lapatinib monotherapy (1500g) PO once daily.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "1b8403ac-7eb3-41cb-8b7e-a89af3492805": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02924883", "Statement": "In the primary trial, all cases of Enteritis, Vertigo and Anemia occurred in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "ad853675-40ed-4a65-a401-d09ac3153570": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03004534", "Statement": "Participants with a T2 N1 M0 breast carcinoma are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 6, 7, 8]}, "b43bee02-cc3f-4dc8-b13f-8a93de5dc422": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00493636", "Statement": "The primary trial cohort 1 had median, maximum and minimum values longer than those in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "62258901-8207-413d-913f-a04682635add": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00050011", "Statement": "The primary test results show that Upfront Zoledronic acid is a better treatment than delayed zoledronic acid to increase the mineral density of the lumbar spine (L1-L4) bones.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "d23aee47-e80f-42fe-b095-9cd81f9e0ed3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02657889", "Statement": "The two primary test cohorts showed identical results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d23eb56e-c232-4754-94aa-903bc174cb35": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00524303", "Statement": "The Trastuzumab arm of the primary trial achieved 9% better results than the Lapatinib arm.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1c0dcd29-4a04-4b78-abbf-b047d4c29597": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00562718", "Statement": "Patients with breast implants are always excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [6]}, "b1a17048-dfe8-4173-ae80-6ec273244848": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01298193", "Statement": "More than 20% of patients in cohort 1 of the primary trial experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "33652443-0bb4-493e-adfe-f5032b96b13d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01808573", "Statement": "The primary trial Patients receiving Neratinib Plus Capecitabine had a significantly longer PFS than the 38-month study time.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "74dba58a-8f5d-478b-a886-0e9758847fe3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00228943", "Statement": "Patients with clinical anxiety are not able to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [8, 9]}, "5344044c-127d-4a39-80dc-277538b5ad33": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02131064", "Statement": "Less than 60 participants in the primary trial TCH + P group obtained the total pathological response (tpCR) evaluated on the basis of tumour samples.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ed43519d-9954-4e0f-9d42-39a3ed81e4a5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00820872", "Statement": "Hyperglycaemia was the most common adverse event in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "8d2fde27-a5e8-40ee-a35d-3d4697198a4e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00929240", "Statement": "There are no cases of febrile neutropenia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "fc0da76b-e5b5-44e3-abaf-6231fff493c3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00676663", "Statement": "The placebo group in the primary trial was less effective than the control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1a32e1c1-31b1-40e5-bbb6-84041ef796fe": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00119262", "Statement": "Both cohorts 1 and 2 of the primary trial had 3 patients with congestive heart failure.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9a31db67-e28a-4114-a308-e899f9c22813": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02291913", "Statement": "One primary trial patient suffered from inflammation of the esophagus.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "f948a2d1-2e22-47c8-9345-0eb68569bd3f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00996632", "Secondary_id": "NCT01644890", "Statement": "Emily has inoperable breast cancer, she is eligible for the secondary trial and the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e3265040-8316-4f62-969c-27af396ba18c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00479674", "Statement": "Patients who have previously been treated with bevacizumab are not eligible for the primary trial unless they have also received carboplatin 2 weeks prior to entry into the study.", "Label": "Contradiction", "Primary_evidence_index": [22, 24]}, "6c25e195-47cd-48af-bb51-5b5c44772baa": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00656019", "Statement": "Hyperparathyroid candidates are automatically excluded from the primary test.", "Label": "Entailment", "Primary_evidence_index": [6, 7]}, "382747d3-69df-41be-a771-4218407ce5d3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171340", "Statement": "The primary test results imply that zoledronic acid 4 mg Upstream causes a change in bone mineral density, while zoledronic acid 4 mg Late causes a loss of bone mineral density (within a certain group of patients).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d05ec90a-f267-44be-aaa6-3be960a0d50c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00376688", "Statement": "Most subjects in the primary trial had a complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "37301690-9b68-48de-b280-6307e632043e": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02301988", "Secondary_id": "NCT00728949", "Statement": "The only types of adverse events recorded in the secondary and primary trials are diarrhoea and various pains.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "b61e798c-d38f-4c72-91bb-4d3e28b6184c": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00356148", "Secondary_id": "NCT01856543", "Statement": "Women of any age may participate in the primary trial, but only adults may be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "3ca27248-0728-4b10-b940-6e2603acef30": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00201760", "Secondary_id": "NCT00127933", "Statement": "Patients should have infiltrating breast carcinoma to participate in the secondary trial or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 3]}, "c2da6504-96a1-4669-b609-16731a5330d3": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00248170", "Secondary_id": "NCT01299038", "Statement": "Ae-Cha is a 32-year-old Korean woman with inoperative breast cancer who is not eligible for the secondary trial and the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [6, 10]}, "646959e4-25d0-4eb1-b7b0-2d7b1e02e132": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01262027", "Statement": "Less than 5% of patients in the primary trial had an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "0e6eebe9-46c2-4fa5-b9ed-e0997044960b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01293032", "Secondary_id": "NCT00849472", "Statement": "None of the patients in the primary or secondary trials are required to undergo radiation therapy or surgery.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "a781374c-99e1-47ee-a266-bff9267c2ed1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00950742", "Statement": "100% of participants in the Afatinib 30mg + Herceptin group in the primary trial have dose-limiting toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 10, 11, 12, 13, 8, 15]}, "9aea5a84-bced-4441-b8b8-154c307f5a03": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01151046", "Statement": "In the primary trial, the placebo group had a significantly lower median PFS than the MM-121 cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "deb77d34-76a5-4e6e-bc9d-176cc30eca07": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00917735", "Statement": "A patient in cohort 2 of the primary trial died in a motorcycle accident.", "Label": "Contradiction", "Primary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "bfe97430-fcec-4c4a-9621-51f6ec05d8d3": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00068341", "Statement": "More patients in cohort 1 of the primary trial experienced progressive disease compared to cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "568beebd-b350-4ba1-b8fc-c43f4d6ed517": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01421017", "Statement": "The primary studies focus on the effects of CTX/IMQ/RT and IMQ+RT on systemic response rates to tumours 9 weeks after initiation of treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "6bcc18b7-b063-49a1-8ab7-773636c02f1d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00076024", "Statement": "The minimum number of days between the start of the study treatment and the first documentation of objective tumour progression or cancer-related deaths for any patient in the primary trial was 191.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "dfa2ecee-96cf-4551-875e-aedd8aac5df9": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01519700", "Statement": "There was less than 24 hours of difference in mean grade 4 neutropenia duration during cycle 1 chemotherapy for both arms of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "81c85a29-d449-4f79-a3b3-682ba5f288ca": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00190671", "Secondary_id": "NCT00455533", "Statement": "In cohort 2 of the primary trial, the number of patients with leukopenia was higher than in cohort 1, while in cohort 1 of the secondary trial, the number of patients with leukopenia was higher than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 14, 19], "Secondary_evidence_index": [0, 3, 12, 15]}, "9c48c5d6-83fd-42cc-aacc-2e888099bcdb": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00338728", "Statement": "The primary trial participants were more imatinib mesylate than Letrozole on a daily basis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "79a3bb0d-315f-4c39-8786-2aa98e2e3f6f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00293540", "Statement": "Men are not eligible for the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "cea17554-6736-4b52-b76c-b3c5dc9ecb77": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00503750", "Statement": "All participants in the primary trial must have recently undergone an echocardiography or MUGA scan.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "b250a17c-9d4d-405d-ba64-40f7eda16707": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00368875", "Statement": "The primary test results indicate that the recommended Phase II dose for paclitaxel, assessed according to the common NCI terminology criteria for adverse events, is 90 mg/m2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "698849c5-78fa-4c15-a1dc-f44eb9c970c2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00082641", "Statement": "At least one patient in the primary trial had reduced mobility.", "Label": "Entailment", "Primary_evidence_index": [8, 14]}, "4b4e6ac7-107c-46f4-adbb-c77c01f51935": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00075764", "Statement": "The most common adverse event in cohort 1 of the primary trial is the low haemoglobin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6b73dee4-0291-455e-90c2-786f0c2371d4": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00579826", "Statement": "The primary trial cannot currently receive treatment for rheumatoid arthritis, experience poorly controlled migraines, or have a history of invasive breast cancer in the past three years.", "Label": "Entailment", "Primary_evidence_index": [6, 8, 10, 11]}, "2a1d9064-fde9-4645-95ab-7ddaea4ad322": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00324259", "Statement": "In primary trial 3, cohort 2 had more patients with a complete response than cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "847de3fe-b584-4d43-b82d-93263ce88830": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00509587", "Statement": "Patients in the primary trial receive 300 mg pazopanib once daily intravenously until disease progression or unacceptable toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "3c798991-6366-43e2-94ca-0523629930c2": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00149214", "Secondary_id": "NCT01004744", "Statement": "The prior use of cancer drugs in the last 6 months for cancer treatment is prohibited for patients in the primary trial, but not for patients in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [4, 5], "Secondary_evidence_index": [0, 4]}, "64fe54a2-8897-4324-af88-f627c1c208ed": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01764022", "Statement": "The primary trial cohort 2 recorded multiple thrombocytopenia incidents.", "Label": "Contradiction", "Primary_evidence_index": [10, 13]}, "4eac6a2d-64cd-4289-a545-211eb835f0e9": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01328249", "Statement": "The percentage of participants with feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02435680", "Secondary_id": "NCT01743560", "Statement": "The secondary and primary tests use the best overall response (OR) as evaluation parameters, but they use significantly different time frames.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "da1e1019-adb5-47bf-8093-e03352ca9e51": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01340300", "Secondary_id": "NCT00671918", "Statement": "However, this is not a requirement for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "e7fb6490-1ec7-48ff-95b1-715d79faec92": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01042938", "Statement": "Patients must be English to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "d5ea3443-103f-4d29-9be3-522210b84152": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00618826", "Secondary_id": "NCT02040857", "Statement": "The primary and secondary tests only record 2 of the same adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 8, 10, 5], "Secondary_evidence_index": [0, 9, 3, 6, 11]}, "d54cae08-3ac9-4460-bf6d-7338b45d8cd7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00193050", "Statement": "Patients must be over 18 years of age and have a life expectancy greater than 6 months to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 11, 13]}, "608c5521-c9a6-47de-9ebf-791ce317a02d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00086957", "Statement": "All patients in cohort 1 of the primary trial experienced an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "14a8e9e9-0a46-4537-bc07-53c786bcbe97": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00593827", "Secondary_id": "NCT00478257", "Statement": "Patients with a negative HER2 BCM are eligible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "2d97bfa0-336f-4976-95e5-1262327a730b": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01048099", "Secondary_id": "NCT02502864", "Statement": "The primary test recorded 2 more adverse events than the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00003199", "Statement": "The group of patients with the highest percentage of event-free survival in the primary trial were Stage IIIB patients, and the worst was Stage IV patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "8c83330f-f2f3-48e1-9905-dc2ba1970c54": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03765996", "Statement": "The primary trial group 2 participants receive the same Dognestive complex physiotherapy as those in Group 1, with the addition of the registration application in the anastomosis regions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4613834d-c178-475c-b9fd-c9c66d5681eb": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04080297", "Secondary_id": "NCT02780713", "Statement": "The primary trial cohort 2 receives higher doses of Q-122 than any of the secondary trial cohorts receive AZD9496 variants.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b4555685-6e25-4797-8616-bcab5b06a135": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00259090", "Statement": "The primary studies focus on the impact of Fulvestrant, Docetaxel, on the H-score estrogen receptor.", "Label": "Contradiction", "Primary_evidence_index": [1]}, "c1b90c18-45f4-4e28-b50a-a00b0eadc523": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00290732", "Secondary_id": "NCT02748213", "Statement": "Patients with a breast tumour of 0.1 cm or less are eligible for the secondary trial, but not for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2, 8], "Secondary_evidence_index": [0, 1]}, "33ef3abf-97c0-4d15-909d-258fb47ac54a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00232479", "Statement": "Only patients with positive HER2 breast carcinoma are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "a381e340-18b1-4baa-91ce-0c420bcb411c": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01323530", "Secondary_id": "NCT01106040", "Statement": "The results of the secondary and primary trials indicate that the participants' PFS is partly related to age, degree of cancer, and ethnicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00383500", "Statement": "The primary trial is not to test a drug-based intervention, it is to test a medical device called Manual Lymphatic Drainage.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8e246d8f-e063-4f2e-a382-5d201a946b87": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00436566", "Statement": "No patients in the primary trial experienced congestive heart failure during active treatment with Trastuzumab and RAD001.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "8154bd8c-90a2-4b2f-8090-fcc89aeae30c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00097721", "Statement": "Patients of any ethnic origin may participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]}, "537781f9-3693-479e-af22-824cdd827b9c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02657889", "Statement": "The primary trial indicates that the change in the dose of Pembolizumab has no effect on the number of subjects with dose-limiting toxicity (DLT).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "5feefe8b-ddca-4eb8-af68-d1e211963d1f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02748213", "Statement": "In cohort 1 of the primary trial, 2 patients had a superactive pituitary gland.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "2a5d8ca7-1608-4607-b996-490fc447b593": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00956813", "Statement": "All subjects in the primary trial are required to take the PO intervention tablet per day.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "178c50cc-49ee-4083-bc8e-b5832037498a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00258960", "Statement": "Four patients in the primary trial experienced a Grade 3 or higher adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "92ace4fa-4426-4f34-af52-ee62913e60aa": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01026142", "Secondary_id": "NCT00846027", "Statement": "There were 10% more patients with left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 12, 19], "Secondary_evidence_index": [0, 4]}, "7dbde84d-f1c9-4197-9d44-500fd337bebd": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01823107", "Statement": "Not more than 12 patients implanted with a Meso BioMatrix Acellular peritoneal matrix had breast-related adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "824da29f-b2ff-440e-8b78-7a8291cbd6d2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02340221", "Statement": "A total of 89 patients in the primary trial had supraventricular tachycardia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02748213", "Statement": "One patient in cohort 1 of the primary trial was recorded as having a superactive thyroid gland.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "052ee533-7daa-4cbf-a64c-bc9a50444173": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00244933", "Statement": "The primary trial does not monitor the occurrence of hemoglobin C disease in its adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00444587", "Statement": "A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary Impairment or Diarrhoea.", "Label": "Entailment", "Primary_evidence_index": [3, 6, 8]}, "9b622b9b-3ad3-4cff-acb3-4127d0304de0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00571987", "Statement": "Occupational exposure to ionizing radiation will not disqualify a patient from entering the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "825ba6fd-8c08-49d2-941b-3338ef01e7fd": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02673918", "Secondary_id": "NCT01042938", "Statement": "African-American patients are eligible for the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 4]}, "0421750d-66c6-47be-bde7-0c41ee43a28b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01730729", "Statement": "Patients with severe malabsorption disorders are not eligible for the primary trial, even if they are able to receive intravenous (IV) nutrition.", "Label": "Entailment", "Primary_evidence_index": [24, 31, 30]}, "95345dbe-446f-4999-8f3e-a429b77ea554": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02872103", "Secondary_id": "NCT02995980", "Statement": "- Adequate renal, hepatic and blood work is required for entry into the primary test, which includes the following criteria: hemoglobin 11.5 g/dL, as well as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and serum creatinine should be less than 1.7 x ULN. These conditions are not explicitly required for the secondary test.", "Label": "Entailment", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "b05fde86-4004-427f-8baf-2ea4a0a535c7": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00376597", "Statement": "The primary test is performed twice, first at 2 weeks, then again a month later.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "21e24c6c-d282-48fb-8d68-3e723458794e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00825734", "Statement": "Patients with one of the following conditions will be excluded from the primary trial: Grade 3 infection, unstable angina, or Grade 4 hemorrhage in the last month.", "Label": "Entailment", "Primary_evidence_index": [87, 94, 95, 108, 117, 118, 119, 120]}, "d1e579e2-b057-43da-8a2f-64dad964b789": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00821964", "Statement": "The primary participants apply topical imiquimod to skin lesions once daily every other day for a total of 14 days every 28 days of the cycle.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093145", "Secondary_id": "NCT00703326", "Statement": "Some heart-related adverse events were recorded in the secondary trial, but not in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 7, 8, 9, 10]}, "d130c981-f602-4f17-b1cb-11a7ad632b92": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01234402", "Statement": "More than 6 different types of heart-related adverse reactions were studied in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5, 6, 7, 8, 9, 10, 13, 17, 18, 19, 20, 21, 22, 23]}, "c1f9982f-c4c9-48dc-887a-7ae05f508c21": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03329937", "Statement": "The primary trial Participants received 200 milligrams of niraparib (mg) PO once daily for a 28-day cycle, for 2 cycles", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "e966302f-9378-4681-b2c6-9d8b5b5f709f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00182793", "Statement": "The majority of patients in the primary trial experienced an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "75130da8-77be-45d1-bc32-dfc97c1a1dae": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02441946", "Secondary_id": "NCT00325598", "Statement": "The secondary test is much longer than the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 3]}, "c71cbcd6-3786-4b90-8991-b3c6e159ae77": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00975676", "Secondary_id": "NCT00632489", "Statement": "The primary trial uses the same dose of Triptoreline as the secondary trial for capecitabine and lapatinib.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ed48936e-4933-437b-a7ba-e65b4c1fd276": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03167359", "Secondary_id": "NCT01385137", "Statement": "Integrated simultaneous radiotherapy is used in the secondary trial, but not in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b01e966e-6624-4740-b477-a8bbbd8eec50": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02102490", "Secondary_id": "NCT00768222", "Statement": "In contrast to the secondary trial, no cases of skin lymphangitis, bone marrow suppression or allergic shock were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "92acd36d-ea44-4b98-acbc-e51382233089": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00820872", "Statement": "Diarrhoea was the most common adverse event in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "01280892-ca31-4e46-831b-a076426f65e5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01401062", "Statement": "A patient who has undergone T-cell transfer treatment in the past six months and has fully recovered from associated toxicity would be excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [4, 8]}, "959bd67a-1b2a-48da-ae44-211cbab4b665": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00393939", "Statement": "Median (95% confidence interval) Progression-free survival (PFS) was 1 month higher in patients in the Docetaxel + Sunitinib group in the primary trial than in the Docetaxel group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "92923765-76d4-4a27-a240-101690d9fea4": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01432145", "Statement": "cyclophosphamide is administered more frequently and at higher doses than methotrexate and 6-Mercaptopurine.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429507", "Secondary_id": "NCT00038467", "Statement": "Unlike the secondary trial, the primary trial does not administer any oral or intravenous drugs.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "5a5695e8-9b84-42ad-9f34-6dd043153943": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02872103", "Secondary_id": "NCT02995980", "Statement": "In addition to ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and serum creatinine should be less than 1.7 x ULN, adequate renal, hepatic and blood work is required for entry into the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "33634c51-0fb9-4de1-966d-14784bca93f8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01847001", "Statement": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "8e46dc77-fa36-4231-a124-0ff6392891a1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02297412", "Secondary_id": "NCT02667626", "Statement": "The secondary trial cohort 2 and the primary trial are control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "d11b0673-42a9-46c0-887f-d5a9b038264f": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00407888", "Statement": "The arm 1 of the primary trial receives high-dose chemotherapy over a one-week cycle up to 12 times in the absence of disease progression or unacceptable toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e08c196a-e3f0-420b-a252-7e2818949038": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03197389", "Statement": "All women (regardless of their reproductive status) must use adequate contraceptive methods to qualify for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 16, 17, 18]}, "83511f04-e07c-438d-bf1e-f680fa49b384": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01901146", "Secondary_id": "NCT00209092", "Statement": "In cohort 1 of the primary trial, more cases of neutropenic fever were recorded than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 4]}, "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00290758", "Statement": "A genitourinary adverse event was recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "72bb3c6e-66b0-4380-9da2-5a5867d715fd": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00475670", "Statement": "Compared to cohort 1 of the primary trial, there are more cases of each adverse event observed in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "1b433096-f36a-4205-b16e-f9a370be3d05": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01365845", "Statement": "More than 18 primary test participants had radioactive dermatitis.", "Label": "Contradiction", "Primary_evidence_index": [3]}, "076ead15-ce03-4c33-9050-1f6eb13764a1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01490892", "Secondary_id": "NCT02364388", "Statement": "The intervention in the primary trial requires one injection and two different imaging modalities, while the secondary trial does not provide much detail in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00323479", "Secondary_id": "NCT03078751", "Statement": "There have been more cases of pulmonary embolism in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "3e1037fd-cc1e-4229-892f-95d0987d9a68": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01042535", "Statement": "The maximum tolerated dose (LMD) of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "f25adbc7-c0a0-44ed-af93-02f4bced7208": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00343382", "Secondary_id": "NCT00798135", "Statement": "The primary trial cohort 2 receives the same dose of Pilocarpine as cohort 2 of the oral itraconazole secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "99951bae-37c8-4299-8ec1-4577a97d0b81": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00394082", "Secondary_id": "NCT01033032", "Statement": "In the primary trial, pleural effusion and spinal compression fractures were recorded, none of which were observed in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b66b62c4-902d-4e19-929e-2086b349bd93": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00149214", "Statement": "For patients in the primary trial, prior use of anthracycline anticancer medicinal products is proposed.", "Label": "Entailment", "Primary_evidence_index": [4, 5]}, "c789e79c-a254-4bb1-9d15-73d1726da8a6": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00334802", "Secondary_id": "NCT00167414", "Statement": "There is no age limit for the secondary or primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "2b182323-9357-486a-87aa-09ddc6230bf1": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02481050", "Statement": "Only one adverse event occurred in the primary trial more than once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "9681ec15-7545-455e-ac8c-1052fc199b11": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02162667", "Statement": "The Herceptin group in the primary trial had a higher number of patients with a complete pathological response than the CT-P6 group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "8ca512c3-72d8-4179-a63e-51d83d76445f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00256243", "Secondary_id": "NCT00721630", "Statement": "Both the secondary and primary trials take place at the Memorial Sloan Kettering Cancer Center.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "171d0a20-8943-4994-a48a-7dff124e62ee": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00046891", "Statement": "The primary trial cohort 1 receives 60 mg of Ginkgo Biloba twice daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "25cc9a6e-656d-44ee-a301-93f5879407a0": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01923168", "Statement": "Intervention 1 of the primary trial requires participants to take a total of 150 mg of alpelisib every other day.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "d9b4d4aa-0094-405e-83a3-cf2978cfda38": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00347919", "Statement": "56.9 % of the primary trial subjects treated with Lapatinib 1500 mg had no progressive disease at week 12.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "caa55802-329d-4a1f-a9a7-b99afc44fd67": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00038467", "Statement": "The groups of patients in the primary trial each receive the same doses of different oral medicines, either tamoxifen or exemestane.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02525718", "Secondary_id": "NCT02606708", "Statement": "Patients in group 1 of the secondary and primary trials receive the same dose of placebo orally.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00262834", "Secondary_id": "NCT01106898", "Statement": "In the secondary trial, patients with Her-2-positive neu breast cancer receive additional maintenance treatment compared to other patients, while all participants in the primary trial receive the same treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02780713", "Statement": "The two cohorts in the primary trial receive the same drugs at different doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "01f89936-1621-4dd5-93b7-8b0c64b397fd": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00054275", "Statement": "A patient with severe anginal syndrome but normal angiographic coronary arteries would not be able to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [33, 35]}, "ee7fe82e-de91-45c7-bd12-bff5d6c887a3": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00320411", "Statement": "The primary trial participants should take 6 tablets of Lapatinib monotherapy (250mg) PO once daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "888a8d39-3ad6-401e-acf2-cf5e01a73bf2": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00266110", "Secondary_id": "NCT00879086", "Statement": "The primary test had a much higher rate of adverse reactions than the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "13466cbb-9f78-46ff-a983-09e2e9ad5a2c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00679211", "Statement": "One primary trial patient experienced fever, in addition to coughing or sore throat.", "Label": "Entailment", "Primary_evidence_index": [0, 12]}, "0beaef44-a39a-462c-a084-d3f824857673": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00374322", "Statement": "The primary test results showed that participants receiving lapatinib at 1500 milligrams (mg) orally were more likely to reach DFS at 5 years of age than patients on placebo, but there was less than 30% difference in DFS levels between the two cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "8e45da73-f016-4ca0-b106-a3fabc960b36": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01432145", "Statement": "Patients in the primary trial receive 6-Mercaptopurine more frequently and at higher doses than methotrexate.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "37dc56a4-4756-4ab0-8055-7637bf579740": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01420146", "Secondary_id": "NCT00077376", "Statement": "Both primary and secondary trials are single arm clinical trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "65e370b7-7726-477e-8730-8cea734d1609": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02115607", "Secondary_id": "NCT01823107", "Statement": "In the primary trial, patients receive a 3 ml infusion of Perflutren lipid microspheres at a rate of approximately 3ml/min, while in the secondary trial, subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum matrix.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "affdd551-15e2-4a47-8c20-209cc01570ec": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03012477", "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhoea.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2152f503-4fa4-4f32-b766-a05a4c69742f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02176083", "Secondary_id": "NCT03061175", "Statement": "Neither the primary trial nor the NCT0306117 use chemotherapy, adverse event management or radiotherapy courses in their intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "a7903e59-9620-457a-8d83-eb6eb5dd8a2b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01300351", "Statement": "At least one participant from each cohort in the primary trial showed signs of poor liver function.", "Label": "Contradiction", "Primary_evidence_index": [0, 7]}, "dc7e7fbe-eed9-4307-b584-30ecaeb77c95": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00186121", "Statement": "Patients with E2 outside the premenopausal interval are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5]}, "a34c6194-b6d9-49c3-8ddb-72de10c8a18c": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02006979", "Statement": "No cohort in the primary trial requires a low intensity exercise before each cycle of anthracyclines.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "da00532d-57a8-4fe2-a2de-acc525161fd9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01120184", "Statement": "At least one patient in cohort 1 of the primary trial had a coagulation disorder.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "f90364e9-caee-4075-b444-2db1bf846d3a": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02511730", "Secondary_id": "NCT00193206", "Statement": "Patients with prior chemotherapy are excluded from the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 6]}, "deb78676-8f04-44c4-a5f6-389740d8a268": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01908101", "Statement": "Prior exposure to doxatel is mandatory for patients in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a06d1ca5-c890-4157-b1d2-0b70fd0092bd": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00591851", "Statement": "There were 4 different cardiac adverse events in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "5bc0d21d-a040-4d30-b0c7-8793cba6aba8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091168", "Statement": "Patients in the primary control group had median overall survival of less than one year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 11, 12, 13, 14, 15, 9, 17]}, "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00952731", "Secondary_id": "NCT00956813", "Statement": "The cohort 2 in the primary and secondary trials, but received daily doses of placebo.", "Label": "Entailment", "Primary_evidence_index": [5, 6, 7, 8, 9], "Secondary_evidence_index": [3, 4, 5]}, "5a1358af-f51b-49f8-b1c0-99a0b108b0a2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00091442", "Statement": "There have been more cases of febrile neutropenia than of leukopenia in the primary trial, but fewer cases of neutropenia than of leukopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 3, 4]}, "ed0e1b04-aea7-4da0-922f-2be69c768c09": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02635737", "Statement": "\u2022 Patients with implantable cardioverter defibrillator are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [6, 7]}, "73d323e7-1a38-49d4-97f4-a15f1664fb3e": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01439711", "Statement": "One primary trial patient showed an increase of 0.98 cm3 in the total volume of functional MRI tumours (FTV) over 3 months, almost 1 cm3 less than the average.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "02dea6a3-d94f-4650-bf4f-be8fdb0a382f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02010021", "Statement": "One patient has recently had an oophorectomy, they are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 11]}, "4c8a124b-f015-42e2-8ad3-6168f21fe705": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00943670", "Statement": "The change from baseline in mean QTcF interval duration for primary trial patients was greatest on day 1 of the third cycle prior to intravenous infusion of T-DM1 (IV).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "fb43432d-6c1b-4ff7-aea8-72bc2519a12d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00130533", "Statement": "No one in cohort 1 of the primary trial had hyperbilirrubinemia.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "d6df95f5-472f-4b14-9cd4-5d5ef238175a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00005879", "Statement": "There are criteria for CONCURENT PRIOR THERAPY, PATIENT CHARACTERISTICS, and DISEASE CHARACTERISTICS for entry into the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64]}, "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00553410", "Statement": "A 55-year-old postmenopausal sarcoidosis patient would be excluded from the primary trial because of her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]}, "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00982319", "Statement": "Only postmenopausal postmenopausal women may participate in the primary trial, provided they do not have prior hormone replacement therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01425268", "Secondary_id": "NCT01373671", "Statement": "The CO2 is used as part of the intervention in only one of the primary test study groups, and the saline solution is used in both study groups of the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f820384b-0bf5-4f2e-96fd-2c8b13a4646c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01289353", "Secondary_id": "NCT00429182", "Statement": "The primary and secondary trials share at least one drug in their chemotherapy regiment.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2, 3]}, "f7410166-82a7-4d15-8a04-47287ef6884c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448591", "Statement": "Only two types of adverse reactions occurred in more than 1% of patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "80726ab0-e8e4-4c42-860b-fdedad407517": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121836", "Statement": "Patients who are not willing to sign and give written informed consent to participate in the primary trial will always be included.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02725801", "Secondary_id": "NCT04030104", "Statement": "Neither the primary nor the secondary trial have a placebo group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "d42054cd-deb6-4436-941c-9e3a06c713cc": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00036270", "Statement": "In total, less than 10% of patients in the primary trial experienced a relapse or died.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0507fbf8-3557-4ace-b015-5e106b96f6a9": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02041429", "Secondary_id": "NCT00068588", "Statement": "The primary and secondary tests shall use the maximum tolerated dose determined by dose-limiting toxicity as a measure of the results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "49ecc5a6-89be-48b6-85c5-c809c83f5baf": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00825734", "Statement": "Patients with one of the following conditions will be excluded from the primary trial: Grade 1 infection, unstable angina, or Grade 4 hemorrhage in the last month.", "Label": "Contradiction", "Primary_evidence_index": [87, 94, 95, 108, 117, 118, 119, 120]}, "68792f63-d7b5-4570-bf8e-95e4cb8094e9": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00343382", "Secondary_id": "NCT00798135", "Statement": "The primary trial cohort 2 received a lower dose of Pilocarpine than the oral itraconazole secondary trial cohort 2.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00483223", "Secondary_id": "NCT00811135", "Statement": "There are more cases of intestinal perforation, chest pain, death, erysipelas and pneumonia in the secondary trial than in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 7, 8, 9, 10, 11]}, "a1a5767f-07e7-4a33-a26f-586cf71a208d": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01852032", "Secondary_id": "NCT01118624", "Statement": "We cannot compare the doses and frequencies provided in the intervention sections of the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "9c80fb61-66dc-4b3d-82b9-4fb62db89422": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01326481", "Statement": "Patients with myocardial infarction or deep venous thrombosis in the last 3 months are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 18]}, "6755a378-08bf-4e9b-a6de-166733d0307b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00181363", "Statement": "The only difference between the interventions used in the primary trial is the patient location.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b7f3e657-638b-4463-9639-4fb0da2be042": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00262834", "Secondary_id": "NCT01106898", "Statement": "In the secondary and primary trials, patients with Her-2-positive neu breast cancer receive additional maintenance treatment compared to other patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "5498a85b-a086-4d5d-b677-9ae44646a382": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00546156", "Secondary_id": "NCT00398567", "Statement": "There are no cases of Vertigo, abdominal distension or Neutropenia in the primary test or primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00418457", "Statement": "\u2022 Antibiotics within 10 days of starting are acceptable to patients entering the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "f25d63c8-9033-4db6-9c15-2151d82e2a6d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00068588", "Statement": "Between the two arms of the primary trial, cohort 1 far exceeded cohort 2 in terms of the number of patients with a complete tumour response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00209092", "Secondary_id": "NCT00631852", "Statement": "A patient with histologically confirmed breast cancer would be accepted for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "4fd10abc-81d1-44f4-825a-26e2eaeae979": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02308020", "Statement": "There were 23 participants in cohort 1 of the primary trial with one (CR) or one (PR) based on the response criteria of the Neuro-oncology Response Evaluation Brain Metastasis (RANO-BM).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "a12a46de-9d3e-4c6a-becb-d43653040bf0": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00089973", "Statement": "The primary trial uses a 3-week cycle for the administration of SB-715992, and the study lasts 21 cycles.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "66ee10ac-1bfe-44d6-9b91-8a2bb1983606": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01017549", "Secondary_id": "NCT01390064", "Statement": "The secondary trial has 5 cohorts more patients than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "714c540c-1fa1-47c7-ac13-1e8f056d1e31": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02115984", "Statement": "A total of 3 patients in cohort 1 of the primary trial experienced an adverse event related to Herpes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3948b30d-934d-485c-b324-b3571e2957a3": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688740", "Secondary_id": "NCT00191815", "Statement": "The most common adverse reactions in the primary and secondary trials are Neutropenia, which has a total of 3 cases in all cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "45cf29ce-25f5-4719-8468-69d94893c9e7": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01166763", "Statement": "The primary trial recorded 4 life-threatening adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "7502090d-1bcb-4be9-9358-81afb9440a17": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01823991", "Statement": "Patients with metal vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms are eligible for primary testing.", "Label": "Contradiction", "Primary_evidence_index": [9, 19]}, "89f84928-82a9-413e-ab25-400657002c55": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01840163", "Secondary_id": "NCT02005549", "Statement": "The primary and secondary trials do not exclude patients with concomitant systemic antitumour therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "79dbf7bf-e08d-4eae-a804-0daeb83d6f01": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00930930", "Statement": "The most common adverse event in cohort 1 of the primary trial was lymphopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01381874", "Statement": "The Exemestane group in the primary trial had better median progression-free survival than the Abiraterone Acetate + Prednisone group, but the patient with maximum SSP was in the Abiraterone Acetate + Prednisone group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "23040754-d1ad-4660-aacf-3298aefa5dae": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00777101", "Secondary_id": "NCT00559845", "Statement": "There were no depressed patients in the primary or secondary trial, but there was a suicide attempt in cohort 2 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "e3be834c-c311-4132-8529-d354b9e620b9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01033032", "Statement": "The only adverse event recorded in the primary trial was a single case of pleural effusion.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "8115b5e3-e178-433b-b114-09d97daaa8d7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01326481", "Statement": "Patients with myocardial infarction, percutaneous transluminal coronary angioplasty or deep venous thrombosis in the last 2 to 6 months are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 18]}, "bbcfc019-2d60-413f-88f9-04cacec55e30": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00333775", "Secondary_id": "NCT00201864", "Statement": "There are several cardiac adverse events recorded in the primary trial, but not one in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "e7899445-9b80-4429-b4c3-d47bd36a2347": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00232479", "Statement": "Patients with positive HER2 breast or colon cancer are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "2a50cc2a-281b-4bc6-9f18-6bd9686c682d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00754845", "Statement": "Patients who received more than 5 years of anastrozole therapy, completed two years earlier, are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2, 3]}, "26419cec-e256-46a7-9026-94dbe026c63d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01151046", "Statement": "In the primary trial, the placebo group had a significantly lower median PFS than the MM-121 cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "8ef93fe0-0a12-4a7e-93aa-c40af7154a57": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02336737", "Secondary_id": "NCT01432886", "Statement": "The secondary test consists of testing the DLT for its interventions, while the primary test evaluates the dose limit toxicity for SentiMag and SiennaXP.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "f5d50d87-b419-4537-87ec-7c9d23b765db": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171340", "Statement": "The primary test results imply that zoledronic acid 4 mg Upstream causes a +ve change in bone mineral density, while zoledronic acid 4 mg Late causes a less significant but always positive change in bone mineral density (within a certain patient population).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f52ab54b-7a78-4449-9dfe-5fc67323e5c2": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01797120", "Statement": "The primary trial cohort 2 receives only placebo tablets and no other drugs.", "Label": "Entailment", "Primary_evidence_index": [7, 8, 9, 3, 4, 12]}, "c0277198-6eef-4cf3-9527-dea5d01a4000": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00426556", "Statement": "There were more than 3 cases of febrile neutropenia, leukopenia and neutropenia in all cohorts in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 14, 15, 16, 17, 18]}, "fea87f74-c8ef-4efd-944a-053f5e5a752f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01582971", "Statement": "To participate in the primary trial, participants must have a 20/20 vision and a confirmed and measurable invasive breast carcinoma.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "43560d8e-0767-40ce-b2fb-1b8dda231bdf": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00394251", "Statement": "There have been more cases of heart failure than pericardial effusion in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "2417fea2-7c8e-4f03-a918-c3cfcbe97425": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01998906", "Statement": "The same number of cases of neutropenia, febrile neutropenia and pancytopenia is observed in patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 3, 4]}, "55391bc6-41a8-4686-82d6-6814166d32b8": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01904903", "Secondary_id": "NCT01663727", "Statement": "Patients must have a LVF < 50% to be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00091832", "Statement": "Cohort 1 of the primary trial showed a negative percentage change (median) from the urea-adjusted N-telopeptide reference base (uNTx/Ur).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "15553950-e26b-4fbb-a576-8455e6bb7b23": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02122796", "Secondary_id": "NCT01575522", "Statement": "The primary trial intervention section does not detail the type, dosage or duration of the procedure, as opposed to the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "58838d25-bf87-44e7-a604-23468d67a1e3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02606708", "Secondary_id": "NCT02504424", "Statement": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Moduled Radiation Therapy, patients in the secondary trial receive no radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "02426c34-ebf9-4bd4-9d55-86fad89baf20": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01959490", "Statement": "In total, only 20% of primary trial participants did not get the complete pathological response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9e28c807-8d88-4eea-87ee-48a42bd002ab": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00618826", "Secondary_id": "NCT02040857", "Statement": "Only 4 of the same adverse events were recorded in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 8, 10, 5], "Secondary_evidence_index": [0, 9, 3, 6, 11]}, "80ac126e-c756-4031-9541-e50d51c18b38": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02600923", "Statement": "Patients with leukaemia, hepatitis or polycystic kidney disease cannot be included in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8, 9]}, "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02953860", "Statement": "In the primary trial, patients receive fewer mg of Enzalutamide than Fulvestrant per week.", "Label": "Contradiction", "Primary_evidence_index": [3]}, "68a9f2f0-cf11-4cd4-847c-53b8befd6002": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00717886", "Statement": "A prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5, 6, 7]}, "9bcd40cf-8221-4383-8891-76a4bcc5c766": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00756717", "Statement": "Patients with early, non-metastatic, cytologically confirmed invasive breast cancer with an Allred score of 1 are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "341156fc-9cbd-492f-8e9e-8fbf98191625": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00291577", "Statement": "It is not possible for a primary trial participant to have time to reach a maximum plasma concentration of 6, 24 or 12 hours.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "44ae021e-241b-4dbf-b88f-0b9d41eab555": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201851", "Statement": "No cases of esophageal spasming were observed in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "523a44a3-6b90-4be7-ab46-6b6addd7b5b9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00080301", "Statement": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial than in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 13, 20]}, "258a51ca-e1f0-4d9a-88a6-8749f4822034": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03475992", "Secondary_id": "NCT03106077", "Statement": "The primary trial participants receive different interventions depending on their cancer hormone status, so Triple-Negative patients are separated from HER2+ patients, for example, while all patients in the secondary trial took the same procedure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "83bacd68-871a-4777-ba23-1f9a3df9227d": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00057941", "Secondary_id": "NCT01806259", "Statement": "Non-recurrence survival, used as a measure of results in the secondary trial and the rate of clinical benefit, used in the primary trial, are not synonymous and represent entirely different characteristics of the patient.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00369655", "Secondary_id": "NCT00091832", "Statement": "One patient in the primary trial had a confirmed partial tumour response, while 30 patients in the secondary trial had a partial tumour response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3]}, "1a451f2e-0818-4a86-8808-0e4cce700aef": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00391092", "Statement": "In total, there were 32 cases of febrile neutropenia in the primary trial, and only one case of anaemia.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 4, 12, 14, 16]}, "52333afb-0e7a-4823-ae9b-746e0ce57c8c": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01325207", "Secondary_id": "NCT02429427", "Statement": "Patients participating in the primary and secondary trials experienced a variety of heart problems.", "Label": "Entailment", "Primary_evidence_index": [2], "Secondary_evidence_index": [6, 7, 8, 9, 10, 11]}, "4216b27f-4d3e-4029-9637-2e6dade15b73": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00005908", "Statement": "There was only one cohort of patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "14a32a42-424b-4b97-bae9-05f4bb2b415b": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00246090", "Secondary_id": "NCT00266799", "Statement": "- Cohort 1 of the primary trial 0.0015% less total adverse reactions than cohort 2 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16]}, "4d83c630-d767-40cf-9aec-c871c6fc7f38": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00030823", "Statement": "Patients with Stage I, II, III or IV breast cancer may be elongated for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 2, 11]}, "4fd230f2-caf1-44d6-81f2-4f51dda6da3a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03371732", "Statement": "All patients with a Karnofsky index < 80 are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "7a3d1ca7-8776-4ace-bbc0-107635b93583": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00764322", "Statement": "The ultrafast Metabolizer group in the primary trial experienced an average increase in endoxifene concentration over 6 ng/mL over 4 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02040857", "Statement": "Only men and women who are menopausal are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2]}, "1196db61-0846-4185-afc9-dc4b2fccd059": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01966471", "Secondary_id": "NCT00981812", "Statement": "A patient who had undergone breast preservation surgery in the year prior to entry into the study would be excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [5, 12]}, "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02005887", "Secondary_id": "NCT00050011", "Statement": "All participants in the primary and secondary trials receive the same daily dose of oral Letrozole for the same duration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "7e629f62-2981-4462-a4c1-f0cc9c24777a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00490646", "Statement": "The primary trial cohort 1 had 25% more cholecystitis patients than cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "c660faec-58d8-4ba9-8e18-1775b1135819": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00600340", "Statement": "Cohorts 1 in the primary trial were more common in Bevacizumab than in cohorts 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03078751", "Statement": "One case of AML was reported in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [9, 10, 11, 12, 13, 14, 15, 16, 17]}, "3ee5742b-6bc3-400f-92eb-641384a75201": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01830933", "Secondary_id": "NCT01224678", "Statement": "Patients in the primary trial do not receive any additional drugs for the study, while in the secondary trial they receive an oral drug.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [5]}, "f6af788f-ee96-4308-8dec-12d0c46e957a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01823991", "Statement": "Patients with irrational fear of confined spaces are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 19]}, "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00118157", "Secondary_id": "NCT01401959", "Statement": "The primary trial participants were more likely to have a two-year disease-free survival than either of the secondary trial cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e0b7a120-8735-413d-9a47-8508b2feffb3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01231659", "Statement": "Less than 20 primary test participants received a partial response (PR).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "1393c5d9-d2be-433b-9abf-9449b46588c4": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981812", "Statement": "Women who have undergone breast enlargement surgery and have since had the implants removed are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "abfa5699-2863-4319-9386-4b359f2062f2": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00195013", "Secondary_id": "NCT00620373", "Statement": "The cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4038f7c3-87e2-47d6-811b-fd2b21679577": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01196052", "Statement": "Participants in the primary trial should be prepared to undergo chemotherapy based on anthracycline or have already received cyclophosphamide or epirubicin.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "5097f4cd-9118-473d-a2a0-72f0cd12c7a5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01031446", "Statement": "Sarah had epileptic seizures of a brain tumor, which precluded her from participating in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5]}, "68e6a088-ab80-4a89-90d4-39308bccb1c2": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00956813", "Statement": "All subjects in the primary trial are required to take the PO intervention every day.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00446030", "Secondary_id": "NCT00975676", "Statement": "The primary and secondary trials do not overlap in the drugs they use for their interventions, but both have placebo groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "08917306-11b0-44ad-8f45-9a67d7f6073e": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00971737", "Secondary_id": "NCT00392392", "Statement": "Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 3]}, "9702cb6a-bdb1-415f-bb99-3b740728a4ea": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00073073", "Secondary_id": "NCT00054028", "Statement": "There is no placebo or control group in the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "7afa2d1f-7922-4b09-b52a-43bd9a4788a9": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00706030", "Secondary_id": "NCT00171704", "Statement": "Participants in both cohorts of the primary trial had an objective CNS response rate significantly lower than those in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "dfd5acc2-6824-4b63-93ad-34e6a0a4c621": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01299038", "Statement": "Joe has had an alcohol addiction for 15 years, which results in cirrhosis, so he is likely to be excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "97e9967e-6525-4082-bd11-8c30e14d23fd": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03273426", "Secondary_id": "NCT01091168", "Statement": "Patients with a concomitantly uncontrolled serious medical condition may be eligible for the primary trial, but are still excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [4]}, "d11dd4ae-28be-4ad2-a452-4374c48f08d1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00082433", "Statement": "The primary test results suggest that 40 mg/m2 administered as an intravenous infusion (IV) of 3 hours at day 1 of each cycle + Capecitabine may increase SOS levels compared to Capecitabine alone.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3b6229a9-00a1-4d26-9285-6d9f6a25fd77": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02273973", "Statement": "Two times as many patients in cohort 1 of the primary trial suffered from erysipelas as from diarrhoea.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 11]}, "9eab20ad-ffc6-473f-8087-c6c3f06f356f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00322348", "Secondary_id": "NCT00429572", "Statement": "The primary and secondary trials use different measures to assess the performance status of potential candidates.", "Label": "Entailment", "Primary_evidence_index": [2], "Secondary_evidence_index": [2]}, "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00368875", "Statement": "The primary test results indicate that the recommended Phase II dose for vorinostat, assessed according to the common NCI terminology criteria for adverse events, is 300 mg.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "b3dd4e23-f78c-4bf9-9268-d1018c966980": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02550210", "Statement": "Patients must have cancer that can be felt by contact to be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "553d7721-289e-4ab1-a9b9-7b2c939f47c1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01997333", "Statement": "The maximum progression-free survival for patients in cohort 1 of the primary trial was one year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "01c6f82e-710d-4fa4-aa62-2d26e72f4533": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00894504", "Statement": "There were no adverse events in the primary trial that occurred more than 71 times.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02018458", "Secondary_id": "NCT00895414", "Statement": "Patients with unexplained fever above 39\u00b0C are excluded from the primary trial but may be included in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [25, 28], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "862c0bfe-10a6-453c-9ada-929dd00141a0": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00295620", "Secondary_id": "NCT03366428", "Statement": "The secondary test and the primary test use non-comparable performance measurements.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01094184", "Statement": "A patient who has had an oophorectomy in the last month would not be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 7]}, "5501dae3-0d3c-4812-96c2-35ca863e24a5": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00343863", "Statement": "On the first day of the primary trial, cohort 1 received doxorubicin IV hydrochloride, oral cyclophosphamide, dexamethasone IV or orally, and ondansetron IV.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "ece8e7df-790d-4e26-9c34-40cf66d2abf5": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02005887", "Secondary_id": "NCT00050011", "Statement": "All participants in the primary and secondary trials receive the same daily dose of Degarelix injected into the muscle for the same duration.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "550a36e2-43bb-40af-b0c8-49498fbe2c8c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00077376", "Secondary_id": "NCT01256008", "Statement": "The primary trial examines new radiation therapy, while the secondary trial tests a type of psychological therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "95869347-6c3d-4de8-a325-a9a652f11edf": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02102490", "Secondary_id": "NCT00768222", "Statement": "In contrast to the secondary trial, there were no cases of Sinus bradycardia, bone marrow suppression or Constipation in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00509769", "Statement": "3/112 patients (2.68%) in the primary trial had insipid diabetes", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "1d4a385f-1c72-4c61-8d49-9ada0e3b716a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02556632", "Statement": "Both cohorts in the primary trial use the same topical intervention for approximately every 4-6 hours per day during one week of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b15aa13a-fbd9-4b2e-9dd2-b16628084d07": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091428", "Statement": "The maximum tolerated dose (LDT) and the recommended Phase 2 dose (RP2D) for Alisertib in combination with Paclitaxel, supported by the results of cohort 2 of the primary trial, are 40 mg/m^2 orally, twice daily (BID) on days 1-3, 8-10 and 15-17.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c9214d06-2733-4c78-99e5-a42015908eae": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00246571", "Statement": "\u2022 Kidney cancer Patients in the primary trial receiving Standard of Care had a median PFS of 2.5 months per baseline radiology laboratory assessment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "a318fc31-4f28-4356-b09a-59741bb7c97a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02660788", "Secondary_id": "NCT01490892", "Statement": "The primary trial examines different ways of communicating with women aged 51 to 73, while the secondary trial is not.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3]}, "70ec4bc8-f8fa-4901-aa7a-2388b53960c6": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00206518", "Statement": "The most common Chevalier grades in primary trial patients treated with Taxotere/Docetaxel were 3A and 3C.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "00dc0e37-1d0b-4f53-a037-86bf9799dae6": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00570323", "Secondary_id": "NCT00193180", "Statement": "Women with a uterus may not participate in the secondary trial or in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "a1a421cc-01c9-4afb-8f09-6b10b0ff5094": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01663727", "Secondary_id": "NCT00072293", "Statement": "Patients must be between 13 and 76 years of age to participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [16, 17, 18]}, "9316ef0d-55b0-4547-88ae-887e0132a263": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00246571", "Statement": "The primary trial patients receiving Standard of Care had a median PFS of 2.7 months per baseline radiology laboratory assessment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "5d815fac-c66c-43fe-9ac8-a352b6e47a5b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01929395", "Secondary_id": "NCT01857882", "Statement": "The primary and secondary trials use both test groups and control groups in their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "7b9fdeaa-5cb7-4453-b174-07b44bb58234": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00127205", "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations.", "Label": "Entailment", "Primary_evidence_index": [10, 17, 18]}, "c330f152-c64e-47ab-8568-5129a1a2099e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00875979", "Statement": "None of the 60 patients in cohort 2 experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31]}, "e3b88c8c-241d-4ead-8573-534a46210707": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00811135", "Statement": "The majority of patients in the primary trial did not have left ventricular dysfunction.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "e621f354-dea0-4d0f-a252-5480028c1712": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00022516", "Statement": "At least one patient in the primary trial suffered from an adverse event induced by radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "ee209156-74dc-475e-87af-ae51160982ef": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00244881", "Statement": "30% of primary trial participants had increased CEC after 3 weeks of treatment with Cediranib Maleate.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "edf813c0-2271-49ca-a040-a355bf71d8b4": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01519700", "Statement": "There were slightly more than 36 hours of difference in the median duration of Grade 4 neutropenia during Cycle 1 chemotherapy for both arms of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "352475ea-1b17-4d1a-a5e3-71f1b87cffd8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01827163", "Statement": "All patients with HER2/neu immunohistochemistry 3+ adenocarcinoma, ECOG <2 performance and HCG negative pregnancy test are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [13, 14]}, "c7c745d6-03ee-4740-9ef4-641fb6546e46": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00544167", "Statement": "Each adverse event in the primary trial occurred more than 8 times.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00617942", "Secondary_id": "NCT00388726", "Statement": "The total percentage of patients with adverse reactions compared to the secondary trial was lower than that of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01827787", "Statement": "The Triple-Negative breast cancer cohort in the primary trial had a significantly lower ORR than the cohort receiving 1.4 mg/m2 of Eribilin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "8f1959e4-b93a-4112-9726-27a4034f0e07": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00191854", "Statement": "Patients should have a unique two-dimensional and measurable indicator lesion to be included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "e1782960-8d44-4acc-aaae-bfa4f8e38de0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00254592", "Statement": "Patients must have an ECOG score of less than 3 to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 9]}, "61bd93b2-b38f-496d-acd9-f8b188d28a39": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365599", "Secondary_id": "NCT01771666", "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubine > 2.0 mg/dl, PLT >100 x 10^9/L and no history of blood clots are eligible for the primary test but excluded from the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 10, 12, 15, 25], "Secondary_evidence_index": [0, 6]}, "741c95c7-825c-4321-8d12-9037bb701ab8": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02667626", "Statement": "The primary trial is a web-based educational tool and the secondary trial tests the effects of Adjuvant Letrozole on postmenopausal women.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "6ce047b6-c18f-4f63-90ec-8643f5145efe": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00305448", "Statement": "At least 11 patients in both cohorts of the primary trial received a complete (CR) or partial (PR) response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "d647aad0-47f7-4b77-a265-e77dcf5e0983": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02781051", "Secondary_id": "NCT01067976", "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing clothing, unlike a full year of daily physical exercise is explicitly required for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "74fed085-3389-49c6-bdd2-a95c97071f2d": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00841828", "Secondary_id": "NCT01959490", "Statement": "All cohorts in the primary trial had a percentage of participants with a lower SPC than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "986ffe33-8e8b-4cbf-8408-eb9489fb2314": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00450723", "Statement": "There are several types of surgical and therapeutic treatments, such as appendices and radiation therapy, which are prohibited for patients who want to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00483223", "Secondary_id": "NCT00811135", "Statement": "There are more cases of intestinal perforation, chest pain, death, hyperglycaemia and pneumonia in the secondary trial than in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 7, 8, 9, 10, 11]}, "3f98cd71-ec28-4fd1-9ca0-2184eef3390a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02455453", "Statement": "Patients with tumours that are HER2+, PR and ER - are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 10]}, "11138479-1666-4973-84c2-c6779b5444f5": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01912612", "Secondary_id": "NCT02392611", "Statement": "In the primary trial, only one cohort receives the intervention, while in the secondary trial, both cohorts receive the same intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "35c62055-2832-4119-9080-5603beea1934": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02402764", "Secondary_id": "NCT00490646", "Statement": "There were no cases of pneumonitis in either the primary or secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "59ff0501-f6af-4739-bd07-71e12e8cd8a7": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02244580", "Secondary_id": "NCT01901146", "Statement": "Patients whose expression of the human epidermal growth factor receptor 2 is not determined cannot be accepted either in the primary or secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5]}, "ab52c559-5712-44ff-becd-1c491e107472": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00605267", "Statement": "Men are not eligible for the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "4619b957-3368-47b9-b949-01ec91208f96": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01629615", "Secondary_id": "NCT00320541", "Statement": "The secondary trial recorded more cardiac adverse events than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5bb09d7b-622f-4bdd-8dfd-809ea014a278": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559754", "Secondary_id": "NCT02924883", "Statement": "A higher percentage of patients in cohort 1 of the secondary trial experienced adverse reactions than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "07327b61-973b-48bb-b42b-dfde1efcfb7d": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00435409", "Secondary_id": "NCT00319254", "Statement": "The patient with the shortest PFS was in the secondary trial and the longest PFS was in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3307a083-0c8a-47b8-94cb-0bf4095b9c3b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00633750", "Statement": "Patients with clinical stage II invasive breast carcinoma (T2 N2) are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 4, 10]}, "bda2752e-082e-4d06-926a-04ade3f61c26": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03165955", "Secondary_id": "NCT00912340", "Statement": "11 patients in the primary trial suffer from liver disease, 0 in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00118157", "Statement": "Only one primary trial patient treated with oral lapatinib and oral tamoxifen received a complete and partial tumour response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f418c027-439a-4b19-bfb0-e1c1241886d8": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01127763", "Statement": "There were 4 other cases of Dyspnea than Dehydration in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [3, 6]}, "4805e49a-b99e-46d8-b937-13ac2501c4a4": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00009945", "Statement": "Patients with positive sentinel lymph node biopsy should undergo surgery to remove lymph nodes from the groin or will not be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "9a3cb836-66a8-4c68-980c-97e5841f331f": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091428", "Statement": "The maximum tolerated dose (LDT) and the recommended Phase 2 dose (RP2D) for Alisertib in combination with paclitaxel, supported by the results of the primary trial, are 40 mg orally, twice daily (BID) on days 1-3, 8-10 and 15-17.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "45d4f78f-04d4-434c-9679-fd92291e97b6": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00553410", "Statement": "A 55-year-old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prolonged follow-up.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]}, "5338f894-aecb-4678-bb67-fe058653e12b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01365845", "Statement": "Less than a quarter of primary test participants had radioactive dermatitis.", "Label": "Entailment", "Primary_evidence_index": [3]}, "2cebae78-f4a3-4e09-ac54-cd2388670274": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01953003", "Statement": "Patients receiving intervention 1 of the primary trial should be administered topically and intravenously.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "d8a98ace-009c-47e4-a812-3bc0df91ed2b": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01516736", "Secondary_id": "NCT00733408", "Statement": "The results of the primary and secondary tests are not comparable, as the parameters they record are completely different.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c8cfd67e-5fac-4bff-9296-6e42dcb09f80": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00300781", "Statement": "The primary test participants are assigned an intervention based on their hormonal recpetor status.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "57cf3760-1692-439f-bbe2-82a6bc8862ce": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01376349", "Secondary_id": "NCT01912612", "Statement": "In the primary trial, cohort 2 received 3.25 mg of vaginal DHEA gel QD more than subjects in cohort 1, of the two cohorts in the secondary trial only patients in cohort 1 Duloxetine 30 mg per day.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "7db1447c-b4e8-49c6-a125-8161bcd98560": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00364611", "Statement": "Patients with injuries that have not recovered within five to eight weeks are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [18]}, "626a05e9-2caf-4e73-a132-5432a5b2c7d9": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00550771", "Secondary_id": "NCT00143390", "Statement": "More than 20% of patients in the primary and secondary trials experienced myocardial infarction or arrhythmia, the majority of patients from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00066573", "Secondary_id": "NCT01091454", "Statement": "There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "b1cd4818-9623-45e5-a2b3-4c80016e3c82": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00186121", "Statement": "Patients with E2 outside the premenopausal interval are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5]}, "3050bca2-a8bc-412e-b679-5be1055e3749": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03061175", "Secondary_id": "NCT03098550", "Statement": "The cohort 1 of the secondary trial did not receive the same doses of Daratumumab throughout the duration of the study, whereas cohort 1 of the primary trial received a constant dose of Daratumumab for the full study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "a49666fd-f278-4dcf-b6bf-287ace3969aa": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02001974", "Statement": "No cases of CNS metastases were recorded in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "f6c014af-63db-4578-9b2d-74ea95901842": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00445458", "Secondary_id": "NCT00950742", "Statement": "The primary and secondary tests measure the DLT of their respective interventions using the same time frame and unit of measurement.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c8ef1457-63a9-4eac-a98b-edb805afd35b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02660788", "Secondary_id": "NCT01490892", "Statement": "The primary trial examines ways to communicate with women aged 51 to 73, while the secondary trial evaluates the impact of regular exercise and diet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3]}, "515d0710-429b-4c28-b881-8a6531ee973e": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03097653", "Secondary_id": "NCT00662129", "Statement": "Women between the ages of 18 and 25 with bone injury or Leptomeninge disease cannot be included in the secondary trial or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [4, 5, 6]}, "b4d261a4-9b42-4158-9b21-159859b59e2a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02104895", "Statement": "None of the cohorts in the primary trial receive any medication orally or intravenously.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "1c043d17-15a9-496c-a69b-9ec95a7ab8df": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00293540", "Statement": "Males are not eligible for primary testing because they do not produce estrogen.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "79c69498-7dd5-41fa-8946-36d452a5b9ec": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00328783", "Statement": "Patients diagnosed with COPD by spirometry are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "93fc76a9-5f3d-490b-8802-21d0fa806728": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00633464", "Statement": "The primary trial cohort 2 reported worse results than the cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9f5e55af-8a94-4531-ab00-f16199795b64": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02104895", "Statement": "None of the primary trial cohorts receive oral, IV or radiation drugs.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "ee85e355-3d0a-4e40-8a8d-6a0b71c77148": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00945061", "Statement": "Patients with multicentre breast cancer may be accepted for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "c4a2ca0b-c4a7-4366-92c7-145dadd38af3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00629499", "Statement": "Patients with peripheral neuropathy leading to intolerable paresthesia are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 13]}, "c6ca8c6a-7eae-4671-9eff-c44a1222fadb": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00399529", "Statement": "Women with rheumatoid arthritis who do not need systemic corticosteroids for treatment are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [8]}, "e591b3bb-0628-46e7-9d60-28989fd6a3d0": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01674062", "Statement": "One patient in the primary trial was observed vomiting blood.", "Label": "Entailment", "Primary_evidence_index": [3]}, "75da6329-e8a1-4808-bb0f-78fd3a2dde9c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00463788", "Statement": "The best overall response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "dab9d582-eaf3-443f-bdb9-073aec304ee6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01629615", "Secondary_id": "NCT00320541", "Statement": "The secondary trial recorded more cardiac adverse events than the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "8b9bb672-1de3-4220-956c-9e86ed78063d": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00265759", "Secondary_id": "NCT00866905", "Statement": "One case of haematolysis was recorded in the primary trial, none in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "3194a043-d156-49d6-97bb-81867ed188f0": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00712985", "Secondary_id": "NCT02038010", "Statement": "Patients in the primary trial receive a lower dose of Zometa IV than patients in the secondary trial receive PI3K BYL719 IV inhibitor.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "8c3ab1eb-c473-4399-b18c-512ef16e4a47": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01027416", "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by a nucleus biopsy and a human chorionic gonadotropin urine test.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 8]}, "aeac1009-91c3-40ad-8583-5b548e1f4b3b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00902330", "Secondary_id": "NCT00952731", "Statement": "The primary and secondary trials include only cohorts of tests in their studies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3058d104-172e-41be-b641-9f0f9cb172be": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00240071", "Statement": "At least one primary trial participant survived for 200 days without documented disease progression.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "bc845a3d-1f69-41a3-bf84-36a62e8127a4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01439282", "Statement": "In cohort 1 of the primary trial, the number of adverse events in cohort 2 was more than 10 times.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 14, 15]}, "69ced998-f3c9-460a-a272-b2c95421b89d": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00570323", "Secondary_id": "NCT00193180", "Statement": "Pregnant women over 6 months of age may not participate in the secondary trial or the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [8, 18]}, "45fb84a3-674c-40f5-ac8c-26a3c7844e7b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00354640", "Statement": "Patients taking primary trial 1 receive 4 times more simvastatin than anastrozole.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00146172", "Statement": "The primary trial cohort 1 is less than 60% of the Neratinb dose in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00912340", "Statement": "More patients in cohort 2 of the primary trial had pleural effusions than in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8, 15]}, "b3effb24-6ec0-4fa3-9c91-74a45bcc4602": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01448447", "Secondary_id": "NCT03252145", "Statement": "The primary trial is to test an intervention in radiotherapy while the secondary trial is to test a new portable medical device, which patients must use themselves to drain their lymphatic vessels.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03106077", "Statement": "Patients in the primary trial receive at least 150 mg of IMGN853 intravenously every 3 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "341c0861-b9a3-491d-8d49-aa61a8501a4f": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00083174", "Secondary_id": "NCT00190671", "Statement": "The highest number of occurrences for any adverse event during the primary and secondary trials was 39.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "16d6e554-a1df-42f9-b051-947d70595cbb": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00915018", "Statement": "The only cases of Leukopenia in the primary trial occurred in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "8f0159ce-1044-4f31-94b7-e394cf91d4e1": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00316199", "Statement": "All women with Stage 4 breast cancer or non-resectable, locally recurrent cancer are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "ccc5e420-dda4-4fb9-8d68-82551d69017f": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688909", "Secondary_id": "NCT00129376", "Statement": "Patients in the primary and secondary trials suffered from pulmonary embolism.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "89f8ba8c-e626-4bd4-9994-3d0264018932": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00429104", "Statement": "Patients with terminal liver disease are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [7, 12]}, "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00375505", "Statement": "In primary trials, patients in the control group had better health outcomes than the control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "57e6f0e1-6157-43bc-8bdf-c3649ed49133": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01129336", "Secondary_id": "NCT01945775", "Statement": "More than half of the participants in the primary trial are considered censored. The secondary trial used the same measure of results, but did not have censored patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "300dbe96-0be8-4ca0-aa3b-41bc059bac7f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02725801", "Secondary_id": "NCT04030104", "Statement": "There are no control groups in either the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f40c8d92-2921-45fd-8389-15048b08e229": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00670982", "Statement": "Neutropenia was the most common adverse event in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "31387af4-aad1-4f3c-bd81-641340ad4096": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00256698", "Secondary_id": "NCT03573804", "Statement": "The primary and secondary trials use completely different drugs and techniques for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "eabe9a78-965e-4984-82c2-25598b6b35da": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00534417", "Statement": "The median TTP in cohort one of the primary trial is just under 27 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "006f6b4e-6245-4f09-9786-327bbed3d766": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01328249", "Statement": "The percentage of participants with feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "88b13330-b937-4bbc-80ea-4bf8ccc17bd1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00699491", "Statement": "The 3/4 participants in the primary trial had dose-limiting toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "e90e2368-808d-454d-8080-30427235b89d": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01009918", "Secondary_id": "NCT01688609", "Statement": "There are no racial criteria for entering the primary trial, but there are some for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], "Secondary_evidence_index": [17]}, "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00723398", "Statement": "Patients with Type 1 and Type 2 diabetes are not suitable for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 9]}, "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00245219", "Secondary_id": "NCT00038103", "Statement": "In both the primary and secondary trials there are only groups of tests, so all patients receive new interventions (approved by the FDA).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "eea73ae4-0985-4f74-957d-e2aad7ab453c": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00248170", "Secondary_id": "NCT01299038", "Statement": "Ae-Cha is a 32-year-old Korean woman with inoperative breast cancer, too old to participate in the secondary trial and primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6550c068-14e6-4e93-8f98-756338c91e35": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00313170", "Statement": "The primary trial patients treated with Fulvestant 250 mg had a higher objective response rate than those treated with Fulvestant 250 mg + loading dose.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0f5b81f0-b422-4000-8e0e-9f09c612ebc3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01293032", "Secondary_id": "NCT00849472", "Statement": "None of the patients in the primary or secondary trial are required to take a radiotherapy or support group course.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "f6bba549-3d18-4a53-8685-96b4e321b1a7": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00645333", "Secondary_id": "NCT00006110", "Statement": "The primary trial records several adverse events related to the immune system in its patients, while the secondary trial does not.", "Label": "Entailment", "Primary_evidence_index": [7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "1fe36432-40f8-4c53-ac2b-0f8e50e5743f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00602043", "Secondary_id": "NCT01720602", "Statement": "Several treatments in the secondary and primary trials are administered orally.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "3576f3e7-a1b9-4a75-934a-1ad2165b69dd": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01091454", "Secondary_id": "NCT00054275", "Statement": "There were more cases of anaemia and vomiting in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "de71f285-4382-465f-9e7e-d163662f6d9c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01446159", "Statement": "The primary trial included only 66 patients in both cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 13, 14]}, "406247fb-003a-47b7-8fe4-b6b963b98f08": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00281697", "Statement": "The primary test does not record any pain-related adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "47553222-0aff-4394-bcfc-9f19c0863835": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02441946", "Secondary_id": "NCT00325598", "Statement": "The secondary test does not have a defined end date, whereas the primary test lasted 2 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 3]}, "e4756896-55c2-46e1-be19-14697ad3b39f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201864", "Statement": "One primary trial patient had levels of calcium in the blood well above normal.", "Label": "Entailment", "Primary_evidence_index": [5]}, "594c9a79-d601-46b4-ae30-0b48a1117693": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02447003", "Secondary_id": "NCT00917735", "Statement": "The difference in cohort size between cohort 2 in the secondary trial and cohort 2 in the primary trial makes it impossible to make meaningful comparisons.", "Label": "Entailment", "Primary_evidence_index": [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26], "Secondary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "99e8ee0e-d72d-4e19-9424-20e5891bb2b6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02447003", "Secondary_id": "NCT00917735", "Statement": "Clinical conclusions should be made comparing cohort 2 of the secondary trial and cohort 2 of the primary trial, despite the difference in size of the cohort.", "Label": "Contradiction", "Primary_evidence_index": [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26], "Secondary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "f1b0653f-b5ce-4558-b325-56244940c0cd": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01273896", "Statement": "There were twice as many cases of Dyspnea as of cardiac adverse events in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 8]}, "24b24d36-2500-4841-99a3-13cba905d77d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01234402", "Statement": "At least 8 different types of heart-related adverse reactions were tested in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5, 6, 7, 8, 9, 10, 13, 17, 18, 19, 20, 21, 22, 23]}, "0797ff90-f847-4442-92fd-017c539bb38f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00546104", "Statement": "A patient in the primary trial suffered from a blood clot blocking his trachea.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "6b595151-7e51-4062-b587-3207ea251677": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00606931", "Statement": "The primary test tests positron emission tomography as a technique for guiding a medical procedure.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "e802b1f6-62fb-4759-b261-c69dbdc1d7ef": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04080297", "Secondary_id": "NCT02780713", "Statement": "The two cohorts in the primary trial receive higher doses of Q-122 than one of the cohorts in the secondary trial receive variants of AZD9496.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0a24a07e-2cb4-4591-aea4-a370f462cc49": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00593346", "Secondary_id": "NCT00902330", "Statement": "The duration of the primary test treatment is shorter than the duration of the secondary test treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "97d0bbf0-c2c5-409b-820b-6e14a6326b06": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02322814", "Secondary_id": "NCT00356148", "Statement": "A patient with positive breast cancer of epidermal growth factor 2, without known brain metastases and a history of histology-confirmed cardiac dysfunction, may be eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 22, 15, 33], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "bbb5ebc0-83c8-46cb-89b4-e1c67e042350": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00859651", "Statement": "Helen had stage III ovarian cancer 7 years ago, but has not been ill for 5 years., she is excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [13, 14]}, "620106e8-2a7f-4078-80b6-d5f1840c66e1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00699491", "Statement": "The primary test results show that the recommended dose for Phase II (Phase I) trials is 3 mg/k cixutumumab.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "94a7b007-0332-4d01-979e-9677e5da4316": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00513292", "Statement": "In the primary trial, the FEC-75 group then Paclitaxel/Trastuzumab had more invasive tumours in the breast than the Paclitaxel/Trastuzumab group then Trastuzumab/FEC-75 group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2849d0ce-fed2-4c49-bec1-777c440caaeb": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00127205", "Statement": "More patients in the primary trial suffer from dysfunction with ventricular contractions than the ventricular systole.", "Label": "Contradiction", "Primary_evidence_index": [10, 17, 18]}, "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00992225", "Statement": "Only 2 of the 12 types of adverse events recorded during the primary trial occurred more than once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "01a57096-0278-4c70-be43-acd57010cd6f": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01332630", "Secondary_id": "NCT00121134", "Statement": "There were more patients with significantly high blood pressure in cohort 1 of the primary trial than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "49213077-0a5b-4368-a48a-282d2ca9d77a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02953860", "Statement": "Patients in the primary study receive more mg of Enzalutamide than Fulvestrant during the study.", "Label": "Entailment", "Primary_evidence_index": [3]}, "426d3ecd-73e3-4226-83c6-cfcb9212ed62": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00263588", "Statement": "All subjects in the primary trial had a progressive disease, a complete objective CNS response rate, or a partial response rate.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "7c12676c-7973-4e9d-b1fc-3b14d241d0c8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00696072", "Statement": "Twenty patients treated with Dasatinib and Letrozole in the primary trial had a disease-free interval (DFI) of more than 2 years.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "3419e901-5880-488d-912c-023e8d1b51c7": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01466972", "Secondary_id": "NCT01446159", "Statement": "The primary trial had one patient with congestive heart failure, and the secondary trial had more.", "Label": "Contradiction", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 5, 13, 18]}, "cd645637-0a31-4f54-bc75-4a52349cf100": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00748553", "Statement": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 every 5 days for each 4-week cycle.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "adfc79ba-2996-47ce-9986-7d287931df89": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02115984", "Statement": "A total of 3 patients in the primary trial experienced an adverse event related to Herpes.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "414ae027-b420-4f01-afd5-164cd8146a30": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01129336", "Secondary_id": "NCT01945775", "Statement": "Sixteen primary trial participants are considered to be censored. The secondary trial used the same measure of results, but did not have censored patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "45b2b9ec-ba58-4323-810a-4baed9c84a0e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470847", "Statement": "The primary trial participants will not receive any post-WBRT Lapatinib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "72ffdfbf-aa72-4d44-814a-1d6ab8883898": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00971945", "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "db613a72-e300-41a7-987f-788c306d94a4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00403130", "Statement": "No cases of Leukopenia or Arrhythmia were observed in patients participating in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2667d301-2efb-4d92-bc12-ccfc869e4835": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02202252", "Statement": "The difference between cohorts 1 and 2 in the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "60bff573-0251-4f05-b2b7-dec74c7363cc": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00934856", "Statement": "In total, in both cohorts of the primary trial, there were at least 2 tired patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "f6f8a0d3-6288-44cf-9b34-27444110dd10": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01581619", "Secondary_id": "NCT01008150", "Statement": "A significant intraductal component of primary breast carcinoma, confirmed by histology, would result in the exclusion from the primary trial, but not from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43]}, "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00572728", "Secondary_id": "NCT02472964", "Statement": "Patients in the primary and secondary trials will take Herceptin?\u00a9 (trastuzumab) or paclitaxel intravenously.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "878dcfeb-c3db-4077-9a3e-8098efa80a99": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00836186", "Statement": "Patients cannot be excluded from the primary trial because of their race or ethnicity.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "fc5dbfec-ba79-4c5d-9e38-3c97d0397570": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT04396665", "Secondary_id": "NCT00493636", "Statement": "Any patient may enter the primary or secondary trial; as long as he or she is willing to give his or her informed consent and is able to use the Internet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38]}, "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01234337", "Secondary_id": "NCT00217672", "Statement": "No cases of anaphylaxis occurred in the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "64411610-090b-42d2-a176-d2b13ffef591": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03210220", "Secondary_id": "NCT00290745", "Statement": "Unlike the primary test, the secondary test does not have a control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "82bd50ac-9407-413b-9eb8-653cef49706c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02364388", "Secondary_id": "NCT01425268", "Statement": "The hot saline solution is used in the primary test and in the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "470611af-16b2-4094-ae2a-c9c6155e2672": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02122796", "Secondary_id": "NCT01575522", "Statement": "The primary test intervention section does not specify the type or duration of the procedure, as opposed to the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "f3a03aec-194d-4538-9be3-cea8281d995c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00693719", "Statement": "The primary test recorded less than 3 different adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "14a5e557-b223-4649-9867-0ff0e9001f5e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00911898", "Secondary_id": "NCT02352779", "Statement": "The primary and secondary trials do not explain their interventions in the intervention section.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "c8df3461-4063-4fb0-ae48-f57062eb0a68": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03329937", "Statement": "Participants received niraparib 200 milligrams (mg) PO once daily for a 28-day cycle, for 3 cycles, after which all participants underwent neoadjuvant chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "1cd7cf90-bf66-480b-9227-2f7d2eccd647": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01539317", "Secondary_id": "NCT01323530", "Statement": "The primary test uses topical intervention and the secondary test uses only intravenous treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "15f9d033-ebf7-44b3-94e2-3b8ee90b862b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00370552", "Statement": "There is more than 20% difference in the percentage of participants with the best tumour response of the partial response (PR) or complete response (CR) between the two cohorts in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00266799", "Statement": "None of the patients in cohort 1 of the primary trial experienced acute coronary syndrome.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "51cf1333-78b1-410a-82fe-aabfaa00a840": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02995980", "Statement": "A patient with a glomerular filtration rate of 63, a severe iodized contrast allergy and BI-RADS category c breast tissue would be eligilbic for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 4, 5, 6]}, "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00662025", "Statement": "At the time of evaluation 0, participants in the primary trial had a confirmed disappearance of all target and non-target lesions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "aef2367d-78a5-4dc7-a6f7-d96415082362": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00570921", "Secondary_id": "NCT00274456", "Statement": "There is one case of cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [13, 14, 15, 3, 4, 5, 19, 20, 21, 22, 10, 11, 25]}, "29ae75a2-d8d2-4427-bba3-ab2c411d5718": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201851", "Statement": "No cases of oesophageal spasming, diastolic dysfunction or thrombosis were observed in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "985c4cb3-2684-4a67-a479-998602044a0d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00475670", "Statement": "Compared to cohort 1 in the primary trial, with the exception of sudden death, there are more cases of each adverse event observed in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00107276", "Secondary_id": "NCT00232505", "Statement": "Less than 5% of patients treated in the primary trial experienced adverse reactions, compared to almost 10% of patients in cohort 1 of the secondary trial experienced adverse reactions, and less than a third of those in cohort 2 of the secondary trial experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 8, 9]}, "d695120e-db68-481d-9023-881e48654e29": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00617539", "Statement": "Patients with extracranial metastases are still allowed to enter the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "5319ac1a-07ae-4531-bf93-5fce83016c87": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00941330", "Statement": "Patients in cohort 1 of the primary trial receive Exemestane more often than patients in cohort 2 receive Cytoxan.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "087aba29-40c6-4453-a44b-e63c3867e5b4": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00388726", "Statement": "A 75-year-old patient with an ECOG of 3 years and an estimated life expectancy of more than one year would be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 11, 12, 13]}, "c66f3e9e-f232-4035-b705-2785946d1542": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03624972", "Secondary_id": "NCT01216176", "Statement": "A 72-year-old patient with dementia would be excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [4, 7], "Secondary_evidence_index": [56, 73]}, "c679f426-b235-4ae9-ad6c-4f1a46a494d2": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01390064", "Secondary_id": "NCT00485953", "Statement": "All primary and secondary trial cohorts are treated subcutaneously.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "122b1aef-4506-464d-9852-47caa508b047": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00879086", "Statement": "While cohorts 1 and 2 in the primary trial had the same number of patients with anaemia and Neutropenia, Cohort 1 had 8 more cases of Leukopenia than cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 4, 5, 14, 17, 18, 19]}, "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00841828", "Secondary_id": "NCT01959490", "Statement": "All cohorts in the primary trial had a lower number of participants than in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9f7dc38b-1945-4035-a0ff-e08ead55145b": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00297596", "Secondary_id": "NCT00580333", "Statement": "Patients who have completed a trastuzumab regiment to treat breast cancer > 2 weeks prior to entry into the study are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8, 10], "Secondary_evidence_index": [8, 9]}, "b259774e-410a-49aa-b5d4-31b8d9505fc3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01525589", "Statement": "People who inherit undamaged variants of the BREast Cancer 1 or 2 gene are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 13]}, "e09a11e4-afc8-4351-a5bc-d847424c79ce": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01565499", "Secondary_id": "NCT01234402", "Statement": "Some of the patients in the primary trial were reported to have heart-related adverse reactions, while many of the patients in the secondary trial had several breathing problems.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d22f01f0-b2be-45b9-8996-11727750b91e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01720602", "Secondary_id": "NCT00082810", "Statement": "The primary trial participants receive more anastrozole, Fulvestran and exemestane than the secondary trial patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2]}, "893d5684-03f8-4acd-86e4-6d38eea3ce16": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129935", "Statement": "There were 80% more cases of embolism in cohort 2 of the primary trial than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "4b46164d-a4c2-4738-be36-588ab231ceb1": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01596751", "Secondary_id": "NCT00193050", "Statement": "There were 0 patients with dysphagia or fever in the primary trial and in the secondary trial cohorts.", "Label": "Entailment", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "d9236874-7f3d-4402-9699-2889db9f5c61": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320541", "Statement": "The primary trial cohort 2 recorded 10% more cases of Leukopenia than cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 13, 17]}, "e33825f1-45df-41f5-ba07-e9059636a146": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00057941", "Secondary_id": "NCT01806259", "Statement": "The occurrence of DLT, used as a measure of results in the secondary trial and the rate of clinical benefit, used in the primary trial are not synonymous and represent entirely different characteristics of the patient.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "5b0295e1-a322-40af-9acf-9cc1d55d3e64": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00295620", "Secondary_id": "NCT03366428", "Statement": "The secondary and primary trials use similar outcome measures, assessing the duration of patient survival after treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "3658f2f7-a497-4abb-badb-c877036456f2": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00077857", "Statement": "Patients must be over 18 years of age, female, have three or more target lesions and more than one chemotherapy regiment to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 5]}, "37bc71d5-d9c0-4174-8da5-725d2d53a91b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00303108", "Statement": "The cohort of the primary trial that received D+C and Taxane Na\u201a\u00e0\u00f6\u00f6ve produced slightly better results than those of the other cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02781051", "Secondary_id": "NCT01067976", "Statement": "The primary trial procedure requires participants to exercise for 12 weeks while wearing clothing, and no physical activity is explicitly required for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "8bcc9fa3-0317-471a-a5b5-b115b5b72dea": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01302379", "Statement": "Both cohorts of patients in the primary trial showed a median change in insulin from baseline of less than -15%.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "52610141-321d-4e3d-8660-ebc14b9f1696": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00082433", "Statement": "The primary test results suggest that 40 mg/m2 administered as an intravenous infusion (IV) of 3 hours to day 1 of each cycle + Capecitabine triples the patient's SOS compared to Capecitabine alone.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "90203158-6477-4486-b8d9-09dcaca63617": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00570921", "Secondary_id": "NCT00274456", "Statement": "There is one case of cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "03334f23-49ab-47e5-b420-a6753ce6e832": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00574587", "Secondary_id": "NCT00777049", "Statement": "There were no cases of myocardial ischemia in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "a847cfc1-9556-4a55-9698-69c22696148f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02370238", "Statement": "There were 2 cases of Angina in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "fcbb7e0f-d106-44bd-a252-9b57adc6f071": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01075100", "Statement": "No mental health problems were observed in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "f82d94fe-c633-4bae-b28d-074196a08577": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03584009", "Statement": "Participants in the primary trial administered with Fulvestant 500mg intramuscular injection had a higher percentage of clinical benefits than participants who received 160 mg additional Neratinib.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e5379a89-f880-44c1-bee0-a0d8ad2abfce": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00659373", "Secondary_id": "NCT02202252", "Statement": "The primary trial has a duration of intervention of 5 years, the duration of the secondary trial is not specified in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "d811aaec-b3bd-4376-a9d6-d14eacae875a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00717886", "Statement": "\u2022 Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not allowed for entry into the primary trial, patients with high-dose chemotherapy may still enter if they meet all other inclusion criteria.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "99312d82-614c-4422-b6e6-104fe5a7fa54": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00050167", "Statement": "Only patients with metastases in less than 9 infraclavicular lymph nodes are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "b02c99f3-70bd-4404-8d80-c57c6dfef7b7": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02049957", "Secondary_id": "NCT01506609", "Statement": "There is the same total number of patients in the primary trial as in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "3cbf2726-ddb0-460c-9dd2-082b8dda495d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454532", "Statement": "Less than half of the patients in cohort 1 of the primary trial experienced adverse reactions, but more than 45% of patients in cohort 2 experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "e7741151-2b2c-4e78-a4df-fe998c580714": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01912612", "Secondary_id": "NCT02392611", "Statement": "In the primary trial, only one cohort receives the intervention, while in the secondary trial, both cohorts receive the intervention, but cohort 2 receives more than double the dose of cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8cff36b0-a022-4469-8d14-7120be891cb1": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00376688", "Statement": "Less than 1/10 of subjects in the primary trial had a complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "4ce24508-3d12-499f-ab7f-4b437ea51366": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00304096", "Secondary_id": "NCT00876395", "Statement": "A minimum body weight of 50 kg is required to participate in the primary or secondary test.", "Label": "Contradiction", "Primary_evidence_index": [14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "2514da19-b30a-44bb-8853-4545e97295da": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00633464", "Statement": "The Ixabepilone 40 mg/m^2 group in the primary trial had worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "cb9f8a52-b88e-4b04-bb28-a0eabead1439": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00728949", "Statement": "There were 6 categories of adverse reactions for cohort 1 of the primary trial that recorded at least one case.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02806544", "Secondary_id": "NCT00605267", "Statement": "A patient with positive breast cancer at stage 2B estrogen receptors, confirmed pathologically, is preventable for both the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3]}, "358a1d3c-9ccc-48fc-badc-1644e326c8cb": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02301988", "Secondary_id": "NCT00728949", "Statement": "The only type of adverse event recorded in the secondary and primary trials is diarrhoea and abdominal pain.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "60a86c87-7387-4eae-b5dd-6245f8bf541e": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00045032", "Secondary_id": "NCT00416572", "Statement": "WHOCBP which refuses to use contraception is excluded from the primary test, but may be eligible for the secondary test if it is a resident of the United Kingdom.", "Label": "Contradiction", "Primary_evidence_index": [18], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "bd3055c6-09aa-47f0-89ed-67ad3798a580": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00090857", "Statement": "If the results of this study are greater than 2 standard deviations below normal, they should be excluded.", "Label": "Contradiction", "Primary_evidence_index": [7, 8]}, "21d7d726-8557-459f-a307-fae3e08f45d8": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00656019", "Secondary_id": "NCT00328783", "Statement": "Hyperparathyroid candidates are automatically excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9a8157a9-82fc-4d7e-9254-295123459430": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00054132", "Statement": "The majority of patients in the primary trial had an EGFR expression rate of 0, and 0 patients had an EGFR of 3 or more.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "ff37494d-2c61-4c06-86c1-d6bcfbe9e360": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01856543", "Secondary_id": "NCT00365599", "Statement": "In all secondary and primary trial cohorts, there was only one recorded case of myocarditis and pericarditis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "eb00b609-f17b-4595-87bd-d0843ec9e39a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01857882", "Secondary_id": "NCT01439945", "Statement": "The secondary trial gives 150 mg of magnesium oxide per day more to its patients than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "8bc9ea31-b731-4799-a1cc-a5ba63da00c1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00904033", "Secondary_id": "NCT03592121", "Statement": "While patients are not required to be sexually active to receive the primary trial intervention, this is a requirement for the secondary trial where the intervention should be applied during sexual activity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "0864493d-9f64-49d1-a585-21be71704c59": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01684215", "Statement": "In the primary trial, there was no difference in the number/percentage of participants with dose-limiting toxicity taking 100 mg vs 125 mg PD-0332991 orally, meaning that 0% of patients in the primary trial had Grade 4 or higher thrombocytopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c49428a7-cc55-474e-a773-88ff2019de1b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02780713", "Statement": "The two cohorts in the primary trial receive the same doses of their respective drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "78136809-c8de-4c40-9a7e-1d61d879ba27": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00611624", "Secondary_id": "NCT00600340", "Statement": "The primary and secondary trials administer their interventions at different frequencies.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b430ea52-fa55-4280-9e23-8a7392afca58": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00009945", "Statement": "Patients with positive sentinel ganglia biopsy should undergo surgery to remove lymph nodes from the armpit (subarm or axilla) or will not be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "adfeff22-7bdd-4868-ab6e-90dd43d9621d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00038103", "Statement": "There is no difference in the proportions of subjects with clinical benefit in the Exemestane + Celecoxib cohort and in the Exemestane only cohort of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00371345", "Secondary_id": "NCT00475670", "Statement": "There is only overlap between the adverse events observed in the primary and secondary trials, and Sepsis occurred in both trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "276f5523-f45b-45b0-ad30-b737f2c1b1d0": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00468585", "Statement": "The primary trial recorded several skin infections in their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "884ba067-d3fe-4837-ad2a-a802b671b53c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00295867", "Statement": "Patients with an ECOG score between 3 and 5 are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "6619c75a-4073-47e9-8586-5070be1b3d39": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02222337", "Statement": "The primary test participants must be in a couple, a breast cancer survivor and a caregiver, both must be fluent in English or Spanish.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "d81fafa4-1196-407b-a8c2-27d7b5da2f4f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01816594", "Secondary_id": "NCT02222337", "Statement": "Patients with newly diagnosed stage 0 breast cancer may not participate in the primary or secondary trial unless they have a LVIF of less than 50%.", "Label": "Contradiction", "Primary_evidence_index": [11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6d8b4720-e600-47d7-b6c5-3b8627f2358f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320710", "Statement": "There were no adverse events in cohort 2 of the primary trial in more than 0.5% of patients.", "Label": "Contradiction", "Primary_evidence_index": [13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "1b84007d-0002-4ab6-8e05-609e7de58684": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01646346", "Secondary_id": "NCT03283553", "Statement": "The secondary and primary trials do not use topical drugs in their studies.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00213980", "Secondary_id": "NCT02536339", "Statement": "While adequate haematological, renal and hepatic function is required to participate in the secondary and primary trials, patients with severe loss of cognitive function are still eligible.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "dc7c4409-32e5-4211-83fe-0a97b6176ca0": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01007942", "Statement": "In cohort 1 of the primary trial, febrile neutropenia was more than 5 times more common than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 12, 16]}, "73e7447b-a940-4126-a1d9-fffd7c56c900": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00337103", "Statement": "Several patients in the Eribilin Mesylate group in the primary trial survived less than a year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00629499", "Statement": "Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 13]}, "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00129389", "Secondary_id": "NCT00304096", "Statement": "Patients with permanent sensory loss who interfere with daily activities are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [22, 30], "Secondary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]}, "a7106a35-36da-423a-a6b3-3da62fc0eea8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01908101", "Statement": "A prior exposure to taxane is mandatory for patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "f4f50a05-9d63-4006-9680-b7ef68dbb5fe": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00952731", "Secondary_id": "NCT00956813", "Statement": "Cohort 2 in primary and secondary trials, but receive daily doses of placebo PO.", "Label": "Contradiction", "Primary_evidence_index": [5, 6, 7, 8, 9], "Secondary_evidence_index": [3, 4, 5]}, "f34760f4-965e-4bbb-b88f-8b63a7045808": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00741260", "Statement": "Patients with HER2 positive tumours are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "f4a33395-7e6b-46b9-b222-af3bbfff1591": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00866905", "Statement": "Less than 2% of patients in the primary trial experienced an adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "e7d00591-381f-45e2-abdb-2ae1e568b193": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01421472", "Statement": "More than 3 patients in the primary trial had side effects associated with a small number of white blood cells.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "59da1fb5-2636-4ca8-8970-6cb45dedbed3": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00885755", "Secondary_id": "NCT01075100", "Statement": "Patients' appetites were not affected during the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "f144c34b-9428-4836-bf01-5f7030eb579c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04030104", "Secondary_id": "NCT02525718", "Statement": "Intervention 1 for the secondary and primary trials is for control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e7e87023-2227-4594-931a-0a3d89ec686e": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02073487", "Secondary_id": "NCT03371732", "Statement": "\u2022 Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opioid dependence are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36], "Secondary_evidence_index": [0, 1, 2]}, "ca4a190a-9007-4f8f-a199-b8fe4064e55b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02149524", "Statement": "Several adverse events in the primary trial were not heart-related.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00711529", "Secondary_id": "NCT02835625", "Statement": "The primary trial participants are treated with cognitive behavioural therapy, which is not used at all in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "cb133915-dc40-4f93-a6a7-076e4d7f07a1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02685566", "Secondary_id": "NCT03076190", "Statement": "The primary and secondary trials have the same number of study groups but test different interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1f0825b6-8e32-44ff-96b7-ab082e24b493": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00045032", "Secondary_id": "NCT00416572", "Statement": "WHOCBP, which refuses to use contraception, is excluded from the primary test, but may be eligible for the secondary test.", "Label": "Entailment", "Primary_evidence_index": [18], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "db96c4d6-ffcd-401a-8af3-807f665f16f7": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00375427", "Secondary_id": "NCT00579826", "Statement": "Patients with osteonecrosis are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [6, 7]}, "b74dc1bc-76c3-4ce6-9735-634e7a507ff5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00976989", "Statement": "Patients with a LEVF of 53.5% are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "f078c722-b879-40f2-ac72-c733001b93dd": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01740323", "Secondary_id": "NCT00127205", "Statement": "The secondary trial and the primary trial only accept 18-year-olds.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16, 17]}, "c33d78e5-13be-4cde-b36e-7cc097f180a2": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02041429", "Secondary_id": "NCT00068588", "Statement": "The primary and secondary trials use the same outcome measures, the same drugs, and the same cohort size.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "58dbc33b-d32c-4e91-a940-ca1148bbdae4": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00075270", "Secondary_id": "NCT01781299", "Statement": "The primary trial is to test a chemotherapy treatment while the secondary trial is to test an implant.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00602043", "Secondary_id": "NCT01720602", "Statement": "Several treatments in the secondary trial are administered orally, none of the treatments in the primary trial are administered orally.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "2c462296-35f5-482a-9ece-3b4ed4c2f53a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01216176", "Statement": "Urosepsis was the only adverse event recorded in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "16358be6-3895-48f7-8006-4effeb3f74b3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01196052", "Statement": "The primary trial participants must be prepared to undergo cyclophosphamide-based chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "6d4ecb16-6586-4ea8-a1dc-f825e951e060": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00703326", "Secondary_id": "NCT00274768", "Statement": "Participants with HER2- primary liver tumours, confirmed by in situ fluorescence hybridization, are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 5], "Secondary_evidence_index": [0, 1, 7, 8]}, "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01252290", "Secondary_id": "NCT00479674", "Statement": "Unlike the secondary trial, the primary trial does not record any cases of anaemia, dyspepsia, nausea or vomiting.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2731552d-195a-4f43-b6b5-02a3fbda81d9": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01323530", "Secondary_id": "NCT01106040", "Statement": "The results of the secondary and primary tests are not comparable.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "8fee5ce4-3e46-4731-842e-a5b1df451c7d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01231659", "Statement": "Less than 40% of primary test participants received a complete (RC) or partial (PR) response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "def4199f-a22d-4939-b15d-66fd073fb280": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02518191", "Statement": "The primary trial cohort 2 is the control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00871858", "Statement": "One primary trial patient was diagnosed with clear cell renal carcinoma.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "d97c3981-50f9-4221-aec6-60661b831c8e": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03624972", "Secondary_id": "NCT01216176", "Statement": "A 56-year-old patient with occasional memory loss would be excluded from both the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [4, 7], "Secondary_evidence_index": [56, 73]}, "86c1430c-553b-4388-a034-b82f78afdc0d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01028352", "Statement": "Patients with musculoskeletal symptoms associated with an aromatase inhibitor, such as grade 1 or higher musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5, 6]}, "b7cef0e1-7bd8-4c0e-a044-b11708cf927c": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01905592", "Statement": "The two primary trial cohorts receive a selection of physicians from among 4 metastatic breast cancer chemotherapy standards.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00444587", "Statement": "A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary Impairment or Diarrhoea.", "Label": "Contradiction", "Primary_evidence_index": [3, 6, 8]}, "225f95a5-7c22-4cb7-a463-1c57d5b69d7a": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01217385", "Secondary_id": "NCT01202591", "Statement": "Prior exposure to exemestane is not explicitly prohibited for patients in the secondary or primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [6, 7]}, "5464e8a7-159c-4e00-8710-45a44ceaeda3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03061175", "Secondary_id": "NCT03098550", "Statement": "The cohort 1 of the secondary trial did not receive the same doses of Daratumumab throughout the entire study, whereas cohort 1 of the primary trial had the same intervention for the full study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "98965d07-e2db-41bf-ac3e-a5c130513275": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00382018", "Secondary_id": "NCT03012477", "Statement": "Between primary and secondary trial patients, only 1.56% had sepsis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [5]}, "784cc905-937f-43fd-96a6-34ea8dce9e8d": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00429104", "Secondary_id": "NCT00878709", "Statement": "Patients with terminal liver disease are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [7, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "2e3f2fde-569e-46ef-958d-710599fec9a1": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00706030", "Secondary_id": "NCT00171704", "Statement": "Thus, the results of these two studies are not directly comparable.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "d1080199-2591-44bd-bdad-0dea3830e657": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00106002", "Statement": "The primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until a complete response or progression of the disease.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "c37c21f5-19a0-4fcc-af92-89690fb64091": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02352779", "Secondary_id": "NCT00263588", "Statement": "The differences between the cohorts in the primary trial are once the cohort receives an omega-3 fatty acid at a low dose of 750 mg and the remaining 500 mg, while the difference in the secondary trial is the patient's characteristics.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bea7f10e-09d6-42c3-9e89-dfd1112a33d5": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01276041", "Secondary_id": "NCT00688909", "Statement": "0 patient in the primary trial or secondary trial died.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "3d41d86b-f53f-4bf9-a4dd-eae2412c485e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00545077", "Statement": "Only cohort 2 of the primary trial receives letrozole, but both cohorts undergo endocrine therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "0159bfb3-231e-4711-b3ee-2798c66f5f6a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01015131", "Secondary_id": "NCT00312208", "Statement": "Both the primary and secondary trials recorded cases of rectal haemorrhage in their patient cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "9e7628cd-931e-4b1f-b4c1-f03f0449ac27": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00392392", "Secondary_id": "NCT00503906", "Statement": "The primary trial records two different types of pain in its adverse events, in the cranial zone and in the foot, the secondary trial does not record any type of pain in its participants.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "f1108cbc-db27-431d-9154-1a267278bda4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00312208", "Statement": "There were only cases of cardiomyopathy and leukopenia in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "8eb69e3e-ac08-4e85-98be-211aecd4525d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT04396665", "Statement": "Any patient may enter the primary trial as long as he or she is willing to give his or her informed consent and is able to use the Internet.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "baf7e338-91fd-47d0-b766-a4e039efc5d7": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01432886", "Statement": "None of the patients in either cohort of the primary trial had DLT.", "Label": "Entailment", "Primary_evidence_index": [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9401b12d-3888-4a41-93a1-b2075930098b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00458237", "Statement": "The patient who has undergone external radiation therapy and major surgery in the last two weeks is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 12, 21]}, "c7aa030a-6b76-4bd7-a934-f02a4638a1ac": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00908791", "Secondary_id": "NCT00297596", "Statement": "Patients over 60 years of age with histology-confirmed breast cancer and advanced Alzheimer's disease are not eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 21]}, "94f9a957-33bb-4409-8878-ba734d6b0d5c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01823107", "Statement": "Several Patients implanted with a BioMatrix Acellular Meso Peritoneum Matrix suffered breast-related adverse reactions in both reconstructed breasts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "04fd88c2-cf92-468d-bbc4-567cae19948d": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00087152", "Secondary_id": "NCT00203502", "Statement": "The primary test recorded fewer nausea than the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5]}, "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00499122", "Secondary_id": "NCT00454805", "Statement": "There were no cases of multi-organism failure in cohort 1 of the secondary trial and cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "8074c35f-b74c-4250-94f1-9ad22fa315d7": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00375427", "Secondary_id": "NCT00579826", "Statement": "Patients with osteoporosis are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [6, 7]}, "afc4a45b-6592-4ca8-b174-033fb6a0624a": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00580333", "Secondary_id": "NCT00934856", "Statement": "In order to participate in the primary and secondary trials, applicants must have a life expectancy of less than 12 weeks.", "Label": "Contradiction", "Primary_evidence_index": [8, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "2e1d4811-ae58-4b81-b53a-dbcb8c980a08": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00033514", "Statement": "Elizabeth has positive HER2 breast cancer, she is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "d4f738c5-c99a-4d8d-b335-5821ce97fbd5": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00568022", "Secondary_id": "NCT01120184", "Statement": "Patients who are completely disabled, completely confined to bed or chair and unable to take care of themselves are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 5]}, "f27b25bd-c28e-4aac-8ad6-951fd7381ce4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01262027", "Statement": "More than one patient in the primary trial suffered from an adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "5311216c-94e0-4d04-acd2-b95b932ddc02": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00127933", "Secondary_id": "NCT00191789", "Statement": "In the primary trial, at least one patient was infected, while in the secondary trial, no patients were observed.", "Label": "Contradiction", "Primary_evidence_index": [12, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "01dfa37b-ce65-4e90-addc-395241c92f5f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191451", "Statement": "Patients in the primary trial experienced a variety of oesophageal and cardiac side effects.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "43588c50-7dc4-4d46-a53d-e94576e8ab55": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03197389", "Statement": "Men and women of childbearing potential must use adequate contraceptive methods to qualify for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 16, 17, 18]}, "f419f810-ca53-4168-86fd-d1d9a9154d3a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02683083", "Statement": "People with hyperthyroidism are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [11, 12, 13, 14, 15, 16]}, "630a8241-b776-4799-a7ca-b1fddf17686c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00206518", "Statement": "The least common Chevalier grades in primary trial patients treated with Taxotere/Docetaxel were 1, 3D and 3C.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "8f3fddf2-97ab-4456-bff7-8f83b27e3849": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00675259", "Secondary_id": "NCT01875367", "Statement": "Patients with an immuno-Historical test of 3+ are excluded from the primary trial but included in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [15, 18], "Secondary_evidence_index": [0, 3]}, "11617367-193f-4f6b-bc3e-e58ea76d1052": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00485953", "Secondary_id": "NCT00068601", "Statement": "The dose of cyclophosphamide in the secondary trial is 150 mg once every 4 weeks and the dose of Placebo in the primary trial is 12 mg QD.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "882f22f6-36d9-4c2f-8f49-52469d570977": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01840163", "Secondary_id": "NCT02005549", "Statement": "The primary and secondary trials do not exclude patients with non-melanoma skin cancer.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "8f5423c9-17b5-4f66-aa9f-1fc9763958b2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01250379", "Statement": "None of the patients in the primary trial had thrombocytopenia, heart failure, pancytopenia, acute coronary syndrome or atrial fibrillation.", "Label": "Contradiction", "Primary_evidence_index": [0, 8, 5, 7, 9, 10, 11]}, "0c45a782-1a3d-4e9b-a258-136ab080dbb6": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00846027", "Statement": "None of the adverse events recorded for the primary test occurred less than twice.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "4e42302d-2cd9-4a91-9338-8e3b0ffb9292": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00654836", "Statement": "Patients with metastatic positive HER-2 adenocarcinoma in the breast may never be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 5]}, "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00270894", "Statement": "60% of subjects in the primary trial were able to complete at least 85% of the dose set out in the schedule.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "da2ea2e9-3109-433e-9033-9ae322c30c4b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981812", "Statement": "Women who have undergone breast enlargement in the last two years are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 8]}, "c77c8e02-7abb-4b63-8917-01babe5cd372": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00863655", "Statement": "There were 5 other cases of anaemia and 1 other cases of intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 12, 13, 14, 15]}, "f2b14720-6ff2-4ff7-a5bc-3841b93f647e": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00911898", "Statement": "The primary test does not explain its intervention in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "03e9368b-18a7-4643-a38b-a7b002403bf1": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00568022", "Secondary_id": "NCT01120184", "Statement": "\u2022 Patients who are completely disabled under the age of 20, who are completely confined to bed or chair and unable to take care of themselves, are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 5]}, "c5dbd52d-01d4-4919-bfe9-2b7885490d6a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00422903", "Statement": "The percentage of participants who received an objective clinical response (ORC) in the breast, assessed by an independent radiological assessment monitoring committee, was highest in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "83115abd-1c07-4ee7-8ba5-b4575be2d50f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00630032", "Secondary_id": "NCT00428922", "Statement": "Patients with radiologically confirmed bone metatases are excluded from both the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [13, 14], "Secondary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "784872db-8ccf-4ddc-a432-6ee00fd0b0cc": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01857882", "Secondary_id": "NCT01439945", "Statement": "The secondary trial administers magnesium oxide to its patients while the primary trial tests an educational intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "adae7d81-bc8e-48e4-b966-27c2633eb72d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02131064", "Statement": "More than 100 participants in the primary trial TCH + P group obtained the total pathological response (tpCR) from tumour samples.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "4ee4061e-a532-459e-8d03-3055bd92419c": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00082810", "Statement": "During the entire duration of the primary test, paritiquants receive tipifarnib more often than Fulvestrant.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "4cbb7f8f-ea60-453d-b4ab-e967944426d3": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00992225", "Statement": "Only 2 of the 16 types of adverse events recorded during the primary trial occurred more than once.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "47f11df7-6c82-4c50-9249-5085313a5064": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00209092", "Secondary_id": "NCT00631852", "Statement": "A patient with cytologically confirmed breast cancer with a diameter of 5 mm larger on imaging would be accepted for the primary trial, but not for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "3114ff0f-184c-48ba-b33d-631505cffeef": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01961544", "Statement": "The primary trial revealed a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8, 9]}, "edf31a43-a774-4f2a-8a02-89b84de941bb": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02595372", "Statement": "27.6% of patients with fatty acid synthase (FSFA) expression in the primary high-dose omeprazole trial did not receive a complete pathological response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01596751", "Secondary_id": "NCT00193050", "Statement": "There were at least 15 patients with dysphagia or fever between the primary trial and the secondary trial cohorts.", "Label": "Contradiction", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00632489", "Statement": "The primary trial uses a determined dose of 1000 mg PO per day of Lapatinib, while the dose of Capecitabine changes with patient body weight.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5a076708-c8d4-4341-9c1d-3ee762f57be5": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03456427", "Secondary_id": "NCT02685566", "Statement": "There are no details of the types of imaging used in the intervention sections of the primary and secondary tests.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "98a946b0-2be1-474c-b373-043f329ba261": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02038010", "Secondary_id": "NCT00764322", "Statement": "Neither the primary nor the secondary trial measures the percentage of participants with an overall response rate after administration of Ispinesib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3]}, "b82e6861-3908-43e9-8e54-cf60c7d96a4e": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00721409", "Secondary_id": "NCT02413320", "Statement": "Patients with ER-positive tumours are eligible for the primary trial, but not for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "b8e5baf7-ddc5-407f-84d3-4c93224477cd": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02445586", "Secondary_id": "NCT02115984", "Statement": "More than half of the patients in the primary trial experienced adverse reactions, and there was no single patient in either cohort of the secondary trial who had no adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "79c34b71-a90f-4ddb-9aee-5f61f71f0846": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01277757", "Statement": "The primary trial does not consist of testing a new physiotherapy or chemotherapy procedure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02995980", "Statement": "A patient with a glomerular filtration rate of 63 and a breast tissue category c BI-RADS would be eligilbe for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 4]}, "02d5fe7a-60e2-422f-98c0-92461b8fa13f": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00438659", "Secondary_id": "NCT01271725", "Statement": "The primary test and the secondary test have a topical intervention, to be applied to the breast or face.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "869e413e-01c5-4a9e-8a4a-b6079f7ae300": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00996632", "Secondary_id": "NCT01644890", "Statement": "Emily has inoperable non-metastatic breast cancer and is eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c0b528ef-ae9f-4c01-8915-b47856f07c95": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01142661", "Statement": "The primary trial accepts patients with grade 3 neuropathy.", "Label": "Contradiction", "Primary_evidence_index": [17, 19]}, "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01743560", "Statement": "By week 48 of the primary trial, the majority of patients had a stable disease, none of them had a complete or partial response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "da15fae6-7fa1-4fe0-b61c-e043df3e9e74": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01011946", "Statement": "All patients in the primary trial should have bilateral breast MRI prior to entry into the study.", "Label": "Entailment", "Primary_evidence_index": [2, 7]}, "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02455453", "Statement": "Patients with positive HER2, PR and ER tumours are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 10]}, "01236718-14da-450c-8051-0207d31743a5": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02555657", "Statement": "The median time between randomization and death for any cause was one month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3419af1a-7923-419d-a673-2de96d41eabb": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03719677", "Statement": "The potential participants will be considered regardless of the hormonal susceptibility of their breast cancer, unless they overexpress the ERBB2.", "Label": "Entailment", "Primary_evidence_index": [7]}, "2048912d-9e9f-4cbc-89cc-19020f20a976": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01966471", "Secondary_id": "NCT00981812", "Statement": "A patient who had a total bilateral mastectomy in the year prior to entering the study would be excluded from the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [5, 12]}, "f5907902-d4d1-4d73-a196-7fbe0dcb44ad": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00245219", "Secondary_id": "NCT00038103", "Statement": "Both the primary and secondary trials have control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "93a8e018-ac25-48b2-81d2-fd5b01be8f37": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01463007", "Secondary_id": "NCT00965523", "Statement": "A higher number of patients in the secondary trial were infective compared to those in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d72c45e5-6654-4afe-91a0-1f47b0c13dc0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00464646", "Statement": "Anna is a 57-year-old woman with an ECOG of 0, diagnosed with a positive HER2 invasive adenocarcinoma of the breast, with pN2 ipsilateral lymph nodes. She is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 15, 16, 17, 18, 19, 10]}, "e68b5690-11fd-4567-8dcc-dec91d1e4bb8": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01033032", "Statement": "The only adverse event recorded in the primary trial was a single case of spinal fracture.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "e1417a26-2f40-4dd6-b598-e66e57312595": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01931163", "Secondary_id": "NCT00274469", "Statement": "Less than 5% of patients in cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of patients in the secondary trial were registered as having LACRIMAL DISORDER.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6ee89773-958b-4eb9-bc67-18fa98a70c2d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00365365", "Statement": "The primary test recorded only one type of acute adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "4d776c28-8ed1-4f3f-9837-0821029d3775": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00063570", "Statement": "None of the patients in cohort 1 of the primary trial had platelet deficiency and none of the patients in cohort 2 were constipated.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "50e54a67-9cfb-4259-b810-2e9bc0b09b4c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00611624", "Secondary_id": "NCT00600340", "Statement": "The primary and secondary trials require patients to undergo at least two weeks of mammositis treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "9f23f617-b8ec-4665-ad0b-9a9bc8b19691": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688740", "Secondary_id": "NCT00191815", "Statement": "The most common adverse reactions in the primary and secondary trials are Neutropenia, which has a total of 3 cases in all cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b76c9c21-64f7-487b-bf08-e232a9da0174": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01490892", "Secondary_id": "NCT02364388", "Statement": "The intervention in the primary trial requires one injection and two different imaging modalities, while the secondary trial requires consultation followed by intensive radiation therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "66aaca41-f5f9-4ed4-b165-9510b7c64456": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03136367", "Secondary_id": "NCT00129935", "Statement": "Only patients who identify themselves as women are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 6, 7], "Secondary_evidence_index": [18, 38]}, "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00206427", "Statement": "One patient in the primary trial had a fungal infection of the mouth.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d6b09c0f-979c-4151-87f9-830b964e275d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01216176", "Statement": "Urosepsis was the most common adverse event in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "92da8d30-a7e9-4fb4-95e4-484b53279ad7": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01570036", "Secondary_id": "NCT00021255", "Statement": "The primary and secondary trials monitor the DSV of their patient cohorts, but the secondary trials indicate the percentage of patients with DSV >= 5 years, while the primary trials indicate the percentage of participants with DSV >= 2 years.", "Label": "Entailment", "Primary_evidence_index": [1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "762c3b23-547a-40cb-86c9-767294f4a142": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02165605", "Statement": "A 56-year-old patient with a masectomy would not be eligible for the primary trial because of her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3]}, "95a509d6-2990-49ac-b36c-aedf842f17ee": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01111825", "Statement": "No cases of Constipation, Diarrhoea, edema or febrile neutropenia were observed in cohorts 1 and 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00258960", "Statement": "One patient in the primary trial had a Grade 4 adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "19c2c2d7-4c33-4842-9ed4-02cfae663ce2": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00066573", "Secondary_id": "NCT01091454", "Statement": "There were 1 cases of night blindness in the primary test and 0 in the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "1fdaafdc-766b-488e-9cc4-cbcad74ade97": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01818063", "Secondary_id": "NCT00559507", "Statement": "In both the primary and secondary trials, the only drugs administered orally are doxorubicin and v\u00e9liparib.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2]}, "2e591059-5a3b-4a69-84c5-59d9604394a8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02040857", "Statement": "All sexes are eligible for the primary test.", "Label": "Entailment", "Primary_evidence_index": [2]}, "94a54cdf-4c1c-4994-929a-ced7a33f2b43": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00866905", "Statement": "Less than 1% of patients in the primary trial became depressed.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "b217583e-2dbb-4951-8f73-cac08e365a7a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00562718", "Statement": "Patients with heart pacemakers or stents may be allowed to participate in the primary trial at the discretion of their physician.", "Label": "Entailment", "Primary_evidence_index": [6]}, "42086f11-1fb1-4041-8d1e-e150d4cc09ea": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00304096", "Statement": "A minimum body weight of 50 kg is required to participate in the primary test.", "Label": "Entailment", "Primary_evidence_index": [14]}, "0d75c493-58ce-4a45-8823-a9a1126751b3": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00916578", "Statement": "The primary trial is to test a combination of chemotherapy and radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "d0d4e184-0764-4c28-9af7-4535c7ed1aad": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00303108", "Statement": "The primary trial cohort 2 produced slightly better results than the cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e45886af-1edd-4987-a280-2609a86fd3dd": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02413320", "Statement": "Women over 20 years of age who have received chemotherapy in the last 4 weeks are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5]}, "c207ff16-b7d0-49e4-9177-0597044f3008": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03374995", "Statement": "Some subjects in the primary trial receiving keratin are administered topically twice a day for approximately 3 to 6 weeks, while others may administer it by subcutaneous injection.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "35234f08-cf01-478f-b739-600b5a6ea3d9": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00550771", "Statement": "16/179 patients in the primary trial Experienced cardiac events, the majority of those from cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "87adb323-6f56-4e1a-a04d-8437ac571eab": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01805089", "Statement": "Patients with lactate duct carcinomas are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "94410f2c-9c1c-4130-b479-738e343ba9f7": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00194779", "Secondary_id": "NCT04080297", "Statement": "There is at least one route of administration shared by the interventions used in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2]}, "b811e872-90ef-4649-9c8d-f5488f316ccc": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00671918", "Secondary_id": "NCT00571987", "Statement": "Patients with pure ductal carcinoma in situ (CDIS) are eligible for both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 12], "Secondary_evidence_index": [0, 9]}, "f66f4c30-2d39-4e29-876a-487bca9a8ccf": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02835625", "Secondary_id": "NCT00486525", "Statement": "The primary and secondary trials do not use chemotherapy or radiotherapy in their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00452673", "Statement": "Seven patients in cohort 1 of the primary trial had dose-limiting toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "011991a5-724d-4b95-b9ab-9e1371d77368": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00086957", "Statement": "All patients in cohort 1 of the primary trial had neutropenia of Leukopenia and Febrile.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "8421197a-3a35-4738-b1c8-83cce0ac4115": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02896855", "Secondary_id": "NCT00171314", "Statement": "The secondary trial recorded more total cardiac adverse events than the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "d09091f1-3fc5-498b-8c59-4678590c8464": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03176238", "Secondary_id": "NCT01498458", "Statement": "While there is a much higher percentage of patients with enterocolitis in the secondary trial than in cohort 1 of the primary trial, no solid comparison can be made due to significant differences in cohort size.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "203a2e22-cae9-4bfe-b82d-6dc665a66ce6": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00821886", "Statement": "Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [20, 33]}, "f4909215-5b14-42d9-bda4-4d112cf2a108": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02574455", "Statement": "More than one third of patients in cohort 1 of the primary trial experienced an adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "9c27202c-7090-4be5-840e-351992aeb81c": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093808", "Secondary_id": "NCT00394082", "Statement": "The primary and secondary trials reported the same number of dehydrated patients in the studies.", "Label": "Entailment", "Primary_evidence_index": [11], "Secondary_evidence_index": [11]}, "fc7d8ffd-9896-4806-a095-d435cde83c88": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00528567", "Secondary_id": "NCT01196052", "Statement": "The total number of patients affected by adverse events in cohort 2 of the primary trial is greater than the size of the secondary trial cohort.", "Label": "Entailment", "Primary_evidence_index": [11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "23116aca-0064-4426-b147-7af688a82443": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00876395", "Secondary_id": "NCT02287675", "Statement": "Men with ulcerative colitis are excluded from the primary test but are eligible for the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [9, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00005879", "Secondary_id": "NCT01217385", "Statement": "The only criterion for admission to the primary and secondary trials is that patients must be women over 21 years of age and British.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "98850daf-738c-4005-b476-8c5479ad3b79": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00033514", "Statement": "Mark has a positive HER2 breast cancer, he is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00916578", "Statement": "The primary test is to test a combination of capecitabine once daily and radiotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a4ed4cc0-9444-4a5d-863c-578fd42b8794": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425854", "Statement": "The intervention in cohort B is described as Afatinib 50 mg taken orally twice a week.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a4dcb9b6-7b6f-4467-a159-d6e770f6762f": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01313039", "Secondary_id": "NCT01031446", "Statement": "\u2022 Nursing patients are not eligible for the primary or secondary trial because of the potential harm to the infant caused by the study interventions.", "Label": "Entailment", "Primary_evidence_index": [9], "Secondary_evidence_index": [19]}, "be1c82e6-200d-4bef-b723-c78655fa40e5": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00291694", "Statement": "The primary test does not specify the route of administration of his intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "790047b1-43e3-486e-b41c-eaa89026eae7": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02447328", "Statement": "In the primary trial, 11.1% of patients experienced serious adverse reactions, no patients experienced serious adverse reactions to the drug, and more than half of patients experienced unexpected adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "fc8ed290-e2b3-4eea-a837-d369dcd9b5da": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00875979", "Statement": "None of the 3 patients in cohort 1 of the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "207b0895-91de-4238-8d50-e2b8b7420fb0": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559845", "Secondary_id": "NCT00426556", "Statement": "In total, there were more adverse reactions in the secondary trial than in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 14, 15]}, "1340769c-b55c-480c-a4c4-130034e128ce": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317720", "Statement": "Patients must have received at least one prior treatment with trastuzumab to be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "a4d6e27f-737b-4597-86e1-79b3f064cbee": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02694029", "Statement": "The primary test candidates should be able to hold their breath under water for 30 seconds.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00887575", "Secondary_id": "NCT01610284", "Statement": "The cohort 1 of the secondary trial was more than 3 times the size of cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "030eded8-6513-4028-b1fe-fefd6dd388ad": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02429427", "Statement": "Patients with a platelet count of 50,000 x 109/l are not eligible for primary testing", "Label": "Contradiction", "Primary_evidence_index": [0, 7]}, "412d3ee2-bbfb-4e24-b159-684ae144e742": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00054275", "Statement": "A patient with minimal symptoms but severe obstruction of the left main coronary artery would not be able to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [33, 35]}, "d1d77877-9c85-41c8-9eca-6fd75b254a15": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00768222", "Statement": "Rachel is 19 years old and has skin ulcers and allergic reactions to triclosan, she cannot participate in the primary trial because of her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 4, 8, 9]}, "c32d1b74-07ab-4afb-9db6-878e20727661": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02279108", "Statement": "Adult patients with HER2- histologically infiltrating breast cancer who have not undergone prior lumpectomy or breast reduction on the same side and have no indication to the contrary to surgery are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "ba0c0dc6-826b-426f-8738-eec23e47f6b0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03045653", "Statement": "Sharone had a hip replacement 2 months before, it is not possible for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [4, 6]}, "77982c81-d147-48d9-909c-18b9a98224e9": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01301729", "Secondary_id": "NCT02129556", "Statement": "Only one type of infection was recorded during the duration of the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00687440", "Secondary_id": "NCT01307891", "Statement": "The primary and secondary test results indicate that Abraxane + Tigatuzumab produces better ORR than Caelyx, Docetax and Trastuzumab.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2e03f6f1-0d4f-4ebf-8781-20918d70d78f": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02165605", "Statement": "A 56-year-old patient with a masectomy would not be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 3]}, "57e74ef2-f170-47bd-a908-2a7b3cec150d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00482391", "Statement": "Patients with no QT prolongation are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [29]}, "b5957a75-140f-445b-99dc-199b8182b8ed": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01805089", "Statement": "Premenopausal patients with lactating duct carcinomas are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3]}, "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00486525", "Statement": "The difference between the two cohorts in the primary trial was that cohort 1 received higher doses of IMGN853, while cohort 2 received lower doses more frequently.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f57350c2-ac90-47ea-92b4-d903509bf07a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03252431", "Statement": "Patients in both arms of the primary trial had Grade 4 Neutropenia at the same time. There was no difference at all.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "77c61307-567d-4ac2-a7f7-85feffd30473": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00167414", "Statement": "Patients do not need to have a known hormonal receptor status to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "35dd977f-53d8-4400-b5cb-34caaa938e78": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00764322", "Statement": "The ultrafast Metabolizer group in the primary trial experienced an average increase in endoxifene concentration over 6 mg/m2 over 4 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "54554da5-e67f-4da5-819b-a85b7bc5d52c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00444535", "Statement": "Less than one-third of primary trial participants achieved progression-free survival after 12 weeks of treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "592edd64-7841-4c19-ba75-583066308137": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00343863", "Statement": "On days 1-7 of the primary trial, cohort 1 received doxorubicin IV hydrochloride, oral cyclophosphamide, dexamethasone IV or orally, and ondansetron IV.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "a1d207c8-2d57-4c49-89fa-60ceacf65829": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00228943", "Statement": "Clinically depressed patients are not able to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [8, 9]}, "4a8f0562-355b-4a68-8790-c283d93ce766": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093808", "Secondary_id": "NCT00394082", "Statement": "The primary and secondary trials reported the same percentage of dehydrated patients in the studies.", "Label": "Contradiction", "Primary_evidence_index": [11], "Secondary_evidence_index": [11]}, "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02491892", "Secondary_id": "NCT00887575", "Statement": "In cohort 1 of the secondary trial, more cases of diarrhoea and dyspepsia were recorded than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 7, 8]}, "3cd353ed-af0d-4356-8f45-efc1e91a2a0d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02878057", "Statement": "\u2022 Outpatients capable of self-care but unable to perform work activities are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "b8473ae8-11c9-4578-aab8-ee96e6287715": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00580333", "Secondary_id": "NCT00934856", "Statement": "\u2022 Applicants must have a life expectancy of more than 3 months to participate in the primary trial, there is no defined minimum life expectancy for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [8, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "4243dc45-5a64-486d-ae2a-11448db00dcf": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00246090", "Secondary_id": "NCT00266799", "Statement": "Cohort 1 of the primary trial 15% less total adverse reactions than cohort 2 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16]}, "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00073528", "Secondary_id": "NCT00191152", "Statement": "The secondary trial cohort 1 had a median PFS much longer than cohort 1 in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f616e3d8-6c1a-4b99-ac79-ea87895e37b7": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00902330", "Secondary_id": "NCT00952731", "Statement": "The primary trial cohort 2 is the control group and cohort 1 is the secondary trial control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "2f700407-8baf-4e5f-8fc0-378a294512f5": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01313039", "Secondary_id": "NCT01031446", "Statement": "\u2022 Nursing patients are not eligible for the primary or secondary trial because of potential harm to the father from the study interventions.", "Label": "Contradiction", "Primary_evidence_index": [9], "Secondary_evidence_index": [19]}, "cebee448-235d-49ff-8e87-56639399548b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02287675", "Statement": "Informed consent is optional for entry into the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01073865", "Statement": "Women over 18 years of age whose last period was 2 years prior to randomisation are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02187744", "Statement": "Septicemia, due to the presence of an implanted device, was a common adverse event in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 7]}, "af677d94-a376-42ea-93fe-91963a071199": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00676793", "Secondary_id": "NCT01931163", "Statement": "Patients with dysphagia may not participate in the secondary trial but may be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 26]}, "6579e25e-8dcf-44b5-a50d-7c84672cba89": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981305", "Statement": "Only those who have already been diagnosed with cancer and are currently receiving treatment for their primary tumour are eligible for the primary trial as long as they are over 20 years of age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "1ac9c526-91e6-4e0d-8570-0a78e3ec78db": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00451555", "Statement": "Cohorts 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "79c07f36-daf9-4844-ad8a-f362fbbaaf81": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00767520", "Statement": "Both cohorts in the primary trial reported the same precentage of patients who vomited during the trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 13, 18]}, "bced9c90-5ce0-416c-a168-f9e74359b332": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01381874", "Statement": "The Exemestane group in the primary trial had a better median response to tumours than the Abiraterone Acetate + Prednisone group, but the patient with maximum TR was in the Abiraterone Acetate + Prednisone group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "ce88c763-0062-48dc-b5e1-f81af32f2628": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00593827", "Secondary_id": "NCT00478257", "Statement": "Patients with B.C. HER2 are eligible for both the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "982469a3-2fc1-40b4-92a9-d531b6c0ab5d": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00296036", "Statement": "The primary trial administered lactic acid-Urea/Creme topically twice daily, and placebo was administered orally once daily.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00334802", "Secondary_id": "NCT00167414", "Statement": "There is no age limit for secondary or primary testing.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "e6901a45-4c97-4618-bfcb-6f6dd046ef0c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00143390", "Statement": "In the primary trial, there was a difference of less than 3 months between the maximum TTP and the minimum recorded TTP of the Exemestane group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e94ea1b1-1816-4bac-b1ca-f6d66b95702a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00004888", "Statement": "Most primary trial participants experienced third-year or higher cardiotoxicity events after Cycle 8 of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "0e3c62f7-a152-4370-9d09-b69a715c0a21": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01216319", "Secondary_id": "NCT03346161", "Statement": "The secondary and primary trials evaluate surgical procedures for breast reconstruction of patients who have had mastectomies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "7191b5e9-4f29-4261-8a64-51653ee151fe": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00410813", "Statement": "In the primary trial, Dasatinib 70 mg twice daily gives a median PFS better than Dasatinib 100 mg daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "639ccada-370d-4709-bdd7-1b29bbcc8769": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01597193", "Statement": "ECOG > 1 and life expectancy greater than 12 weeks are required to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5]}, "8c6e6c06-c409-4c42-b195-e9d2a1065b97": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02069093", "Statement": "All patients in the primary trial had tiny symptoms of stomatitis and a normal diet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b5183c1c-adb5-4877-b061-50a16d6a5b52": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00191815", "Secondary_id": "NCT01301729", "Statement": "None of the patients in the primary trial committed suicide, but there was one such case in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "69f57cdb-22e9-4a3a-8f19-6095c66c6497": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01855828", "Secondary_id": "NCT00696072", "Statement": "The secondary trial uses clinical benefit (CBR) as a measure of outcomes, which is different from the proportion of participants with a complete pathological response rate that is used for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "ea505463-c509-416e-ad88-11576764b734": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01771666", "Secondary_id": "NCT01256567", "Statement": "Japanese participants with an ECOG <=1 are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 7], "Secondary_evidence_index": [0, 1, 2]}, "81669281-db01-4493-a797-0d60f448f706": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00930930", "Statement": "The most common adverse event in the primary trial was dehydration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "40dbf023-ead5-45fc-bdce-bf40e1955578": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00382785", "Secondary_id": "NCT00784849", "Statement": "Neither the primary test nor the secondary test use low-dose magnesium oxide, high-dose magnesium oxide or mometasone in their intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "b64ae9c9-956a-421e-a41f-1886408fec2a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003782", "Statement": "One of the cohorts in the primary trial had more than 5% of patients with side effects.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 11, 12]}, "e0980234-0611-44de-9165-54bdd086663d": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01539317", "Secondary_id": "NCT01323530", "Statement": "The primary trial uses topical intervention and the secondary trial uses a combination of oral and intravenous treatments.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "3366c10a-3d41-48ae-bfa8-26b9e655761e": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00005908", "Statement": "There were 8 cases of pharyngitis in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "be29030a-98e8-40ad-9138-90076fdb50d3": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01572727", "Statement": "In cohort 1 of the primary trial, more white blood cell-related adverse events were recorded than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "a31298d5-20ae-4a3d-a57b-e97288fff6c0": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01097460", "Statement": "Each patient in the primary trial had at least one adverse event that occurred over a 2 year period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "54e93334-0f21-4ea2-b0f2-34473385da53": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003830", "Statement": "The most common adverse reaction in both cohorts of the primary trial was anaphylaxis, which affected less than 1% of patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "fbedd8fc-05e8-4438-b780-d7483aed3b45": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00404066", "Statement": "When an abnormal EVAF, pregnancy or breast-feeding automatically eliminates patients from participating in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [22, 28, 29]}, "4bd9f061-6420-443d-8f84-b703733644ac": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01202591", "Statement": "100% of patients in the primary trial experienced life-threatening adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e6d3354b-b36a-42b9-b406-61a9af594686": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00046891", "Statement": "The primary trial cohort 1 receives 120 mg of Ginkgo Biloba twice daily.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "62b3d09e-6b2a-4827-8ceb-96ccafca18d4": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00896649", "Statement": "A prior hormonal treatment(s) in a metastatic or adjuvant medium is not necessary for patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317603", "Statement": "The primary trial participants must be over 18 years of age, have a confirmed stage 3 histologically or above breast cancer, an ECOG < 2 and a life expectancy greater than 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 6, 7, 8]}, "85c315e5-7ae4-4764-8b02-87d36f67a159": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00278109", "Secondary_id": "NCT01881230", "Statement": "- Gemcitabine is not used in the primary test and is only used in one of the arms of the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "497188e0-9d88-406f-b163-c154516cb12c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01560416", "Statement": "There were more than 10% more adverse event cases in cohort 2 than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 12, 13]}, "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00438100", "Secondary_id": "NCT00662025", "Statement": "Patients with BUN < 20 mg/dL, platelet count < 90,000/mm3, leukocyte count 5,000/mm3 to 8,000/mm3 may be eligible for both the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "f26fb90b-a9a5-4614-9680-2e9f6f0ba649": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01828021", "Secondary_id": "NCT01326481", "Statement": "Patients in the primary and secondary trials did not have the same adverse reactions, with the exception of supraventricular extrasystoles that were most common in both trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "90dd042b-c16c-4ea7-b360-625bd5e64590": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00388726", "Statement": "A 75-year-old patient with an ECG of 1 and an estimated life expectancy of more than one year would be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 11, 12, 13]}, "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01271725", "Statement": "In the primary trial, the percentage of participants with an objective response (OR) for Afatinib monotherapy was 13% lower than that for Afatinib and Paclitaxel or Vinorelbine Combine Therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "20cc98f8-a71a-466d-a39c-735899791613": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00915603", "Secondary_id": "NCT02511730", "Statement": "The INR equal to or greater than 1.5 is mandatory for participation in the primary test, it is not necessary for the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 24], "Secondary_evidence_index": [0, 1, 2, 3]}, "fa1c6f63-ae37-4c18-918b-7b9ba445fd81": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00391092", "Statement": "In total, there were 32 cases of febrile neutropenia in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 12, 14]}, "6d0b2acc-11f4-479f-9a86-004e2f5f7599": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00194779", "Secondary_id": "NCT04080297", "Statement": "IA is used as a route of administration through interventions in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2]}, "7e9c3980-9f12-40c7-920e-76594db26fd1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02352779", "Secondary_id": "NCT00263588", "Statement": "The differences between cohorts in the primary trial are once the cohort receives placebo and the other low-dose omega-3 fatty acid, unlike the difference in the secondary trial is the patient's characteristics.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c83e003d-d12d-4f72-ab1f-c39f3a13326b": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00499083", "Secondary_id": "NCT03045653", "Statement": "To be eligible for both the secondary and primary trials, patients must be women over 18 years of age, ECOG <2 and have negative breast cancer confirmed by HER2.", "Label": "Entailment", "Primary_evidence_index": [6, 10, 12], "Secondary_evidence_index": [0, 1]}, "cae58656-76e7-447a-940e-dfcc78159173": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00244933", "Statement": "The primary trial monitors the onset of anaemia in its adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "94c4c3fc-7bcb-407b-86b5-6699305d3dbd": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02481050", "Statement": "There are no adverse reactions in the primary trial that occurred more than once.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "103fbaa8-1852-402a-9368-36bbf6c747b2": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00022516", "Statement": "At most 3 patients in the primary trial had Neutropenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "731dc36f-983d-4d4c-97ac-6e3eeee23a40": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00581256", "Statement": "Patients with left-hand breast cancer and an ECOG of 3 are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 8, 14, 17]}, "b2883781-f4e9-405e-9231-7a07e46c35b0": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00429299", "Statement": "Only one cohort in the primary trial is administered to trastuzumab at 4 milligrams per kilogram.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "932c2135-381a-4675-a782-e683eca8d935": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00791037", "Secondary_id": "NCT00606931", "Statement": "Both primary and secondary trials use vaccine-based interventions, but this is done at different intervals and for a different duration.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "6461007d-fc18-43e2-a797-11cb0a4512ce": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01648322", "Secondary_id": "NCT00436566", "Statement": "The primary test is shorter than the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "819e85b0-2d4e-4535-b920-4e18868da883": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00630032", "Secondary_id": "NCT00428922", "Statement": "Patients with radiologically confirmed metatases in CNS are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [13, 14], "Secondary_evidence_index": [6, 7]}, "cc0d6fe8-69c4-49d3-b321-00e47c155db6": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03098550", "Statement": "The results of cohort 3 of the primary trial were not conclusive.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0fbb4fb4-620b-4ee9-aaa8-956992026cef": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454532", "Statement": "Less than half of the patients in cohorts 1 and 2 of the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "69b12ff4-6bb4-4207-b400-67795709c3c8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02679755", "Statement": "Each patient of Palbociclib+L\u00e9trozole Australia Cohort in the primary trial experienced adverse events of therapeutic origin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 14, 15, 16, 17, 8, 19, 20, 21, 22, 23]}, "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00829166", "Statement": "Women with Grade 3 or 4 peripheral neuropathy are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 12]}, "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00464646", "Statement": "Anna is a 57-year-old woman with an ECOG of 0, diagnosed with invasive adenocarcinoma of the breast, the IHC results were 1+. She is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 15, 16, 17, 18, 19, 10]}, "efc15257-5e19-4b7e-8b51-da94840784d8": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00623233", "Secondary_id": "NCT01525589", "Statement": "The primary trial recorded 1 patient with platelet deficiency in the blood, while a total of 6 patients with platelet deficiency were found in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01310231", "Secondary_id": "NCT00093808", "Statement": "19.57% of patients in the secondary trial developed a eating disorder, there were no cases of this in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02129556", "Statement": "The cohort 1 of the primary trial had a much higher number of deaths than the cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 10, 13, 23]}, "e4961c1a-83e2-40ed-93ac-64d5cef1f84a": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01819233", "Statement": "All participants in the primary trial should reduce the number of calories in their diet by a quarter throughout the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9cb1c975-0d49-4437-af56-1a4f97e30aef": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01663727", "Secondary_id": "NCT00072293", "Statement": "There is no maximum or minimum age for participation in the primary or secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [16, 17, 18]}, "51699ae8-d297-4635-95c1-4ed38c8706c3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02732119", "Statement": "Mark has undergone refractory ventricular fibrillation twice in the last month, so he is excluded from the primary test.", "Label": "Entailment", "Primary_evidence_index": [8, 14]}, "c2c73b99-f89c-4dd3-8362-295f9a7965f3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02756364", "Statement": "In order to meet the inclusion criteria for patients undergoing the primary trial, ineffective treatment with the aromatase inhibitor (AI) must be received prior to entry into the study.", "Label": "Entailment", "Primary_evidence_index": [0, 9]}, "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02129556", "Statement": "The primary trial cohort 1 had a much higher mortality rate than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 10, 13, 23]}, "949ac54b-a871-4134-a507-c98a4de55720": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00394082", "Secondary_id": "NCT01033032", "Statement": "In the primary trial, cases of anaphylaxis and spinal compression fracture were recorded, none of which were observed in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "02407f87-235d-4240-98fe-498b352cce75": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00167414", "Statement": "Patients should have overexpressive tumours of the human epidermal growth factor (HER2) receptor 2 to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "61a524d4-1697-4a10-b36a-a0c6cda79526": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00030823", "Statement": "Patients with triple negative breast cancer of stage I, II, III or IV are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [12, 13]}, "304977b6-9742-4c3b-84fd-e5ef1737a143": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01597193", "Statement": "ECOG < 2 and life expectancy greater than 12 weeks are required to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5]}, "87c65217-85d9-4f05-87aa-f4dfacd9f25a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01790932", "Statement": "Patients with phosphoinositide 3-kinase inhibitor treatment are not eligible for primary testing.", "Label": "Entailment", "Primary_evidence_index": [5, 6]}, "19e89ebc-a417-47a8-bfa7-1778baead178": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01385137", "Secondary_id": "NCT00593346", "Statement": "While placebo treatment is used in the secondary trial, there is only one trial group in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "561a0631-1eb3-48d1-baa2-81eb3fa79b98": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00950300", "Secondary_id": "NCT00615901", "Statement": "The primary trial recorded one patient with chest pain, while the secondary trial observed one patient with abdominal pain.", "Label": "Entailment", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 3]}, "bc617e84-a0c1-400b-9ad5-88b56d1805e8": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01671319", "Statement": "1/42 patients in cohort 1 of the primary trial passed out.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01097642", "Statement": "Adult patients with histological confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 3, 4, 5]}, "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00354640", "Statement": "Patients in primary trial 1 receive higher doses of anastrozole than simvastatin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b059e44b-9830-4c45-858e-ebd007fbaf69": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00148668", "Statement": "Cohorts 1 and 2 in the primary trial recorded the same number of patients with febrile neutropenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "fec065ca-fbde-476d-ab0d-7e7054e29858": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00436917", "Statement": "Patients with scoliosis with a Cobb angle greater than 20 degrees to the lumbar spine, or with surgery prior to the lumbosacral spine, are excluded from the primary trial as they interfere with CT and MRI scans required for the study.", "Label": "Contradiction", "Primary_evidence_index": [39, 40, 41]}, "ea3bd229-001c-487f-9cda-edf2e699dbb2": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01153672", "Secondary_id": "NCT01432145", "Statement": "In the primary trial, patients receive vorinostat at the same frequency, dose and route of administration as in the secondary trial, 6-Mercaptopurine.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "576e519a-1ef3-43e5-a13c-6058ad71f388": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00297596", "Secondary_id": "NCT00580333", "Statement": "Patients who have already received radioactive treatment to treat current breast cancer in the last two weeks prior to entry into the study are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 8, 10], "Secondary_evidence_index": [8, 9]}, "699d0cb5-1ebb-441d-aa7e-041a48923b00": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03374995", "Statement": "Subjects in the primary trial receiving keratin are given topically twice daily for approximately 3 to 6 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01127373", "Statement": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumours are eligrbs for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "6e882de6-e55f-40a4-95a1-bdb176e68a18": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00266799", "Statement": "None of the patients in cohort 1 of the primary trial had acute coronary syndrome or VESTIBULAR ACUTE.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "525ed182-07e9-4548-87b3-c831e0b7389e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00834678", "Statement": "Patients with lymphopenia may participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [18]}, "233d2ec1-1383-4088-90af-c5a948847631": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00110084", "Secondary_id": "NCT01961544", "Statement": "Both the primary and secondary trials reported cases of Pseudomonal septicaemia in their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 12]}, "8e3fe244-d47d-48ce-ab29-4a5226024aad": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00426556", "Statement": "There was an equal number of cases of febrile neutropenia, leukopenia and neutropenia in the cohorts in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 14, 15, 16, 17, 18]}, "670443b0-89bf-4af4-a9ab-4cdff26d09a8": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00005957", "Statement": "T4 N3 M0 breast adenocarcinoma are eligible for primary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "455748bf-8e12-4834-8126-ab77cab16200": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00332709", "Secondary_id": "NCT00659373", "Statement": "All participants in the primary trial receive the same dose of Letrozole, only some patients in the secondary trial are treated with Exemestane.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "d29bd9dd-b52e-4b18-82ea-e2914dfb9579": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01808573", "Statement": "The primary trial Patients treated with Neratinib Plus Capecitabine had an average free survival (95% confidence interval) of more than 2 months compared to patients treated with Lapatinib Plus Capecitabine.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2649c857-f98d-4529-9a4a-4f8b17813cb8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00337103", "Statement": "The median overall survival of patients in cohort 1 was 44 days longer than that of patients in cohort 2 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0a6e8720-ea47-4520-bd02-e0eb8fcd880f": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00399802", "Statement": "The single infusion IV in the ZA 4 mg group of the primary trial showed a lower percentage change from the baseline in the urinary N-telopeptide of collagen type I than in the Odanacatib 5 mg group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "ce6630d3-d3b7-4870-a486-9b6284a454f0": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02679755", "Statement": "More patients in the Palbociclib+Letrozole Australia cohort of the primary trial experienced emerging adverse events compared to patients in the Palbociclib+Letrozole India cohort.", "Label": "Contradiction", "Primary_evidence_index": [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "27e31574-5a73-4a68-997d-daa84797a65a": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00054028", "Secondary_id": "NCT02162719", "Statement": "The primary and secondary trials administer at least partially their intravenous procedures.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "e21171de-ad49-4fc5-9c5d-aa362ca61c8a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00014222", "Statement": "Cohort one of the primary trials reported 2,680 patients with eye-related adverse events, while cohort two reported 41.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02518191", "Statement": "The primary trial cohort 2 is the control group, as eligible patients with breast cancer treated with GnRHA every 28 days.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "38f47a03-f71d-4072-a005-b954fb6069da": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00684983", "Statement": "The median period during which a patient in the A arm of the primary trial lived with the disease without worsening was half a year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e41917b8-d921-4797-b845-0121a75104a4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129376", "Statement": "More than 2% of patients in the primary trial experienced clinically significant inflammation of the back of the throat.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02513472", "Statement": "Cohort 1 patients in the primary trial survived almost twice as long as those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02491892", "Secondary_id": "NCT00887575", "Statement": "In the secondary trial cohort 1 there were more cases of diarrhoea and dyspepsia than in the primary trial cohort 1, which is due to the significant difference in cohort size.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 7, 8]}, "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01881230", "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier estimate of progression-free survival more than 83% lower than that of the Carboplatin group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "6214280f-f665-48d3-b33f-9d798deff71f": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01855828", "Secondary_id": "NCT00696072", "Statement": "The secondary trial uses overall survival (SG) as a measure of results, which is different from the proportion of participants with a complete pathological response rate that is used for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "108b54a9-b5cc-4f31-956f-e4e2e653d756": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089999", "Statement": "In total, more participants in the primary trial had no tumour response, than a partial response, and 0 participants had a complete response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "662f4992-0155-4a82-926f-b1821539aab7": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00723125", "Secondary_id": "NCT00617942", "Statement": "57% of patients in cohort 1 of the primary trial had complete pathological response rates to surgery, compared to 60% in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "398f744b-97cf-4f95-b162-99ec6652d327": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01091454", "Secondary_id": "NCT00054275", "Statement": "There were more cases of anaemia and leukopenia in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "43421f19-878e-46f7-b456-8031835af649": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00632489", "Statement": "The primary trial uses a determined dose of 1000 mg PO per day of Lapatinib, while the dose of Capecitabine changes with the body surface area.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "13fa44e7-38be-48fb-a0eb-6b212549f526": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02260531", "Statement": "The percentage of participants with a complete (CR) or partial (PR) response was much lower in the HER2 positive group in the primary trial than in the ER+ and/or PR+ group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "12ae2315-cc50-43ac-a595-762c85c1ec58": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02308020", "Statement": "There were no participants in cohort 1 of the primary trial with a (CR) or a (PR) based on the assessment of response in the neuro-oncology (RANO-BM) brain metastasis response criteria.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "11403f92-661b-4334-8dfb-098586610ec6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02536339", "Secondary_id": "NCT00371345", "Statement": "In the primary and secondary trials, respiratory diseases were observed in most patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2823adfc-b3a4-4626-9690-0c292aa8da04": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01422408", "Statement": "The primary trial is a Phase II trial in which all participants will receive topical fluoronide 0.05% facial cream twice daily for two weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "1cda051f-27d0-4027-94cf-7b5340173ca2": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02504424", "Secondary_id": "NCT03708393", "Statement": "The primary and secondary trials do not have the same number of study groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00435409", "Secondary_id": "NCT00319254", "Statement": "The patient with the shortest PFS was in the secondary trial at only 5 days, and the longest PFS recorded was in the primary trial at 78 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "1e91c023-96e8-459b-9070-02df13339617": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00513292", "Statement": "In the primary trial, the FEC-75 group then Paclitaxel/Trastuzumab produced better complete pathological response rates (pCR) than the Paclitaxel/Trastuzumab group then Trastuzumab/FEC-75.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a15b4c0c-232b-4209-bf60-35d160e41d2c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03012477", "Statement": "One primary trial patient experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was anaemia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "795d634a-9f9c-49a2-a4e7-ec99bd3600f2": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02667626", "Statement": "The primary trial is to test an educational tool online and the secondary trial is to test a medical device on menopausal women.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e2d4c56c-a68f-4751-907d-9c2355c9528b": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01463007", "Secondary_id": "NCT00965523", "Statement": "A significantly higher proportion of patients in the secondary infection test than in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00193050", "Secondary_id": "NCT00232479", "Statement": "Patients must be over 18 years of age and have a life expectancy greater than 6 months to participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 11, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "9ad3444c-143d-4c28-a08a-e0c9cda44900": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00243503", "Secondary_id": "NCT00448279", "Statement": "The primary and secondary trials did not observe any of the same adverse events in their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3], "Secondary_evidence_index": [0, 2]}, "43061a8b-c1b2-4b5e-b935-73733d674fb4": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01401959", "Secondary_id": "NCT00852930", "Statement": "The primary trial refers to specific interventions for its patients based on their tumour response, patients with a complete response go to cohort A and all other patients in cohort B, contrary to the secondary trial assigns random interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fc7369dc-0fc5-4823-a8eb-5ac85188fd60": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00416572", "Statement": "Patients with ovarian or lung cancer are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [12, 13]}, "25ec56f0-e472-4423-92ae-8d4840b067b5": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03475992", "Secondary_id": "NCT03106077", "Statement": "The primary trial participants receive different interventions depending on their pre-diagnosis, while all patients in the secondary trial did the same intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "2c9e9407-e990-41bd-a87b-9d294c78f727": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02286843", "Statement": "The primary test consists of testing a new radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "f3cebdf7-be0c-45ad-85bd-bde827524e20": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00693719", "Statement": "The primary test recorded less than 5 different adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b5c7bfd2-d491-400c-8444-8bc424cd5dbf": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01705691", "Statement": "One primary trial patient suffered from kidney stones.", "Label": "Entailment", "Primary_evidence_index": [9, 14]}, "53c62057-d6ea-4639-adaf-98cb1544a394": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425672", "Statement": "Patients receiving Intervention 1 of the primary trial undergo a 21-day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer from an unacceptable disease progression or toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "599b37cd-f380-48ac-864d-e766a7af963e": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01570036", "Secondary_id": "NCT00021255", "Statement": "The primary and secondary trials monitor the percentage of their cohorts of patients with DSS below 6 years of age.", "Label": "Contradiction", "Primary_evidence_index": [1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c428ec76-4d22-4d2d-8c06-1675bd431d41": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02222337", "Statement": "The primary test participants must be in a couple, a breast cancer survivor and a caregiver, both must be ethnically Hispanic.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03283553", "Statement": "The primary trial has two cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a9d5c664-896f-4bb1-95e7-1deaa88848ef": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00089479", "Secondary_id": "NCT02964234", "Statement": "Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, without any evidence of metastatic disease. Agatha is of white-British origin. she is eligible for the primary trial but not the secondary trial, due to her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2]}, "62b5fe62-470d-46e3-82a6-d57cd6cab452": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00471276", "Secondary_id": "NCT00951665", "Statement": "gastrointestinal haemorrhage was more common in patients in cohort 1 of the primary trial than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "de349a2d-80ee-4c34-ab9f-38eb467c77d7": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01106040", "Secondary_id": "NCT01441596", "Statement": "The primary and secondary trials do not study the patient's PFS, RROs or DLTs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "0d37bf26-bc74-4a01-9bc9-61e2fa3051da": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00446030", "Secondary_id": "NCT00975676", "Statement": "The primary and secondary trials do not overlap with the drugs they use for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "69f7a93d-7134-40ec-aff3-50acd7119d2c": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02425891", "Secondary_id": "NCT00593827", "Statement": "The secondary and primary trials measure the PFS of their patient cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "8de31b0f-7127-4c8b-b5e0-060e7a83fae5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01299038", "Statement": "Joe has a known history of hepatitis. However, as he is over 18 years of age is still eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "207a1d82-a61b-4b5f-bebf-0706def6729d": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01008150", "Secondary_id": "NCT00375427", "Statement": "In total, only 1 more cases of mucosal inflammation were recorded in the secondary trial than in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "968aeaf1-44b9-4454-8c99-e3c207037485": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01491737", "Statement": "There were 4 cases of febrile neutropenia and heart failure in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 5]}, "2b79f9cc-4262-4353-ad28-91cda07a9b9a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02988986", "Statement": "Patients should have an AST, an ALP and an ALT < 1.5 LSN to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 20]}, "d56ffd81-4007-477b-b3c3-0fdb89806931": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00723398", "Statement": "Insipidusare diabetes patients are not suitable for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f62e6c20-862b-4ce3-9121-0d93ff050839": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01373671", "Secondary_id": "NCT00686127", "Statement": "The Lidoderm products are used in response arm 1 of the secondary test, and an FFDM product is used in arm 1 of the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "833eeb4b-4921-468a-947d-bacfc7816ae6": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02162719", "Secondary_id": "NCT02131064", "Statement": "The primary and secondary trials investigate the effects of their intervention on the patient's PRT.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1]}, "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00006110", "Secondary_id": "NCT00464646", "Statement": "The secondary trial has several gastrointestinal adverse events, while the primary trial has no gastrointestinal adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 7, 8, 9]}, "c317750d-6ef7-494d-8040-2c7fa3d777fb": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01129622", "Secondary_id": "NCT01156987", "Statement": "Both the secondary and primary trials used MRI for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "87eca8d2-72fe-4285-9884-6d2ec7bae6df": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00567190", "Statement": "There was exactly the same proportion of anemic patnets in both cohorts of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 12, 14]}, "7a87c605-fc41-4d0a-9291-85e88f6eb510": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01000662", "Secondary_id": "NCT02413008", "Statement": "The secondary test is to test a gel that is applied inside the vagina, and the primary test is to test an intervention that requires daily radiation from the breast(s).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "fbb853c9-bed4-4cde-a283-2d91b23d35bf": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01964924", "Secondary_id": "NCT00524303", "Statement": "Both the primary and secondary trials gave results on pathological evidence of invasive diseases with their patient cohorts after their interventions, using different measures of results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00482391", "Statement": "Patients with a QT interval greater than half a second are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [29]}, "84aa97cf-efce-484e-825e-5af509e5988f": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01441596", "Statement": "Patients in cohort 1 of the primary trial may receive a progressive increase in Afatinib monotherapy doses, up to 160% of the initial dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a40e172a-8839-499d-896d-be71a7ca4905": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03076190", "Secondary_id": "NCT03196635", "Statement": "While molecular breast imaging is not applied in either the primary trial or secondary trial interventions, all participants in these studies will be required to receive stem cell transplants.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "9e972e33-9ecd-4a8b-8337-7bee209f790b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02202252", "Statement": "The difference between cohorts 1 and 2 in the primary trial is assessed by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "f29768ba-5d79-4528-839f-933ab13faaa1": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01943916", "Secondary_id": "NCT01653964", "Statement": "All subjects in the primary and secondary trials will be administered 4 mCi Tc-99m sestamibi and subjected to molecular breast imaging.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "343e0a32-aebe-4bbb-97c0-b2c597c36802": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00392392", "Secondary_id": "NCT00503906", "Statement": "The primary trial records two different types of pain in its adverse events, in the abdomen and chest, the secondary trial does not record any type of pain in its participants.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "4d51608c-b0d8-4019-9b9a-34cf1c3d5087": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00558103", "Statement": "All participants in the primary trial are treated with Lapatinib 1500 mg PO QD and Pazopanib 800 mg.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "7bb88699-1536-4fdc-9cb2-c5ef350d559b": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00331552", "Secondary_id": "NCT01306942", "Statement": "Trastuzumab was used for interventions in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "c86ef61b-7565-465a-82ba-25e7ac050ccc": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02139358", "Secondary_id": "NCT02574455", "Statement": "There was one case of haemorrhage in the primary trial, and no case was recorded in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "58dec898-e0af-41c1-96f9-7163d3e3e855": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02019277", "Secondary_id": "NCT00863655", "Statement": "The primary and secondary trials recorded three of the same types of adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "5cf74526-9f91-498d-a13a-6393dcd45b7b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02291913", "Statement": "One patient in the primary trial suffered from inflammation of the liver.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "154caa20-3be1-4cee-a838-2d90b44566c4": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191269", "Statement": "The primary trial did not use the PFS to assess the performance of its interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "c40d8532-4e66-4eef-9644-91f20a02066d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02001974", "Statement": "No cases of esophageal adenocarcinoma were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "3d450be5-4587-48e5-ae2e-745623606631": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01289353", "Secondary_id": "NCT00429182", "Statement": "Both the primary and secondary trials administer biweekly oral carboplatin to their test groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2, 3]}, "fa28753a-aa3b-4642-9fd4-a2414fd8a472": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00943670", "Statement": "The change from baseline in mean QTcF interval duration in primary trial patients was greatest on day 1 of the third cycle after intravenous infusion of T-DM1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "5e700303-cd26-4024-a260-62f6a1c297ed": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01000662", "Secondary_id": "NCT02413008", "Statement": "The secondary test is to test a gel that is applied to the breast, while the primary test is to test an intervention that requires daily radiation from the breast.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "4c4c191c-de68-44c8-a23c-2455acc43d46": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00371345", "Secondary_id": "NCT00475670", "Statement": "There is no overlap between the adverse events observed in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "e5a4cb11-2a00-4144-93ba-f5462d7efbf0": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01818063", "Secondary_id": "NCT00559507", "Statement": "In both the primary and secondary trials, the only drugs administered orally are saracatinib and Veliparib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2]}, "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01720602", "Secondary_id": "NCT00082810", "Statement": "The primary trial participants receive more anastrozole, letrozole and exemestane than the secondary trial patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2]}, "27a4d1a8-185b-4483-85ce-0fbb3d323b99": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01945775", "Statement": "In the Talazoparib group of the primary trial, the shortest PFS was more than one month higher than the duration of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ff797dd4-0b4d-42fc-808d-27c439563ce2": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01743560", "Statement": "At week 48 of the primary trial, none of the patients had a complete response, 7 had a partial response and 15 had a progressive disease.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "9f666667-0fde-4d79-b53c-33c0ffbbed90": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00494481", "Statement": "Paula recently fell from a staircase and fractured her hip, she is excluded from the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "47084742-d031-4e59-865c-d8687282c782": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00494481", "Statement": "Paula has recently had a heart attack, she is excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5]}, "ae583ea3-36a5-472c-acda-825cd7d513b6": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454805", "Statement": "In the primary trial, there were no cases of subendocardial myocardial infarction in cohort 1 or 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "a18c447b-de08-48ef-8e65-0ecaa775c2b0": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00206427", "Statement": "One primary trial patient had vaginal fungal infection.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "18b900fb-b071-43df-b37d-c68a89ef78c0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00050167", "Statement": "Patients with metastases in four or more axillary lymph nodes are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00932373", "Statement": "Patients with peripheral neuropathy of grade III or more are eliminated from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 16]}, "d56745c3-ba0b-4b42-b3cf-ac060f658d83": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00670982", "Statement": "Acute coronary syndrome was the most common adverse event in the primary trial, other than thrombocytopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01446159", "Statement": "The primary trial included only a total of 6 patients in both cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 13, 14]}, "03c7f31f-788c-4edb-a885-b6cb0fca05da": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00375505", "Statement": "In the primary trial, patients in the control group had a Z score of 0.037, higher than the control group score.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e43c01e9-20a2-4435-a32b-224d5f460d7c": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01997333", "Statement": "The minimum progression-free survival for patients in cohort 1 of the primary trial was 1.6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c55f34ab-b883-465e-89dc-75bbeb8afa77": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00369655", "Secondary_id": "NCT00091832", "Statement": "One patient in the primary trial had a confirmed partial tumour response, No patients in the secondary trial were evaluated for tumour response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3]}, "0ee36ceb-5790-440e-b6ad-10a0b7a23f43": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01925170", "Secondary_id": "NCT00324259", "Statement": "Participants in cohort 1 of the primary trial undergo mammography, while patients in cohort 1 of the secondary trial receive 6 mg estradiol and no mammography.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "2535da13-e0f7-44df-aa02-89765d8d51cb": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02419807", "Secondary_id": "NCT00777101", "Statement": "Patients with HER2+ breast cancer in stage 1-4 are eligible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "94fc6e05-8a73-43d9-a48c-531d36dfbbcd": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00548184", "Statement": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab had at least one almost complete or better pathological response after 12 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "0057172f-d019-401b-a516-993a7b46a67b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01306942", "Statement": "Participants in cohort 1 of the primary trial received more Dasatinib than those in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bb23e8b8-c7d6-4e58-80a2-0555db5645e9": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03096847", "Secondary_id": "NCT01840163", "Statement": "Recently prescribed Rapamycin patients are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a Stage 1 to 2 Ductal Carcinoma in situ and can speak English.", "Label": "Entailment", "Primary_evidence_index": [9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c4588d2c-b0d4-428d-a958-29787b9d4ec5": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00545077", "Statement": "Only cohort 2 of the primary trial receives Bevacizumab, but both cohorts undergo endocrine therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00364611", "Statement": "Patients with clinically significant grade 3 DVP are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [18]}, "00466f98-52b8-41f3-9bf1-2edaad950be9": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02504424", "Secondary_id": "NCT03708393", "Statement": "Both the primary and secondary trials require patients to activate remote control procedures.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "50a524ae-2135-45f7-ae9b-515fd4e2e404": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02445586", "Secondary_id": "NCT02115984", "Statement": "More than half of patients in the primary study experienced adverse reactions and 100% of patients in the secondary study did not experience adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "b2062e01-0ea6-4ee8-94a1-b59dc40901d3": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01688609", "Statement": "Patients should have histologically or cytologically confirmed invasive breast cancer ERBB2+ with a primary tumour greater than 2 cm in diameter to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00826267", "Statement": "Cohorts 1 and 2 of the primary trial receive different amounts of different drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "43a9cc96-4020-459c-8fa4-4bbde7173f7a": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02447328", "Statement": "In the primary trial, 11 patients experienced serious adverse reactions, no patients experienced serious adverse reactions to the drug, and more than half of patients died of unexpected adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "ff319fa6-89b6-4f1a-871d-456edb91b69b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03045653", "Statement": "Sharone had a hip replacement 3 weeks before, it is not possible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 6]}, "a321acf0-2296-4588-bf96-85b22bf1420f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274456", "Statement": "There are a total of 14 cases of neutropenia-related adverse reactions in the primary trial in both cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "b841dfd8-4676-4d3c-a57d-6ba1055b8597": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02027376", "Statement": "One patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to entry into the study and the patient fully recovered from the resulting side effects, so this patient is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 25]}, "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01042535", "Statement": "The maximum tolerated dose (LMD) of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "48d40c7e-3514-43c3-a31a-7b391727f012": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01209195", "Statement": "In both cohorts, lower doses of MM-121 are used in cohort 1 of the primary trial than in cohort 2, the doses of paclitaxel are the same.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "dd98fca1-27a7-41c2-ba0c-3ff90aceab54": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01305941", "Statement": "Patients should submit IHC 3+ or FISH amplified results to participate in the primary trial, which means that their cancer is histologically confirmed as HER2-positive.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "b975dc12-757e-4ef5-af33-83dfce12e6cc": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01989676", "Statement": "The primary test records only IG adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2c4254c9-9c40-492f-aa45-2a9ab47579b3": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02658734", "Secondary_id": "NCT02073487", "Statement": "Women Patients with FEVL > 50% who have already undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]}, "e140b055-b7fc-4802-a79b-9dfe7d136876": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01575522", "Secondary_id": "NCT00181363", "Statement": "The primary and secondary tests test completely different methods of intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0a6418c8-63a6-4900-bfc9-1659acbe1ad7": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02581839", "Statement": "At least 8 primary test participants had a central nervous system (CNS) progression-free survival >= 3 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2db9e0c7-d94b-47d2-a61f-55a0896d714e": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00789581", "Secondary_id": "NCT02445586", "Statement": "The secondary trial reported more cases of Haemamesis, but the primary trial had more cases of Sinus tachycardia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "3129e58d-0c16-42a5-90b4-f26e048dfe58": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01644890", "Statement": "Throughout the primary trial, a cohort 1 patient developed vision problems.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "7be7cecb-d265-4098-9969-a40555702573": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00679211", "Statement": "One patient in the primary trial was diangosed with influenza.", "Label": "Contradiction", "Primary_evidence_index": [0, 12]}, "5b0d3709-7879-4dea-96c3-29178cd9f162": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00767520", "Statement": "The two cohorts in the primary trial reported the same number of patients who vomited during the trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 13, 18]}, "af70a3a9-d2d0-4d65-81fe-15a1becb5e95": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01420146", "Secondary_id": "NCT00077376", "Statement": "Both the primary and secondary tests have one control arm and several test arms.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "a378f448-eef0-465a-abc0-8b4dd1156bb5": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00372424", "Secondary_id": "NCT00041067", "Statement": "Patients with positive HER2 breast tumours are eligible for the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [3]}, "f30182a1-b82a-497c-885c-9bd2e805db62": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01487954", "Statement": "All patients in the primary trial had to drink 237 ml of water, either alkaline water or distilled water, depending on the cohort in which they were located.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ae87e5a3-fdd8-4003-ae80-4b370cade158": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01106898", "Statement": "2% of patients in the primary trial had non-recidivism survival < 3 years.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "9f3062db-16fb-41b8-ac10-f205f66070c8": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00696072", "Statement": "Most patients treated with Dasatinib and Letrozole in the primary trial had a disease-free interval (DFI) of more than 2 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "a1c5685a-8e6e-4733-aa8b-7040bac1a397": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00022672", "Statement": "There were no patients in either cohort of the primary trial with PFS greater than 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "d58683e2-d276-4184-a8e9-c9df6ffd8047": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00559507", "Statement": "The primary trial participants receive saracatinib PO for a maximum of 28 days.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "28d8f88a-e8cb-40c0-a12b-ef555f83ff59": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01904903", "Secondary_id": "NCT01663727", "Statement": "Patients must have a LEVF < 50% to be eligible for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "0ee4c935-18bd-4807-a2af-041a3d84e125": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02721147", "Statement": "Stephanie has been living with her boyfriend for 2 months, she is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 6]}, "355fb813-cbe0-44f5-b04a-87813e060d54": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00371254", "Statement": "Patients should have an eceptorsestrogen (ER) receptor -, a progesterone receptor (PR) - and a human epidermal growth factor receptor 2 (HER2) - breast cancer, as well as the absence of Dysphagia.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 8, 12]}, "274d9d2b-9227-4496-a525-d5477b0003ce": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00796978", "Secondary_id": "NCT01276041", "Statement": "A greater number of patients in cohort 1 of the secondary trial had oedema in their limbs, compared to patients in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "3ab9c66c-06fc-4bc5-b504-d9193efa8701": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00290745", "Statement": "In primary trials, participants from different ethnic groups receive different interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "d39078d9-9bc3-4b91-a012-e95f14813c9a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01252277", "Statement": "The 34-year-old sister-in-law of Fiona has been diagnosed with channel carcinoma, so fiona may be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "02538194-97ac-4749-9301-83f108927478": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00041067", "Secondary_id": "NCT01273896", "Statement": "Patients with positive ER, RA or HER2 tumours may be eligible for the secondary or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 14, 19, 20, 21, 22, 23, 24, 25, 26, 14, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 14, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]}, "6d9113b4-9d18-4a1b-bc78-cc3ac1150876": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01572038", "Secondary_id": "NCT00826267", "Statement": "Each patient in the primary trial receives 3 different drugs, while in the secondary trial, patients receive 1 of the 2 possible drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "99599b71-85d7-4c15-8d23-4294732f87cf": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00558103", "Statement": "All participants in the primary trial are treated with Lapatinib 1500 mg PO QD.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "adbc193f-ffd6-49ce-9acd-7b1675adf0c0": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00768222", "Statement": "Rachel is 19 years old and has skin ulcers and allergic reactions to triclosan, she cannot participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 4, 8, 9]}, "c476f92a-a450-4e5c-9688-6557ff3d822b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01617668", "Statement": "Patients must have healthy kidneys, liver and ovaries to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "39d685a4-b179-4687-a273-2a44e675f2c6": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00900627", "Statement": "Both groups in the primary trial receive the same drug treatment, but group 2 receives twice the dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c66963b9-19e0-4c0f-bb65-2fec15e60b8f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00965523", "Statement": "The most common adverse events in the primary trial where infection and stomatitis affect a total of 14 patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f541ce25-c43e-496b-98e6-8470fe23f840": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559845", "Secondary_id": "NCT00426556", "Statement": "In total, there were more adverse reactions in cohort 1 of the secondary trial than in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 14, 15]}, "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01224678", "Statement": "Intervention 2 of the primary test resulted in a lower percentage of mammographic density than intervention 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "24d81b18-ce9c-4927-9386-9ebef969a159": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00291135", "Secondary_id": "NCT00291694", "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0046e113-8ac5-4725-a285-e78b8c26f825": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02756364", "Statement": "To meet the inclusion criteria for patients in the primary trial, treatment with the aromatase inhibitor (AI) must be received prior to entry into the study, resulting in a complete tumour response.", "Label": "Contradiction", "Primary_evidence_index": [0, 9]}, "e90f7748-f4b4-4822-8768-586c3f2f9980": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00499083", "Secondary_id": "NCT03045653", "Statement": "To be eligible for both the secondary and primary trials, patients must be women over 18 years of age, ECOG < 2 years of age and have a HER2 + breast cancer confirmation.", "Label": "Contradiction", "Primary_evidence_index": [6, 10, 12], "Secondary_evidence_index": [0, 1]}, "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00429572", "Secondary_id": "NCT02455453", "Statement": "\u2022 Menopausal patients are excluded from the secondary trial but eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1]}, "3c3fb5e3-1994-455a-bae4-6d267c5c89d7": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00932373", "Statement": "Patients with peripheral neuropathy of grade I or higher are eliminated from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 16]}, "2ecd62df-f5ea-417d-8783-2174a6d77087": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03573804", "Secondary_id": "NCT02781051", "Statement": "The primary trial participants must undergo at least one MRI during the procedure and a strict chemotherapy regiment, while in the secondary trial patients must use an adaptation device.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "b43c02bf-c4b0-495f-b7ba-879f409cb685": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01781299", "Statement": "All subjects in the primary trial must engage in a regular exercise program.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fdff0cf1-a0a2-4516-bdf7-109ac7adb266": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03136367", "Secondary_id": "NCT00129935", "Statement": "Only patients who have been assigned as women at birth are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 6, 7], "Secondary_evidence_index": [18, 38]}, "6babfc60-5043-4f2b-9605-3e44744265e9": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00398567", "Statement": "80% of patients in the primary trial did not experience any adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "5ca02204-6120-4b02-bf3b-fba94d6fac4f": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274469", "Statement": "Not more than 1% of the two cohorts in the primary trial felt sick.", "Label": "Entailment", "Primary_evidence_index": [0, 12, 13, 25]}, "625c2690-ec9e-4ecc-85c0-9b5ca8467848": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00836186", "Statement": "Patients cannot be excluded from the primary trial on the basis of sex or ethnicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "c28ad685-4c91-492a-85ab-180f37d9cef5": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00290758", "Statement": "There was an adverse reaction GU and three GIs during the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "52e8d676-1744-4fdb-bab4-a553874329bd": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00829166", "Statement": "Women with peripheral neuropathy > 0 are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [9, 12]}, "beff8878-9405-412d-af3a-0f2720275bf3": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00068601", "Secondary_id": "NCT01684215", "Statement": "Both the primary and secondary trials use subcutaneous injections as the route of administration for their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "96f41881-6ba5-4688-8471-9462fc727919": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089661", "Statement": "On average, cohort 1 participants in the primary trial had an increased mineral density of the lumbar spine, whereas cohort 2 participants had a lost mineral density.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9dbf55d5-6af3-4250-b5cb-97799cdf778a": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02370238", "Statement": "There were no cases of intracranial haemorrhage in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00338728", "Statement": "While primary trial participants receive higher doses of imatinib mesylate than letrozole, letrozole is administered twice as often.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "d72709fd-e94e-4c27-bf56-3f028c0bbd3f": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01118624", "Statement": "The majority of participants in the primary trial achieved either CR or PR.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00463788", "Statement": "The best overall response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "49f44497-2382-4658-b716-38e66c5c52b7": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425854", "Statement": "The intervention in cohort B is described as Afatinib 50 mg taken orally for each day of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "4a6dc84a-3afd-4060-b8c5-981895f31099": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00312208", "Statement": "There were only cases of cardiomyopathy and coagulation disorders in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02574455", "Statement": "More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "f1f2e066-a016-422f-8627-d0e477933352": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193063", "Statement": "In the cohort of patients in the primary trial, three different types of infections are observed.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "efbd87d7-f8ac-42c6-ac9a-e3a35d354885": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00295867", "Statement": "Patients with a Karnofsky status of 94% are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [13, 16]}, "a604244f-789f-4c12-8c5a-96c86d1b976e": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00558272", "Statement": "The greatest change from baseline in the collagen type I cross-link telopeptide (betaCTX) of beta-terminal serum at week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a change of -75.9% from baseline.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01565083", "Statement": "Two different types of tachycardia occurred in patients in cohort 2 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [12, 22, 23]}, "987b1da5-0276-417d-a659-8e298529ccac": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01684215", "Statement": "In the primary trial, there was no difference in the number/percentage of participants with dose limit toxicity taking 100 mg vs 125 mg PD-0332991.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "b9e8a0b3-574f-4079-9191-214af99e97a8": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01176916", "Secondary_id": "NCT00186121", "Statement": "\u2022 Postmenopausal women with T1-4N1-3M1 Early invasive breast cancer is eligible for primary testing, and premenopausal women with T4-4N1-3M1 Early invasive breast cancer is eligible for secondary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2]}, "0151d1fa-05c8-45a0-b21e-f08478ea5110": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01697345", "Secondary_id": "NCT00513292", "Statement": "fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01075100", "Secondary_id": "NCT00290758", "Statement": "Several different mental health problems were observed in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "b838a265-99e4-42f0-bd72-b4f72d7eb16e": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02027376", "Statement": "One patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than a month before entering the study and the patient did not fully recover the resulting side effects, so this patient is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 25]}, "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00676793", "Secondary_id": "NCT01931163", "Statement": "Patients with vomiting are still eligible for both the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 26]}, "a1644573-fba8-4598-8353-a40d3ef1968c": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00428922", "Secondary_id": "NCT00499083", "Statement": "Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [26]}, "ba533122-db9d-49e1-a2d1-936c8fdfdd00": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01298193", "Statement": "More than 15 patients in cohort 1 of the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "f20cd859-7159-457a-a1cb-56bdb01d521b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274456", "Statement": "There are a total of 7 cases of Gastritis in the primary trial in both cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d33df923-6c12-4135-b339-5cefdd240985": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003782", "Statement": "None of the primary trial cohorts had more than 5% of patients with side effects.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 11, 12]}, "0f49a1ec-ed73-465b-be20-b70fe990b1f0": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00333775", "Secondary_id": "NCT00201864", "Statement": "There are several coagulative adverse events recorded in the primary trial, but not one in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "7370c10d-f6e7-4153-9649-9d2598ce1ed7": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03196635", "Secondary_id": "NCT01943916", "Statement": "The primary and secondary tests evaluate imaging techniques.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "3f89537a-479e-4314-b9de-4caf845850fc": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00558272", "Statement": "The greatest change from baseline in collagen type I cross-link telopeptide (betaCTX) at week 4 observed in the primary trial was a zoledronic acid 4 mg patient with a change of -73.0% from baseline.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "8e9f417a-dc0f-4c20-9cf7-5f8586c23df2": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01985971", "Secondary_id": "NCT03273426", "Statement": "Patients will have to undergo spinal MRI prior to entry for the secondary and primary trials, as patients in the primary trials will also have to have brain MR and PET imaging after entry into the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 2], "Secondary_evidence_index": [0, 6]}, "8ba451be-606a-4a57-a85e-82b5e5b286fc": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03366428", "Statement": "3/49 Primary Trial Participants with metastatic and/or non-resectable breast cancer with HER2 showed a maximum change of more than 30 ms from the initial QTcF test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "46906361-5133-4db9-b9e5-b9b7f80a8666": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00721630", "Secondary_id": "NCT00364611", "Statement": "The primary and secondary trials recorded the same proportion of patients with nausea.", "Label": "Contradiction", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 7]}, "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121992", "Statement": "To be eligible for the primary trial, patients must not have prior radiation therapy, systemic anthracycline or anticancer and must have breast cancer T1-3, N0 and M0.", "Label": "Entailment", "Primary_evidence_index": [12, 13, 14, 15, 19]}, "3320983d-55cb-49f9-9265-ca4e77acf62a": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01094184", "Statement": "A patient who received a joint injection in the last month would not be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "6c57e451-a706-4b32-ae71-254e9d0e04de": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01250379", "Statement": "None of the patients in the primary trial experienced thrombocytopenia, congestive heart failure, pancytopenia, acute coronary syndrome or atrial fibrillation.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 7, 9, 10, 11]}, "73a5f715-6d4c-43f3-ace4-9f1217d3d0c4": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00383500", "Statement": "The primary test is not a drug-based intervention test, it is a test of a medical device called Flexitouch.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "83883edd-ea16-4b20-8a97-2a545f957add": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00006110", "Secondary_id": "NCT00464646", "Statement": "The secondary trial records only gastrointestinal adverse events, while the primary trial does not record any gastrointestinal adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "ad0628ef-be51-4d54-a5c6-7608df258629": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00895414", "Statement": "- Orange juice is prohibited for patients who undertake the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 8]}, "619d88fd-cef5-4f1a-83dc-3cc710c1c93d": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00203502", "Statement": "Less than 30% of patients in the primary trial experienced at least one adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "42d6a15e-fa43-4ebc-b627-70f4dd0233f8": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00322374", "Statement": "The primary trial cohort 2 received a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "fc60c272-ceeb-47b5-b25b-dca832a2a57e": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02203565", "Secondary_id": "NCT00194779", "Statement": "The laboratory biomarker analysis and questionnaires are used in the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "dfe1236f-ac29-4c1c-a287-6f46abb7703d": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00810797", "Secondary_id": "NCT00828074", "Statement": "Skin infections were more common in patients in cohort 2 of the secondary trial than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [13, 21]}, "b1060434-0f7c-4c4a-bcff-53c3124bb51e": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02513472", "Statement": "The primary trial cohort 1 produced better objective response results than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e2862bbf-562f-4c96-abf1-fc9f07655b46": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00627978", "Statement": "Women with leptomenenic metastases are unfortunately excluded from the primary trial, as this would complicate the assessment of neurological and other adverse events.", "Label": "Entailment", "Primary_evidence_index": [18, 19]}, "aed75656-1594-4d99-be42-7097f7926c18": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00240071", "Statement": "At least one primary trial participant died within 100 days.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6ce5a9d7-5793-43b0-92ed-980cca3be02b": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01961544", "Statement": "The primary trial revealed a combined total of 3 cases of pericardial effusion, asthenia, and gastritis in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 8, 9]}, "b2a4f905-c6b5-4977-95de-5aa6424a5bb6": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00217399", "Statement": "To be included in the primary trial, patients must have at least one measurable one-dimensional lesion, there are no size limits for eligibility.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5, 8]}, "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00591851", "Statement": "There were 4 different gastrointestinal adverse events in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6, 7, 8]}, "4db02d9b-d96e-4ced-947c-71cebcccc933": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00847171", "Secondary_id": "NCT01764022", "Statement": "Patients with systemic lupus erythematosus are excluded from the primary trial, but may still be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [24, 32], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35]}, "cfb07772-e485-491c-8ae3-9009e3d04415": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201864", "Statement": "A primary test patient had a significantly lower BCE than normal.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "a283b69c-0f36-4773-a711-9e6088a8ee63": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01712009", "Secondary_id": "NCT00343382", "Statement": "Cohort patients 2 in the primary trial receive naproxen at the same frequency as patients in cohort 2 in the secondary trial receive Pilocarpine.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [3, 4, 5]}, "8d90d538-3b56-48dd-bd58-007d266c923c": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00915018", "Statement": "The only cases of heart problems in the primary trial occurred in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00904033", "Secondary_id": "NCT03592121", "Statement": "While patients are not required to be sexually active to receive primary trial intervention, this is a secondary trial requirement.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "8502cb9e-e382-41bc-b547-02d2d7beb381": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00620373", "Statement": "The primary trial tests two different methods of breast imaging, i.e. X-ray and gamma-ray imaging.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f6c64bb3-1836-4685-8541-8856f003524b": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01105312", "Statement": "Patients with non-measurable diseases are only eligible for Phase I of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 6]}, "79272218-91b9-4331-ba44-6a3709a13f62": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00073528", "Secondary_id": "NCT00191152", "Statement": "In the secondary and primary studies of progression-free survival (PFS) of their participants, however, they use different units of measurement.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 8, 9], "Secondary_evidence_index": [0, 1, 9, 10]}, "97e3b0d7-3320-4eb5-bc42-5031db87692e": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01964924", "Secondary_id": "NCT00524303", "Statement": "Both the primary and secondary trials indicate the objective response rate (ORR) of their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "83251670-803e-4fec-a5cf-50f052932752": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00708214", "Statement": "All participants with disease progression (after 16 weeks of treatment) in the primary trial were in the Afatinib 50 mg group with Letrozole.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01610284", "Statement": "One patient in the primary trial had a sudden loss of cardiac function.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01256567", "Secondary_id": "NCT01926886", "Statement": "The most common adverse reaction in the primary trial was febrile neutropenia (42.86%), while in the secondary trial it was a decrease in ejection fraction (4.95%).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "97812fde-57f3-4299-be34-dd436757adde": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00093795", "Statement": "Patients with cancer cells in the lymph nodes above the clavicle cannot enter the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "f37774f4-db96-4aa6-b3a1-626953faeecf": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00213980", "Secondary_id": "NCT02536339", "Statement": "The necessary blood, kidney and liver function are required to participate in the secondary trial, but this condition is not specified in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 7]}, "4fef4cdf-53bf-4239-9d31-4710fd3edc6f": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01605396", "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group in the primary trial had a median PFS of more than 38.43 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00181363", "Statement": "The only difference between the interventions used in the primary trial is the patient's position.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a577e819-c928-4217-8743-f4809e852919": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00834678", "Statement": "Patients should have a white blood cell count greater than 1500/mm\u00ac\u2032\u2022 to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [18]}, "bd073d05-3ba2-4898-9d86-a51951a7ad1f": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01004172", "Secondary_id": "NCT00802945", "Statement": "Both the primary and secondary trials use the objective response rate tumour to measure the effects of their different interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "5bc844fc-e852-4270-bfaf-36ea9eface3d_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01928186_BT", "Secondary_id": "NCT00684983_BT", "Statement": "Not all participants in the primary trial receive oral capecitabine, oral lapatinib ditosylate or cixutumumab IV in the conrast all subjects in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "86b7cb3d-6186-4a04-9aa6-b174ab764eed_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00662129_BT", "Statement": "Patients with platelet counts greater than 100,000 per millilitre, ANC < 1700 per millilitre, and hemoglobin counts between 4 and 5 grams per decilitre are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [18, 22, 23, 24]}, "dbed5471-c2fc-45b5-b26f-430c9fa37a37_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093145_BT", "Secondary_id": "NCT00703326_BT", "Statement": "In both the primary and secondary trials, heart-related adverse events were recorded.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 7, 8, 9, 10]}, "20c35c89-8d23-4be3-b603-ac0ee0f3b4de_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01097642_BT", "Statement": "Adult patients with histological confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3, 4, 5]}, "f17cb242-419d-4f5d-bfa4-41494ed5ac0e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00852930_BT", "Secondary_id": "NCT02308020_BT", "Statement": "Laser Therapy is in each cohort of the primary and secondary trials, as well as neoadjuvant chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "fc5c4554-7ce9-4c16-b374-a3cd9d15b021_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00971945_BT", "Secondary_id": "NCT01027416_BT", "Statement": "Patients must have already participated in a specific clinical trial to participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "96b77cdd-aa9f-4770-8447-8a04d9ca5da7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00633750_BT", "Statement": "Patients with clinical stage II invasive breast carcinoma (T2 N1) are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 4, 10]}, "c73faed2-371b-4238-bf7d-293fae380203_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00003404_BT", "Secondary_id": "NCT00711529_BT", "Statement": "The primary and secondary trials have hypnotherapy-based interventions, the secondary trials also used pain medications in their intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8765009d-ffc4-4395-ab7a-11ecdfd43a40_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00201773_BT", "Statement": "\u2022 Adele is an 85-year-old woman with histologically confirmed ER+ breast cancer at stage II with an ECOG of 0, she is eligible for the primary trial", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 6]}, "0ad7293d-df35-42e8-881d-f2afc3f7d3fd_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02606708_BT", "Secondary_id": "NCT02504424_BT", "Statement": "Only patients in the primary trial receive 40.5 Gy brachytherapy, patients in the secondary trial receive no radiation therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "2bc1e094-41a1-46d9-9b0c-b5a47f23323d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00895414_BT", "Statement": "Some drinks are prohibited for patients who undertake the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "83b83400-1439-462d-bba3-42817b5b1fa1_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00777049_BT", "Statement": "Most cases of CHF in the primary trial were in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 14, 20]}, "c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00058058_BT", "Statement": "\u2022 Applicants for the primary trial must have a life expectancy of more than 6 months.", "Label": "Contradiction", "Primary_evidence_index": [19, 9]}, "17a821f8-5e68-4bf7-ac01-3f96ddfc5187_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02964234_BT", "Statement": "Patients eligible for the primary trial must live in the United States.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "d76d6c7f-ba39-483c-a89e-152af5ae2878_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02525718_BT", "Secondary_id": "NCT02606708_BT", "Statement": "Patients in group 1 of the secondary and primary trials do not receive the same dose of AIMRT.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "65f3e755-3e23-4e84-a218-87922759094d_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01669343_BT", "Secondary_id": "NCT00146172_BT", "Statement": "The primary trial administers letrozole for 28 days, while the secondary trial administers a 4-cycle 21-day intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "d3590771-806b-4754-a455-38113bfedfca_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00952692_BT", "Statement": "\u2022 Applicants for the primary trial should have adequate colon and liver function and should not currently receive amiodarone or amiodarone in the last 28 days. Renal function is not relevant for inclusion.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61]}, "941b960f-8d57-4830-9d4c-8e96765ba76c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00994279_BT", "Secondary_id": "NCT00545077_BT", "Statement": "The primary and secondary trials administer Bevacizumab to each HER2+ patient.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f79a9011-0a68-4255-a40f-5d73af412bf0_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01425268_BT", "Secondary_id": "NCT01373671_BT", "Statement": "The CO2 is used as part of the intervention in only one of the primary test study groups and is not used in any of the secondary test study groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00777101_BT", "Secondary_id": "NCT00559845_BT", "Statement": "There was no complete suicide in the primary or secondary trial, but there was an attempt in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "57f3a264-9119-4931-9f9c-9cb20e945973_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00075270_BT", "Secondary_id": "NCT01781299_BT", "Statement": "The primary trial is to test a chemotherapeutic treatment while the secondary trial is to test a physiotherapy course.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "589e2f5b-9286-465b-8162-bb1549cd5ece_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00305448_BT", "Statement": "At least 4 patients in both cohorts of the primary trial received a complete (CR) or partial (PR) response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "8275f846-59b6-404d-a6d8-e01335279f1a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03066947_BT", "Statement": "Less than 1/4 of patients in the primary trial experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01390064_BT", "Statement": "Both cohorts in the primary trial are treated subcutaneously.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "18d9991c-ca96-4bab-93af-77654857a07f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01142661_BT", "Statement": "The primary trial does not accept patients with grade 1 alopecia.", "Label": "Entailment", "Primary_evidence_index": [17, 19]}, "6fb9056d-277c-4dc2-9b45-d7661bb41831_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01925170_BT", "Secondary_id": "NCT00324259_BT", "Statement": "Participants in cohort 1 of the primary trial undergo mammography, while patients in cohort 1 of the secondary trial receive 6 mg estradiol in addition to mammography.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "52b23601-2276-4634-96c7-8b6e55596085_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129376_BT", "Statement": "Only one patient in the primary trial experienced clinically significant inflammation of the back of the throat.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "95e05332-4926-4381-90a4-87941269e7bf_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00431067_BT", "Statement": "More than 5% of primary test participants received a partial response (PR).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "20d51467-b059-4f39-b636-d32f2dc692da_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00054028_BT", "Secondary_id": "NCT02162719_BT", "Statement": "The primary and secondary trials administer at least partially their oral interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "15c83d26-f9ba-44cc-a920-6941781cdd8b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01427933_BT", "Statement": "Neutropenia affected the majority of patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "e100212f-5bef-4f84-a3c1-d18a6b3e8355_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01648322_BT", "Secondary_id": "NCT00436566_BT", "Statement": "The primary test is shorter than the secondary test, and both studies use the same units of measurement in their evaluation.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 10], "Secondary_evidence_index": [0, 1, 2, 3, 9]}, "56d2a387-49dd-49b9-93bb-bcb092bf2714_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02286843_BT", "Statement": "The primary test consists of testing a new radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "2485a3e1-7520-47d2-b941-32ebf91e5b65_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00300781_BT", "Statement": "The primary trial participants receive an intervention based on their previous treatments.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b97d9465-db14-43af-9451-4b824e67abb8_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00899574_BT", "Secondary_id": "NCT01007942_BT", "Statement": "The primary and secondary trials use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not for the other.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "798c0983-5265-47ea-bfcd-735738793482_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02010021_BT", "Statement": "One patient recently received Tamoxifene to treat breast cancer, they are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 11]}, "127e9179-6781-4b9a-abe9-080d2ffad591_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02176083_BT", "Secondary_id": "NCT03061175_BT", "Statement": "Neither the primary trial nor the NCT0306117 use chemotherapy or radiotherapy in their intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00089479_BT", "Secondary_id": "NCT02964234_BT", "Statement": "Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, without evidence of metastatic disease. She is eligible for the primary trial but not for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "16dc5a77-5758-4d19-9801-6e9932d9fbc9_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01401166_BT", "Statement": "Several patients in cohort 1 of the primary trial prefer oral tablets as a method of drug administration.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2ed770a0-fe98-4029-9511-ad04a94a1a69_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00190671_BT", "Secondary_id": "NCT00455533_BT", "Statement": "In cohort 2 of the primary trial, the number of patients with leukopenia was higher than in cohort 1, while in cohort 1 of the secondary trial, the number of patients with leukopenia was higher than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 14, 19], "Secondary_evidence_index": [0, 3, 12, 15]}, "b4c97206-66fd-468b-8388-fac076222c10_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00863655_BT", "Statement": "There were 7 other cases of anaemia and 1 other cases of intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 12, 13, 14, 15]}, "6e22d118-af77-41bd-bd47-9385779f33aa_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00450723_BT", "Statement": "There are several types of surgical and therapeutic treatments that are prohibited for patients who want to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [19, 20, 21, 22, 23, 24]}, "ccc5362a-33d0-4f1b-be46-d31729ba9194_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01945775_BT", "Statement": "The shortest PFS in the Talazoparib group in the primary trial was more than a month shorter than the median PFS for this group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "fa530b28-9142-49f2-aa80-4d04fa532910_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03765996_BT", "Statement": "The primary trial group 2 participants are registered in anastomosis regions, but no complex physiotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00063570_BT", "Statement": "None of the patients in cohort 1 of the primary trial had platelet deficiency, and none of the patients in cohort 2 had pyrexia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "41cf791e-ed7a-48e5-af84-eefc9fa41ba7_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00503906_BT", "Secondary_id": "NCT01142661_BT", "Statement": "The adverse reactions of the primary trial where all are also common, while in the secondary trial alcohol intoxication was reported as the most common event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d417aa7b-6d2c-46f8-812c-426ea60e0328_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00894504_BT", "Statement": "There were only 3 adverse events in the primary trial that occurred more than twice.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "2744cc0a-86e9-4764-ae1c-f10f635dc283_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171704_BT", "Statement": "Most patients in the Letrozole group in the primary trial experienced a decrease in bone mineral density of the lumbar spine after 24 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2e4717fd-b349-48a3-b751-88674dfaaa18_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02392611_BT", "Statement": "In the primary trial, cohort 1 patients must have failed or become intolerant to the standard treatment, or have no standard treatment available, and cohort 2 patients must respond well to the standard treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b0c65cd7-8cad-404d-8704-ee074e480f57_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01237327_BT", "Secondary_id": "NCT00030823_BT", "Statement": "The primary and secondary trials do not have overlapping inclusion criteria, with the exception of the age limit of 18 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 51, 54, 55, 56, 51, 58, 59]}, "28e20650-e100-4e30-a319-5eceb69a979d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00509769_BT", "Statement": "One patient in the primary trial had toxic hepatitis.", "Label": "Entailment", "Primary_evidence_index": [0, 9]}, "8cf0c320-9486-4531-9212-bb3284b734f1_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02336737_BT", "Secondary_id": "NCT01432886_BT", "Statement": "The secondary test consists of testing the DLT for its interventions, while the primary test evaluates the effectiveness of lymph node detection using SentiMag and SiennaXP.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "34a75478-e7cc-495e-86c3-d0accdaf1ddd_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317603_BT", "Statement": "The primary trial participants must be over 18 years of age, have histologically confirmed stage 4 breast cancer, an ECOG < 2 and a life expectancy greater than 6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 6, 7, 8]}, "47780450-1202-4934-8e50-b29416b124f5_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00332709_BT", "Secondary_id": "NCT00659373_BT", "Statement": "All participants in the primary trial receive the same dose of Letrozole and all patients in the secondary trial receive the same dose of Tamoxifen.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00179309_BT", "Statement": "There were 2 cases of severe back pain observed during the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "c5e6497a-2e2f-4663-97fd-e73ba8904b0c_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01856543_BT", "Secondary_id": "NCT00365599_BT", "Statement": "In all secondary and primary trial cohorts, there was only one recorded case of myocarditis and thrombosis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "c4dd814d-f525-465f-abe1-a7975771d57e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01105650_BT", "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less than IL-2 than participants over 45 kg, but all participants will receive methylprednisolone 3 times a week for 6 doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "cfd93077-87c5-458b-8712-e1896929309d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00924352_BT", "Statement": "One primary test patient had abnormally low red blood cells, white blood cells, and platelets.", "Label": "Entailment", "Primary_evidence_index": [4]}, "a3faaf85-62c6-430f-acf2-9c5992ee5221_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00503906_BT", "Secondary_id": "NCT01142661_BT", "Statement": "\u2022 Adverse reactions in the primary trial where all were also common, while in the secondary trial disease progression was reported as the most common event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01931163_BT", "Secondary_id": "NCT00274469_BT", "Statement": "Less than 5% of patients in cohort 1 of the primary trial had high blood sugar levels, with 0% of patients in the secondary trial having high blood sugar levels.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "335936e4-9eaa-43b3-84fe-6f112c0d0226_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00574145_BT", "Secondary_id": "NCT03167359_BT", "Statement": "Radiotherapy and tactile curative therapy are used in all cohorts of the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "19921113-538e-4fd2-81a6-6053f2dd6459_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02622074_BT", "Statement": "In cohort 2 of the primary trial, patients with DLT were 38% more likely than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "6a013bb4-0688-4f02-96c5-062f3ca67ae1_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448279_BT", "Statement": "In total, there were 5 times more adverse reactions in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "c103a786-0b1d-4124-aa5d-4945ded2c384_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01106040_BT", "Secondary_id": "NCT01441596_BT", "Statement": "The primary and secondary tests do not study PFS, PBR or DLT.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "2746a75c-7f01-4dc3-a05e-5c7499e75555_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00274768_BT", "Secondary_id": "NCT00654836_BT", "Statement": "Patients with no more than one stage 3 cancer are eligible for the secondary trial and the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61]}, "df64a4c5-08f3-40c7-a4e7-2a6271bc9e53_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00416572_BT", "Statement": "Patients with anterior skin cancer malignancies are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [12, 13]}, "682f5e80-75c4-4a36-9bc1-b389a98ad160_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193037_BT", "Statement": "None of the patients in cohort 1 of the primary trial had hypotension.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02673918_BT", "Secondary_id": "NCT01042938_BT", "Statement": "Only white and Asian patients are eligible for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 4]}, "348c9273-6aa1-43a8-840d-3cf080874669_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00934856_BT", "Statement": "In total, in both cohorts of the primary trial, there were at least 2 patients with fever.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "dfe6228e-6bfb-49d3-b0b4-397aab177bea_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00068588_BT", "Statement": "The results between the two arms of the primary trial cannot be compared because there were no patients in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9f424ebb-63b8-4930-b2c1-cd46fff4d706_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01302379_BT", "Statement": "Only one cohort of patients in the primary trial showed a positive median change in insulin from baseline.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "c1f8c7fb-22de-4501-af86-d9eb59542ae3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00324259_BT", "Statement": "The cohort 2 of the primary trial had one more patient with a stable disease than the cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6630047b-7ebc-4435-8203-cf6bbe6b6ee7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00331630_BT", "Statement": "A left ventricular ejection fraction > 50% is required to participate in the primary test.", "Label": "Entailment", "Primary_evidence_index": [18]}, "039c3fc2-f798-4d97-b904-9aa7d363eeef_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00903162_BT", "Secondary_id": "NCT01674062_BT", "Statement": "Patients with in situ cervical cancer are eligible for the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [10, 12], "Secondary_evidence_index": [6, 10]}, "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121134_BT", "Statement": "The primary test requires participants to have undergone a PTR.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "f8028143-35d1-4cc3-895a-acb577db4715_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00537771_BT", "Secondary_id": "NCT00354640_BT", "Statement": "The cohort 1 participants in the primary trial and all participants in the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 5]}, "907f7e56-b6ec-4a43-bf3a-14f93c644bc1_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00193180_BT", "Statement": "A patient over 18 years of age with chronic viral hepatitis would be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 8, 16]}, "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00853996_BT", "Statement": "Women classified as at high risk of developing breast cancer over the next five years and over their lifetime by the Gail model are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "a41bf7b0-9a09-4ce0-8832-f13758581f20_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01572727_BT", "Statement": "The primary trial cohort 1 recorded more optical adversity events than the cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5f2d2015-eaf9-45a8-9583-fddbc9807287_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00130533_BT", "Statement": "Less than 0.25 % of patients in cohort 1 of the primary trial had hyperbilirrubinemia.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "609ddd08-ebd5-4661-be43-874b65dbfe52_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03273426_BT", "Secondary_id": "NCT01091168_BT", "Statement": "Patients with dementia or schizophrenia may be eligible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [4]}, "b6ac985d-87ae-4e0f-83e1-38033c1db5cc_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00322348_BT", "Secondary_id": "NCT00429572_BT", "Statement": "The primary and secondary trials use ECOG to assess the performance of potential candidates.", "Label": "Contradiction", "Primary_evidence_index": [2], "Secondary_evidence_index": [2]}, "43ff9425-5e6e-4a85-a8ca-0c0c67a96623_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00431067_BT", "Statement": "More than 5% of primary test participants met the response target (OR).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "b3ccde30-cdfc-4e18-aee0-8b3a921dde39_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470301_BT", "Statement": "Each primary trial patient receives tipifarnib PO, as well as paclitaxel, doxorubicin hydrochloride, and acyclophosphamide IV, but only one subgroup of participants undergoes dissection of axillary lymph nodes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "8697a59e-0f1c-452a-b15a-6d24e2df387f_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00191815_BT", "Secondary_id": "NCT01301729_BT", "Statement": "None of the patients in the primary or secondary trial committed suicide.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4ab74186-5f4e-4139-af05-d4a9871a251d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02721147_BT", "Statement": "Stephanie has been living with her husband for 31 years, she is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6]}, "082ee581-f420-4892-b098-ce82c6ad0210_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00432172_BT", "Statement": "All adverse events recorded in the primary trial were heart-related.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "7bf084eb-873a-4011-9b98-3a899ee582ee_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00982319_BT", "Statement": "Pre- and post-menopausal women may enter the primary trial as long as they do not have prior hormone replacement therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01575522_BT", "Secondary_id": "NCT00181363_BT", "Statement": "The primary and secondary trials test completely different methods of intervention, but use the same 21-day cycle.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00741260_BT", "Statement": "Patients with positive ERBB2 tumours are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "f6c85ce8-e0fc-4186-a961-6207dd4cacd2_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01268150_BT", "Statement": "Most primary trial patients treated with Eribilin Mesylate did not obtain a complete (CR) or partial (PR) response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5bdd61d9-aadf-4944-afe3-a04242d9c2b2_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02321527_BT", "Statement": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2]}, "b8ce7d6a-d707-48e0-816c-de7ac3a63823_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01252277_BT", "Statement": "The 34-year-old sister of Fiona has been diagnosed with channel carcinoma, so fiona may be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "53d88010-e7d7-41c7-b20d-6328c8e507d1_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01498458_BT", "Statement": "For some types of adverse events in the primary trial, there have been no recorded cases.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8257bf5c-fae6-44c0-a86d-293746fdc468_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01416389_BT", "Statement": "In the primary trial cohort 1 there were more cases of hepatic encephalopathy and pneumonia than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00372424_BT", "Secondary_id": "NCT00041067_BT", "Statement": "Patients with positive HER2 breast tumours are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [3]}, "974225b7-9089-499c-9550-0a7207fd28b2_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03346161_BT", "Secondary_id": "NCT01000662_BT", "Statement": "The primary trial procedure does not require that patients undergo medical treatment during the study, while in the secondary trial all patients receive radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6f533f52-c8e4-4983-8968-69af03a9e34a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01506609_BT", "Statement": "Patients with cytologically confirmed breast cancer who have a local recurrent disease are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "690b8562-7d68-4642-bacb-601f227bb763_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00591864_BT", "Statement": "The primary test does not have an intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "75f94edd-dbde-4a19-be18-e67c767f6d8f_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03618017_BT", "Statement": "The intervention section of the primary trial does not describe the dose, frequency or duration of the intervention for cohort 2, but cohort 1 receives placebo twice daily for two months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00687440_BT", "Secondary_id": "NCT01307891_BT", "Statement": "The primary trial had a higher percentage of patients with at least partial response than either cohort in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "34ee4f66-e6f7-458c-964c-12fa730a9d56_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02556632_BT", "Statement": "The two cohorts in the primary trial apply the topical intervention for approximately every 4-6 hours per day during one week of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "9b0451fe-f760-46d3-b555-0a9b83546e73_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00087152_BT", "Secondary_id": "NCT00203502_BT", "Statement": "The primary trial recorded half of the number of patients who vomited like the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5]}, "b9304415-073d-476e-a056-cb2a747d56fa_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00021255_BT", "Statement": "The primary trial cohort 2 was for doxorubicin only during Cycles 1 to 4, followed by doxorubicin, cyclophosphamide, herceptin, and docetaxel during Cycle 5 of the study.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5]}, "6e365e33-16b8-43e1-99b5-49dfed6f7b13_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00316199_BT", "Statement": "Only Chinese women with breast cancer in stage 4 or non-resectable and local repeaters are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01306942_BT", "Statement": "Participants in cohort 1 of the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "27acc6d7-c12d-4a38-9133-a5c8429dd264_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00656669_BT", "Statement": "The primary trial recorded 23 adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "5919a080-2f0d-4c3b-9b03-10df80b2e680_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01007942_BT", "Statement": "There were no adverse events in the primary trial that affected more than 10% of a given cohort of patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "91f6e62a-97e7-49fa-8509-7ff8c1f0155e_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00671918_BT", "Secondary_id": "NCT00571987_BT", "Statement": "Patients with pure in situ ductal carcinoma (DCIS) or melanoma are eligible for both the secondary and primary trials, and may participate in these trials in conjunction with other clinical trials, up to a maximum of 3.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 12], "Secondary_evidence_index": [0, 9]}, "b351a091-d5fb-49f9-a864-5c89c6316b1b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01688609_BT", "Statement": "Patients should have histologically or cytologically confirmed invasive PR+ breast cancer with a primary tumour > 2 cm in diameter TO PARTICIPATE in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "d5ca2086-8404-42d1-bf45-5370f3d4e8e8_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02139358_BT", "Secondary_id": "NCT02574455_BT", "Statement": "There were 16.67% more bleeding cases in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "4c038972-20a9-4031-a1cd-ba00e9dd0908_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00410813_BT", "Secondary_id": "NCT00617539_BT", "Statement": "In the primary trial, Dasatinib, 70 mg, twice daily, gives a median PFS better than Dasatinib, 100 mg, daily. The opposite was true in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "82d6275a-97e6-4d13-84eb-5f7c2585db8b_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02132949_BT", "Secondary_id": "NCT01111825_BT", "Statement": "Between the primary trial cohort and the secondary trial, there was only one patient with heart failure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "286e74e5-74ed-4d42-b32d-f1398c514d37_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01125566_BT", "Statement": "At least one primary trial participant receiving oral treatment of the afatitinib film-coated tablet at an initial dose of 40 milligrams (mg) once daily and a 10-minute weekly intravenous injection of Vinorelbine 25 mg/metre^2 (metre=m) experienced PFS over a 9-month period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "634642da-db6d-49cc-a999-67f46e91dbca_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01237327_BT", "Secondary_id": "NCT00030823_BT", "Statement": "The primary and secondary trials do not have overlapping inclusion or exclusion criteria.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 51, 54, 55, 56, 51, 58, 59]}, "a529e364-2da7-4067-acb6-9fb2f0adf08b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01401062_BT", "Statement": "A patient who has undergone T-cell transfer treatment in the last 2 weeks would be excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 8]}, "317e00ae-9d17-4f85-8787-602cc2548fdb_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00004092_BT", "Statement": "\u2022 Cancer patients who have spread a breast tumour to their bone marrow are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4]}, "de955acc-ce0e-4416-9884-644a06971603_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00195013_BT", "Secondary_id": "NCT00620373_BT", "Statement": "The Primary Trial Cohort 2 and the Secondary Trial are test groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4956f0d0-4df4-4de3-9a46-6073927485c3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01017549_BT", "Secondary_id": "NCT01390064_BT", "Statement": "The secondary trial has more cohorts of patients than the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9ca0cc75-58b3-451d-abcc-378526744ca4_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01985971_BT", "Secondary_id": "NCT03273426_BT", "Statement": "Patients will have to undergo MRI prior to entry for the secondary and primary trials, as patients in the primary trials will also have to have MR and PET imaging after entry into the study.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 2], "Secondary_evidence_index": [0, 6]}, "6efb001b-5ed3-470b-a206-7768a1adf597_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01581619_BT", "Statement": "Invasive canal breast cancer confirmed histologically would result in the exclusion from the primary trial, but not from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [4, 10]}, "70dd1a42-6e40-4880-80a8-45dfd4941ce4_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00089973_BT", "Statement": "The primary test uses a 3-week cycle for the administration of SB-715992.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "85f43677-b680-4127-b1da-7e1cc966e4b2_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01943916_BT", "Secondary_id": "NCT01653964_BT", "Statement": "Not all subjects in the primary and secondary trials will be administered 4-8 mCi Tc-99m sestamibi.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "4cccea8a-22ae-4813-96df-b902850f4991_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01783444_BT", "Secondary_id": "NCT03136367_BT", "Statement": "Women of any age may participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "8574ecd7-4da7-49b0-a273-de495bc1fee7_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00951665_BT", "Statement": "Both nausea and death are the most common adverse events in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "01b82c51-dd3d-430b-9523-0e93a9eb9c1a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00950300_BT", "Secondary_id": "NCT00615901_BT", "Statement": "The primary trial recorded a multitude of patients suffering from chest pain, whereas the secondary trial observed only one patient suffering from abdominal pain.", "Label": "Contradiction", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 3]}, "93149dfc-667b-48d3-a46d-ad48b15e701f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00451555_BT", "Statement": "Cohorts 1 and 2 of the primary trial recorded exactly the same number of each type of adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "d080eec7-412f-4a44-8c56-91e0ec459acc_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01422408_BT", "Statement": "The primary trial is a Phase II trial in which all participants will receive 0.05% topical fluoconide cream to apply to their genitals twice daily for two weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "fd18a599-f94a-478a-975f-854a4210ccad_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00659373_BT", "Secondary_id": "NCT02202252_BT", "Statement": "The primary trial has a duration of intervention of 5 years, the duration of the secondary trial is only one day after the drains have been removed.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "ac9ca070-80b2-4913-97d8-06d1b90fcfce_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01797120_BT", "Secondary_id": "NCT02005887_BT", "Statement": "Both the secondary and primary trials have a placebo arm and a test arm.", "Label": "Contradiction", "Primary_evidence_index": [7, 8, 9, 3, 4, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00082810_BT", "Statement": "During the entire duration of the primary trial, paritiquants receive increasing doses of Fulvestrant.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "009d23bb-2179-4ce3-927d-4dedca6b32a8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00479674_BT", "Statement": "Patients who have already been treated with bevacizumab are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [22, 24]}, "5152d810-7669-4fb2-a66b-a0a1d6026af5_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00577122_BT", "Secondary_id": "NCT01923168_BT", "Statement": "The secondary and primary trials use both the complete pathological response (CTR) as a measure of the results and a 6-month delay.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "e8f4a600-0296-47d4-903b-2fa840ebcf28_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02005549_BT", "Statement": "Patients with stage 3 cervical carcinoma are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "3fa8b747-b48d-4fb4-995d-38a23c64ccb3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02069093_BT", "Statement": "In the primary trial, 2 of the patients were either symptomatic but were able to swallow a modified diet; symptomatic and unable to feed or hydrate orally or had symptoms associated with potentially fatal consequences.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b9c294c3-93b7-4681-be02-285f9e5cd867_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03167359_BT", "Secondary_id": "NCT01385137_BT", "Statement": "Between all primary and secondary trial cohorts, omega-3 fatty acids are only used in one cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "9df90d78-d857-4e1d-a650-e47f7b6b68d6_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00322374_BT", "Statement": "The primary trial cohort 2 receives a higher dose of Ixabepilone at a higher frequency than cohort 1,", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03098550_BT", "Statement": "The results section indicates that there were no patients in the primary trial with 0 adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "92ac6e0c-8427-454d-9218-36eda1c580a7_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01653964_BT", "Secondary_id": "NCT02660788_BT", "Statement": "The interventions in the primary and secondary trials are so different that it is not possible or useful to compare them.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "f0aff1fc-4a67-4b28-a974-a4a67a5c930f_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00733408_BT", "Statement": "There were more than 14 weeks of difference in progression-free survival between minimum and maximum PFS in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00121836_BT", "Secondary_id": "NCT00256243_BT", "Statement": "Patients who are not willing to sign and give written informed consent to participate in the primary or secondary trial will not be invited to participate.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [11]}, "96ab702d-cfe1-48fb-b348-a7c7b8db3f16_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00684983_BT", "Statement": "The median duration during which a patient in the A arm of the primary trial survived after receiving a TBBC diagnosis was 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6224d2de-c62b-4b43-8517-475eaa565491_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00811135_BT", "Statement": "The majority of patients in the primary trial had at least one adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "95154c62-9f79-4d80-90fd-2f61612285b0_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01095003_BT", "Secondary_id": "NCT01702571_BT", "Statement": "In total, more than 5 patients in the primary and secondary trials suffered from Earache.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "2f6243a9-af40-426d-9a6a-a5c5708cf1b4_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00721630_BT", "Secondary_id": "NCT00364611_BT", "Statement": "The primary and secondary tests recorded exactly the same number of cases of nausea.", "Label": "Entailment", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 7]}, "837f0588-22fc-4069-b2bc-297b3f6aabf7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00058058_BT", "Statement": "\u2022 Applicants for the primary test do not need to meet a specific life expectancy criterion.", "Label": "Entailment", "Primary_evidence_index": [19, 9]}, "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00572728_BT", "Secondary_id": "NCT02472964_BT", "Statement": "Patients in the primary trial will not be required to take Herceptin?\u00a9 (trastuzumab) or paclitaxel intravenously as in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03511378_BT", "Statement": "Patients must have a life expectancy of more than half a year to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02630693_BT", "Statement": "One 30% of patients in the primary trial had a life-threatening reaction to infection.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d72ecaae-c132-480c-af5e-87c58dd26082_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00679341_BT", "Secondary_id": "NCT00201851_BT", "Statement": "The only adverse reaction observed in patients in the secondary and primary trials was endocervical cancer.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "80245791-4a95-4682-bd5f-856694c9f52f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00721409_BT", "Secondary_id": "NCT02413320_BT", "Statement": "Patients with negative HER2 tumours are eligible for the primary trial, but not for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01325428_BT", "Secondary_id": "NCT00073073_BT", "Statement": "The secondary trial and the primary trial do not require participants to be of a particular ethnic group, to be able to speak a particular language, or to be above a certain threshold.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "f0da58e6-e937-41ac-b53a-d46ec8a28d11_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01923168_BT", "Statement": "Intervention 1 of the primary trial requires participants to take 300 mg of alpelisib once daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "5a74a63a-3912-44f0-9e83-4e6b678cbe90_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02685566_BT", "Secondary_id": "NCT03076190_BT", "Statement": "The primary and secondary trials have the same number of study groups and test the effectiveness of digital mammography in the field.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "43f03ba4-ef03-4f57-b059-3d9267f0dcf8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00325234_BT", "Statement": "Patients under the age of 18 who wish to participate in the primary trial should discontinue any anti-tumour hormone therapy prior to entry into the study and have a life expectancy of more than 3 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 8, 13]}, "6e106caf-2522-4022-898d-64b82093d77a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02413320_BT", "Statement": "Women over 20 years of age without prior chemotherapy with therapeutic intent for current cancer are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5]}, "7f8a918c-fab8-4129-8178-0cda7d0441e1_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00021255_BT", "Statement": "Cohort 2 of the primary trial with Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the study cycles.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5]}, "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01125566_BT", "Statement": "At least 400 primary trial participants receiving oral treatment of the afatitinib film-coated tablet at an initial dose of 40 milligrams (mg) once daily and a 10-minute weekly intravenous injection of Vinorelbine 25 mg/metre^2 (metre=m) experienced PFS for 9 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02018458_BT", "Secondary_id": "NCT00895414_BT", "Statement": "Patients with unexplained fever below 38 degrees Celsius may be included in the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [25, 28], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "0290bc2d-9cd3-44ab-9b04-385f19527c42_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02550210_BT", "Statement": "Patients should have a channel carcinoma, which may be felt by contact to be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "505afbf8-b2b4-4b12-99c5-e0feef473248_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00577122_BT", "Secondary_id": "NCT01923168_BT", "Statement": "Both the secondary and primary trials do not use the rate of clinical benefit as a measure of their results, and they do not use the same time frame.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01816594_BT", "Secondary_id": "NCT02222337_BT", "Statement": "Patients with newly diagnosed stage 0 bilateral breast cancer may not participate in the primary trial, but may still be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2e540abd-06e3-483d-bd69-6eb5d2275e9e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01830933_BT", "Secondary_id": "NCT01224678_BT", "Statement": "Patients in the primary and secondary trials are treated daily orally.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [5]}, "d905f4cb-32aa-41b8-8f61-40578d8ea9ae_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274469_BT", "Statement": "No less than 2 patients in either cohort of the primary trial felt sick.", "Label": "Contradiction", "Primary_evidence_index": [0, 12, 13, 25]}, "45510043-7931-493b-8251-41b0be9aabbd_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00232505_BT", "Statement": "There were 2 cases of patients with ear tachycardia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e7037f34-bd2e-402e-a19c-48073781885a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193037_BT", "Statement": "Ten of the patients in cohort 1 of the primary trial had hypotension.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "5275a332-46c1-4941-8850-26a8033012e3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981305_BT", "Statement": "Only those who have already been diagnosed with cancer and have no signs of cancer after completion of treatment are elected for the primary trial, as long as they are over 20 years of age.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01129622_BT", "Secondary_id": "NCT01156987_BT", "Statement": "Both the secondary and primary trials used MRI and Letrozole for their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "b02f43d7-44bb-4219-9a08-fd70e7cc9b87_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01004744_BT", "Statement": "Patients should have a confirmed postmenopausal status, defined as a lack of period for more than one year, if they are to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2]}, "1a6661e0-343f-4056-b568-611e7cc7750c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01827163_BT", "Statement": "All breast cancer patients above the stage who are currently receiving radiotherapy or biotherapy are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [13, 14]}, "ec97c90e-f904-4cf2-9567-8525edf747cf_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03196635_BT", "Secondary_id": "NCT01943916_BT", "Statement": "Both the primary and secondary trials evaluate patient-assisted imaging interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "7a129a1e-20d9-4f5a-a921-d30957460e27_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00820222_BT", "Secondary_id": "NCT01819233_BT", "Statement": "The secondary and primary trials do not test the same treatment methods for cancer.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01566721_BT", "Statement": "The percentage difference for participants with at least one adverse event (AE) during the treatment period in both cohorts of the primary trial is less than 1%.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a1c99d5b-d53a-4195-ad5f-5e1b48c22078_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03176238_BT", "Secondary_id": "NCT01498458_BT", "Statement": "While there is a much higher percentage of thrombocytopenia patients in the secondary trial than in cohort 1 of the primary trial, no solid comparison can be made due to significant differences in cohort size.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "0203435e-03a0-4c41-afdf-6c497d8908c1_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00331630_BT", "Statement": "Men with a left ventricular ejection fraction > 50% are excluded from the primary test.", "Label": "Contradiction", "Primary_evidence_index": [18, 9]}, "e6388dc2-b096-467d-8b70-fd5346dd581a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00083174_BT", "Secondary_id": "NCT00190671_BT", "Statement": "The highest number of occurrences for any adverse event during the primary and secondary trials was 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "93511e52-1c12-4dee-858e-13b10793e2a6_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429182_BT", "Secondary_id": "NCT00429507_BT", "Statement": "The secondary trial uses radiotherapy exclusively in its intervention, while the primary trial gives its cohorts stem cell transplants on the first day of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "cb932dbf-4c98-4488-b189-1286442968b6_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02005549_BT", "Statement": "Patients with cervical carcinoma in situ are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "0b9aa7e8-5912-44db-b9b0-6a84df769e19_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00545688_BT", "Statement": "There were no patients with paranasal sinus reactions in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "570ab6bb-b23c-4955-b6b0-d756d1b69c0e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00756717_BT", "Statement": "Patients with cytologically confirmed metastatic invasive breast cancer at an early stage with an Allred score of 3 are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "daf105f8-58e8-47d7-b0a2-5949620b0a2b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00296036_BT", "Statement": "The primary trial administers placebo and urea/lactic acid cream at the same frequency and over the same areas of the skin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c4b671ae-4701-43a3-ada1-659c265d1f3a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01582971_BT", "Statement": "To participate in the primary trial, participants need to know where they are and what day they are.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "0a17a404-ed1d-4c31-a192-509b68198ea8_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00717405_BT", "Statement": "There was a dental adverse event in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02699983_BT", "Secondary_id": "NCT00994279_BT", "Statement": "Neither the primary test nor the secondary trial requires participants to practice yoga while wearing a Fitbit activity monitoring device.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e8b86ef4-3ce8-4d81-a632-f30672c80ff5_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02115607_BT", "Secondary_id": "NCT01823107_BT", "Statement": "In the primary trial, patients receive infusions of Perflutren lipid microspheres, whereas in the secondary trial, subjects are implanted with a Meso BioMatrix Acellular peritoneic matrix.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "879f2f14-38a8-419a-bae0-e62ed81eb9dd_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00146172_BT", "Statement": "The primary trial cohort 1 is less than 60% of the LA-EP2006 dose in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2ec46285-dd0c-4420-b9f6-e44a1ac74f20_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01752907_BT", "Secondary_id": "NCT01940497_BT", "Statement": "There were 0 cases of fractures of Tibia or Fibula during the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "f8afffdc-649b-4921-942a-66b804a3717f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121992_BT", "Statement": "To be eligible for the primary trial, patients must not have prior radiation therapy, systemic anthracycline or anticancer, and must have bilateral breast cancer T1-4, N1 and M1.", "Label": "Contradiction", "Primary_evidence_index": [12, 13, 14, 15, 19]}, "65f22210-47dd-4865-99e2-ddd414dddb08_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01806259_BT", "Statement": "More than 82% of patients in the primary trial achieve non-recurrence survival after 5 years.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00915603_BT", "Secondary_id": "NCT02511730_BT", "Statement": "The INR of 1.35 is sufficient to participate in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 24], "Secondary_evidence_index": [0, 1, 2, 3]}, "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00917735_BT", "Statement": "A patient in cohort 2 of the primary trial crashed his motorcycle.", "Label": "Entailment", "Primary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "0aa3c085-b9c6-4918-a5d0-eabc55bdd177_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01560416_BT", "Statement": "There were more than 10 more adverse events in cohort 2 than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 12, 13]}, "333c2723-e2e8-4c68-9591-36b7f169ff26_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00828074_BT", "Statement": "A higher percentage of cohort 1 in the primary trial showed signs of fever compared to cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 13, 18]}, "1fa01b9a-1288-404c-ad58-8dcf3db3264c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00477464_BT", "Statement": "59% of the primary A arm received a better overall response, classified as a complete or partial (confirmed) tumour response or stable disease for at least 6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ed272c3f-37a1-4db7-8990-bf226f8c9822_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02049957_BT", "Secondary_id": "NCT01506609_BT", "Statement": "There are the same number of cases of Diplopie in the primary trial as anemia in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "b1497cf4-6b06-4227-b679-19e2ac5fb5c3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01421017_BT", "Statement": "The primary studies focus on the effects of CTX/IMQ/RT and Epothilone on central nervous system (CNS) progression-free survival 9 weeks after initiation of treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "186d5a67-1309-4abc-b31a-de026c5b8bda_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00405938_BT", "Statement": "Patients diagnosed with intradural tumours are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 10]}, "6b86f306-f989-4676-8f5e-c4c8a6aa4258_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470847_BT", "Statement": "The primary trial participants will receive either Lapatinib, WBRT or Herceptin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "0e8e4a92-b104-4192-ad36-33b683f94216_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02463032_BT", "Statement": "There was less than 5% difference in the 9 mg and 18 mg results in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00438659_BT", "Secondary_id": "NCT01271725_BT", "Statement": "The primary trial has a topical intervention, while the secondary trial has oral interventions and IV.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "03a8a787-2bf3-43e5-9c9e-7bd9c3278751_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171704_BT", "Statement": "All patients in the Letrozole group in the primary trial experienced a decrease in bone mineral density of the lumbar spine after 3 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "7d7a9a69-533a-4480-b2e7-aa59eb8a738b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02260531_BT", "Statement": "The percentage of participants with a complete (CR) or partial (PR) response was 6 times higher in the HER2-positive group in the primary trial than in the ER+ and/or PR+ group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "c6fc8336-7c74-443e-9548-3bbafe21fc37_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00036270_BT", "Statement": "In total, less than 10% of patients in the primary trial experienced a relapse or died.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9035000f-d87b-439f-882a-e6e30694e391_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01351376_BT", "Statement": "Currently prescribed patients Diuretics are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 18]}, "522ca0ec-aeb0-4083-a274-ab58c2cddb8a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03210220_BT", "Secondary_id": "NCT00290745_BT", "Statement": "Unlike the primary test, the secondary test does not test hormonal analogues or gonadotrophin medical devices.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "46d65581-7a0a-423b-907e-662c1f5843cc_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01127763_BT", "Statement": "There were 4% more cases (1 more) of Dyspnea than of Dehydration in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 6]}, "f4ea6e98-75e1-43a0-8202-548bb7ceb66c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02413008_BT", "Secondary_id": "NCT02725801_BT", "Statement": "The primary trial procedure requires patients to receive multiple treatment applications over a period of several weeks, while the secondary trial procedures are applied only once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00534417_BT", "Statement": "The median TTP for patients in cohort one of the primary trials is NA.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "932728c5-2e7f-401f-be64-e90597ff2ce2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129935_BT", "Statement": "There were more cases of embolism in cohort 2 of the primary trial than in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "54ad9406-852c-40fc-bd0e-8e7e81eacc71_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00291577_BT", "Statement": "It is not possible for a primary trial participant to have time to reach a maximum plasma concentration of 16, 17 or 20 hours.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "7021a4a9-b474-4568-a3b8-015a50c9d9cc_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00201760_BT", "Secondary_id": "NCT00127933_BT", "Statement": "Patients should have a triple negative breast carcinoma to participate in the secondary or primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 3]}, "24eced44-40b2-4365-abd3-42eb13220cf0_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00290745_BT", "Statement": "There is no radiation therapy or educational part of the intervention used in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "3e2dda3a-815f-4681-a470-009d9f9b30d6_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01448447_BT", "Secondary_id": "NCT03252145_BT", "Statement": "The primary test consists of testing a radiotherapy intervention while the secondary test consists of testing a new portable medical device.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "1a293e7c-691f-4f93-bab8-6bf5d9b3f904_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01653964_BT", "Secondary_id": "NCT02660788_BT", "Statement": "The interventions in the primary and secondary trials are similar because they test the same drug, but they do not use the same doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "a87e6e20-c7d0-4941-9933-204fab99b299_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00444535_BT", "Statement": "Less than one-third of participants in the primary trial treated with Lapatinib achieved progression-free survival after 6 months of study treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "6c3427a8-27a1-459c-9fbc-175649210868_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01940497_BT", "Statement": "In the primary trial cohort 1 there were more allergic reactions than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "883bec6a-bce2-4e60-9304-49a056e66df7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00101400_BT", "Statement": "One female with hemoglobin > 10.0 g/dl, the absolute number of neutrophils 1.733 mm3, the number of platelets = 100,000/\u00ac\u00ac\u03bcl and total bilirubin < 1.2 x ULN are eligilbic for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [9, 10, 11, 12]}, "8720143a-2611-4502-a5ee-da4e641df918_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02402764_BT", "Secondary_id": "NCT00490646_BT", "Statement": "There have been no cases of extravasation in either the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "0fdda7a2-4119-40a7-84f3-6c5c6077df49_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02186015_BT", "Statement": "Women in cohort A and B of the primary trial with a serum level of 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly additions of cholecalciferol.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e7eae332-6b6a-41e0-aa31-86a781fd373f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01273896_BT", "Statement": "There were twice as many cardiac adverse events as the cases of Dyspnea in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 8]}, "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01439945_BT", "Statement": "In the primary test, low dose magnesium oxide is 400 mg/day lower than the high dose of magnesium oxide.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "c09b9f7c-2d22-4c44-a79d-32929530dd9e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01735175_BT", "Secondary_id": "NCT01216319_BT", "Statement": "Both the secondary and primary trials are biodesign interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "6f143256-52e4-40b7-950c-5c892f8632b9_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00003199_BT", "Statement": "The group of patients with the highest percentage of PFS at 5 months in the primary trial was in stage IIIB patients, and the worst was in stage IV patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "d2718f05-1d35-4c84-a054-06a3fe4a0a9c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00217399_BT", "Statement": "To be included in the primary trial, patients must have at least one measurable one-dimensional lesion and must meet certain specific size conditions.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5, 8]}, "7f49cafd-3a27-4fc8-872d-914b9176442e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01427933_BT", "Statement": "Neutropenia was the most common adverse event in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01998906_BT", "Statement": "The same number of cases of Neutropenia and Pancytopenia is observed in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 4]}, "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00428922_BT", "Secondary_id": "NCT00499083_BT", "Statement": "Patients who received pre-stage 4 radiation therapy more than 5 years ago are not eligible for the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [26]}, "4ab00376-83a4-467e-8a1e-6b8b1643a8f0_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365599_BT", "Secondary_id": "NCT01771666_BT", "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no history of blood clots are eligible for the primary test but excluded from the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 10, 12, 15, 25], "Secondary_evidence_index": [0, 6]}, "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01565499_BT", "Secondary_id": "NCT01234402_BT", "Statement": "None of the patients in the primary trial were reported to have heart-related adverse reactions, while many of the patients in the secondary trial had several heart-related problems.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "407369fa-92ba-4994-8a0f-d372995f3241_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02699983_BT", "Secondary_id": "NCT00994279_BT", "Statement": "Neither the primary test nor the secondary trial requires participants to practice yoga.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "05e50a3d-d5b2-4fe6-9709-c884c89c5f71_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01004172_BT", "Secondary_id": "NCT00802945_BT", "Statement": "Both the primary and secondary trials evaluate the response rates, but the primary trials investigate the CNS response, while the secondary trials study the tumour response, and they test different treatments.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "59fd53e4-b38c-4018-bafc-6fd7f7becebe_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00546104_BT", "Statement": "A patient in the primary trial suffered from a blood clot blocking his blood vessels.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c17eaeab-4e99-4cc4-8681-ae6ccddba572_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01926886_BT", "Statement": "There were no cases of cellulitis, nausea or anaemia in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "621d06ac-12dd-42c2-a012-15c1d94a4f0b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00952692_BT", "Statement": "The primary test must have adequate renal and hepatic function and must not currently receive amiodarone or amiodarone in the following 6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 27, 28, 38, 43]}, "021e79d2-ce70-43cf-aac9-fa8d4c8d3770_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193063_BT", "Statement": "In the primary trial cohort, three different types of infections are observed: pneumonia, urinary tract, and athlete's foot.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "06aa0fbc-fe49-4715-88cc-507646f6323f_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00486525_BT", "Statement": "The difference between the two cohorts in the primary trial is that cohort 1 participated in a Hatha yoga, while cohort 2 abstained from yoga.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "21947261-bbef-4d3a-adda-02bb4a91a3ca_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00754325_BT", "Secondary_id": "NCT00399529_BT", "Statement": "Both the secondary and primary trials accept patients with breast progesterone receptor adenocarcinoma (PgR+).", "Label": "Contradiction", "Primary_evidence_index": [1, 2], "Secondary_evidence_index": [0, 1]}, "71daae7c-3ee5-4451-91e2-273d8ff55aae_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00617942_BT", "Secondary_id": "NCT00388726_BT", "Statement": "The secondary trial had a total number of patients with lower adverse reactions than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00203502_BT", "Statement": "Each patient in the primary trial had at least one adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "7d22937b-9823-45fa-a914-261f993e4d64_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01644890_BT", "Statement": "Throughout the primary trial, a patient developed problems with his vision.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "507a4189-4905-4752-8348-d715a5ce3962_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01940497_BT", "Statement": "There were 3 more allergic reactions in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "24001e83-6a8c-4f67-9c24-55dc285c4cc2_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00096356_BT", "Statement": "The results of the primary trials indicate that CoQ10 reduces the level of fatigue experienced by patients compared to placebo.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d179396d-94fe-465f-a4f1-e7c3291a0a9a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00513695_BT", "Statement": "Filgrastim is the only drug in the primary trial administered by subcutaneous injection.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "4b893eeb-80a4-4a83-8df5-b5c668ce55b1_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00796978_BT", "Secondary_id": "NCT01276041_BT", "Statement": "More patients in the secondary trial had oedema in their limbs, compared to patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "44cd16f5-6638-4d82-9121-1941eb8ce4b5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448279_BT", "Statement": "In total, there were more adverse reactions in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "50ac2c53-3b63-4507-8712-41f8c257b4da_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01697345_BT", "Secondary_id": "NCT00513292_BT", "Statement": "fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "14607d45-9aef-458d-89cc-d47c62c23322_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02322814_BT", "Secondary_id": "NCT00356148_BT", "Statement": "A patient with histologically confirmed triple negative breast cancer without known brain metastases and without a history of autoimmune disease or cardiac dysfunction may be eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 22, 15, 33], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d2961e96-bd3b-4994-aa7e-2b310eb6204e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01300351_BT", "Statement": "At least 1 primary test participant showed signs of poor liver function.", "Label": "Entailment", "Primary_evidence_index": [0, 7]}, "8a5d7285-f4be-4e50-9057-19f74bcc410b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03106077_BT", "Statement": "Patients in the primary trial receive no more than 200 mg IMGN853 intravenously every 3 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "512990dd-45d2-4b31-b571-66735ff02308_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00394251_BT", "Statement": "There were 4 different adverse events, for which 0 cases were recorded in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "383db144-4bcd-4ebc-989c-b6ae7d282026_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00471276_BT", "Secondary_id": "NCT00951665_BT", "Statement": "gastrointestinal haemorrhage was more common in patients in cohort 2 of the secondary trial than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00951665_BT", "Statement": "Most patients in cohort 1 of the primary trial died from unknown causes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "228e80ab-84d6-4b60-9960-dcdcbd78c03c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00328783_BT", "Statement": "Patients with a MSV of 80% to 120% are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "b7caad28-5fb2-4eb6-845e-8315cff97318_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00896649_BT", "Statement": "Prior hormonal treatment in the metastatic or adjuvant setting is not necessary for patients in the primary trial, nor is it necessary to have adequate organ function or a particular racial or ethnic origin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "73c37b9c-e7ba-4c90-b26e-23b7a65509c4_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00005957_BT", "Statement": "T2 N1 M0 breast adenocarcinoma are eligible for primary testing.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "d5b81f6c-821a-4db5-8810-9cc47a952913_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02287675_BT", "Statement": "Informed consent is required for entry into the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "cdba382e-894b-4f79-a8e2-ff818746adc5_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01202591_BT", "Statement": "100% of patients in the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0093175a-38cb-4f63-b391-709ac48158b8_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00971737_BT", "Secondary_id": "NCT00392392_BT", "Statement": "Patients with HER-2 overexpressing tumours are eligible for the secondary trial, but not for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 3]}, "19106207-4fa2-4cc4-8e22-6e5330bf05ce_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00846027_BT", "Statement": "None of the adverse events recorded for the primary trial occurred more than once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "a015685e-f744-4bb2-a6d3-893f081d6dcc_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02597452_BT", "Secondary_id": "NCT01929395_BT", "Statement": "Both the primary and secondary trials use 21-day cycles for their interventions up to a maximum of 10 and 4 cycles respectively.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "b9578bae-6640-4ef1-ba2c-899b45c602ee_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01487954_BT", "Statement": "All patients in the primary trial had to drink 4 cups of water, either alkaline water or distilled water, depending on the cohort in which they were located.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "405369ef-d216-4d81-a04f-46f36f466a19_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01416389_BT", "Statement": "In the primary trial cohort 1 there were more cases of urinary infections and lumbar fractures than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 10, 11, 14, 24, 25]}, "e424c65e-7c6f-43a4-95e4-6beb705d9903_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559754_BT", "Secondary_id": "NCT02924883_BT", "Statement": "A higher percentage of patients in cohort 1 of the secondary trial had stomatitis than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01466270_BT", "Statement": "The placebo group in the primary trial had better mean retention than the QD group of dodopezil hydrochloride.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00072293_BT", "Statement": "Patients with non-palpable breast injury and 0 palpable axillary lymph nodes are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 12]}, "6843daf8-8136-4973-9bf2-62a622d5a890_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01156987_BT", "Secondary_id": "NCT02234479_BT", "Statement": "The primary trial participants receive an intervention based on their diagnosis of HIV, whereas in the secondary trial, interventions are attributed to randomity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2, 5, 6, 7]}, "2687b547-c225-4838-bbcd-99212a74d815_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01828021_BT", "Secondary_id": "NCT01326481_BT", "Statement": "Patients in the primary and secondary trials did not have the same adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fadf7710-6e4d-49d6-82fc-4f3137b5e26b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00759785_BT", "Statement": "Only one adverse event was observed in patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00074152_BT", "Statement": "All cases of adverse reactions in the primary trial occurred in patients in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "6c0896ac-db42-45b4-a6e2-620a27fd321a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01439945_BT", "Statement": "In the primary test, low-dose magnesium oxide is 5% lower than the high-dose magnesium oxide.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "3a80ba8a-265f-4931-a9a8-b7e00e372599_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00432172_BT", "Statement": "All adverse events recorded in the primary trial occurred in patients in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "df4b98f2-7ca9-4855-8d94-d62407ff8535_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01929395_BT", "Secondary_id": "NCT01857882_BT", "Statement": "The primary trial has only one trial cohort while the secondary trial has a control group and a control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "5d2542fa-5482-4aff-af29-80875a0a9dcc_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01015131_BT", "Secondary_id": "NCT00312208_BT", "Statement": "The primary trial records cases of rectal haemorrhage in its cohort of patients, while the secondary trial records vaginal haemorrhage.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "5deb8ebd-fbd2-4d84-8ad2-a1248426908b_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00880464_BT", "Secondary_id": "NCT00458237_BT", "Statement": "\u2022 Patients infected with HIV+ are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [14, 18], "Secondary_evidence_index": [12, 26]}, "5f4880ac-1ce2-4b89-841b-a9918720b6ea_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365417_BT", "Secondary_id": "NCT00853996_BT", "Statement": "To be eligible for both the secondary and primary trials, patients must meet all of the following conditions: alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and hemoglobin > 10 g/dL.", "Label": "Entailment", "Primary_evidence_index": [11, 13, 14, 9, 10], "Secondary_evidence_index": [17, 18, 20, 23]}, "b3aabfaa-23cb-4a75-8416-761d8574f0a4_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01441596_BT", "Statement": "Patients in cohort 1 of the primary trial may receive a progressive increase in Afatinib monotherapy doses from 40 mg PO to 50 mg PO.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "f697c2d8-e0dd-476e-8ff4-dffe053076f8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00524303_BT", "Statement": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse than the Lapatinib arm, which reached a pCR rate of 45%.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f2c0f753-1775-42af-94f0-b87b20156e65_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02835625_BT", "Secondary_id": "NCT00486525_BT", "Statement": "The primary and secondary trials do not use chemotherapy, radiotherapy or mammography in their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "17b31c1d-db62-4628-b390-02da22512079_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01028352_BT", "Statement": "Patients with musculoskeletal symptoms associated with the aromatase inhibitor, such as grade 1 or higher musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5, 6]}, "2e6e1044-8b4a-41f7-8319-85fc5bba4482_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00574145_BT", "Secondary_id": "NCT03167359_BT", "Statement": "Radiotherapy is used in all cohorts of the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00493649_BT", "Secondary_id": "NCT01201265_BT", "Statement": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "0c0324d2-0672-45cb-b715-e51e48786afb_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03618017_BT", "Statement": "The intervention section of the primary trial does not describe the dose, frequency or duration of the intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "b3bd3522-8731-448a-bade-a5a350697a98_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01421472_BT", "Statement": "More than 9 patients in the primary trial had side effects associated with a small number of white blood cells in the bloodstream.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "8607e8c1-6e99-49be-a63e-e707856c805a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01572038_BT", "Secondary_id": "NCT00826267_BT", "Statement": "Each patient in the primary trial receives 3 different medications, while in the secondary trial, patients receive expressive and supportive group psychotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1c26e1a7-9d77-46ff-b1c6-179ece7c190f_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03252431_BT", "Statement": "On average, patients in both arms of the primary trial experienced Grade 4 Neutropenia during the same period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "0a156ee2-eb90-40d2-9802-27b9b4a42ff3_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191789_BT", "Statement": "In cohorts 2 and 3 of the primary trial, there was only one case of jaundice.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "82895f11-37bf-4d03-8de2-84818d93cce0_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00266110_BT", "Secondary_id": "NCT00879086_BT", "Statement": "The primary and secondary trials have completely different adverse event reports.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "f94643de-7122-4a58-972d-b0bb7e59d441_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00878709_BT", "Secondary_id": "NCT02447003_BT", "Statement": "The primary trial had a total of 3 patients with pancreatic cancer, the secondary trial had 0.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "1485315b-3169-42a3-a672-6f7963d49a51_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01869764_BT", "Secondary_id": "NCT02556632_BT", "Statement": "Each participant in the secondary and primary trials undergoes a laboratory biomarker analysis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b4ef27ca-52b4-4af3-9b60-e9e0285e0e86_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03719677_BT", "Statement": "Potential participants will be considered regardless of the hormonal susceptibility of their breast cancer.", "Label": "Contradiction", "Primary_evidence_index": [7]}, "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03371732_BT", "Statement": "Patients with the Karnofsky Index = 72 are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "426196d8-44ab-4c5c-8f81-5cb12345ad69_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00899574_BT", "Secondary_id": "NCT01007942_BT", "Statement": "The primary trial uses different inclusion criteria for its cohorts, the secondary trial uses only one inclusion criterion for all cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "bcf433b6-4029-4d00-9ccf-d8d94f1722d8_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00365365_BT", "Secondary_id": "NCT00005908_BT", "Statement": "The primary and secondary trials recorded only one type of acute adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "1268edfc-cce2-4f07-9fbb-392341b7f399_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01605396_BT", "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group in the primary trial had a median PFS of more than 5 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "58ccfd13-aa6d-4604-bf3d-c69270fe50d2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01276041_BT", "Statement": "A patient in the primary trial died in a case not associated with a specific term CTCAE.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00182793_BT", "Secondary_id": "NCT00509769_BT", "Statement": "The majority of patients in the primary and secondary trials experienced an adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "8c84c96f-1635-40dc-839b-fc937ed566a2_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01105312_BT", "Statement": "\u2022 Patients with measurable diseases are only eligible for Phase 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5, 6]}, "7b48355e-3b9c-4cca-b7fa-1cbd612d1523_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320710_BT", "Statement": "There were no adverse events in cohort 2 of the primary trial in more than 5% of patients.", "Label": "Entailment", "Primary_evidence_index": [13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "3d188d93-13c6-48f3-b231-dcdeef81080e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00617539_BT", "Statement": "The presence of extracranial metastases is one of the exclusion criteria for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01209195_BT", "Statement": "Lower doses of MM-121 and Paclitaxel are used in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "2206dc2a-93da-4c11-b110-81f9c39af807_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00101400_BT", "Statement": "One female with hemoglobin > 10.0 g/dl, the absolute number of neutrophils 1.733 mm3, the number of platelets = 100,000/\u00ac\u00ac\u03bcl and total bilirubin > 1.6 x ULN are eligilbic for the primary test.", "Label": "Entailment", "Primary_evidence_index": [9, 10, 11, 12]}, "6173faf3-f845-4cf1-94a9-756d1bff48bb_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01419197_BT", "Statement": "There was a patient in the primary trial who suffered from a significant decrease in granulocyte count in his blood.", "Label": "Contradiction", "Primary_evidence_index": [13, 17]}, "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02006979_BT", "Statement": "Only one cohort in the primary trial should receive manual lymphatic drainage prior to each cycle of anthracyclines.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00849472_BT", "Statement": "More than a dozen participants in the primary trial are classified as having a complete pathological response (PTR) in the breast and nodes.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "87987ebb-6799-4d1d-8529-d33c6b7799f8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00548184_BT", "Statement": "64 of primary trial participants receiving lapatinib 1000mg per day and trauzumab 4mg/kg load dose, followed by 2mg/kg per week, had at least one almost complete or better pathological response after 12 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "bf94f208-a29b-4d8f-92a7-3cb8241ce344_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00097721_BT", "Secondary_id": "NCT00896649_BT", "Statement": "Black women may not participate in the secondary trial or in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36], "Secondary_evidence_index": [5, 6, 7, 8, 9, 10]}, "c68f6822-24fa-44b5-bf63-c272a8031fab_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02988986_BT", "Statement": "Patients should have an AST or ALT < 1.5 ULN to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 20]}, "54a459cf-f01a-4abc-a8cf-0efebc01c694_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02019277_BT", "Secondary_id": "NCT00863655_BT", "Statement": "The primary and secondary trials did not record any of the same types of adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "dd4b5a08-c033-4429-81d0-1ad59596edbd_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02683083_BT", "Statement": "People with hyperthyroidism and diabetes mellitus are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [11, 12, 13, 14, 15, 16]}, "d97ebc59-ab4b-462a-9057-12f4fc46df56_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01153672_BT", "Secondary_id": "NCT01432145_BT", "Statement": "In the primary trial, patients receive vorinostat at the same frequency and route of administration as in the secondary trial, 6-Mercaptopurine.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2e4c7d0b-f1a2-4204-bac3-7445852fd916_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01727011_BT", "Secondary_id": "NCT01420146_BT", "Statement": "The primary test and secondary test procedures involve a variety of scans, such as CT, PET, MRI and dosimetry.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01928186_BT", "Secondary_id": "NCT00684983_BT", "Statement": "All participants in the primary trial and in cohort 1 of the secondary trial did not receive oral capecitabine, oral lapatinib ditosylate, or cixutumumab IV, but cohort 2 of the secondary trial received all of these elements.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4546c169-cc5c-4e03-bcce-31d491ed18e0_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01989676_BT", "Statement": "The primary test records only cardiovasuclar adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "1bb3badf-41c6-4741-90f0-367473ce254d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00612560_BT", "Statement": "Children and adults who are illiterate are not able to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 12, 13]}, "87953ba3-3e94-421c-b426-b716562b8b5d_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02806544_BT", "Secondary_id": "NCT00605267_BT", "Statement": "A patient with RA positive breast cancer at stage 2B, confirmed pathologically, is possible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3]}, "847b4dbe-428f-431c-8916-2a9c0c80cce4_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00686127_BT", "Secondary_id": "NCT01129622_BT", "Statement": "The doses are specified in the intervention section of the secondary and primary tests.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "9c00b318-0a3a-43c9-a6cd-2983c07be393_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00232505_BT", "Statement": "There have been no cases of patients with abnormal heart rates in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "cbfe14a5-5169-4de3-b69f-13b489be949a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02597452_BT", "Secondary_id": "NCT01929395_BT", "Statement": "The primary and secondary tests do not use cyclic interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00325598_BT", "Statement": "There is a significant difference in the percentage of participants obtaining a dosimetrically satisfactory treatment plan between cohort 1 and 2 of the primary trial, the increase in the number of Gy has a huge effect.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01332630_BT", "Secondary_id": "NCT00121134_BT", "Statement": "There were more patients with hypotension in cohort 1 of the primary trial than in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "eae76b80-107c-4469-b06f-73d5f7a4c1d5_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02073487_BT", "Secondary_id": "NCT03371732_BT", "Statement": "\u2022 Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary test and the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00347919_BT", "Statement": "Less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive disease at Week 12.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "91ad45ae-6714-4c27-ac1a-d8ff8e89684f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00334542_BT", "Statement": "A patient with a bilateral mastectomy would be excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [6]}, "91cf53f9-7233-49ee-a619-c027f6db67ac_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00605267_BT", "Statement": "Only men may be eligible for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "78894316-fc7d-4d61-a2d4-9ea369bfce20_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02273973_BT", "Statement": "Two times as many patients in cohort 1 of the primary trial had erysipelas as bacterial diarrhea.", "Label": "Entailment", "Primary_evidence_index": [0, 11, 12]}, "889e6622-1614-4f6c-a47c-e7caad6e154f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00879086_BT", "Statement": "While cohorts 1 and 2 in the primary trial had the same number of patients with anaemia and Neutropenia, Cohort 1 had 1 case of Leukopenia more than cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 4, 5, 14, 17, 18, 19]}, "4577d986-d7e5-4b5d-9852-b944a6f7f252_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01740323_BT", "Secondary_id": "NCT00127205_BT", "Statement": "The secondary and primary trials accept patients of the same age group.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16, 17]}, "e83b56ba-d129-4cde-976d-2865e67ef4a3_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02472964_BT", "Secondary_id": "NCT00089661_BT", "Statement": "The primary study studies the response of tumours, while the secondary study studies changes in bone mineral density.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "eee75423-9a61-4a57-8baf-8f91b9562486_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01705691_BT", "Statement": "The majority of patients in the primary trial suffered from kidney stones.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "9e046221-7d4b-4681-a374-96793350927d_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00802945_BT", "Secondary_id": "NCT01231659_BT", "Statement": "Group 1 of the secondary trial has a higher rate of OR than the Everolimus + Letrozole cohort of the primary trial and trastuzumab cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5448c6b8-244c-4a42-bbef-e1a1a2e254e2_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01738438_BT", "Secondary_id": "NCT00331552_BT", "Statement": "- Cyclophosphamide, Doxil and Trastuzumab were used in the secondary test procedure, but not in the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00429572_BT", "Secondary_id": "NCT02455453_BT", "Statement": "Premenopausal patients are excluded from the secondary trial but eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1]}, "8d450d42-4eb1-4edb-be76-b2885964aa90_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01506609_BT", "Secondary_id": "NCT00656019_BT", "Statement": "Patients with cytologically confirmed breast cancer who have a local recurrent disease are not eligible for the secondary trial but are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "2674e194-3113-4a11-b2cc-f089d960d194_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01104584_BT", "Statement": "The primary trial does not use trastuzumab, tamoxifen or exemestane in its intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "a7232387-b266-4bfb-8df8-ca9789188500_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00490646_BT", "Statement": "The primary trial cohort 1 had 25% more patients with adverse reactions than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "2e317381-2704-4d06-a793-1d2b29139969_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01959490_BT", "Statement": "In total, only one primary trial participant did not obtain the complete pathological response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "030316a2-fb48-469d-9c55-04cdc9a37fb6_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00559507_BT", "Statement": "The primary trial participants receive saracatinib PO every day of the duration of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "2c723e02-14d8-4a80-a95f-517e904bbbad_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00338286_BT", "Statement": "No primary trial participants had progression-free survival over 1 year, but several patients had PFS of less than 1 month.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "8befa03f-c3da-4950-8d27-491ea06b51ed_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00885755_BT", "Secondary_id": "NCT01075100_BT", "Statement": "While patients' appetites were not affected in the primary trial, at least one was affected in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "32424458-a3e2-440a-9693-6a2f8d4aaddb_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01307891_BT", "Statement": "The Abraxane + Capecitabine group in the primary trial has 61 additional patients who have either a complete response (RC) disappearance of all target lesions; Partial Response (PR) decrease by at least 30% in the sum of the longest diameter of target lesions compared to the Abraxane Alone group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a2b25229-c003-49c3-8b0b-94b68f756d3c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00468585_BT", "Statement": "The primary trial did not record skin infections in their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "728721c4-6376-4ab8-9e4a-af8596bd1ab3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00852930_BT", "Secondary_id": "NCT02308020_BT", "Statement": "The Laser Therapy is only used in cohort 1 of the primary trial, and none of the cohorts in the secondary trial use it.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "c7151ad6-bcac-48e1-ba1e-e6f56a043804_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01086605_BT", "Secondary_id": "NCT00570921_BT", "Statement": "Both Cholecystitis cases are recorded in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "4f71e33c-4f0f-4952-bb03-52402be5f9f4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02015676_BT", "Statement": "There is 1 case (1.45%) of thrombocytopenia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "ef675459-a7d9-4ea1-8963-c95682c38d15_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03004534_BT", "Statement": "Participants with a T4 N1 M0 breast carcinoma are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5, 6, 7, 8]}, "f9df9e45-eb68-4257-801e-b086a89374b8_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02658734_BT", "Secondary_id": "NCT02073487_BT", "Statement": "Women Patients with FEVL > 50% who have already been treated with one of the following medicines; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]}, "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00319254_BT", "Statement": "The primary trial did not use the overall response rate, tumour response rate, or progression-free survival rate as a measure of the results.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "958721dc-e374-4fd1-abb9-071add70bde3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00820170_BT", "Statement": "Based on the results of the primary test, the DMT for paclitaxel is approximately 120 mg.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "19c0b2c7-e45c-4740-b25d-f6e738b59893_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01764022_BT", "Statement": "The primary trial cohort 2 recorded 1 thrombocytopenia incident.", "Label": "Entailment", "Primary_evidence_index": [10, 13]}, "7bcfca9e-1b09-45d4-8165-cb6ac96b8815_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02896855_BT", "Secondary_id": "NCT00171314_BT", "Statement": "The secondary trial recorded more gastrointestinal adverse events than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e3a8be03-20e4-460d-9ebc-f958a515ac45_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01095003_BT", "Statement": "Less than 5 patients in the primary trial had Earache.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "f1096271-3160-4483-9246-ba0d96735efb_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01118624_BT", "Statement": "Less than 5% of primary test participants achieved either RC or PR.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "329b6871-2edc-4142-a4af-e7f8cef118ee_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00004888_BT", "Statement": "The primary test participants suffered more from first-year cardiotoxicity events after Cycle 8 than from third-year events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "67522762-9423-4e3d-bf75-247f84ba7f05_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365417_BT", "Secondary_id": "NCT00853996_BT", "Statement": "To be eligible for both the secondary and primary trials, patients must meet all of the following conditions: alkaline phosphatase < 2.5 x ULN, aspartate aminotransferase <= 1.5 x ULN and hemoglobin > 10 g/dL.", "Label": "Contradiction", "Primary_evidence_index": [11, 13, 14, 9, 10], "Secondary_evidence_index": [17, 18, 20, 23]}, "efd37946-54f3-4813-b63d-6d7df6123677_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02630693_BT", "Statement": "A total of 3 patients in the primary trial experienced a life-threatening reaction to infection.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "dcf62f43-04b7-4acb-b444-2d805238a8b1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02162667_BT", "Statement": "In the primary trial, the Herceptin group had a higher percentage of patients with partial pathological response than the CT-P6 and ZA groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "83dc7b9a-b863-4f81-88fb-763afc3b79e8_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03252145_BT", "Secondary_id": "NCT00904033_BT", "Statement": "None of the subjects in the primary trial are required to inject pills, and half of the subjects in the secondary trial should take one tablet weekly.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "d446920a-2b8e-4452-b9f2-17d2771dbb07_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00075764_BT", "Statement": "The most common adverse event in cohort 1 of the primary trial is Neutropenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "aa710138-bf2a-4a7f-8014-4513fa1f448b_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01269346_BT", "Secondary_id": "NCT01597193_BT", "Statement": "Both cohort 1 of the primary trial and cohort 1 of the secondary trial have less than 30% adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01340300_BT", "Secondary_id": "NCT00671918_BT", "Statement": "While patients must take less than 2 hours of physical exercise per week to participate in the primary trial, this is not a requirement for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "6a71c114-2e38-4d57-8f8b-8252d9c62cbe_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01491737_BT", "Statement": "There were 4 cases of febrile neutropenia in cohort 1 of the primary trial and 0 cases of heart failure.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 5]}, "4333aaa3-dbe4-4275-a982-881fe25c96c0_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00407888_BT", "Statement": "The arm 2 of the primary trial receives high-dose chemotherapy over a 21-day cycle up to 3 times in the absence of disease progression or unacceptable toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "d605b820-2915-4b19-b9cd-ca7850645f83_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00357110_BT", "Statement": "Only 6 patients in cohort 1 of the primary trial had varicose veins.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "d6de70df-d113-4bc8-9d3b-b71f31937ebe_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01525589_BT", "Statement": "People who inherit harmful variants of the BREast Cancer 1 or 2 gene are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 13]}, "9f897b29-7cfa-414c-8cf6-212a68ec2216_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03346161_BT", "Secondary_id": "NCT01000662_BT", "Statement": "Neither the secondary trial nor the primary trial requires patients to undergo any medical treatment during their procedures, but they only test the effectiveness of the consultations.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00676663_BT", "Statement": "The placebo group in the primary trial was much more effective than the test group, as a lower PFS is ideal.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "4606f64f-64cc-4d73-a8be-75701c97008d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00024102_BT", "Statement": "One patient in cohort 2 of the primary trial received plasma transfusion.", "Label": "Contradiction", "Primary_evidence_index": [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "40bef815-18ed-4db5-8108-9a1cdbdd0a13_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00478257_BT", "Statement": "There is no need for adequate haematological, hepatic and renal function to participate in the primary trial. However, being pregnant is necessary.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "5c676007-9ea4-4f80-82dd-89293237cb07_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00319254_BT", "Statement": "The primary test did not use the overall response rate, the tumour response rate, or the preference score as a measure of the results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "a6682883-ace7-4d83-a35c-956928fdc75a_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01325428_BT", "Secondary_id": "NCT00073073_BT", "Statement": "The secondary trial and the primary trial do not require participants to be ethnic, gender, size or speak a particular language.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "1a271e29-477b-4819-a472-5c7c7df99e70_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00265759_BT", "Secondary_id": "NCT00866905_BT", "Statement": "Two cases of haematolysis were recorded in the primary trial, none in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "060e833e-384f-48f0-8e56-ebd95f55f221_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01926886_BT", "Statement": "There were no cases of cellulite, vertigo or anaemia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "ac193d32-156e-48bf-bc6b-d613691f869c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01166763_BT", "Statement": "Only three types of adverse reactions were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "d79173da-5e59-4150-99bd-f1c20118dddc_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00503750_BT", "Statement": "All participants in the primary trial must have recently undergone either an echocardiography.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "50559f15-636d-4265-8f8c-4aad016c6c50_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01176916_BT", "Secondary_id": "NCT00186121_BT", "Statement": "\u2022 Postmenopausal women are eligible for the primary trial, and premenopausal women are eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2]}, "a5af6d2b-4cea-40aa-acdc-59fab5362b3e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00635050_BT", "Statement": "\u2022 Patients with breast cancer who have estrogen receptors are included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "7e89b190-b8f7-4281-b0f1-0e65dcebf402_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00941330_BT", "Statement": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as patients in cohort 2 receive Cytoxan.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "6036d341-9c6a-49fc-a2f4-19c0e2399f4c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01565083_BT", "Statement": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [12, 22, 23]}, "a84afa25-2741-4a08-9e6c-4049f5feca48_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01790932_BT", "Statement": "Patients with phosphoinositide 3-kinase inhibitor treatment are eligible for primary testing if this treatment has been completed more than 5 years previously.", "Label": "Contradiction", "Primary_evidence_index": [5, 6]}, "09e4c746-642a-4a5d-a267-25258a3f2ec0_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01669343_BT", "Secondary_id": "NCT00146172_BT", "Statement": "The primary and secondary trials do not have the same duration of intervention administration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "99855d11-e2e4-4a0e-b40e-2264ff128ac5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02502864_BT", "Statement": "The primary test recorded the same number of occurrences for each type of adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "54fe69c7-5a67-49b1-8bc5-c975133e2bb7_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00712985_BT", "Secondary_id": "NCT02038010_BT", "Statement": "Patients in the primary trial receive a lower dose of Zometa IV than patients in the secondary trial receiving ado-trastuzumab emtansine.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "76362fd3-3a07-4aa3-a072-b9075d2ea791_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00436566_BT", "Statement": "No patients in the primary trial had congestive heart failure (during active therapy).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "064b39e9-e9d8-4c51-a76a-ad150bb127f1_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00878709_BT", "Secondary_id": "NCT02447003_BT", "Statement": "The primary study involved a total of 3 patients with pancreatic-related adverse reactions, the secondary study was 0.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "67a628d7-d883-44b9-b351-901f20fd5d0a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429182_BT", "Secondary_id": "NCT00429507_BT", "Statement": "The secondary and primary trials give their patient cohorts stem cell transplants on the first day of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "78c60212-28f7-4306-9f63-549be04687b2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448591_BT", "Statement": "Only two types of adverse reactions, leukopenia and anaemia, occurred in more than 1% of patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "a72e1259-50be-48e5-bdf8-296040cbf7ce_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01593020_BT", "Secondary_id": "NCT00834678_BT", "Statement": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from the secondary trial but eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [13, 18], "Secondary_evidence_index": [23]}, "19cfd511-8582-4116-8d51-7ec4a6221022_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03366428_BT", "Statement": "0/49 Primary Trial Participants with metastatic and/or non-resectable breast cancer with HER2 showed a maximum change from the initial QTcF trial of less than 60ms.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "3f012bd3-bb89-414b-9dd9-35cef524a69a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00820170_BT", "Statement": "Based on primary test results, dasatinib DMT in combination with paclitaxel weekly is approximately 120 mg.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "5eafb3a1-473a-4270-848d-173e5dca9466_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02600923_BT", "Statement": "Patients with leukaemia, hepatitis or cataract cannot be included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "ed956644-5228-4915-b706-1cedb0462577_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00711529_BT", "Secondary_id": "NCT02835625_BT", "Statement": "The primary test participants are treated with hypnosis, which is not used at all in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "02158762-9490-46a1-b494-0589885fd4ce_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00281697_BT", "Statement": "The primary trial does not record any cardiac adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00217672_BT", "Secondary_id": "NCT00110084_BT", "Statement": "The rate of occurrence of enterovedic fistula was higher in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "7ec286e9-f519-41da-848d-a0bc5a50c0ee_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00686127_BT", "Secondary_id": "NCT01129622_BT", "Statement": "The doses are specified in the intervention section of the secondary test, whereas for the primary test they are not clearly specified.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "d0af59a9-04ae-4922-97eb-dc29f5bc44e3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00256698_BT", "Secondary_id": "NCT03573804_BT", "Statement": "Both primary and secondary trials use completely different drugs and techniques for their interventions, but both require locally trained radiologists for evaluation.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "5d4cbb15-ea50-4394-b1b9-ab4553b5b275_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00509587_BT", "Statement": "Patients in the primary trial receive oral pazopanib once daily until disease progression or unacceptable toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00777049_BT", "Statement": "The 4 cases of FHC in the primary trial were in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 14, 20]}, "78a5162d-140a-4631-b776-5c284446b5ec_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02366130_BT", "Secondary_id": "NCT01262027_BT", "Statement": "The primary and secondary trials have completely different adverse reaction profiles.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3]}, "633ef768-9e9b-4336-9142-8d4ce7ee2342_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01026142_BT", "Secondary_id": "NCT00846027_BT", "Statement": "There were 10 times more patients with left ventricular systolic dysfunction in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 12, 19], "Secondary_evidence_index": [0, 4]}, "7c5b29bc-ac37-48bb-abb1-a102174f79ef_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00826267_BT", "Statement": "Cohorts 1 and 2 in the primary trial receive 50 mg of various medications administered orally from day 1 to day 21.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00708214_BT", "Statement": "All free progression participants (after 16 weeks of treatment) in the primary trial were in the Afatinib 50 mg group with Letrozole.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00615901_BT", "Secondary_id": "NCT00829166_BT", "Statement": "The primary trial had much more seizures than the secondary trial, although it had less than one-tenth of the total number of patients in its cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e852619c-312a-470f-8b77-149e79f69a3f_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00390455_BT", "Secondary_id": "NCT00558103_BT", "Statement": "In the secondary and primary trials, the test cohorts produced better results than the control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "27160f45-e4cb-48be-8cf2-c23ced4578c0_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003830_BT", "Statement": "The most common adverse reaction in both cohorts of the primary trial was anaphylaxis, which affected more than 10 patients in total.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "e4b65e9f-10f6-4424-95d2-837e29587a63_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00754325_BT", "Secondary_id": "NCT00399529_BT", "Statement": "Both the secondary and primary trials accept patients with HER-2/neu-overpressant adenocarcinoma.", "Label": "Entailment", "Primary_evidence_index": [1, 2], "Secondary_evidence_index": [0, 1]}, "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01127373_BT", "Statement": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumours are eligrbs for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "7796fe1b-1952-4339-90f3-47b051ebe927_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01432886_BT", "Statement": "One of the patients in cohort 2 of the primary trial had persistent neutropenia for more than 7 days.", "Label": "Contradiction", "Primary_evidence_index": [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c7df7b38-068b-48a8-b805-b8ebb3e854e6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01086605_BT", "Secondary_id": "NCT00570921_BT", "Statement": "The primary and secondary tests do not record any of the same adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "39227bbb-0e26-4ba0-94a7-762376541889_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00945061_BT", "Statement": "Patients with multifocal breast cancer cannot be accepted for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3]}, "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03283553_BT", "Secondary_id": "NCT02679755_BT", "Statement": "The primary and secondary trials have a different number of cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "fd15ddaf-1abc-4551-a5b3-08217b975e36_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02321527_BT", "Statement": "Patients with invasive breast cancer greater than 70 mm in diameter are included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2]}, "067f4671-0720-4980-a0fa-8d01d31daa9a_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00054132_BT", "Secondary_id": "NCT01421017_BT", "Statement": "Because the primary and secondary tests use very similar result parameters, we can easily compare and contrast their results.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "026e7eb7-37fd-4aae-b74f-dacf905db262_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02366130_BT", "Secondary_id": "NCT01262027_BT", "Statement": "The primary trial reported more than 10 times the number of patients with adverse reactions such as the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3]}, "a79fc503-215f-40d4-9cc1-e101cec3a9c9_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02878057_BT", "Statement": "Patients who are fully active and able to pursue all pre-disease performance without restriction are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191269_BT", "Statement": "The primary trial measured the number of participants with disease progression (PD) or death to assess the performance of its interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00574587_BT", "Secondary_id": "NCT00777049_BT", "Statement": "There were no cases of heart padding in the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "ccb703ea-df18-451b-8db8-ed0e510a4c0f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03592121_BT", "Secondary_id": "NCT01439711_BT", "Statement": "Unlike the secondary test, the primary test does not specify the dose or frequency of its intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "56cd4492-3884-4b2a-a000-7c859d86f6f5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00284180_BT", "Statement": "In both cohorts of the primary trial, a total of two patients had low levels of oxygen in their body tissues.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "08b79e0d-5e97-45fb-ac83-0096b56f714b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01492101_BT", "Statement": "Less than 1% of any of the cohorts in the primary trial were affected by pancytopenia or coagulopathy.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5, 11, 15, 16]}, "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01466270_BT", "Statement": "The placebo group in the primary trial had mean retention greater than 10% higher than the QD PO group of dodopezil hydrochloride.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6d549a9b-47bf-4369-962b-2759cfd7051e_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00798135_BT", "Secondary_id": "NCT01209195_BT", "Statement": "Both the primary and secondary trials focus on the pharmacokinetics of Itraconazole 500mg QD.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3]}, "596f20cf-299d-40a3-881a-cdd49bcb21f6_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00703326_BT", "Secondary_id": "NCT00274768_BT", "Statement": "Participants with primary HER2- breast tumours, confirmed by in situ fluorescence hybridization, are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 5], "Secondary_evidence_index": [0, 1, 7, 8]}, "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03066947_BT", "Statement": "At least one patient in the primary trial had gastroesophageal reflux.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00418028_BT", "Secondary_id": "NCT00293540_BT", "Statement": "Sam has recently received a liver transplant, is not eligible for the primary trial, but is eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [7, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "d4b2d877-34af-4944-84f7-046e22c2854e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01781299_BT", "Statement": "All subjects in the primary trial must undergo minor surgery.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "d3ca3729-2795-4cd5-9968-666781d17fac_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00119262_BT", "Statement": "Cohorts 1 and 2 of the primary trial had a different number of patients with congestive heart failure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01752907_BT", "Statement": "In the primary trial, there were 0 cases of Tibia or Fibula fractures.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "b98c7a50-ed79-41ff-9733-fff143f630be_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01901146_BT", "Secondary_id": "NCT00209092_BT", "Statement": "The primary trial cohort 1 recorded the same number of neutropenic fever cases as cohort 1 in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 4]}, "47aa5686-75af-4ed8-b4ff-715b458ce40a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02203565_BT", "Secondary_id": "NCT00194779_BT", "Statement": "The analysis of laboratory biomarkers is used in the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "e89fdc93-d624-4ba7-aa64-574a278e982b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00077376_BT", "Secondary_id": "NCT01256008_BT", "Statement": "The primary trial is studying a new chemotherapy treatment, while the secondary trial is testing a type of psychological therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1739541a-2d3f-4a13-b956-769a1cbed4d7_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00871858_BT", "Statement": "One patient in cohort 1 of the primary trial was diagnosed with clear cell renal carcinoma.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02187744_BT", "Statement": "One patient in the primary trial suffered sepsis due to the presence of an implanted device.", "Label": "Entailment", "Primary_evidence_index": [0, 7]}, "206fc00c-2c34-42bc-8fca-44be696e03c9_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02312622_BT", "Statement": "The two cohorts in the primary trial receive identical interventions; the pegylated irinotecan administered intravenously (IV) at 145 mg/m\u00ac\u00c2\u00a7 in monotherapy once every 21 days, the differences between cohorts are the type of cancer diagnosed, cohort 1 is the NSCLC, while cohort 2 is the MBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00393939_BT", "Statement": "Median (95% confidence interval) Progression-free survival (PFS) was 1 year higher in Trastuzumab + Sunitinib patients in the primary trial than in the Docetaxel group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "83cef795-d4a8-486c-8ac1-34a9acee9672_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00581256_BT", "Statement": "Patients with breast cancer on the left side and ECOG between 1 and 2 are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 8, 14, 17]}, "b3cee7a6-cec1-4676-974d-7cfb3ccd9919_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00127933_BT", "Secondary_id": "NCT00191789_BT", "Statement": "In the primary trial, one patient had a catheter-related complication, while in the secondary trial, no patients were observed.", "Label": "Entailment", "Primary_evidence_index": [12, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "007de11b-4265-4695-b18e-e0d6909a347a_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00944047_BT", "Secondary_id": "NCT00228943_BT", "Statement": "Patients with HER2 positive tumours are excluded from the primary trial but may be included in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ce621235-b584-439b-bb11-ab2fa04c3195_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01869764_BT", "Secondary_id": "NCT02556632_BT", "Statement": "Each participant in the secondary and primary trials undergoes a laboratory biomarker analysis and completes a questionnaire.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f358f023-2393-44eb-9535-3f0e1851318d_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01646346_BT", "Secondary_id": "NCT03283553_BT", "Statement": "Both secondary and primary tests use irradiation techniques in their studies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0e963b25-0d2b-4fc6-89c6-1eb068bc092e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470301_BT", "Statement": "Each patient in the primary trial receives tipifarnib PO, as well as paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "390b08d3-e147-47f9-82d7-0643b8d5c8ae_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00733408_BT", "Statement": "There was a slightly less than 8 weeks difference in progression-free survival between the minimum PFS and the maximum PFS in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2570cb04-4edd-48c9-b634-9f2e086469de_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00994279_BT", "Secondary_id": "NCT00545077_BT", "Statement": "Between the primary trial and the secondary trial, Bevacizumab is administered only to patients in cohort 2 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f6a7e279-b923-45e3-8ad5-e81e17c0a682_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00270894_BT", "Statement": "60 patients in the primary trial were able to complete at least 85% of the schedule dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3d82851c-f302-4988-bd78-232583e04e96_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02511730_BT", "Secondary_id": "NCT00193206_BT", "Statement": "Patients with prior chemotherapy are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 6]}, "5c9f5916-37d3-4f6f-977b-be70204cf57c_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01819233_BT", "Statement": "All participants in the primary trial have the same number of calories in their diet throughout the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "0c5f2498-4c10-4e51-8915-d86b37b08156_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01156987_BT", "Secondary_id": "NCT02234479_BT", "Statement": "The primary trial participants receive an intervention based on their diagnosis of cancer, while in the secondary trial, interventions are attributed to randomity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2, 5, 6, 7]}, "c54dc963-671a-4384-8b1f-d8058a832131_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00545688_BT", "Statement": "No patients experienced paranasal sinus reactions or left ventricular dysfunction in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02340221_BT", "Statement": "A total of 32 patients in the primary trial experienced diarrhoea.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "91adb350-ab20-41a6-944d-c13b55cf33f2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00014222_BT", "Statement": "Cohort one of the primary trials reported 2,680 patients experiencing eye-related adverse events, while cohort two reported none.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "78949f1f-6738-4220-a233-e7831902e6f3_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02038010_BT", "Secondary_id": "NCT00764322_BT", "Statement": "Neither the primary nor the secondary test measures the dose limit toxicity of BYL719 in combination with T-DM1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3]}, "135311d8-c579-4568-913e-937be00dde7e_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00390455_BT", "Secondary_id": "NCT00558103_BT", "Statement": "In the secondary and primary trials, the test cohorts obtained a better overall response than the control groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0984431d-4997-41dc-9ba4-07134568c3fa_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00258349_BT", "Secondary_id": "NCT01328249_BT", "Statement": "The primary trial cohort 1 does not receive Eribilin Mesylate With Prophylactic Filgrastim, while the two secondary trial cohorts receive it.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "d9dc4a6d-a913-46ac-b0aa-d50823ff2305_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00662129_BT", "Statement": "Patients with platelet counts greater than 100,000 per millilitre, ANC < 1700 per millilitre, and hemoglobin counts between 11 and 18 grams per decilitre are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [18, 22, 23, 24]}, "9d9ab190-cdcf-4320-b69a-12f2dad9dba9_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02435680_BT", "Secondary_id": "NCT01743560_BT", "Statement": "The secondary test and the primary test use non-comparable evaluation parameters and significantly different time frames.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "89fdf182-7474-4e70-baf7-03c8920c4ff3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01385137_BT", "Secondary_id": "NCT00593346_BT", "Statement": "While placebo treatment is used in cohort 2 of the secondary trial, there is only one trial group in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "9f2fd0cc-af87-433d-9d2f-6235591d6cb1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00422903_BT", "Statement": "The percentage of participants who received an objective clinical response (ORC) in the breast, assessed by an independent radiological assessment monitoring committee, was highest in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "90364098-7e9a-47be-ab2e-f66958cfb09d_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02413008_BT", "Secondary_id": "NCT02725801_BT", "Statement": "\u2022 Interventions in the primary and secondary trials are conducted daily for a period of several months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "021c3f62-8067-49e3-9d4b-c7641feb2548_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00331552_BT", "Secondary_id": "NCT01306942_BT", "Statement": "The same dose of trastuzumab was used for interventions in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "6893c9b4-d3a3-47a8-ada9-8aef67de2375_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01702571_BT", "Statement": "Patients with incurable and non-resectable breast cancer are eligible for the primary trial unless they are metastatic.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "b88cde11-ae29-48e8-832b-4b9cb2596c30_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00859651_BT", "Statement": "Helen had stage III ovarian cancer two years earlier, from which she is still recovering, she is excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [13, 14]}, "ebe7078c-fd8b-439a-b1f5-7bd482071ead_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02472964_BT", "Secondary_id": "NCT00089661_BT", "Statement": "The primary studies focus on the evolution of the tumour diameter, while the secondary study focuses on the evolution of the frequency of heart failure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "d0b9c11c-50f2-4803-a96c-fff3ca90cf36_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02312622_BT", "Statement": "The two cohorts in the primary trial receive identical interventions; the pegylated irinotecan administered intravenously (IV) at 145 mg/m\u00ac\u00c2\u00a7 as monotherapy once every 21 days (1 cycle), the difference between cohorts is the type of cancer diagnosed in patients, cohort 1 is NSCLC, while cohort 2 is mBC.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "b620e1c5-69c4-4c30-9006-faa346200b60_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01256008_BT", "Secondary_id": "NCT00300781_BT", "Statement": "The primary trial focuses on cognitive behavioural therapy, a type of psychotherapy, as opposed to secondary studies, Trastuzumab, a type of chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0900325b-6ecd-46f1-b3f1-a2ce1605d151_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00325598_BT", "Statement": "There is no difference in the results or size of the cohort between cohort 1 and 2 of the primary trial, the Gy increase has no significant effect.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6f10e1f3-1197-464e-b574-d697fb49331d_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02419807_BT", "Secondary_id": "NCT00777101_BT", "Statement": "Patients with HER2 + breast cancer are eligible for both the primary and secondary trials. However, only patients with Stage 1-2 breast cancer are eligible for the primary trials, and patients with Stage 3-4 are eligible for the secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "cbf91beb-829b-488f-8e80-3b08b891a181_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03592121_BT", "Secondary_id": "NCT01439711_BT", "Statement": "Both secondary and primary trials require that their patients receive their respective interventions on a daily basis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "985df98b-b397-4dbc-8fad-43ada30927d7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00254592_BT", "Statement": "Patients in need of acute supportive care may participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 9]}, "0d4fdeef-89b2-463b-8252-66fa51d9ce8c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00356811_BT", "Secondary_id": "NCT00296036_BT", "Statement": "The secondary test procedure is applied to the palms and soles twice a day, the primary test participants do not receive any medication on the skin of the hands or feet, but rather on the chest or chest wall.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02595372_BT", "Statement": "27.6% of patients with fatty acid synthase (FSFA) expression in the primary trial treated with Minocycline hydrochloride did not receive a complete pathological response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "494c1f01-5a2d-409e-b614-5871f408fbe6_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00450866_BT", "Statement": "In primary trial group A, the percentage of patients with an increase of more than 25% in the tumour area at 3 months after treatment is higher than in group B.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "17881072-2517-483f-9c03-1edad21a58cf_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01008150_BT", "Secondary_id": "NCT00375427_BT", "Statement": "In total, the secondary test recorded only 3 more cases of pyrexia than the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00093795_BT", "Statement": "Patients with metastatic cancer cells in less than 3 lymph nodes, at least one of which is more than 2 mm, cannot enter the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 8]}, "da6ce3a9-b653-47b2-9271-f831e4de3f19_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00912340_BT", "Statement": "In cohort 2 of the primary trial, fewer patients had an unusual amount of fluid around the lungs than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 8, 15]}, "66979ae5-a709-4adf-9067-287f0f92b9e2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00828074_BT", "Statement": "A higher number of participants in cohort 2 of the primary trial experienced fever compared to cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 13, 18]}, "0af6799b-655f-4b8b-a192-ce8dcbb2fcff_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02692755_BT", "Statement": "Only black women are eligible for the primary trial, provided they do not have uncontrolled or symptomatic brain metastases.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 10, 11, 12]}, "3a3e2387-c4c7-48e6-b3ca-1257de7019c2_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00072293_BT", "Statement": "Patients with palpable breast lesions and axillary lymph nodes are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [3, 12]}, "46ac8a9f-77ab-40cf-9421-64aad4ae6976_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00537771_BT", "Secondary_id": "NCT00354640_BT", "Statement": "\u2022 Cohort 1 participants in the primary trial and all participants in the secondary trial take 1 milligram PO QD anastrozole.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 5]}, "d2b7253b-0654-4bb1-a9a4-b203714d64f9_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00445458_BT", "Secondary_id": "NCT00950742_BT", "Statement": "The primary and secondary tests measure the DLT of their respective interventions using the same time frame.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "9a896e4a-ae6b-468c-a7c0-32c1514c0b48_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00107276_BT", "Secondary_id": "NCT00232505_BT", "Statement": "Less than 5% of patients treated in the primary trial experienced adverse reactions, compared to almost 10% of patients in cohort 1 of the secondary trial experienced adverse reactions, and more than 30% of those in cohort 2 of the secondary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 8, 9]}, "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00356811_BT", "Secondary_id": "NCT00296036_BT", "Statement": "The secondary trial procedure applies to palms and soles twice a day, and no topical drugs are given to primary trial participants.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0931065d-35e4-4f82-8ef6-ac6db900127a_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00290732_BT", "Secondary_id": "NCT02748213_BT", "Statement": "Patients whose breast cancer has spread to the skin and chest wall are eligible for the secondary trial, but not for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2, 8], "Secondary_evidence_index": [0, 1]}, "70912726-ba1b-47ef-9005-9584c8caf559_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00853996_BT", "Statement": "Women classified as low risk of developing breast cancer over the next five years by the Gail model, and no family history of hereditary breast cancer, are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 8]}, "6743f85c-8318-49cc-acba-94aeb1f57130_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00493636_BT", "Statement": "The primary trial cohort 1 had a PFS longer than cohort 2, but the patient with the longest PFS was in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "ddffa26d-2581-477a-955c-ebf0c2ab0f97_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00784849_BT", "Secondary_id": "NCT02104895_BT", "Statement": "The accelerated partial irradiation of the breast is used in one form or another for both cohorts of the secondary trial, but not at all in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "f1a45b47-498d-45c8-b6d9-6c8f035da30b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01201265_BT", "Statement": "One patient in the primary trial was affected by Sepsis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "a5272c37-0e32-42db-a44a-d17df7bd70ff_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00179309_BT", "Statement": "No pain-related adverse reactions were observed in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "4c67a7b4-36fa-4c20-a15a-122609550973_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00201773_BT", "Statement": "Adele is an 85-year-old woman with ER+ breast cancer historically confirmed by an ECG of 0, she has a life expectancy of less than 6 months and a history of thrombotic events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 6]}, "120c6aa7-fcaa-4eaa-b520-6382968a6724_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00620373_BT", "Statement": "The primary trial tests two different modes of dental imaging: mammography and gamma imaging.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00050011_BT", "Statement": "The primary test results show that Upfront Zoledronic acid is a better treatment than retarded zoledronic acid to prevent changes in bone mineral density (BMD) in the lumbar spine (L1-L4).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "ac997ae1-7e48-48e2-af9e-f7e289622250_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00798135_BT", "Secondary_id": "NCT01209195_BT", "Statement": "The primary and secondary tests examine different outcome measures for different interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3]}, "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02915744_BT", "Statement": "The difference in median overall survival (SG) of patients between the two cohorts in the primary trial was less than one month, with the patient with the longest GS in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "441c0760-ca4a-4f1d-864e-a77395fd1f18_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00399802_BT", "Statement": "The Lapatinib group in the primary trial showed a lower percentage change from the reference base in urinary collagen type I N-telopeptide than in the Odanacatib 5 mg group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "fbe60029-8944-4e12-b4b2-3413037a10cc_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00723125_BT", "Statement": "57% of patients in cohort 1 of the primary trial had complete pathological response rates to surgery.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "fe1782aa-a871-4608-a7cb-8f83b7f76d8a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00278109_BT", "Secondary_id": "NCT01881230_BT", "Statement": "- Gemcitabine is not used in the primary trial and is only used in cohort 2 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02364388_BT", "Secondary_id": "NCT01425268_BT", "Statement": "There is no overlap between the treatments used in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00405938_BT", "Statement": "Patients with intracranial metastases may be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [9, 10]}, "4dc22366-3ff3-41c8-aa4c-7342d7b7085d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00263588_BT", "Statement": "The majority of subjects in the primary trial had a progressive disease or objective CNS response rate that was unknown.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "196c2132-c735-4b79-bf03-3a830fcaf0fc_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00645333_BT", "Secondary_id": "NCT00006110_BT", "Statement": "The primary trial records several central nervous system-related adverse events in its patients, while the secondary trial does not.", "Label": "Contradiction", "Primary_evidence_index": [7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "72619b0a-57c2-465c-8428-72019b59f8ae_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02924883_BT", "Statement": "In the primary trial, all cases of Enteritis, Vertigo and heart failure occurred in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "b8663fa7-585a-4cd9-afd2-89e8e1a58b82_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02732119_BT", "Statement": "Mark complained of having had a heart racing twice in the last month and is therefore excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [8, 14]}, "7c92d075-ba9d-45b5-9834-83b09d2753bc_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02536794_BT", "Secondary_id": "NCT00712985_BT", "Statement": "Both the primary and secondary trials administer IV treatments to their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00411788_BT", "Statement": "If Hannah takes ketoconazole to treat the athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday.", "Label": "Contradiction", "Primary_evidence_index": [18, 33]}, "9a346aac-46c2-4a50-8f3a-309b3b7bc295_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00382785_BT", "Secondary_id": "NCT00784849_BT", "Statement": "Neither the primary nor secondary test uses low-dose magnesium oxide, biopsies, or mometasone in their intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "949d79e0-95db-47a2-802a-6280c0255923_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02132949_BT", "Secondary_id": "NCT01111825_BT", "Statement": "Between the two cohorts of patients in the primary and secondary trials, there was only one patient with granulocyte deficiency in the blood.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "6e080a1e-a03e-4547-a7c4-c9d5a80de977_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01325207_BT", "Secondary_id": "NCT02429427_BT", "Statement": "Patients participating in the primary and secondary trials experienced serious eye disorders.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "63218fb2-3f5b-4738-bea8-11fbbc560949_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01730729_BT", "Statement": "Patients with severe malabsorption disorders are not eligible for the primary trial unless they are able to receive an intravenous (IV) diet.", "Label": "Contradiction", "Primary_evidence_index": [24, 31, 30]}, "d7fa4f81-e108-491f-9b08-c147a33863e8_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01953003_BT", "Statement": "Patients receiving intervention 1 of the primary trial will be administered orally and intravenously.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "f24afb09-ea65-457f-9f9b-0db3cc3101ac_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00849472_BT", "Statement": "Two dozen primary test participants are classified as having a complete pathological response (CPR) in the breast and nodes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3cd79df2-e6dd-41dd-b819-4d993b5f7aed_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00403130_BT", "Statement": "No cases of Leukopenia, Epitase or Arrhythmia were observed in patients participating in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "d2d6f646-5881-42a2-b965-0c6f79e89463_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00090857_BT", "Statement": "If the results of this analysis are greater than 2 standard deviations below normal, the study physician may still decide to allow them to participate.", "Label": "Entailment", "Primary_evidence_index": [7, 8]}, "428d5165-560b-4783-8c4b-5fd3a3289cab_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00022672_BT", "Statement": "There were no patients in either cohort of the primary trial with PFS greater than one year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6e7df2e4-11b3-4183-aefc-760f85809515_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02536794_BT", "Secondary_id": "NCT00712985_BT", "Statement": "Both the primary and secondary trials administer Zometa to their patients intravenously, although at different doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "45e6b4b6-ca31-4318-936e-5b27cbca47a2_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01439711_BT", "Statement": "One primary trial patient experienced a decrease of 2.87 cm3 in the total volume of functional MRI tumours (FTV) over a 3-month period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "22a6d10e-55c5-4a8c-8010-3e8252bcb279_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00458237_BT", "Statement": "The patient who has recently undergone external beam radiation therapy is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00593346_BT", "Secondary_id": "NCT00902330_BT", "Statement": "The primary test treatment takes less time than the secondary test treatment, but is given much more frequently.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "50d119f6-a657-4619-918e-7617ac57f052_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03078751_BT", "Statement": "In cohort 1 of the primary trial, one case of AML was reported.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "e436827b-10db-4179-bf8f-07786ee6145b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01009918_BT", "Statement": "There are no racial criteria for entry into the primary trial, but there are gender criteria.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "fcc6708a-b0fc-4215-a45f-02b1e0e2d30a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00631852_BT", "Statement": "Patients with haemophilia are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [12, 19]}, "d63706f1-4fb8-488d-8f86-c1a19df341d4_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00944047_BT", "Secondary_id": "NCT00228943_BT", "Statement": "Patients with HER2-substantiated tumours are excluded from the primary trial but may be included in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ab357056-67a7-4227-966d-8c96eb1640fd_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02694029_BT", "Statement": "The primary test candidates should be able to hold their breath for half a minute.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "0359eef3-6339-485e-95bc-0cb6fa7bcd12_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00635050_BT", "Statement": "\u2022 Patients with breast cancer who have estrogen receptors are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "57ef3c6c-b4e1-4302-b423-aa9faca21200_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00791037_BT", "Secondary_id": "NCT00606931_BT", "Statement": "The primary and secondary trials do not use the same route of administration for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "29d5779b-c228-4b82-9ca8-075beadae879_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00091442_BT", "Statement": "There have been more cases of febrile neutropenia than eukopenia in the primary trial, but fewer cases of febrile neutropenia than Neutropenia.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 3, 4]}, "4e124d90-68d7-40bd-a8b1-27cb49d64c64_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00591864_BT", "Statement": "Patients in the primary trial receive Trametinib, Akt inhibitor GSK2141795 PO QD on days 1 to 28, up to a maximum of 8 cycles.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00291694_BT", "Statement": "The route of administration of the two interventions in the primary trial is topical skin cream.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f4c7dae5-012f-4f05-b5ba-da072fe1359c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01674062_BT", "Statement": "One patient in the primary trial was observed with enteritis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "927bbb75-37da-4b75-9483-252d31a0fd98_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01067976_BT", "Secondary_id": "NCT00941330_BT", "Statement": "In contrast to the secondary test, the primary test does not provide for cycles or doses in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "80a5cdbc-0721-41b6-af1a-28e3f46557ce_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01610284_BT", "Statement": "One patient in the primary trial had a cardiac adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "af710d36-8062-4412-8d11-1c57a14b5e5a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00217672_BT", "Secondary_id": "NCT00110084_BT", "Statement": "The primary test had three times the rate of onset of enterovedic fistula as a secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "c91c7dc1-17b7-4475-9aec-38999a18a306_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00717405_BT", "Statement": "There were several patients who contracted pneumonia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "5357ce66-7f7b-4ffd-926c-f6116f5a2e20_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00243503_BT", "Secondary_id": "NCT00448279_BT", "Statement": "The primary and secondary trials observed a different number of adverse reactions in their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "3c7ecca8-5397-41f5-b72b-84217bf3acd2_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00399529_BT", "Statement": "Women with chronic obstructive pulmonary disease who do not need systemic corticosteroids are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [8]}, "2c53e14a-719c-4994-9090-73f9bddb60ba_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00615901_BT", "Secondary_id": "NCT00829166_BT", "Statement": "The primary trial recorded more seizures than the secondary trial, although it had less than one-tenth of the total number of patients in its cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089999_BT", "Statement": "In total, more primary trial participants had no tumour response, than partial response, and only 3 patients had a complete response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "bfb617c8-51ae-4ab2-be05-6346daad5437_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00820222_BT", "Secondary_id": "NCT01819233_BT", "Statement": "Both the secondary trial and the primary trial interventions require subjects to follow restricted calorie diets or gluten-free diets, while complementing food journals.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "dcc5c3b0-848b-4ef4-afe6-e9c9933e33af_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00404066_BT", "Statement": "\u2022 Abnormal LVEF, pregnancy or breast-feeding automatically eliminates patients from participating in the primary trial, unless they are treated with herbal medicines.", "Label": "Contradiction", "Primary_evidence_index": [17, 22, 28, 29]}, "18fcd396-cb03-4e80-bb2d-ee03c12ba32a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00455533_BT", "Secondary_id": "NCT00767520_BT", "Statement": "During the secondary and primary trials, there was only one case of pregnancy in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "694c5820-ebb6-4271-8685-a0b51c637f7f_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00038103_BT", "Statement": "There is no significant difference in the proportions of subjects with clinical benefit in the Exemestane + Celecoxib cohort and in the Exemestane only cohort of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "b87abb47-13b6-4dbe-9cfd-e63075b676aa_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00662025_BT", "Statement": "At the time of evaluation 0, participants in the primary trial had a confirmed disappearance of all target and non-target lesions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00754845_BT", "Statement": "Patients who received more than 5 years of anastrozole therapy, completed less than a year ago, are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2, 3]}, "23df2cc2-6aae-4251-a8a7-e2f5a65f176a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02149524_BT", "Statement": "None of the adverse events in the primary trial were related to IG.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "1bd51c93-d7a8-4da4-825d-ada625033c34_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00418028_BT", "Secondary_id": "NCT00293540_BT", "Statement": "Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for the primary trial, but is eligible for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [7, 10], "Secondary_evidence_index": [3, 4]}, "58c58b68-fc9a-438c-8a85-9233dde714c9_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01827787_BT", "Statement": "The Triple-Negative breast cancer cohort in the primary trial had a much lower OR than the HR+/HER2- cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "843778c6-a320-49a1-93a0-5dc6239b822a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00965523_BT", "Statement": "The most common adverse reactions in the primary trial where infection and stomatitis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a5486f80-69e5-4a5a-8435-f82f39cddf85_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00080301_BT", "Statement": "There were 2 more cases of gastrointestinal haemorrhage in cohort 2 of the primary trial than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "c2c60b25-f255-48ba-bcb7-2bcd2de4315d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00171314_BT", "Statement": "There are four types of adverse events in the primary trial, for which no events are recorded.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "a8167a90-8ccf-4024-a4cc-8c1b047fd548_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00068601_BT", "Secondary_id": "NCT01684215_BT", "Statement": "The primary and secondary trials do not use the same route of administration for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00106002_BT", "Statement": "The primary trial participants are treated with 600 mg Pemetrexed orally twice a month until a complete response or progression of the disease.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "277f5d17-36cc-44c5-9b94-7e052f2bdb2c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01067976_BT", "Secondary_id": "NCT00941330_BT", "Statement": "In contrast to the secondary trial, the primary trial only provides for the duration of cycles and doses of drugs in the intervention section.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "fcb195de-2143-44d8-8c46-136104554e2d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01492101_BT", "Statement": "There was less than 1% of either cohort in the Pancytopenia primary trial, but slightly more than 5% of patients in cohort 1 had coagulopathy.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5, 11, 15]}, "70337af9-3d4a-44bc-bbfa-0d97ea88553c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317720_BT", "Statement": "Patients must have at least 3 pre-treatments with trastuzumab to be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2]}, "9cf89221-5801-4709-a098-de763b6e702e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00334542_BT", "Statement": "A patient with mastectomy would be excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [6]}, "f89883ea-dd60-4d5f-9354-13fbca2aeec8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01031446_BT", "Statement": "Sarah was the victim of epileptic seizures of a brain tumor, which will not prevent her from participating in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5]}, "a289f67c-ff56-44a9-b3da-152fb0d20271_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01301729_BT", "Secondary_id": "NCT02129556_BT", "Statement": "Only one respiratory adverse event was recorded during the duration of the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "10ed1242-c6ab-4ad0-b93c-4738857f543a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02635737_BT", "Statement": "Patients with ICD may be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [6, 7]}, "683b9885-4027-4108-b37e-61255611538a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02692755_BT", "Statement": "Asian, British and white women are eligible for the primary trial, provided they do not have uncontrolled or symptomatic brain metastases.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 10, 11, 12]}, "a47e048a-56aa-49e0-9903-563f53797b6e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00600340_BT", "Statement": "- Cohorts 1 of the primary trial with Bevacizumab patients at a higher frequency and dose than those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "690de5e2-3d7f-407e-8eb9-783adf58841b_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00356148_BT", "Secondary_id": "NCT01856543_BT", "Statement": "Women of all ages can participate in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "f5477a02-dde7-44c8-80b5-2cdb9fa66f23_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01234337_BT", "Secondary_id": "NCT00217672_BT", "Statement": "More than 2 cases of anaphylaxis occurred either in the primary test or in the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "dc184dcb-a22d-4cac-bee1-6c182692e522_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03511378_BT", "Statement": "In order to participate in the primary trial, patients must have a life expectancy greater than one year.", "Label": "Contradiction", "Primary_evidence_index": [0, 8]}, "4dfbdeba-cae0-48b2-a38d-07338512904e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03076190_BT", "Secondary_id": "NCT03196635_BT", "Statement": "- Molecular mammary imaging is not applied in either the primary trial or the secondary trial interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "62489179-bb30-4b96-a904-ea907dd05e23_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01097460_BT", "Secondary_id": "NCT01009918_BT", "Statement": "Each patient in the primary and secondary trials had at least one adverse event that occurred over a 2 year period.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "45891239-bb78-4f83-8306-8edceb8247fe_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01011946_BT", "Statement": "All patients in the primary trial should have a bilateral breast mammography prior to entry into the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00258349_BT", "Secondary_id": "NCT01328249_BT", "Statement": "The primary trial cohort 1 does not receive Eribilin Mesylate or Vorinostat, while the two secondary trial cohorts receive some of the two.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "91f23b55-38b6-41c4-af30-baa15e989aa7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00371254_BT", "Statement": "Patients should have an eceptorsestrogen (ER) receptor -, a progesterone receptor (PR) - and a human epidermal growth factor receptor 2 (HER2) - non-metastatic breast cancer, as well as the absence of Dysphagia.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 8, 12]}, "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00374322_BT", "Statement": "The primary test results showed that participants receiving lapatinib at 1500 milligrams (mg) orally were twice as likely to reach DFS at 5 years of age as patients on placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "a2d489d5-3677-43ef-b03a-33d571c0c3b2_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02650193_BT", "Secondary_id": "NCT00656669_BT", "Statement": "Patients with Class III obesity may not be included in the primary trial, but may be included in the secondary trial, provided they do not have uncontrolled hypertension.", "Label": "Entailment", "Primary_evidence_index": [0, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "943ff737-4edd-4dbd-a3c9-213e3e0234d8_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00423917_BT", "Secondary_id": "NCT00082641_BT", "Statement": "In both the primary and secondary trials, there are instances of confusion in their patient cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 7, 8, 15]}, "be50c45f-ec51-40c8-904f-ffc200d39d9d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01042938_BT", "Statement": "Only patients able to understand English are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 11]}, "f53c8212-6da8-470f-a392-1bb037ed90e8_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04030104_BT", "Secondary_id": "NCT02525718_BT", "Statement": "Intervention 1 for the secondary and primary trials includes either no treatment at all or placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "7b7e6e8b-aa62-4fcd-af1e-c243995243d1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02622074_BT", "Statement": "There were twice as many patients with DLT in cohort 2 of the primary trial as in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "74a53536-bb9d-4c64-9280-679d7b660cdd_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02162719_BT", "Statement": "The primary trial does not examine the effects of its intervention on the patient's PRT.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "6b35c306-a699-44f2-8606-a58d58fc18f3_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00728949_BT", "Statement": "There were 6 categories of adverse reactions for cohort 1 of the primary trial that recorded at least three cases.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "62f50fe5-a83d-4f07-9dc7-8f495254d398_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00784849_BT", "Secondary_id": "NCT02104895_BT", "Statement": "While breast irradiation is used in one form or another for both cohorts of the secondary trial, it is not used in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "edcae553-8a0a-45d2-a0fa-4db68608ef03_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121134_BT", "Statement": "The primary trial requires participants to have a primary tumour > 5cm in the longest dimension.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "a1b3667f-bfa5-426a-975a-20ed350c12c0_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00748553_BT", "Statement": "Patients in the primary study receive 5 doses of azacitidine (Vidaza) per month and 3 doses of Nab-paclitaxel (Abraxane) per month.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "903617fa-7c40-45ac-a03c-498f51879408_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02915744_BT", "Statement": "The difference in median, maximum, and minimum overall survival (MS) of patients between the two cohorts in the primary trial was less than one month.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9436e18a-a055-41c3-980f-bf451b4da7ee_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00171314_BT", "Statement": "There are four types of adverse events in the primary trial, for which an event is recorded.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f57403d9-7278-481e-bcb9-066bf31b6158_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01201265_BT", "Secondary_id": "NCT00932373_BT", "Statement": "One patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688909_BT", "Secondary_id": "NCT00129376_BT", "Statement": "Patients in the primary and secondary trials did not experience any of the same adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "0f0e5a8e-3972-46c2-84dd-7436e82a9787_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00291135_BT", "Secondary_id": "NCT00291694_BT", "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "420e4977-ce75-4fab-99e0-3e7db837d521_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191152_BT", "Statement": "The primary trial lasted more than 21 days in the docetaxel plus capecitabine group, the longest progression time of the disease.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "d07b4a30-e74f-468a-8420-7ade791d372d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00096356_BT", "Statement": "The results of the primary trial indicate that CoQ10 reduces the PFS of breast cancer patients by approximately 8% compared to placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "412b2743-8f76-494a-af97-f7bf9541a890_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02536339_BT", "Secondary_id": "NCT00371345_BT", "Statement": "At least one type of respiratory disease was observed in patients in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 11]}, "fd43feb6-4a55-4de6-b21d-25ff723b0959_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00631852_BT", "Secondary_id": "NCT00193037_BT", "Statement": "Patients may be forced to participate in the secondary and primary trials, even against their consent, provided that this is in their best interests.", "Label": "Contradiction", "Primary_evidence_index": [0, 8], "Secondary_evidence_index": [0, 9]}, "e1fa68ac-42b4-4223-a362-a89c43562e06_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01256567_BT", "Secondary_id": "NCT01926886_BT", "Statement": "The most common adverse reaction in the primary trial was febrile neutropenia (14.29%), while in the secondary trial it was a decrease in ejection fraction (4.95%).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6f5570c0-4114-47ee-9611-b2e4be91cf9a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03165955_BT", "Secondary_id": "NCT00912340_BT", "Statement": "2 patients in the primary trial suffer from DVT, 0 in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01224678_BT", "Statement": "Intervention 2 of the primary test resulted in a percentage change in tumour diameter lower than intervention 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "6495c223-f7d9-459f-8c57-66a2caac5ee4_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02581839_BT", "Statement": "All participants in the primary trial had a progression-free survival of the central nervous system (CNS) >= 16 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "eb61fee2-30fc-42f9-80bd-4d73d6af592c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01216319_BT", "Secondary_id": "NCT03346161_BT", "Statement": "The secondary and primary trials evaluate interventions associated with breast reconstruction in patients with mastectomy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "79c698bf-a756-4a73-8075-38c3c5eb7a04_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00091832_BT", "Statement": "The two cohorts in the primary trial in a percentage of negative (average) variation from the creatinine-adjusted urinary N-telopeptide reference base (uNTx/Cr).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f7be0a6e-6c63-473e-af00-df009f3d7d46_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00571987_BT", "Statement": "\u2022 Breast implants and Diffuse microcalcifications will not disqualify a patient from entering the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "6f686de9-f110-4be0-9cd8-1ceb0ce6f073_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01376349_BT", "Secondary_id": "NCT01912612_BT", "Statement": "The primary trial cohort 2 receives 3.25 mg of DHEA vaginal QD gel more than the subjects in cohort 1 of the two secondary trial cohorts only the Duloxetine 30 mg pain-free cohort per day.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01004744_BT", "Statement": "Patients should have a pregnancy confirmed by a positive Hcg test if they are to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2]}, "ffa913b7-9875-458e-8a28-476f9e788bb0_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02463032_BT", "Statement": "There was less than 5% difference in the percentage of participants with an objective response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193206_BT", "Statement": "The primary test has a total of 7 different types of infections.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "d8e47fe7-be41-4f74-881b-a80cd3a1e95f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03456427_BT", "Secondary_id": "NCT02685566_BT", "Statement": "There are no details of the duration or frequency of administration in the intervention sections of the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e77e15a3-d851-4174-80c3-7b5156e7f987_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00236899_BT", "Secondary_id": "NCT01153672_BT", "Statement": "The primary and secondary trials do not use any of the same drugs in their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "c003dd08-af3b-44cc-b31c-6fbdadfa1d83_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01806259_BT", "Statement": "In total, more than 85% of patients in the primary trial achieve non-recidivism survival after 3 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "8ddf49c7-316e-4c7c-b2dd-423182a37612_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00455533_BT", "Secondary_id": "NCT00767520_BT", "Statement": "During the secondary and primary trials, there was only one case of sudden and unexpected death in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d9e41be5-1e37-4dff-b51a-166576f351d0_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01498458_BT", "Statement": "For all types of adverse events in the primary test, at least one case has been recorded.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "ee2287bd-af76-4232-9575-d371fe3257dc_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00544167_BT", "Statement": "Each adverse event in the primary trial occurred once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e5495b51-5f42-4e97-80ec-c215652bd3ab_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00675259_BT", "Secondary_id": "NCT01875367_BT", "Statement": "Patients with an immuno-histoChimistry test result of 3+ are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [15, 18], "Secondary_evidence_index": [0, 15]}, "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00612560_BT", "Statement": "Children and adults who are illiterate may participate in the primary trial, unless they can read and write in Italian.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 12, 13]}, "9ae51f9c-8544-4764-b731-e4efe9ae0ba6_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00452673_BT", "Statement": "1/7 patients in cohort 1 of the primary trial had dose-limiting toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5b1915da-1819-4504-81bd-3f44a83b5e95_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320541_BT", "Statement": "In the primary trial cohort 2 there were three times as many cases of Leukopenia as in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 13, 17]}, "edb1e4c0-7669-4b8c-878b-ea8ca060c350_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00074152_BT", "Statement": "Only 2 cases of adverse events in the primary trial occurred in patients in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "915939cf-7813-43e7-b503-e14a7eb4e568_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00429299_BT", "Statement": "Only one cohort in the primary trial is administered to trastuzumab 600 mg/m^2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "126c1169-b375-4f89-95b2-52e971d19565_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00856492_BT", "Statement": "There were no deaths and no cases of infectious enterocolitis in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "11235250-3627-427e-aae9-099507484456_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00284180_BT", "Statement": "In the three cohorts of the primary trial, a total of two patients had low levels of oxygen in their body tissues.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "8a9f2247-7c51-44be-910b-5091d9abb2ea_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00236899_BT", "Secondary_id": "NCT01153672_BT", "Statement": "Both the primary and secondary trials administer Paclitaxel and Gemcitabine to their patient cohorts, but only the secondary trial uses positron emission tomography.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "7e283897-4d9e-4353-8331-00f8db16cc7e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00038467_BT", "Statement": "The groups of patients in the primary trial each receive different oral medications, either tamoxifen or exemestane.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "54b15068-023b-4e60-bb82-2a22512fda62_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00847171_BT", "Secondary_id": "NCT01764022_BT", "Statement": "Male patients with systemic lupus erythematosus are excluded from the primary trial, but may still be eligible for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [24, 32], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35]}, "78764961-52be-4235-a2b7-e581497d0099_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00900627_BT", "Statement": "Both groups of the primary trial receive the same medication treatment, but different doses.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e09fe98c-ec5c-49cf-9f49-92ba8824e82e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03708393_BT", "Secondary_id": "NCT03456427_BT", "Statement": "The primary and secondary trials require the active involvement of the patient to apply the treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "a83d98c9-e3da-4449-878b-5fa2f3bee8cf_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01277757_BT", "Statement": "The primary trial does not consist of testing a new physiotherapy or radiotherapy procedure.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "41db854e-1565-4eda-8236-550556043b47_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01027416_BT", "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by a nucleus biopsy and a human chorionic gonadotropin urine test.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 8]}, "f559cacb-30e7-47cf-9ac6-5929c1a508f7_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00493649_BT", "Secondary_id": "NCT01201265_BT", "Statement": "There was no MRSA infection in the secondary or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "79362f6d-ef2c-4b93-8719-be361d0b5acc_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03096847_BT", "Secondary_id": "NCT01840163_BT", "Statement": "Women Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a Stage 1 to 2 Ductal Carcinoma in situ and can speak English.", "Label": "Contradiction", "Primary_evidence_index": [9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "54918996-1b4d-48bd-a0ca-13d8e259767b_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02650193_BT", "Secondary_id": "NCT00656669_BT", "Statement": "\u2022 Class III obesity patients cannot be included in the primary trial, but may be included in the secondary trial, even if they have uncontrolled hypertension.", "Label": "Contradiction", "Primary_evidence_index": [0, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00679341_BT", "Secondary_id": "NCT00201851_BT", "Statement": "Patients in the secondary and primary trials did not have the same adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "52c8361f-75dc-45f1-a35c-79180a22b931_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02015676_BT", "Statement": "No cases of thrombocytopenia were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091168_BT", "Statement": "Patients in the primary control group had median overall survival of less than one year, but several patients in the B-arm survived for more than one year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 11, 12, 13, 14, 15, 9, 17]}, "db8ffa86-bf52-47bb-89f7-42e7ae47b84d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01271725_BT", "Statement": "In the primary trial, the percentage of participants with an objective response (OR) for Afatinib monotherapy was 18% lower than that for Afatinib and Paclitaxel or Vinorelbine Combine Therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "5a01d00f-8601-4c17-b814-be87e63b0d8a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02392611_BT", "Statement": "The primary test cohorts are not separated according to the patient's characteristics.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "7577f05f-04e9-44de-9e00-b7411ff4010f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01351376_BT", "Statement": "The laxatives currently prescribed are not excluded from the primary test.", "Label": "Contradiction", "Primary_evidence_index": [5, 18]}, "3b0440e6-cf85-4236-8a1d-2e3572143946_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191451_BT", "Statement": "Patients in the primary trial experienced only one type of oesophageal side effects and several types of cardiac side effects.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6f342205-ef33-482a-b74a-74644537538b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00077857_BT", "Statement": "Patients should be over 18 years of age, female, have one or more target lesions and more than 2 chemotherapy regiments to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 5]}, "5b63fffb-0a75-414f-8744-5fea78395f28_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00950742_BT", "Statement": "100 participants in the Afatinib 20mg + Herceptin group in the primary trial suffer from the limiting dose of toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "9e655973-7d1d-4528-8394-a9cbcf0b978f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02279108_BT", "Secondary_id": "NCT00943670_BT", "Statement": "Adult patients with HER2-infiltrating breast cancer who have had a prior lumpectomy or breast reduction on the same side are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "ea62355f-aab9-4796-8658-746c0b669ca7_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00073073_BT", "Secondary_id": "NCT00054028_BT", "Statement": "There is no placebo or control group in the primary trial, in the secondary trial, Suramin acts as a placebo.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "55eaae8d-611c-4dbb-b162-de664902e059_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454805_BT", "Statement": "In the primary trial, there were more cases of intestinal obstruction in cohort 1 than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 8, 14, 22]}, "c3438bb2-4a49-4f14-ae50-a46fb48d0208_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00485953_BT", "Secondary_id": "NCT00068601_BT", "Statement": "The dose of cyclophosphamide in the secondary test and the dose of Placebo in the primary test are not specified.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "8f505cec-6ad4-4142-a861-1771e3ae5cdd_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00821964_BT", "Statement": "The primary trial participants apply topical imiquimod to skin lesions once a day for a total of 13 days every 28 days of the cycle.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "8f4f9793-041d-448b-9da8-b0c787a875bb_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00478257_BT", "Statement": "In order to participate in the primary trial, adequate haematological, hepatic and renal function is not required.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01735175_BT", "Secondary_id": "NCT01216319_BT", "Statement": "The secondary trial consists of testing a surgical procedure, unlike the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "61d56c2a-089f-4fa3-9e97-3a9007576077_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00376597_BT", "Statement": "The primary trial does not receive any IV, oral or surgical interventions during the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00411788_BT", "Statement": "If Hannah takes ketoconazole to treat the athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for next month.", "Label": "Entailment", "Primary_evidence_index": [18, 33]}, "bad4d3e7-a05a-44fd-937a-c94a23655c03_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01712009_BT", "Secondary_id": "NCT00343382_BT", "Statement": "In the primary trial, cohorted patients 2 receive naproxen at the same frequency and dose as cohort 2 patients in the secondary trial receive Pilocarpine.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [3, 4, 5]}, "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00499122_BT", "Secondary_id": "NCT00454805_BT", "Statement": "There have been several cases of multi-organism failure in cohort 1 of the secondary trial and cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "0c435231-a09c-4424-924a-13840c6b7068_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191789_BT", "Statement": "In the primary trial, there were 1 cases of jaundice.", "Label": "Entailment", "Primary_evidence_index": [0, 12]}, "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01217385_BT", "Secondary_id": "NCT01202591_BT", "Statement": "While prior exposure to exemestane is not permitted for patients in the secondary trial, the primary trial may accept patients despite this.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [6, 7]}, "a29e6a86-65f3-4565-93e2-81f49fa837e4_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01252290_BT", "Secondary_id": "NCT00479674_BT", "Statement": "Unlike the secondary test, the primary test does not record any cases of anaemia, dyspepsia, nausea or depression.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00418457_BT", "Statement": "The reconstruction of the components within 10 days of the start is acceptable for patients entering the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "34bb7f09-3b2b-464f-96df-c8d80b1206fc_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03190083_BT", "Secondary_id": "NCT01805089_BT", "Statement": "All stages of cancer are accepted for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "e9824c27-bb70-4707-9599-ff20281f873e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00357110_BT", "Statement": "Less than 20% of patients in cohort 1 of the primary trial had varicose veins.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "43fcba9b-4edd-433d-86a7-370cbbf56853_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00320385_BT", "Secondary_id": "NCT00075270_BT", "Statement": "The median time between randomization and the first documented sign of disease progression or death due to any cause for all primary trial participants was less than the median time for secondary trial patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02555657_BT", "Statement": "The median time between randomization and death for any cause was higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "27e0b995-b3d1-46a6-900a-d6e513504ff3_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00398567_BT", "Statement": "In the primary trial, 3/4 patients did not experience adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "36a5357f-0c5f-4c64-a56a-a84aab165a16_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01727011_BT", "Secondary_id": "NCT01420146_BT", "Statement": "The primary test and secondary test procedures involve a variety of scans, such as CT, PET and dosimetry.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "c876167f-fe1e-4c3b-9183-dd3c1069ed0b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00024102_BT", "Statement": "One patient in cohort 2 of the primary trial received a transfusion of packaged red blood cells.", "Label": "Entailment", "Primary_evidence_index": [12, 18]}, "d6989b67-ae99-4c2a-a67d-c2285cc57058_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191152_BT", "Statement": "The longest progression time of the disease the primary trial was more than 11 months in the Docetaxel Plus Capecitabine group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00320385_BT", "Secondary_id": "NCT00075270_BT", "Statement": "The two cohorts in the primary trial exceeded cohort 1 of the secondary trial in the median PFS.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "886d3280-bc44-4a58-a5ba-66b018210332_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00076024_BT", "Statement": "The minimum period between the start of treatment of the study and the first documentation of objective tumour progression or cancer death for any patient in the primary trial was just over a year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "03dcb6d9-efae-40ec-87ee-68ef89424498_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00323479_BT", "Secondary_id": "NCT03078751_BT", "Statement": "There have been more cases of mental health deterioration in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "b881b717-1c8a-41b8-9554-6ed9e8ee7c77_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193206_BT", "Statement": "The primary trial has a total of 7 patients with various infections.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "20530faf-addb-47bf-896d-b9666e149223_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01439282_BT", "Statement": "In cohort 1 of the primary trial, adverse events were 20% higher than cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 14, 15]}, "52557c9f-f771-4f31-bb71-01f87f9f5821_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00041067_BT", "Secondary_id": "NCT01273896_BT", "Statement": "Patients with positive ER, RA or HER2 tumours in stage 4 may be eligible for secondary or primary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]}, "11472413-533f-45f9-9aac-c46bca318aab_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00373256_BT", "Statement": "The primary trial cohort 1 included more than 200 patients treated with Sunitinib and Paclitaxel for 18 months or until death, and the median PFS for this group was just under 71\u20442 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00191854_BT", "Statement": "Patients do not need a positive Her2neu tumour or measurable lesion to be included in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "6446f085-c6b0-43ce-82ed-16d6952b549e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00880022_BT", "Secondary_id": "NCT00916578_BT", "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression. However, all patients in the secondary trial are treated with Trunk compression.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01104584_BT", "Statement": "The primary test participants receive either 50mg/m2 of trastuzumab, tamoxifen or exemestane.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "db90c9d8-b289-48e2-a7df-f41620b3feab_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00110084_BT", "Secondary_id": "NCT01961544_BT", "Statement": "Both the primary and secondary trials reported cases of sepsis in their patients.", "Label": "Entailment", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 12]}, "f2533676-1e72-444e-8aef-1fa826ceb804_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01419197_BT", "Statement": "There are no cases of agranulocytosis in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "c15309b3-eb08-4d46-94ef-e4a504a111db_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03708393_BT", "Secondary_id": "NCT03456427_BT", "Statement": "The intervention in the primary trial is performed either by a doctor, radiograph or sonograph, while one of the interventions in the secondary trial requires the active participation of the patient.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "4885cd77-628c-4b8f-8345-6bce2165938c_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02964234_BT", "Secondary_id": "NCT00246090_BT", "Statement": "Patients eligible for the primary and secondary trials must live in the United States.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "8809cc5e-36d5-4f7e-b06d-b1915a421f71_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00759785_BT", "Statement": "Only one adverse event, a mammary abscess, was observed in patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00908791_BT", "Secondary_id": "NCT00297596_BT", "Statement": "Patients over 60 years of age with histology-confirmed breast cancer and advanced Alzheimer's disease are not eligible for secondary and primary trials unless they have an ECG>2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 21]}, "ca27db58-14c4-4889-95b1-69be9c10a07a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00623233_BT", "Secondary_id": "NCT01525589_BT", "Statement": "More patients with a low platelet count in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5147b171-b5dc-46d6-a153-1a6d9a062ef1_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03190083_BT", "Statement": "All stages of cancer are accepted for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "a5ed3500-1ea1-40b6-b1cb-3d5ae776f713_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00656669_BT", "Statement": "There were no adverse events in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "3c482d5e-bfad-4a46-9e98-ba9967f2d900_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00903162_BT", "Secondary_id": "NCT01674062_BT", "Statement": "Patients with CWB are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [10, 12], "Secondary_evidence_index": [6, 10]}, "48ccd744-abf1-4e98-bc86-8ecd625e6279_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00654836_BT", "Statement": "Patients with a negative metastatic HER-2 adenocarcinoma in the breast may be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 5]}, "dce5d9c8-7da6-4732-b969-c492c876cdca_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01783444_BT", "Statement": "Women of any age can participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "1882de62-2df2-4b73-a3d2-81811f85f661_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01106898_BT", "Statement": "2% of patients in the primary trial were diagnosed with foie gras disease after 3 years of chemotherapy or maintenance therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "161c852e-a42c-47c2-ab6a-2b7bd6a4b934_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00325234_BT", "Statement": "If patients wish to participate in the primary trial, they should discontinue any anti-tumour hormone therapy and have a life expectancy of more than 3 months.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8]}, "eb152d1b-a0d6-428c-8d1d-eb5d862a8147_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01120184_BT", "Statement": "At least one patient in cohort 1 of the primary trial had haemophilia, a rare coagulation disorder.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "0701ac32-45b3-4199-aa20-a71080ce9bf6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00546156_BT", "Secondary_id": "NCT00398567_BT", "Statement": "There are no cases of Vertigo in the primary trial or the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "866876f5-68de-44bd-b58a-e4b590aa4b39_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03573804_BT", "Secondary_id": "NCT02781051_BT", "Statement": "The primary trial participants must undergo at least one MRI during the procedure, the secondary trial patients must use an adjustment device.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "b4304362-1cb4-4606-9de4-03935ad509f1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00370552_BT", "Statement": "There are 55 more participants with the best tumour response of partial response (PR) or complete response (CR) in cohort 2 of the primary trial than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9cddd86a-4340-4918-b000-7e6e593a3f7f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03097653_BT", "Secondary_id": "NCT00662129_BT", "Statement": "Women between the ages of 18 and 25 with stable angina cannot be included in either the secondary trial or the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72]}, "c3f01101-2259-4677-add1-1b1f48a0202b_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00528567_BT", "Secondary_id": "NCT01196052_BT", "Statement": "The total number of patients affected by adverse events in cohort 2 is greater than 1000.", "Label": "Contradiction", "Primary_evidence_index": [11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "33b827a0-ada5-4204-abb8-d5239ea16f0b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00143390_BT", "Statement": "In the primary trial, there was a difference of less than 3 days between the maximum recorded TTP of the Exemestane group and the Anastrozole group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "40f1d3ce-2ff8-4177-9b11-0bf10b7f6591_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00259090_BT", "Statement": "The primary studies focus on the impact of Fulvestrant, Anastrozole, on the H-score estrogen receptor.", "Label": "Entailment", "Primary_evidence_index": [1]}, "22bff413-a1bd-419b-b19b-2157dedc9948_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00802945_BT", "Secondary_id": "NCT01231659_BT", "Statement": "Group 1 of the secondary trial has a higher RRO than the 14-day NKTR-102 cohort in the primary trial and the 21-day NKTR-102 cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "b64d6e41-7ec7-4e62-beda-c28559a6cee7_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00880022_BT", "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2ea80a50-0db3-4ff2-8ca0-71eb048649f7_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01875367_BT", "Statement": "More than 3 patients in the primary trial had a common cold.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "20545360-b2a1-4be9-997a-97040866b239_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00880464_BT", "Secondary_id": "NCT00458237_BT", "Statement": "\u2022 AIDS patients are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [14, 18], "Secondary_evidence_index": [12, 26]}, "3b1bdc19-62cd-4ff1-9e30-424e124342f3_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02425891_BT", "Secondary_id": "NCT00593827_BT", "Statement": "The secondary and primary trials measure the PFS of their patient cohorts and use the same time frame.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "a44cd0d1-92b3-4add-badf-b8dd5a324138_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01466972_BT", "Secondary_id": "NCT01446159_BT", "Statement": "The primary trial recorded one patient with congestive heart failure, and the secondary trial did not.", "Label": "Entailment", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 5, 13, 18]}, "291bb67e-f02f-49d4-b967-29cc9f5098c4_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01738438_BT", "Secondary_id": "NCT00331552_BT", "Statement": "- Cyclophosphamide, cabozantinib, and trastuzumab were used in the secondary test procedure, but not in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "55704a1f-eab2-44ea-a6de-8df508a28066_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00274768_BT", "Secondary_id": "NCT00654836_BT", "Statement": "Patients with stage 4 cancer are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [2], "Secondary_evidence_index": [2]}, "6e1955b8-e6fa-42b2-a498-7ada9e733304_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01593020_BT", "Secondary_id": "NCT00834678_BT", "Statement": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [13, 18], "Secondary_evidence_index": [23]}, "52337e14-7f51-40c1-b965-fb6aba8ae4e7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00821886_BT", "Statement": "Patients prescribed with bisoprolol or labetalol for the treatment of CHF are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [20, 33]}, "8a6397e9-84cd-4a2e-ac6a-b56ee355d862_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00004092_BT", "Statement": "\u2022 Cancer patients who have spread a breast tumour to their CNS are able to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [4]}, "8b5f946c-71d9-42cd-aa9a-1d3a4845c460_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01401959_BT", "Secondary_id": "NCT00852930_BT", "Statement": "The primary trial refers to specific interventions for its patients based on their hormonal status, the A cohort is NTBC patients and the B cohort is ER/PR +HER2- BC patients, unlike the secondary trial attributes random interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "8f0aff7f-0d9e-498b-bcb6-05e6d309724c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01852032_BT", "Secondary_id": "NCT01118624_BT", "Statement": "The secondary trial administers placebo tablets twice the rate of the primary trial, but less than half the dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "b7936bbc-f0c0-444c-a199-2db323c30396_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00313170_BT", "Secondary_id": "NCT00305448_BT", "Statement": "The primary trial patients treated with Fulvestant 250 mg had an objective response rate of 33% higher than those treated with Fulvestant 250 mg + loading dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "6d6625ec-26b7-4157-a38c-87c770201323_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01373671_BT", "Secondary_id": "NCT00686127_BT", "Statement": "The Lidoderm products are used in response arm 1 of the secondary test, and a Siemens product is used in arm 1 of the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01305941_BT", "Statement": "Patients should submit IHC 3+ or FISH amplified results to participate in the primary trial, which means that their cancer is histologically confirmed to be triple positive.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "7e0259a3-073b-45f5-8e08-2cfaceecef0b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00606931_BT", "Statement": "The primary trial tests MRI as a technique to guide biopsies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "c94ad26b-1f5e-4446-a4fe-bb949c5dc561_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00438100_BT", "Secondary_id": "NCT00662025_BT", "Statement": "Patients should have a BUN < 20 mg/dL, platelet count < 90,000/mm3, leukocyte count from 5,000/mm3 to 8,000/mm3 to be eligible for primary or secondary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00244881_BT", "Statement": "30% of primary trial participants had increased CEC levels after 42 days of treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5c00f992-5066-42f2-88d7-566b8b9104b5_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089661_BT", "Statement": "On average, cohort 1 participants in the primary trial had an increased rate of acute toxicity, whereas cohort 2 participants had no acute toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "4c0ffc50-5cb2-4574-b954-335d142edbe4_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01527487_BT", "Statement": "Patients who have prescribed citalopram as a continuous treatment for depression are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [32, 49]}, "4e3379b9-f971-4ab6-8846-c395f1162bf2_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00810797_BT", "Secondary_id": "NCT00828074_BT", "Statement": "Skin infections were more common in patients in cohort 1 of the secondary trial than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 8]}, "9872394c-18b7-4f88-849e-0e2831e6ebf0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00579826_BT", "Statement": "The primary trial cannot currently receive treatment for rheumatoid arthritis, experience poorly controlled migraines, receive hormone replacement therapy, or have a history of invasive breast cancer in the past three years.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 6, 8, 10, 11]}, "adf3bb50-ec36-467a-987a-f33c10380c60_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01771666_BT", "Secondary_id": "NCT01256567_BT", "Statement": "Japanese participants with an ECOG of 2 are eligible for the secondary and primary tests.", "Label": "Contradiction", "Primary_evidence_index": [0, 7], "Secondary_evidence_index": [0, 1, 2]}, "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01875367_BT", "Statement": "One patient in the primary trial had a cerebral infarction.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "03cb39e4-1d21-47e5-9b09-ebe508eb2a17_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00477464_BT", "Statement": "59 patients in the primary A arm received a better overall response, classified as a complete or partial (confirmed) tumour response or stable disease for at least 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "dca6ba74-441e-482f-b667-6c45800ed8c1_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425672_BT", "Statement": "Patients receiving Intervention 1 of the primary trial must undergo a 21-day treatment cycle for a total of 6 courses, except for deaths.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "aeecc244-13a9-4944-858e-27ef49585e90_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01702571_BT", "Statement": "Patients with locally advanced incurable and non-resectable breast cancer are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "741ca5eb-4737-4a35-a9fd-4235d6552b4f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01256008_BT", "Secondary_id": "NCT00300781_BT", "Statement": "The primary trial involves cognitive behavioural therapy, a type of psychotherapy, unlike secondary studies Neratinib, a type of chemotherapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b8e0458c-b834-42b5-b5fd-8791f89b0853_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01881230_BT", "Statement": "The Gemcitabine group in the primary trial had a median Kaplan-Meier estimate of progression-free survival more than 2 months less than the Carboplatin group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1a112ed3-8318-493b-8973-10de01794892_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00382018_BT", "Secondary_id": "NCT03012477_BT", "Statement": "Between primary and secondary trial patients, only one patient had sepsis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [5]}, "6044590d-0f89-4a6e-8be7-54ca0c0327d9_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00003404_BT", "Secondary_id": "NCT00711529_BT", "Statement": "The primary trial does not have a hypnotherapy-based intervention, and the secondary trial does not have a radiotherapy intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8d3378f7-caaf-4654-b12a-382a0e911eb1_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02429427_BT", "Statement": "Patients with a platelet count of 50 x 109/l are not eligible for primary testing", "Label": "Entailment", "Primary_evidence_index": [0, 7]}, "f701473d-e034-4a06-9829-d20cc483162c_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01516736_BT", "Secondary_id": "NCT00733408_BT", "Statement": "The results of the primary and secondary trials are not comparable, as the different size of the cohort is too large.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "3889cecd-aa2d-4f58-857e-11d7209f9cf4_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00450866_BT", "Statement": "In the primary trial, a cohort 1 has a higher percentage of patients with progression-free survival at 3 months after treatment than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00338286_BT", "Statement": "No primary test participant had progression-free survival for more than one year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "cb023dbc-3e99-4c32-a857-7f8d49ef5a96_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00789581_BT", "Secondary_id": "NCT02445586_BT", "Statement": "The secondary trial reported more cases of haematemesis, but the primary trial revealed more cases of DIASTOLIC DYSFUNCTION in both cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "1d0ce237-70eb-45b4-9c77-f0b70d410387_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00193180_BT", "Statement": "A patient over 18 years of age with cirrhosis cannot participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 8, 16]}, "93290529-38b1-444b-9ac8-fa32b98821c5_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00256243_BT", "Secondary_id": "NCT00721630_BT", "Statement": "Patients who wish to participate in the secondary trial should be in a specific location, which is not necessary for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "dad5ecc6-afcf-496c-8193-778a100c0318_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00436917_BT", "Statement": "- Patients with scoliosis with a Cobb angle greater than 20 degrees at the lumbar spine or with surgery prior to the lumbosacral spine are excluded from the primary trial as they are contraindications to X-ray (DXA) dual-energy absorptiometry.", "Label": "Entailment", "Primary_evidence_index": [39, 40, 41]}, "d0efe29c-1d76-4129-9cf5-2955564d1370_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00976989_BT", "Statement": "Patients with a LEVF greater than or equal to 60% are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "63ec91be-7e12-431e-84b0-ca401bfb157b_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01048099_BT", "Secondary_id": "NCT02502864_BT", "Statement": "The primary test recorded 2.38% more adverse reactions than the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "fd5af11f-7270-49d5-924a-755ff399c463_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00373256_BT", "Statement": "The primary trial cohort 1 included 250 patients treated with Sunitinib and Paclitaxel for 18 months or until their death, and the mean PFS for this group was just under 7 and a half months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 7, 8, 9]}, "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02186015_BT", "Statement": "Women in the B cohort of the primary trial with a serum level of 25 (OH)D greater than or equal to 30 ng/ml did not receive a weekly supplement of cholecalciferol.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6a5ee728-7db9-4ec0-b98c-0500e9a6187e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00924352_BT", "Statement": "One primary trial patient had abnormally low levels of AST, ALT and ANC.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "a495df61-260d-479c-8d5f-d586f295c672_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02297412_BT", "Secondary_id": "NCT02667626_BT", "Statement": "The secondary trial cohort 2 and the primary trial are control groups, receiving a placebo PO BID tablet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "917afeec-5152-4424-89e3-7f3ffad6378f_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01105650_BT", "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m2 less than IL-2 than participants weighing more than 45 kg, but all participants will receive IL-2 3 times a week for 6 doses.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01617668_BT", "Statement": "Patients should have healthy kidneys, liver and bone marrow to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8, 9, 10]}, "f5aa1aa3-7be3-4518-8cc5-df2394e70e96_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02244580_BT", "Secondary_id": "NCT01901146_BT", "Statement": "Patients with indeterminate estrogen receptor status may be accepted both in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5, 7]}, "45338f7c-5aaa-40fb-8503-7c943e1f3a29_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03584009_BT", "Statement": "Participants in the primary trial administered with Fulvestant 500mg intramuscular injection received a higher percentage of clinical benefits than participants who received an additional 800mg of Venetoclax orally.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0964be32-f9e7-49ec-ad22-b030d483702a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429507_BT", "Secondary_id": "NCT00038467_BT", "Statement": "Unlike the secondary trial, the primary trial does not administer any oral drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "73cfc4ea-afc0-465b-a403-c1bd771ded33_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01527487_BT", "Statement": "Patients who have prescribed citalopram as a continuous treatment for depression are not eligible for the primary trial because psychological diseases are not permitted.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]}, "75b67d63-9727-418d-afd5-c0fb867417b5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00876395_BT", "Statement": "Patients with ulcerative colitis are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 15]}, "94cd9451-35a4-4035-a7de-2d385f771607_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01671319_BT", "Statement": "1/42 patients in cohort 2 of the primary trial passed out.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "18310f83-54ca-4530-92f1-7c41419ab69e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00068341_BT", "Statement": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "4fa6b99e-0e70-465d-8b24-b728979b3689_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00567190_BT", "Statement": "There was the same number of anemic skates in both cohorts of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 12, 14]}, "e0fac0a4-a5ab-4089-8986-f601586506af_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00627978_BT", "Statement": "Women with leptomenenic metastases are unfortunately excluded from the primary trial, as this would prevent them from giving their informed consent to enter the study.", "Label": "Contradiction", "Primary_evidence_index": [18, 19]}, "85210693-996a-4ab9-92f4-62060571da21_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01847001_BT", "Statement": "Spanish women with a heart rate of not more than 50 beats per minute are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00148668_BT", "Statement": "Cohorts 1 and 2 in the primary trial recorded the same number of patients with Neutropenia.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6a37e999-4b7e-4654-b9ac-7776a0720040_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01310231_BT", "Secondary_id": "NCT00093808_BT", "Statement": "One patient in the secondary trial developed a eating disorder, and there were no cases of this in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "a625ff4b-9c91-4ab8-a78b-df833d15759a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00423917_BT", "Secondary_id": "NCT00082641_BT", "Statement": "In both the primary and secondary trials, there are cases of confusion in all of their patient cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 7, 8, 15]}, "b25e7c40-a1db-4ae7-9613-0f65ddb4c040_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00082641_BT", "Statement": "At least one patient in the primary trial suffered a life-threatening bone fracture.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00856492_BT", "Statement": "There were no deaths and no cases of anaemia in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "c0ddffa9-4a88-4ee1-8525-a77e887c3d85_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01268150_BT", "Statement": "The Eribilin Mesylate group in the primary trial had a higher proportion of patients with a complete (CR) or partial (PR) response than the control group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "64ea58e5-e28f-42bc-818e-31bbf347080c_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00129389_BT", "Secondary_id": "NCT00304096_BT", "Statement": "Patients with permanent sensory loss who interfere with daily activities are excluded from the primary trial but may still be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [22, 30], "Secondary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]}, "7a0f4365-9775-4f1d-a1c7-4630b41b43ea_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01905592_BT", "Statement": "The primary trial only defines the intervention dose for cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "64dcb690-ef14-4cf2-85e5-670eb0645d7f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01073865_BT", "Statement": "Women over 18 years of age, whose last period was 2 weeks before, are entitled to the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "cacd1b1b-510e-421b-9adb-c5715f281794_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01566721_BT", "Statement": "A greater number of patients in cohort 2 of the primary trial had at least one adverse event (AE) during the treatment period than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02502864_BT", "Statement": "The maximum number of occurrences for an adverse event in the primary trial was 3.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "7926bfa3-cf49-4589-8143-0a0826336b67_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01401166_BT", "Statement": "All patients in cohort 1 of the primary trial had a preferred method of drug administration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00975676_BT", "Secondary_id": "NCT00632489_BT", "Statement": "The primary trial does not explicitly indicate the dose of Triptoreline for any of its patient cohorts, nor does the secondary trial provide details of the doses used for LBH589, capecitabine and lapatinib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00887575_BT", "Secondary_id": "NCT01610284_BT", "Statement": "The cohort 1 of the secondary trial had more than 50 times the number of patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01269346_BT", "Secondary_id": "NCT01597193_BT", "Statement": "The Primary Trial Cohort 1 and Secondary Trial Cohort 1 have the same total number of adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "1aee22c7-96f2-4ea6-909a-48741f87ba07_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01111825_BT", "Statement": "No cases of Constipation, Diarrhoea, Nausea or febrile neutropenia were observed in cohorts 1 and 2 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "d677707e-9ca9-4801-8fcd-7960a9f4f30a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00513695_BT", "Statement": "Paclitaxel is the only medicine in the primary IV trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "5335a9c9-bae1-42e9-9428-eb0eded62d7f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03252145_BT", "Secondary_id": "NCT00904033_BT", "Statement": "None of the subjects in the primary trial are required to inject pills, while both cohorts in the secondary trial are required to take one tablet weekly.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "e6c0f7af-b549-4aad-8f3c-15f367a04a50_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01307891_BT", "Statement": "The Abraxane + Tigatuzumab group in the primary trial has 10% more patients with either the complete response (RC) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions compared to the Abraxane Alone group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1fc3aeac-3bc0-4a47-8222-ea267a822804_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00929240_BT", "Statement": "There are no cases of febrile bone marrow aplasia in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "9e664bcb-38cc-4ca6-9738-28d96248b7f2_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00320411_BT", "Statement": "The primary trial participants should take 6 tablets of Lapatinib monotherapy (1500g) PO once daily.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "1b8403ac-7eb3-41cb-8b7e-a89af3492805_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02924883_BT", "Statement": "In the primary trial, all cases of Enteritis, Vertigo and Anemia occurred in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "ad853675-40ed-4a65-a401-d09ac3153570_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03004534_BT", "Statement": "Participants with a T2 N1 M0 breast carcinoma are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 6, 7, 8]}, "b43bee02-cc3f-4dc8-b13f-8a93de5dc422_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00493636_BT", "Statement": "The primary trial cohort 1 had median, maximum and minimum values longer than those in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "62258901-8207-413d-913f-a04682635add_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00050011_BT", "Statement": "The primary test results show that Upfront Zoledronic acid is a better treatment than delayed zoledronic acid to increase the mineral density of the lumbar spine (L1-L4) bones.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "d23aee47-e80f-42fe-b095-9cd81f9e0ed3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02657889_BT", "Statement": "The two primary test cohorts showed identical results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d23eb56e-c232-4754-94aa-903bc174cb35_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00524303_BT", "Statement": "The Trastuzumab arm of the primary trial achieved 9% better results than the Lapatinib arm.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1c0dcd29-4a04-4b78-abbf-b047d4c29597_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00562718_BT", "Statement": "Patients with breast implants are always excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [6]}, "b1a17048-dfe8-4173-ae80-6ec273244848_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01298193_BT", "Statement": "More than 20% of patients in cohort 1 of the primary trial experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "33652443-0bb4-493e-adfe-f5032b96b13d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01808573_BT", "Statement": "The primary trial Patients receiving Neratinib Plus Capecitabine had a significantly longer PFS than the 38-month study time.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "74dba58a-8f5d-478b-a886-0e9758847fe3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00228943_BT", "Statement": "Patients with clinical anxiety are not able to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [8, 9]}, "5344044c-127d-4a39-80dc-277538b5ad33_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02131064_BT", "Statement": "Less than 60 participants in the primary trial TCH + P group obtained the total pathological response (tpCR) evaluated on the basis of tumour samples.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ed43519d-9954-4e0f-9d42-39a3ed81e4a5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00820872_BT", "Statement": "Hyperglycaemia was the most common adverse event in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "8d2fde27-a5e8-40ee-a35d-3d4697198a4e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00929240_BT", "Statement": "There are no cases of febrile neutropenia in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "fc0da76b-e5b5-44e3-abaf-6231fff493c3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00676663_BT", "Statement": "The placebo group in the primary trial was less effective than the control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "1a32e1c1-31b1-40e5-bbb6-84041ef796fe_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00119262_BT", "Statement": "Both cohorts 1 and 2 of the primary trial had 3 patients with congestive heart failure.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9a31db67-e28a-4114-a308-e899f9c22813_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02291913_BT", "Statement": "One primary trial patient suffered from inflammation of the esophagus.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "f948a2d1-2e22-47c8-9345-0eb68569bd3f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00996632_BT", "Secondary_id": "NCT01644890_BT", "Statement": "Emily has inoperable breast cancer, she is eligible for the secondary trial and the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "e3265040-8316-4f62-969c-27af396ba18c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00479674_BT", "Statement": "Patients who have previously been treated with bevacizumab are not eligible for the primary trial unless they have also received carboplatin 2 weeks prior to entry into the study.", "Label": "Contradiction", "Primary_evidence_index": [22, 24]}, "6c25e195-47cd-48af-bb51-5b5c44772baa_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00656019_BT", "Statement": "Hyperparathyroid candidates are automatically excluded from the primary test.", "Label": "Entailment", "Primary_evidence_index": [6, 7]}, "382747d3-69df-41be-a771-4218407ce5d3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171340_BT", "Statement": "The primary test results imply that zoledronic acid 4 mg Upstream causes a change in bone mineral density, while zoledronic acid 4 mg Late causes a loss of bone mineral density (within a certain group of patients).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d05ec90a-f267-44be-aaa6-3be960a0d50c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00376688_BT", "Statement": "Most subjects in the primary trial had a complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "37301690-9b68-48de-b280-6307e632043e_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02301988_BT", "Secondary_id": "NCT00728949_BT", "Statement": "The only types of adverse events recorded in the secondary and primary trials are diarrhoea and various pains.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "b61e798c-d38f-4c72-91bb-4d3e28b6184c_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00356148_BT", "Secondary_id": "NCT01856543_BT", "Statement": "Women of any age may participate in the primary trial, but only adults may be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "3ca27248-0728-4b10-b940-6e2603acef30_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00201760_BT", "Secondary_id": "NCT00127933_BT", "Statement": "Patients should have infiltrating breast carcinoma to participate in the secondary trial or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 3]}, "c2da6504-96a1-4669-b609-16731a5330d3_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00248170_BT", "Secondary_id": "NCT01299038_BT", "Statement": "Ae-Cha is a 32-year-old Korean woman with inoperative breast cancer who is not eligible for the secondary trial and the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [6, 10]}, "646959e4-25d0-4eb1-b7b0-2d7b1e02e132_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01262027_BT", "Statement": "Less than 5% of patients in the primary trial had an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "0e6eebe9-46c2-4fa5-b9ed-e0997044960b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01293032_BT", "Secondary_id": "NCT00849472_BT", "Statement": "None of the patients in the primary or secondary trials are required to undergo radiation therapy or surgery.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "a781374c-99e1-47ee-a266-bff9267c2ed1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00950742_BT", "Statement": "100% of participants in the Afatinib 30mg + Herceptin group in the primary trial have dose-limiting toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 10, 11, 12, 13, 8, 15]}, "9aea5a84-bced-4441-b8b8-154c307f5a03_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01151046_BT", "Statement": "In the primary trial, the placebo group had a significantly lower median PFS than the MM-121 cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "deb77d34-76a5-4e6e-bc9d-176cc30eca07_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00917735_BT", "Statement": "A patient in cohort 2 of the primary trial died in a motorcycle accident.", "Label": "Contradiction", "Primary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "bfe97430-fcec-4c4a-9621-51f6ec05d8d3_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00068341_BT", "Statement": "More patients in cohort 1 of the primary trial experienced progressive disease compared to cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "568beebd-b350-4ba1-b8fc-c43f4d6ed517_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01421017_BT", "Statement": "The primary studies focus on the effects of CTX/IMQ/RT and IMQ+RT on systemic response rates to tumours 9 weeks after initiation of treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "6bcc18b7-b063-49a1-8ab7-773636c02f1d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00076024_BT", "Statement": "The minimum number of days between the start of the study treatment and the first documentation of objective tumour progression or cancer-related deaths for any patient in the primary trial was 191.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "dfa2ecee-96cf-4551-875e-aedd8aac5df9_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01519700_BT", "Statement": "There was less than 24 hours of difference in mean grade 4 neutropenia duration during cycle 1 chemotherapy for both arms of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "81c85a29-d449-4f79-a3b3-682ba5f288ca_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00190671_BT", "Secondary_id": "NCT00455533_BT", "Statement": "In cohort 2 of the primary trial, the number of patients with leukopenia was higher than in cohort 1, while in cohort 1 of the secondary trial, the number of patients with leukopenia was higher than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 14, 19], "Secondary_evidence_index": [0, 3, 12, 15]}, "9c48c5d6-83fd-42cc-aacc-2e888099bcdb_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00338728_BT", "Statement": "The primary trial participants were more imatinib mesylate than Letrozole on a daily basis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "79a3bb0d-315f-4c39-8786-2aa98e2e3f6f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00293540_BT", "Statement": "Men are not eligible for the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "cea17554-6736-4b52-b76c-b3c5dc9ecb77_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00503750_BT", "Statement": "All participants in the primary trial must have recently undergone an echocardiography or MUGA scan.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "b250a17c-9d4d-405d-ba64-40f7eda16707_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00368875_BT", "Statement": "The primary test results indicate that the recommended Phase II dose for paclitaxel, assessed according to the common NCI terminology criteria for adverse events, is 90 mg/m2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "698849c5-78fa-4c15-a1dc-f44eb9c970c2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00082641_BT", "Statement": "At least one patient in the primary trial had reduced mobility.", "Label": "Entailment", "Primary_evidence_index": [8, 14]}, "4b4e6ac7-107c-46f4-adbb-c77c01f51935_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00075764_BT", "Statement": "The most common adverse event in cohort 1 of the primary trial is the low haemoglobin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6b73dee4-0291-455e-90c2-786f0c2371d4_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00579826_BT", "Statement": "The primary trial cannot currently receive treatment for rheumatoid arthritis, experience poorly controlled migraines, or have a history of invasive breast cancer in the past three years.", "Label": "Entailment", "Primary_evidence_index": [6, 8, 10, 11]}, "2a1d9064-fde9-4645-95ab-7ddaea4ad322_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00324259_BT", "Statement": "In primary trial 3, cohort 2 had more patients with a complete response than cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "847de3fe-b584-4d43-b82d-93263ce88830_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00509587_BT", "Statement": "Patients in the primary trial receive 300 mg pazopanib once daily intravenously until disease progression or unacceptable toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "3c798991-6366-43e2-94ca-0523629930c2_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00149214_BT", "Secondary_id": "NCT01004744_BT", "Statement": "The prior use of cancer drugs in the last 6 months for cancer treatment is prohibited for patients in the primary trial, but not for patients in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [4, 5], "Secondary_evidence_index": [0, 4]}, "64fe54a2-8897-4324-af88-f627c1c208ed_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01764022_BT", "Statement": "The primary trial cohort 2 recorded multiple thrombocytopenia incidents.", "Label": "Contradiction", "Primary_evidence_index": [10, 13]}, "4eac6a2d-64cd-4289-a545-211eb835f0e9_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01328249_BT", "Statement": "The percentage of participants with feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02435680_BT", "Secondary_id": "NCT01743560_BT", "Statement": "The secondary and primary tests use the best overall response (OR) as evaluation parameters, but they use significantly different time frames.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "da1e1019-adb5-47bf-8093-e03352ca9e51_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01340300_BT", "Secondary_id": "NCT00671918_BT", "Statement": "However, this is not a requirement for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "e7fb6490-1ec7-48ff-95b1-715d79faec92_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01042938_BT", "Statement": "Patients must be English to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "d5ea3443-103f-4d29-9be3-522210b84152_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00618826_BT", "Secondary_id": "NCT02040857_BT", "Statement": "The primary and secondary tests only record 2 of the same adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 8, 10, 5], "Secondary_evidence_index": [0, 9, 3, 6, 11]}, "d54cae08-3ac9-4460-bf6d-7338b45d8cd7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00193050_BT", "Statement": "Patients must be over 18 years of age and have a life expectancy greater than 6 months to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 11, 13]}, "608c5521-c9a6-47de-9ebf-791ce317a02d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00086957_BT", "Statement": "All patients in cohort 1 of the primary trial experienced an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "14a8e9e9-0a46-4537-bc07-53c786bcbe97_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00593827_BT", "Secondary_id": "NCT00478257_BT", "Statement": "Patients with a negative HER2 BCM are eligible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "2d97bfa0-336f-4976-95e5-1262327a730b_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01048099_BT", "Secondary_id": "NCT02502864_BT", "Statement": "The primary test recorded 2 more adverse events than the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00003199_BT", "Statement": "The group of patients with the highest percentage of event-free survival in the primary trial were Stage IIIB patients, and the worst was Stage IV patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "8c83330f-f2f3-48e1-9905-dc2ba1970c54_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03765996_BT", "Statement": "The primary trial group 2 participants receive the same Dognestive complex physiotherapy as those in Group 1, with the addition of the registration application in the anastomosis regions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "4613834d-c178-475c-b9fd-c9c66d5681eb_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04080297_BT", "Secondary_id": "NCT02780713_BT", "Statement": "The primary trial cohort 2 receives higher doses of Q-122 than any of the secondary trial cohorts receive AZD9496 variants.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b4555685-6e25-4797-8616-bcab5b06a135_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00259090_BT", "Statement": "The primary studies focus on the impact of Fulvestrant, Docetaxel, on the H-score estrogen receptor.", "Label": "Contradiction", "Primary_evidence_index": [1]}, "c1b90c18-45f4-4e28-b50a-a00b0eadc523_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00290732_BT", "Secondary_id": "NCT02748213_BT", "Statement": "Patients with a breast tumour of 0.1 cm or less are eligible for the secondary trial, but not for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2, 8], "Secondary_evidence_index": [0, 1]}, "33ef3abf-97c0-4d15-909d-258fb47ac54a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00232479_BT", "Statement": "Only patients with positive HER2 breast carcinoma are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "a381e340-18b1-4baa-91ce-0c420bcb411c_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01323530_BT", "Secondary_id": "NCT01106040_BT", "Statement": "The results of the secondary and primary trials indicate that the participants' PFS is partly related to age, degree of cancer, and ethnicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00383500_BT", "Statement": "The primary trial is not to test a drug-based intervention, it is to test a medical device called Manual Lymphatic Drainage.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8e246d8f-e063-4f2e-a382-5d201a946b87_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00436566_BT", "Statement": "No patients in the primary trial experienced congestive heart failure during active treatment with Trastuzumab and RAD001.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "8154bd8c-90a2-4b2f-8090-fcc89aeae30c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00097721_BT", "Statement": "Patients of any ethnic origin may participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]}, "537781f9-3693-479e-af22-824cdd827b9c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02657889_BT", "Statement": "The primary trial indicates that the change in the dose of Pembolizumab has no effect on the number of subjects with dose-limiting toxicity (DLT).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "5feefe8b-ddca-4eb8-af68-d1e211963d1f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02748213_BT", "Statement": "In cohort 1 of the primary trial, 2 patients had a superactive pituitary gland.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "2a5d8ca7-1608-4607-b996-490fc447b593_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00956813_BT", "Statement": "All subjects in the primary trial are required to take the PO intervention tablet per day.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "178c50cc-49ee-4083-bc8e-b5832037498a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00258960_BT", "Statement": "Four patients in the primary trial experienced a Grade 3 or higher adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "92ace4fa-4426-4f34-af52-ee62913e60aa_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01026142_BT", "Secondary_id": "NCT00846027_BT", "Statement": "There were 10% more patients with left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 7, 12, 19], "Secondary_evidence_index": [0, 4]}, "7dbde84d-f1c9-4197-9d44-500fd337bebd_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01823107_BT", "Statement": "Not more than 12 patients implanted with a Meso BioMatrix Acellular peritoneal matrix had breast-related adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "824da29f-b2ff-440e-8b78-7a8291cbd6d2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02340221_BT", "Statement": "A total of 89 patients in the primary trial had supraventricular tachycardia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02748213_BT", "Statement": "One patient in cohort 1 of the primary trial was recorded as having a superactive thyroid gland.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "052ee533-7daa-4cbf-a64c-bc9a50444173_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00244933_BT", "Statement": "The primary trial does not monitor the occurrence of hemoglobin C disease in its adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00444587_BT", "Statement": "A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary Impairment or Diarrhoea.", "Label": "Entailment", "Primary_evidence_index": [3, 6, 8]}, "9b622b9b-3ad3-4cff-acb3-4127d0304de0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00571987_BT", "Statement": "Occupational exposure to ionizing radiation will not disqualify a patient from entering the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "825ba6fd-8c08-49d2-941b-3338ef01e7fd_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02673918_BT", "Secondary_id": "NCT01042938_BT", "Statement": "African-American patients are eligible for the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 4]}, "0421750d-66c6-47be-bde7-0c41ee43a28b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01730729_BT", "Statement": "Patients with severe malabsorption disorders are not eligible for the primary trial, even if they are able to receive intravenous (IV) nutrition.", "Label": "Entailment", "Primary_evidence_index": [24, 31, 30]}, "95345dbe-446f-4999-8f3e-a429b77ea554_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02872103_BT", "Secondary_id": "NCT02995980_BT", "Statement": "- Adequate renal, hepatic and blood work is required for entry into the primary test, which includes the following criteria: hemoglobin 11.5 g/dL, as well as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and serum creatinine should be less than 1.7 x ULN. These conditions are not explicitly required for the secondary test.", "Label": "Entailment", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "b05fde86-4004-427f-8baf-2ea4a0a535c7_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00376597_BT", "Statement": "The primary test is performed twice, first at 2 weeks, then again a month later.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "21e24c6c-d282-48fb-8d68-3e723458794e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00825734_BT", "Statement": "Patients with one of the following conditions will be excluded from the primary trial: Grade 3 infection, unstable angina, or Grade 4 hemorrhage in the last month.", "Label": "Entailment", "Primary_evidence_index": [87, 94, 95, 108, 117, 118, 119, 120]}, "d1e579e2-b057-43da-8a2f-64dad964b789_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00821964_BT", "Statement": "The primary participants apply topical imiquimod to skin lesions once daily every other day for a total of 14 days every 28 days of the cycle.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093145_BT", "Secondary_id": "NCT00703326_BT", "Statement": "Some heart-related adverse events were recorded in the secondary trial, but not in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 7, 8, 9, 10]}, "d130c981-f602-4f17-b1cb-11a7ad632b92_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01234402_BT", "Statement": "More than 6 different types of heart-related adverse reactions were studied in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5, 6, 7, 8, 9, 10, 13, 17, 18, 19, 20, 21, 22, 23]}, "c1f9982f-c4c9-48dc-887a-7ae05f508c21_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03329937_BT", "Statement": "The primary trial Participants received 200 milligrams of niraparib (mg) PO once daily for a 28-day cycle, for 2 cycles", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "e966302f-9378-4681-b2c6-9d8b5b5f709f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00182793_BT", "Statement": "The majority of patients in the primary trial experienced an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "75130da8-77be-45d1-bc32-dfc97c1a1dae_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02441946_BT", "Secondary_id": "NCT00325598_BT", "Statement": "The secondary test is much longer than the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 3]}, "c71cbcd6-3786-4b90-8991-b3c6e159ae77_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00975676_BT", "Secondary_id": "NCT00632489_BT", "Statement": "The primary trial uses the same dose of Triptoreline as the secondary trial for capecitabine and lapatinib.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ed48936e-4933-437b-a7ba-e65b4c1fd276_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03167359_BT", "Secondary_id": "NCT01385137_BT", "Statement": "Integrated simultaneous radiotherapy is used in the secondary trial, but not in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b01e966e-6624-4740-b477-a8bbbd8eec50_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02102490_BT", "Secondary_id": "NCT00768222_BT", "Statement": "In contrast to the secondary trial, no cases of skin lymphangitis, bone marrow suppression or allergic shock were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "92acd36d-ea44-4b98-acbc-e51382233089_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00820872_BT", "Statement": "Diarrhoea was the most common adverse event in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "01280892-ca31-4e46-831b-a076426f65e5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01401062_BT", "Statement": "A patient who has undergone T-cell transfer treatment in the past six months and has fully recovered from associated toxicity would be excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [4, 8]}, "959bd67a-1b2a-48da-ae44-211cbab4b665_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00393939_BT", "Statement": "Median (95% confidence interval) Progression-free survival (PFS) was 1 month higher in patients in the Docetaxel + Sunitinib group in the primary trial than in the Docetaxel group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "92923765-76d4-4a27-a240-101690d9fea4_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01432145_BT", "Statement": "cyclophosphamide is administered more frequently and at higher doses than methotrexate and 6-Mercaptopurine.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00429507_BT", "Secondary_id": "NCT00038467_BT", "Statement": "Unlike the secondary trial, the primary trial does not administer any oral or intravenous drugs.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "5a5695e8-9b84-42ad-9f34-6dd043153943_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02872103_BT", "Secondary_id": "NCT02995980_BT", "Statement": "In addition to ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and serum creatinine should be less than 1.7 x ULN, adequate renal, hepatic and blood work is required for entry into the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "33634c51-0fb9-4de1-966d-14784bca93f8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01847001_BT", "Statement": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "8e46dc77-fa36-4231-a124-0ff6392891a1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02297412_BT", "Secondary_id": "NCT02667626_BT", "Statement": "The secondary trial cohort 2 and the primary trial are control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "d11b0673-42a9-46c0-887f-d5a9b038264f_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00407888_BT", "Statement": "The arm 1 of the primary trial receives high-dose chemotherapy over a one-week cycle up to 12 times in the absence of disease progression or unacceptable toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e08c196a-e3f0-420b-a252-7e2818949038_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03197389_BT", "Statement": "All women (regardless of their reproductive status) must use adequate contraceptive methods to qualify for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 16, 17, 18]}, "83511f04-e07c-438d-bf1e-f680fa49b384_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01901146_BT", "Secondary_id": "NCT00209092_BT", "Statement": "In cohort 1 of the primary trial, more cases of neutropenic fever were recorded than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 4]}, "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00290758_BT", "Statement": "A genitourinary adverse event was recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "72bb3c6e-66b0-4380-9da2-5a5867d715fd_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00475670_BT", "Statement": "Compared to cohort 1 of the primary trial, there are more cases of each adverse event observed in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "1b433096-f36a-4205-b16e-f9a370be3d05_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01365845_BT", "Statement": "More than 18 primary test participants had radioactive dermatitis.", "Label": "Contradiction", "Primary_evidence_index": [3]}, "076ead15-ce03-4c33-9050-1f6eb13764a1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01490892_BT", "Secondary_id": "NCT02364388_BT", "Statement": "The intervention in the primary trial requires one injection and two different imaging modalities, while the secondary trial does not provide much detail in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00323479_BT", "Secondary_id": "NCT03078751_BT", "Statement": "There have been more cases of pulmonary embolism in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "3e1037fd-cc1e-4229-892f-95d0987d9a68_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01042535_BT", "Statement": "The maximum tolerated dose (LMD) of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "f25adbc7-c0a0-44ed-af93-02f4bced7208_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00343382_BT", "Secondary_id": "NCT00798135_BT", "Statement": "The primary trial cohort 2 receives the same dose of Pilocarpine as cohort 2 of the oral itraconazole secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "99951bae-37c8-4299-8ec1-4577a97d0b81_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00394082_BT", "Secondary_id": "NCT01033032_BT", "Statement": "In the primary trial, pleural effusion and spinal compression fractures were recorded, none of which were observed in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b66b62c4-902d-4e19-929e-2086b349bd93_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00149214_BT", "Statement": "For patients in the primary trial, prior use of anthracycline anticancer medicinal products is proposed.", "Label": "Entailment", "Primary_evidence_index": [4, 5]}, "c789e79c-a254-4bb1-9d15-73d1726da8a6_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00334802_BT", "Secondary_id": "NCT00167414_BT", "Statement": "There is no age limit for the secondary or primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "2b182323-9357-486a-87aa-09ddc6230bf1_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02481050_BT", "Statement": "Only one adverse event occurred in the primary trial more than once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "9681ec15-7545-455e-ac8c-1052fc199b11_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02162667_BT", "Statement": "The Herceptin group in the primary trial had a higher number of patients with a complete pathological response than the CT-P6 group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "8ca512c3-72d8-4179-a63e-51d83d76445f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00256243_BT", "Secondary_id": "NCT00721630_BT", "Statement": "Both the secondary and primary trials take place at the Memorial Sloan Kettering Cancer Center.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "171d0a20-8943-4994-a48a-7dff124e62ee_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00046891_BT", "Statement": "The primary trial cohort 1 receives 60 mg of Ginkgo Biloba twice daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "25cc9a6e-656d-44ee-a301-93f5879407a0_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01923168_BT", "Statement": "Intervention 1 of the primary trial requires participants to take a total of 150 mg of alpelisib every other day.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "d9b4d4aa-0094-405e-83a3-cf2978cfda38_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00347919_BT", "Statement": "56.9 % of the primary trial subjects treated with Lapatinib 1500 mg had no progressive disease at week 12.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "caa55802-329d-4a1f-a9a7-b99afc44fd67_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00038467_BT", "Statement": "The groups of patients in the primary trial each receive the same doses of different oral medicines, either tamoxifen or exemestane.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02525718_BT", "Secondary_id": "NCT02606708_BT", "Statement": "Patients in group 1 of the secondary and primary trials receive the same dose of placebo orally.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00262834_BT", "Secondary_id": "NCT01106898_BT", "Statement": "In the secondary trial, patients with Her-2-positive neu breast cancer receive additional maintenance treatment compared to other patients, while all participants in the primary trial receive the same treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02780713_BT", "Statement": "The two cohorts in the primary trial receive the same drugs at different doses.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "01f89936-1621-4dd5-93b7-8b0c64b397fd_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00054275_BT", "Statement": "A patient with severe anginal syndrome but normal angiographic coronary arteries would not be able to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [33, 35]}, "ee7fe82e-de91-45c7-bd12-bff5d6c887a3_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00320411_BT", "Statement": "The primary trial participants should take 6 tablets of Lapatinib monotherapy (250mg) PO once daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "888a8d39-3ad6-401e-acf2-cf5e01a73bf2_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00266110_BT", "Secondary_id": "NCT00879086_BT", "Statement": "The primary test had a much higher rate of adverse reactions than the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "13466cbb-9f78-46ff-a983-09e2e9ad5a2c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00679211_BT", "Statement": "One primary trial patient experienced fever, in addition to coughing or sore throat.", "Label": "Entailment", "Primary_evidence_index": [0, 12]}, "0beaef44-a39a-462c-a084-d3f824857673_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00374322_BT", "Statement": "The primary test results showed that participants receiving lapatinib at 1500 milligrams (mg) orally were more likely to reach DFS at 5 years of age than patients on placebo, but there was less than 30% difference in DFS levels between the two cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "8e45da73-f016-4ca0-b106-a3fabc960b36_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01432145_BT", "Statement": "Patients in the primary trial receive 6-Mercaptopurine more frequently and at higher doses than methotrexate.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "37dc56a4-4756-4ab0-8055-7637bf579740_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01420146_BT", "Secondary_id": "NCT00077376_BT", "Statement": "Both primary and secondary trials are single arm clinical trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "65e370b7-7726-477e-8730-8cea734d1609_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02115607_BT", "Secondary_id": "NCT01823107_BT", "Statement": "In the primary trial, patients receive a 3 ml infusion of Perflutren lipid microspheres at a rate of approximately 3ml/min, while in the secondary trial, subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum matrix.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "affdd551-15e2-4a47-8c20-209cc01570ec_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03012477_BT", "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhoea.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2152f503-4fa4-4f32-b766-a05a4c69742f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02176083_BT", "Secondary_id": "NCT03061175_BT", "Statement": "Neither the primary trial nor the NCT0306117 use chemotherapy, adverse event management or radiotherapy courses in their intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "a7903e59-9620-457a-8d83-eb6eb5dd8a2b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01300351_BT", "Statement": "At least one participant from each cohort in the primary trial showed signs of poor liver function.", "Label": "Contradiction", "Primary_evidence_index": [0, 7]}, "dc7e7fbe-eed9-4307-b584-30ecaeb77c95_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00186121_BT", "Statement": "Patients with E2 outside the premenopausal interval are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5]}, "a34c6194-b6d9-49c3-8ddb-72de10c8a18c_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02006979_BT", "Statement": "No cohort in the primary trial requires a low intensity exercise before each cycle of anthracyclines.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "da00532d-57a8-4fe2-a2de-acc525161fd9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01120184_BT", "Statement": "At least one patient in cohort 1 of the primary trial had a coagulation disorder.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "f90364e9-caee-4075-b444-2db1bf846d3a_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02511730_BT", "Secondary_id": "NCT00193206_BT", "Statement": "Patients with prior chemotherapy are excluded from the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 6]}, "deb78676-8f04-44c4-a5f6-389740d8a268_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01908101_BT", "Statement": "Prior exposure to doxatel is mandatory for patients in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a06d1ca5-c890-4157-b1d2-0b70fd0092bd_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00591851_BT", "Statement": "There were 4 different cardiac adverse events in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "5bc0d21d-a040-4d30-b0c7-8793cba6aba8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091168_BT", "Statement": "Patients in the primary control group had median overall survival of less than one year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 11, 12, 13, 14, 15, 9, 17]}, "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00952731_BT", "Secondary_id": "NCT00956813_BT", "Statement": "The cohort 2 in the primary and secondary trials, but received daily doses of placebo.", "Label": "Entailment", "Primary_evidence_index": [5, 6, 7, 8, 9], "Secondary_evidence_index": [3, 4, 5]}, "5a1358af-f51b-49f8-b1c0-99a0b108b0a2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00091442_BT", "Statement": "There have been more cases of febrile neutropenia than of leukopenia in the primary trial, but fewer cases of neutropenia than of leukopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 3, 4]}, "ed0e1b04-aea7-4da0-922f-2be69c768c09_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02635737_BT", "Statement": "\u2022 Patients with implantable cardioverter defibrillator are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [6, 7]}, "73d323e7-1a38-49d4-97f4-a15f1664fb3e_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01439711_BT", "Statement": "One primary trial patient showed an increase of 0.98 cm3 in the total volume of functional MRI tumours (FTV) over 3 months, almost 1 cm3 less than the average.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "02dea6a3-d94f-4650-bf4f-be8fdb0a382f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02010021_BT", "Statement": "One patient has recently had an oophorectomy, they are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 11]}, "4c8a124b-f015-42e2-8ad3-6168f21fe705_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00943670_BT", "Statement": "The change from baseline in mean QTcF interval duration for primary trial patients was greatest on day 1 of the third cycle prior to intravenous infusion of T-DM1 (IV).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "fb43432d-6c1b-4ff7-aea8-72bc2519a12d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00130533_BT", "Statement": "No one in cohort 1 of the primary trial had hyperbilirrubinemia.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "d6df95f5-472f-4b14-9cd4-5d5ef238175a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00005879_BT", "Statement": "There are criteria for CONCURENT PRIOR THERAPY, PATIENT CHARACTERISTICS, and DISEASE CHARACTERISTICS for entry into the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64]}, "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00553410_BT", "Statement": "A 55-year-old postmenopausal sarcoidosis patient would be excluded from the primary trial because of her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]}, "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00982319_BT", "Statement": "Only postmenopausal postmenopausal women may participate in the primary trial, provided they do not have prior hormone replacement therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01425268_BT", "Secondary_id": "NCT01373671_BT", "Statement": "The CO2 is used as part of the intervention in only one of the primary test study groups, and the saline solution is used in both study groups of the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f820384b-0bf5-4f2e-96fd-2c8b13a4646c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01289353_BT", "Secondary_id": "NCT00429182_BT", "Statement": "The primary and secondary trials share at least one drug in their chemotherapy regiment.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2, 3]}, "f7410166-82a7-4d15-8a04-47287ef6884c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00448591_BT", "Statement": "Only two types of adverse reactions occurred in more than 1% of patients in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "80726ab0-e8e4-4c42-860b-fdedad407517_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121836_BT", "Statement": "Patients who are not willing to sign and give written informed consent to participate in the primary trial will always be included.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02725801_BT", "Secondary_id": "NCT04030104_BT", "Statement": "Neither the primary nor the secondary trial have a placebo group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "d42054cd-deb6-4436-941c-9e3a06c713cc_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00036270_BT", "Statement": "In total, less than 10% of patients in the primary trial experienced a relapse or died.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0507fbf8-3557-4ace-b015-5e106b96f6a9_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02041429_BT", "Secondary_id": "NCT00068588_BT", "Statement": "The primary and secondary tests shall use the maximum tolerated dose determined by dose-limiting toxicity as a measure of the results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "49ecc5a6-89be-48b6-85c5-c809c83f5baf_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00825734_BT", "Statement": "Patients with one of the following conditions will be excluded from the primary trial: Grade 1 infection, unstable angina, or Grade 4 hemorrhage in the last month.", "Label": "Contradiction", "Primary_evidence_index": [87, 94, 95, 108, 117, 118, 119, 120]}, "68792f63-d7b5-4570-bf8e-95e4cb8094e9_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00343382_BT", "Secondary_id": "NCT00798135_BT", "Statement": "The primary trial cohort 2 received a lower dose of Pilocarpine than the oral itraconazole secondary trial cohort 2.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00483223_BT", "Secondary_id": "NCT00811135_BT", "Statement": "There are more cases of intestinal perforation, chest pain, death, erysipelas and pneumonia in the secondary trial than in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 7, 8, 9, 10, 11]}, "a1a5767f-07e7-4a33-a26f-586cf71a208d_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01852032_BT", "Secondary_id": "NCT01118624_BT", "Statement": "We cannot compare the doses and frequencies provided in the intervention sections of the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "9c80fb61-66dc-4b3d-82b9-4fb62db89422_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01326481_BT", "Statement": "Patients with myocardial infarction or deep venous thrombosis in the last 3 months are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 18]}, "6755a378-08bf-4e9b-a6de-166733d0307b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00181363_BT", "Statement": "The only difference between the interventions used in the primary trial is the patient location.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b7f3e657-638b-4463-9639-4fb0da2be042_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00262834_BT", "Secondary_id": "NCT01106898_BT", "Statement": "In the secondary and primary trials, patients with Her-2-positive neu breast cancer receive additional maintenance treatment compared to other patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "5498a85b-a086-4d5d-b677-9ae44646a382_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00546156_BT", "Secondary_id": "NCT00398567_BT", "Statement": "There are no cases of Vertigo, abdominal distension or Neutropenia in the primary test or primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00418457_BT", "Statement": "\u2022 Antibiotics within 10 days of starting are acceptable to patients entering the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "f25d63c8-9033-4db6-9c15-2151d82e2a6d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00068588_BT", "Statement": "Between the two arms of the primary trial, cohort 1 far exceeded cohort 2 in terms of the number of patients with a complete tumour response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00209092_BT", "Secondary_id": "NCT00631852_BT", "Statement": "A patient with histologically confirmed breast cancer would be accepted for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "4fd10abc-81d1-44f4-825a-26e2eaeae979_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02308020_BT", "Statement": "There were 23 participants in cohort 1 of the primary trial with one (CR) or one (PR) based on the response criteria of the Neuro-oncology Response Evaluation Brain Metastasis (RANO-BM).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "a12a46de-9d3e-4c6a-becb-d43653040bf0_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00089973_BT", "Statement": "The primary trial uses a 3-week cycle for the administration of SB-715992, and the study lasts 21 cycles.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "66ee10ac-1bfe-44d6-9b91-8a2bb1983606_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01017549_BT", "Secondary_id": "NCT01390064_BT", "Statement": "The secondary trial has 5 cohorts more patients than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "714c540c-1fa1-47c7-ac13-1e8f056d1e31_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02115984_BT", "Statement": "A total of 3 patients in cohort 1 of the primary trial experienced an adverse event related to Herpes.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3948b30d-934d-485c-b324-b3571e2957a3_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688740_BT", "Secondary_id": "NCT00191815_BT", "Statement": "The most common adverse reactions in the primary and secondary trials are Neutropenia, which has a total of 3 cases in all cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "45cf29ce-25f5-4719-8468-69d94893c9e7_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01166763_BT", "Statement": "The primary trial recorded 4 life-threatening adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "7502090d-1bcb-4be9-9358-81afb9440a17_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01823991_BT", "Statement": "Patients with metal vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms are eligible for primary testing.", "Label": "Contradiction", "Primary_evidence_index": [9, 19]}, "89f84928-82a9-413e-ab25-400657002c55_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01840163_BT", "Secondary_id": "NCT02005549_BT", "Statement": "The primary and secondary trials do not exclude patients with concomitant systemic antitumour therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "79dbf7bf-e08d-4eae-a804-0daeb83d6f01_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00930930_BT", "Statement": "The most common adverse event in cohort 1 of the primary trial was lymphopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01381874_BT", "Statement": "The Exemestane group in the primary trial had better median progression-free survival than the Abiraterone Acetate + Prednisone group, but the patient with maximum SSP was in the Abiraterone Acetate + Prednisone group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "23040754-d1ad-4660-aacf-3298aefa5dae_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00777101_BT", "Secondary_id": "NCT00559845_BT", "Statement": "There were no depressed patients in the primary or secondary trial, but there was a suicide attempt in cohort 2 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "e3be834c-c311-4132-8529-d354b9e620b9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01033032_BT", "Statement": "The only adverse event recorded in the primary trial was a single case of pleural effusion.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "8115b5e3-e178-433b-b114-09d97daaa8d7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01326481_BT", "Statement": "Patients with myocardial infarction, percutaneous transluminal coronary angioplasty or deep venous thrombosis in the last 2 to 6 months are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 18]}, "bbcfc019-2d60-413f-88f9-04cacec55e30_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00333775_BT", "Secondary_id": "NCT00201864_BT", "Statement": "There are several cardiac adverse events recorded in the primary trial, but not one in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "e7899445-9b80-4429-b4c3-d47bd36a2347_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00232479_BT", "Statement": "Patients with positive HER2 breast or colon cancer are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "2a50cc2a-281b-4bc6-9f18-6bd9686c682d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00754845_BT", "Statement": "Patients who received more than 5 years of anastrozole therapy, completed two years earlier, are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [2, 3]}, "26419cec-e256-46a7-9026-94dbe026c63d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01151046_BT", "Statement": "In the primary trial, the placebo group had a significantly lower median PFS than the MM-121 cohort.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "8ef93fe0-0a12-4a7e-93aa-c40af7154a57_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02336737_BT", "Secondary_id": "NCT01432886_BT", "Statement": "The secondary test consists of testing the DLT for its interventions, while the primary test evaluates the dose limit toxicity for SentiMag and SiennaXP.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "f5d50d87-b419-4537-87ec-7c9d23b765db_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00171340_BT", "Statement": "The primary test results imply that zoledronic acid 4 mg Upstream causes a +ve change in bone mineral density, while zoledronic acid 4 mg Late causes a less significant but always positive change in bone mineral density (within a certain patient population).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f52ab54b-7a78-4449-9dfe-5fc67323e5c2_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01797120_BT", "Statement": "The primary trial cohort 2 receives only placebo tablets and no other drugs.", "Label": "Entailment", "Primary_evidence_index": [7, 8, 9, 3, 4, 12]}, "c0277198-6eef-4cf3-9527-dea5d01a4000_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00426556_BT", "Statement": "There were more than 3 cases of febrile neutropenia, leukopenia and neutropenia in all cohorts in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 14, 15, 16, 17, 18]}, "fea87f74-c8ef-4efd-944a-053f5e5a752f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01582971_BT", "Statement": "To participate in the primary trial, participants must have a 20/20 vision and a confirmed and measurable invasive breast carcinoma.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "43560d8e-0767-40ce-b2fb-1b8dda231bdf_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00394251_BT", "Statement": "There have been more cases of heart failure than pericardial effusion in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "2417fea2-7c8e-4f03-a918-c3cfcbe97425_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01998906_BT", "Statement": "The same number of cases of neutropenia, febrile neutropenia and pancytopenia is observed in patients in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 3, 4]}, "55391bc6-41a8-4686-82d6-6814166d32b8_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01904903_BT", "Secondary_id": "NCT01663727_BT", "Statement": "Patients must have a LVF < 50% to be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00091832_BT", "Statement": "Cohort 1 of the primary trial showed a negative percentage change (median) from the urea-adjusted N-telopeptide reference base (uNTx/Ur).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "15553950-e26b-4fbb-a576-8455e6bb7b23_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02122796_BT", "Secondary_id": "NCT01575522_BT", "Statement": "The primary trial intervention section does not detail the type, dosage or duration of the procedure, as opposed to the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "58838d25-bf87-44e7-a604-23468d67a1e3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02606708_BT", "Secondary_id": "NCT02504424_BT", "Statement": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Moduled Radiation Therapy, patients in the secondary trial receive no radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "02426c34-ebf9-4bd4-9d55-86fad89baf20_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01959490_BT", "Statement": "In total, only 20% of primary trial participants did not get the complete pathological response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9e28c807-8d88-4eea-87ee-48a42bd002ab_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00618826_BT", "Secondary_id": "NCT02040857_BT", "Statement": "Only 4 of the same adverse events were recorded in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 8, 10, 5], "Secondary_evidence_index": [0, 9, 3, 6, 11]}, "80ac126e-c756-4031-9541-e50d51c18b38_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02600923_BT", "Statement": "Patients with leukaemia, hepatitis or polycystic kidney disease cannot be included in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8, 9]}, "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02953860_BT", "Statement": "In the primary trial, patients receive fewer mg of Enzalutamide than Fulvestrant per week.", "Label": "Contradiction", "Primary_evidence_index": [3]}, "68a9f2f0-cf11-4cd4-847c-53b8befd6002_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00717886_BT", "Statement": "A prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5, 6, 7]}, "9bcd40cf-8221-4383-8891-76a4bcc5c766_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00756717_BT", "Statement": "Patients with early, non-metastatic, cytologically confirmed invasive breast cancer with an Allred score of 1 are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "341156fc-9cbd-492f-8e9e-8fbf98191625_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00291577_BT", "Statement": "It is not possible for a primary trial participant to have time to reach a maximum plasma concentration of 6, 24 or 12 hours.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "44ae021e-241b-4dbf-b88f-0b9d41eab555_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201851_BT", "Statement": "No cases of esophageal spasming were observed in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "523a44a3-6b90-4be7-ab46-6b6addd7b5b9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00080301_BT", "Statement": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial than in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 13, 20]}, "258a51ca-e1f0-4d9a-88a6-8749f4822034_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03475992_BT", "Secondary_id": "NCT03106077_BT", "Statement": "The primary trial participants receive different interventions depending on their cancer hormone status, so Triple-Negative patients are separated from HER2+ patients, for example, while all patients in the secondary trial took the same procedure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "83bacd68-871a-4777-ba23-1f9a3df9227d_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00057941_BT", "Secondary_id": "NCT01806259_BT", "Statement": "Non-recurrence survival, used as a measure of results in the secondary trial and the rate of clinical benefit, used in the primary trial, are not synonymous and represent entirely different characteristics of the patient.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00369655_BT", "Secondary_id": "NCT00091832_BT", "Statement": "One patient in the primary trial had a confirmed partial tumour response, while 30 patients in the secondary trial had a partial tumour response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3]}, "1a451f2e-0818-4a86-8808-0e4cce700aef_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00391092_BT", "Statement": "In total, there were 32 cases of febrile neutropenia in the primary trial, and only one case of anaemia.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 4, 12, 14, 16]}, "52333afb-0e7a-4823-ae9b-746e0ce57c8c_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01325207_BT", "Secondary_id": "NCT02429427_BT", "Statement": "Patients participating in the primary and secondary trials experienced a variety of heart problems.", "Label": "Entailment", "Primary_evidence_index": [2], "Secondary_evidence_index": [6, 7, 8, 9, 10, 11]}, "4216b27f-4d3e-4029-9637-2e6dade15b73_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00005908_BT", "Statement": "There was only one cohort of patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "14a32a42-424b-4b97-bae9-05f4bb2b415b_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00246090_BT", "Secondary_id": "NCT00266799_BT", "Statement": "- Cohort 1 of the primary trial 0.0015% less total adverse reactions than cohort 2 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16]}, "4d83c630-d767-40cf-9aec-c871c6fc7f38_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00030823_BT", "Statement": "Patients with Stage I, II, III or IV breast cancer may be elongated for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 2, 11]}, "4fd230f2-caf1-44d6-81f2-4f51dda6da3a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03371732_BT", "Statement": "All patients with a Karnofsky index < 80 are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "7a3d1ca7-8776-4ace-bbc0-107635b93583_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00764322_BT", "Statement": "The ultrafast Metabolizer group in the primary trial experienced an average increase in endoxifene concentration over 6 ng/mL over 4 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02040857_BT", "Statement": "Only men and women who are menopausal are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [2]}, "1196db61-0846-4185-afc9-dc4b2fccd059_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01966471_BT", "Secondary_id": "NCT00981812_BT", "Statement": "A patient who had undergone breast preservation surgery in the year prior to entry into the study would be excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [5, 12]}, "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02005887_BT", "Secondary_id": "NCT00050011_BT", "Statement": "All participants in the primary and secondary trials receive the same daily dose of oral Letrozole for the same duration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "7e629f62-2981-4462-a4c1-f0cc9c24777a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00490646_BT", "Statement": "The primary trial cohort 1 had 25% more cholecystitis patients than cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "c660faec-58d8-4ba9-8e18-1775b1135819_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00600340_BT", "Statement": "Cohorts 1 in the primary trial were more common in Bevacizumab than in cohorts 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03078751_BT", "Statement": "One case of AML was reported in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [9, 10, 11, 12, 13, 14, 15, 16, 17]}, "3ee5742b-6bc3-400f-92eb-641384a75201_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01830933_BT", "Secondary_id": "NCT01224678_BT", "Statement": "Patients in the primary trial do not receive any additional drugs for the study, while in the secondary trial they receive an oral drug.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [5]}, "f6af788f-ee96-4308-8dec-12d0c46e957a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01823991_BT", "Statement": "Patients with irrational fear of confined spaces are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 19]}, "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00118157_BT", "Secondary_id": "NCT01401959_BT", "Statement": "The primary trial participants were more likely to have a two-year disease-free survival than either of the secondary trial cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e0b7a120-8735-413d-9a47-8508b2feffb3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01231659_BT", "Statement": "Less than 20 primary test participants received a partial response (PR).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "1393c5d9-d2be-433b-9abf-9449b46588c4_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981812_BT", "Statement": "Women who have undergone breast enlargement surgery and have since had the implants removed are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "abfa5699-2863-4319-9386-4b359f2062f2_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00195013_BT", "Secondary_id": "NCT00620373_BT", "Statement": "The cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "4038f7c3-87e2-47d6-811b-fd2b21679577_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01196052_BT", "Statement": "Participants in the primary trial should be prepared to undergo chemotherapy based on anthracycline or have already received cyclophosphamide or epirubicin.", "Label": "Entailment", "Primary_evidence_index": [0, 4]}, "5097f4cd-9118-473d-a2a0-72f0cd12c7a5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01031446_BT", "Statement": "Sarah had epileptic seizures of a brain tumor, which precluded her from participating in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5]}, "68e6a088-ab80-4a89-90d4-39308bccb1c2_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00956813_BT", "Statement": "All subjects in the primary trial are required to take the PO intervention every day.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00446030_BT", "Secondary_id": "NCT00975676_BT", "Statement": "The primary and secondary trials do not overlap in the drugs they use for their interventions, but both have placebo groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "08917306-11b0-44ad-8f45-9a67d7f6073e_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00971737_BT", "Secondary_id": "NCT00392392_BT", "Statement": "Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 3]}, "9702cb6a-bdb1-415f-bb99-3b740728a4ea_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00073073_BT", "Secondary_id": "NCT00054028_BT", "Statement": "There is no placebo or control group in the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "7afa2d1f-7922-4b09-b52a-43bd9a4788a9_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00706030_BT", "Secondary_id": "NCT00171704_BT", "Statement": "Participants in both cohorts of the primary trial had an objective CNS response rate significantly lower than those in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "dfd5acc2-6824-4b63-93ad-34e6a0a4c621_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01299038_BT", "Statement": "Joe has had an alcohol addiction for 15 years, which results in cirrhosis, so he is likely to be excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "97e9967e-6525-4082-bd11-8c30e14d23fd_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03273426_BT", "Secondary_id": "NCT01091168_BT", "Statement": "Patients with a concomitantly uncontrolled serious medical condition may be eligible for the primary trial, but are still excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [4]}, "d11dd4ae-28be-4ad2-a452-4374c48f08d1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00082433_BT", "Statement": "The primary test results suggest that 40 mg/m2 administered as an intravenous infusion (IV) of 3 hours at day 1 of each cycle + Capecitabine may increase SOS levels compared to Capecitabine alone.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3b6229a9-00a1-4d26-9285-6d9f6a25fd77_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02273973_BT", "Statement": "Two times as many patients in cohort 1 of the primary trial suffered from erysipelas as from diarrhoea.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 11]}, "9eab20ad-ffc6-473f-8087-c6c3f06f356f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00322348_BT", "Secondary_id": "NCT00429572_BT", "Statement": "The primary and secondary trials use different measures to assess the performance status of potential candidates.", "Label": "Entailment", "Primary_evidence_index": [2], "Secondary_evidence_index": [2]}, "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00368875_BT", "Statement": "The primary test results indicate that the recommended Phase II dose for vorinostat, assessed according to the common NCI terminology criteria for adverse events, is 300 mg.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "b3dd4e23-f78c-4bf9-9268-d1018c966980_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02550210_BT", "Statement": "Patients must have cancer that can be felt by contact to be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "553d7721-289e-4ab1-a9b9-7b2c939f47c1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01997333_BT", "Statement": "The maximum progression-free survival for patients in cohort 1 of the primary trial was one year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "01c6f82e-710d-4fa4-aa62-2d26e72f4533_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00894504_BT", "Statement": "There were no adverse events in the primary trial that occurred more than 71 times.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02018458_BT", "Secondary_id": "NCT00895414_BT", "Statement": "Patients with unexplained fever above 39\u00b0C are excluded from the primary trial but may be included in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [25, 28], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "862c0bfe-10a6-453c-9ada-929dd00141a0_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00295620_BT", "Secondary_id": "NCT03366428_BT", "Statement": "The secondary test and the primary test use non-comparable performance measurements.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01094184_BT", "Statement": "A patient who has had an oophorectomy in the last month would not be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 7]}, "5501dae3-0d3c-4812-96c2-35ca863e24a5_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00343863_BT", "Statement": "On the first day of the primary trial, cohort 1 received doxorubicin IV hydrochloride, oral cyclophosphamide, dexamethasone IV or orally, and ondansetron IV.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "ece8e7df-790d-4e26-9c34-40cf66d2abf5_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02005887_BT", "Secondary_id": "NCT00050011_BT", "Statement": "All participants in the primary and secondary trials receive the same daily dose of Degarelix injected into the muscle for the same duration.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "550a36e2-43bb-40af-b0c8-49498fbe2c8c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00077376_BT", "Secondary_id": "NCT01256008_BT", "Statement": "The primary trial examines new radiation therapy, while the secondary trial tests a type of psychological therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "95869347-6c3d-4de8-a325-a9a652f11edf_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02102490_BT", "Secondary_id": "NCT00768222_BT", "Statement": "In contrast to the secondary trial, there were no cases of Sinus bradycardia, bone marrow suppression or Constipation in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00509769_BT", "Statement": "3/112 patients (2.68%) in the primary trial had insipid diabetes", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "1d4a385f-1c72-4c61-8d49-9ada0e3b716a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02556632_BT", "Statement": "Both cohorts in the primary trial use the same topical intervention for approximately every 4-6 hours per day during one week of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b15aa13a-fbd9-4b2e-9dd2-b16628084d07_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091428_BT", "Statement": "The maximum tolerated dose (LDT) and the recommended Phase 2 dose (RP2D) for Alisertib in combination with Paclitaxel, supported by the results of cohort 2 of the primary trial, are 40 mg/m^2 orally, twice daily (BID) on days 1-3, 8-10 and 15-17.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c9214d06-2733-4c78-99e5-a42015908eae_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00246571_BT", "Statement": "\u2022 Kidney cancer Patients in the primary trial receiving Standard of Care had a median PFS of 2.5 months per baseline radiology laboratory assessment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "a318fc31-4f28-4356-b09a-59741bb7c97a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02660788_BT", "Secondary_id": "NCT01490892_BT", "Statement": "The primary trial examines different ways of communicating with women aged 51 to 73, while the secondary trial is not.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3]}, "70ec4bc8-f8fa-4901-aa7a-2388b53960c6_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00206518_BT", "Statement": "The most common Chevalier grades in primary trial patients treated with Taxotere/Docetaxel were 3A and 3C.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "00dc0e37-1d0b-4f53-a037-86bf9799dae6_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00570323_BT", "Secondary_id": "NCT00193180_BT", "Statement": "Women with a uterus may not participate in the secondary trial or in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "a1a421cc-01c9-4afb-8f09-6b10b0ff5094_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01663727_BT", "Secondary_id": "NCT00072293_BT", "Statement": "Patients must be between 13 and 76 years of age to participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [16, 17, 18]}, "9316ef0d-55b0-4547-88ae-887e0132a263_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00246571_BT", "Statement": "The primary trial patients receiving Standard of Care had a median PFS of 2.7 months per baseline radiology laboratory assessment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "5d815fac-c66c-43fe-9ac8-a352b6e47a5b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01929395_BT", "Secondary_id": "NCT01857882_BT", "Statement": "The primary and secondary trials use both test groups and control groups in their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "7b9fdeaa-5cb7-4453-b174-07b44bb58234_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00127205_BT", "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations.", "Label": "Entailment", "Primary_evidence_index": [10, 17, 18]}, "c330f152-c64e-47ab-8568-5129a1a2099e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00875979_BT", "Statement": "None of the 60 patients in cohort 2 experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31]}, "e3b88c8c-241d-4ead-8573-534a46210707_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00811135_BT", "Statement": "The majority of patients in the primary trial did not have left ventricular dysfunction.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "e621f354-dea0-4d0f-a252-5480028c1712_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00022516_BT", "Statement": "At least one patient in the primary trial suffered from an adverse event induced by radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "ee209156-74dc-475e-87af-ae51160982ef_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00244881_BT", "Statement": "30% of primary trial participants had increased CEC after 3 weeks of treatment with Cediranib Maleate.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "edf813c0-2271-49ca-a040-a355bf71d8b4_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01519700_BT", "Statement": "There were slightly more than 36 hours of difference in the median duration of Grade 4 neutropenia during Cycle 1 chemotherapy for both arms of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "352475ea-1b17-4d1a-a5e3-71f1b87cffd8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01827163_BT", "Statement": "All patients with HER2/neu immunohistochemistry 3+ adenocarcinoma, ECOG <2 performance and HCG negative pregnancy test are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [13, 14]}, "c7c745d6-03ee-4740-9ef4-641fb6546e46_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00544167_BT", "Statement": "Each adverse event in the primary trial occurred more than 8 times.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00617942_BT", "Secondary_id": "NCT00388726_BT", "Statement": "The total percentage of patients with adverse reactions compared to the secondary trial was lower than that of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01827787_BT", "Statement": "The Triple-Negative breast cancer cohort in the primary trial had a significantly lower ORR than the cohort receiving 1.4 mg/m2 of Eribilin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "8f1959e4-b93a-4112-9726-27a4034f0e07_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00191854_BT", "Statement": "Patients should have a unique two-dimensional and measurable indicator lesion to be included in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "e1782960-8d44-4acc-aaae-bfa4f8e38de0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00254592_BT", "Statement": "Patients must have an ECOG score of less than 3 to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 9]}, "61bd93b2-b38f-496d-acd9-f8b188d28a39_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00365599_BT", "Secondary_id": "NCT01771666_BT", "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubine > 2.0 mg/dl, PLT >100 x 10^9/L and no history of blood clots are eligible for the primary test but excluded from the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 10, 12, 15, 25], "Secondary_evidence_index": [0, 6]}, "741c95c7-825c-4321-8d12-9037bb701ab8_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02667626_BT", "Statement": "The primary trial is a web-based educational tool and the secondary trial tests the effects of Adjuvant Letrozole on postmenopausal women.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "6ce047b6-c18f-4f63-90ec-8643f5145efe_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00305448_BT", "Statement": "At least 11 patients in both cohorts of the primary trial received a complete (CR) or partial (PR) response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "d647aad0-47f7-4b77-a265-e77dcf5e0983_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02781051_BT", "Secondary_id": "NCT01067976_BT", "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing clothing, unlike a full year of daily physical exercise is explicitly required for the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "74fed085-3389-49c6-bdd2-a95c97071f2d_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00841828_BT", "Secondary_id": "NCT01959490_BT", "Statement": "All cohorts in the primary trial had a percentage of participants with a lower SPC than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "986ffe33-8e8b-4cbf-8408-eb9489fb2314_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00450723_BT", "Statement": "There are several types of surgical and therapeutic treatments, such as appendices and radiation therapy, which are prohibited for patients who want to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}, "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00483223_BT", "Secondary_id": "NCT00811135_BT", "Statement": "There are more cases of intestinal perforation, chest pain, death, hyperglycaemia and pneumonia in the secondary trial than in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 7, 8, 9, 10, 11]}, "3f98cd71-ec28-4fd1-9ca0-2184eef3390a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02455453_BT", "Statement": "Patients with tumours that are HER2+, PR and ER - are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 10]}, "11138479-1666-4973-84c2-c6779b5444f5_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01912612_BT", "Secondary_id": "NCT02392611_BT", "Statement": "In the primary trial, only one cohort receives the intervention, while in the secondary trial, both cohorts receive the same intervention.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "35c62055-2832-4119-9080-5603beea1934_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02402764_BT", "Secondary_id": "NCT00490646_BT", "Statement": "There were no cases of pneumonitis in either the primary or secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "59ff0501-f6af-4739-bd07-71e12e8cd8a7_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02244580_BT", "Secondary_id": "NCT01901146_BT", "Statement": "Patients whose expression of the human epidermal growth factor receptor 2 is not determined cannot be accepted either in the primary or secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5]}, "ab52c559-5712-44ff-becd-1c491e107472_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00605267_BT", "Statement": "Men are not eligible for the primary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "4619b957-3368-47b9-b949-01ec91208f96_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01629615_BT", "Secondary_id": "NCT00320541_BT", "Statement": "The secondary trial recorded more cardiac adverse events than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5bb09d7b-622f-4bdd-8dfd-809ea014a278_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559754_BT", "Secondary_id": "NCT02924883_BT", "Statement": "A higher percentage of patients in cohort 1 of the secondary trial experienced adverse reactions than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "07327b61-973b-48bb-b42b-dfde1efcfb7d_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00435409_BT", "Secondary_id": "NCT00319254_BT", "Statement": "The patient with the shortest PFS was in the secondary trial and the longest PFS was in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3307a083-0c8a-47b8-94cb-0bf4095b9c3b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00633750_BT", "Statement": "Patients with clinical stage II invasive breast carcinoma (T2 N2) are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 4, 10]}, "bda2752e-082e-4d06-926a-04ade3f61c26_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03165955_BT", "Secondary_id": "NCT00912340_BT", "Statement": "11 patients in the primary trial suffer from liver disease, 0 in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00118157_BT", "Statement": "Only one primary trial patient treated with oral lapatinib and oral tamoxifen received a complete and partial tumour response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f418c027-439a-4b19-bfb0-e1c1241886d8_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01127763_BT", "Statement": "There were 4 other cases of Dyspnea than Dehydration in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [3, 6]}, "4805e49a-b99e-46d8-b937-13ac2501c4a4_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00009945_BT", "Statement": "Patients with positive sentinel lymph node biopsy should undergo surgery to remove lymph nodes from the groin or will not be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "9a3cb836-66a8-4c68-980c-97e5841f331f_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01091428_BT", "Statement": "The maximum tolerated dose (LDT) and the recommended Phase 2 dose (RP2D) for Alisertib in combination with paclitaxel, supported by the results of the primary trial, are 40 mg orally, twice daily (BID) on days 1-3, 8-10 and 15-17.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "45d4f78f-04d4-434c-9679-fd92291e97b6_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00553410_BT", "Statement": "A 55-year-old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prolonged follow-up.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]}, "5338f894-aecb-4678-bb67-fe058653e12b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01365845_BT", "Statement": "Less than a quarter of primary test participants had radioactive dermatitis.", "Label": "Entailment", "Primary_evidence_index": [3]}, "2cebae78-f4a3-4e09-ac54-cd2388670274_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01953003_BT", "Statement": "Patients receiving intervention 1 of the primary trial should be administered topically and intravenously.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "d8a98ace-009c-47e4-a812-3bc0df91ed2b_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01516736_BT", "Secondary_id": "NCT00733408_BT", "Statement": "The results of the primary and secondary tests are not comparable, as the parameters they record are completely different.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c8cfd67e-5fac-4bff-9296-6e42dcb09f80_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00300781_BT", "Statement": "The primary test participants are assigned an intervention based on their hormonal recpetor status.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "57cf3760-1692-439f-bbe2-82a6bc8862ce_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01376349_BT", "Secondary_id": "NCT01912612_BT", "Statement": "In the primary trial, cohort 2 received 3.25 mg of vaginal DHEA gel QD more than subjects in cohort 1, of the two cohorts in the secondary trial only patients in cohort 1 Duloxetine 30 mg per day.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "7db1447c-b4e8-49c6-a125-8161bcd98560_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00364611_BT", "Statement": "Patients with injuries that have not recovered within five to eight weeks are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [18]}, "626a05e9-2caf-4e73-a132-5432a5b2c7d9_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00550771_BT", "Secondary_id": "NCT00143390_BT", "Statement": "More than 20% of patients in the primary and secondary trials experienced myocardial infarction or arrhythmia, the majority of patients from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00066573_BT", "Secondary_id": "NCT01091454_BT", "Statement": "There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "b1cd4818-9623-45e5-a2b3-4c80016e3c82_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00186121_BT", "Statement": "Patients with E2 outside the premenopausal interval are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [5]}, "3050bca2-a8bc-412e-b679-5be1055e3749_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03061175_BT", "Secondary_id": "NCT03098550_BT", "Statement": "The cohort 1 of the secondary trial did not receive the same doses of Daratumumab throughout the duration of the study, whereas cohort 1 of the primary trial received a constant dose of Daratumumab for the full study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "a49666fd-f278-4dcf-b6bf-287ace3969aa_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02001974_BT", "Statement": "No cases of CNS metastases were recorded in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "f6c014af-63db-4578-9b2d-74ea95901842_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00445458_BT", "Secondary_id": "NCT00950742_BT", "Statement": "The primary and secondary tests measure the DLT of their respective interventions using the same time frame and unit of measurement.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c8ef1457-63a9-4eac-a98b-edb805afd35b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02660788_BT", "Secondary_id": "NCT01490892_BT", "Statement": "The primary trial examines ways to communicate with women aged 51 to 73, while the secondary trial evaluates the impact of regular exercise and diet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3]}, "515d0710-429b-4c28-b881-8a6531ee973e_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03097653_BT", "Secondary_id": "NCT00662129_BT", "Statement": "Women between the ages of 18 and 25 with bone injury or Leptomeninge disease cannot be included in the secondary trial or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [4, 5, 6]}, "b4d261a4-9b42-4158-9b21-159859b59e2a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02104895_BT", "Statement": "None of the cohorts in the primary trial receive any medication orally or intravenously.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "1c043d17-15a9-496c-a69b-9ec95a7ab8df_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00293540_BT", "Statement": "Males are not eligible for primary testing because they do not produce estrogen.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "79c69498-7dd5-41fa-8946-36d452a5b9ec_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00328783_BT", "Statement": "Patients diagnosed with COPD by spirometry are not eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "93fc76a9-5f3d-490b-8802-21d0fa806728_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00633464_BT", "Statement": "The primary trial cohort 2 reported worse results than the cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9f5e55af-8a94-4531-ab00-f16199795b64_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02104895_BT", "Statement": "None of the primary trial cohorts receive oral, IV or radiation drugs.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "ee85e355-3d0a-4e40-8a8d-6a0b71c77148_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00945061_BT", "Statement": "Patients with multicentre breast cancer may be accepted for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3]}, "c4a2ca0b-c4a7-4366-92c7-145dadd38af3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00629499_BT", "Statement": "Patients with peripheral neuropathy leading to intolerable paresthesia are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 13]}, "c6ca8c6a-7eae-4671-9eff-c44a1222fadb_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00399529_BT", "Statement": "Women with rheumatoid arthritis who do not need systemic corticosteroids for treatment are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [8]}, "e591b3bb-0628-46e7-9d60-28989fd6a3d0_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01674062_BT", "Statement": "One patient in the primary trial was observed vomiting blood.", "Label": "Entailment", "Primary_evidence_index": [3]}, "75da6329-e8a1-4808-bb0f-78fd3a2dde9c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00463788_BT", "Statement": "The best overall response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "dab9d582-eaf3-443f-bdb9-073aec304ee6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01629615_BT", "Secondary_id": "NCT00320541_BT", "Statement": "The secondary trial recorded more cardiac adverse events than the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "8b9bb672-1de3-4220-956c-9e86ed78063d_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00265759_BT", "Secondary_id": "NCT00866905_BT", "Statement": "One case of haematolysis was recorded in the primary trial, none in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "3194a043-d156-49d6-97bb-81867ed188f0_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00712985_BT", "Secondary_id": "NCT02038010_BT", "Statement": "Patients in the primary trial receive a lower dose of Zometa IV than patients in the secondary trial receive PI3K BYL719 IV inhibitor.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "8c3ab1eb-c473-4399-b18c-512ef16e4a47_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01027416_BT", "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by a nucleus biopsy and a human chorionic gonadotropin urine test.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 8]}, "aeac1009-91c3-40ad-8583-5b548e1f4b3b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00902330_BT", "Secondary_id": "NCT00952731_BT", "Statement": "The primary and secondary trials include only cohorts of tests in their studies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "3058d104-172e-41be-b641-9f0f9cb172be_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00240071_BT", "Statement": "At least one primary trial participant survived for 200 days without documented disease progression.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "bc845a3d-1f69-41a3-bf84-36a62e8127a4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01439282_BT", "Statement": "In cohort 1 of the primary trial, the number of adverse events in cohort 2 was more than 10 times.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 14, 15]}, "69ced998-f3c9-460a-a272-b2c95421b89d_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00570323_BT", "Secondary_id": "NCT00193180_BT", "Statement": "Pregnant women over 6 months of age may not participate in the secondary trial or the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [8, 18]}, "45fb84a3-674c-40f5-ac8c-26a3c7844e7b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00354640_BT", "Statement": "Patients taking primary trial 1 receive 4 times more simvastatin than anastrozole.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00146172_BT", "Statement": "The primary trial cohort 1 is less than 60% of the Neratinb dose in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00912340_BT", "Statement": "More patients in cohort 2 of the primary trial had pleural effusions than in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8, 15]}, "b3effb24-6ec0-4fa3-9c91-74a45bcc4602_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01448447_BT", "Secondary_id": "NCT03252145_BT", "Statement": "The primary trial is to test an intervention in radiotherapy while the secondary trial is to test a new portable medical device, which patients must use themselves to drain their lymphatic vessels.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03106077_BT", "Statement": "Patients in the primary trial receive at least 150 mg of IMGN853 intravenously every 3 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "341c0861-b9a3-491d-8d49-aa61a8501a4f_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00083174_BT", "Secondary_id": "NCT00190671_BT", "Statement": "The highest number of occurrences for any adverse event during the primary and secondary trials was 39.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "16d6e554-a1df-42f9-b051-947d70595cbb_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00915018_BT", "Statement": "The only cases of Leukopenia in the primary trial occurred in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "8f0159ce-1044-4f31-94b7-e394cf91d4e1_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00316199_BT", "Statement": "All women with Stage 4 breast cancer or non-resectable, locally recurrent cancer are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "ccc5e420-dda4-4fb9-8d68-82551d69017f_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688909_BT", "Secondary_id": "NCT00129376_BT", "Statement": "Patients in the primary and secondary trials suffered from pulmonary embolism.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "89f8ba8c-e626-4bd4-9994-3d0264018932_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00429104_BT", "Statement": "Patients with terminal liver disease are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [7, 12]}, "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00375505_BT", "Statement": "In primary trials, patients in the control group had better health outcomes than the control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "57e6f0e1-6157-43bc-8bdf-c3649ed49133_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01129336_BT", "Secondary_id": "NCT01945775_BT", "Statement": "More than half of the participants in the primary trial are considered censored. The secondary trial used the same measure of results, but did not have censored patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "300dbe96-0be8-4ca0-aa3b-41bc059bac7f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02725801_BT", "Secondary_id": "NCT04030104_BT", "Statement": "There are no control groups in either the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f40c8d92-2921-45fd-8389-15048b08e229_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00670982_BT", "Statement": "Neutropenia was the most common adverse event in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "31387af4-aad1-4f3c-bd81-641340ad4096_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00256698_BT", "Secondary_id": "NCT03573804_BT", "Statement": "The primary and secondary trials use completely different drugs and techniques for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "eabe9a78-965e-4984-82c2-25598b6b35da_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00534417_BT", "Statement": "The median TTP in cohort one of the primary trial is just under 27 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "006f6b4e-6245-4f09-9786-327bbed3d766_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01328249_BT", "Statement": "The percentage of participants with feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "88b13330-b937-4bbc-80ea-4bf8ccc17bd1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00699491_BT", "Statement": "The 3/4 participants in the primary trial had dose-limiting toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "e90e2368-808d-454d-8080-30427235b89d_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01009918_BT", "Secondary_id": "NCT01688609_BT", "Statement": "There are no racial criteria for entering the primary trial, but there are some for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], "Secondary_evidence_index": [17]}, "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00723398_BT", "Statement": "Patients with Type 1 and Type 2 diabetes are not suitable for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 9]}, "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00245219_BT", "Secondary_id": "NCT00038103_BT", "Statement": "In both the primary and secondary trials there are only groups of tests, so all patients receive new interventions (approved by the FDA).", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "eea73ae4-0985-4f74-957d-e2aad7ab453c_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00248170_BT", "Secondary_id": "NCT01299038_BT", "Statement": "Ae-Cha is a 32-year-old Korean woman with inoperative breast cancer, too old to participate in the secondary trial and primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "6550c068-14e6-4e93-8f98-756338c91e35_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00313170_BT", "Statement": "The primary trial patients treated with Fulvestant 250 mg had a higher objective response rate than those treated with Fulvestant 250 mg + loading dose.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0f5b81f0-b422-4000-8e0e-9f09c612ebc3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01293032_BT", "Secondary_id": "NCT00849472_BT", "Statement": "None of the patients in the primary or secondary trial are required to take a radiotherapy or support group course.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "f6bba549-3d18-4a53-8685-96b4e321b1a7_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00645333_BT", "Secondary_id": "NCT00006110_BT", "Statement": "The primary trial records several adverse events related to the immune system in its patients, while the secondary trial does not.", "Label": "Entailment", "Primary_evidence_index": [7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "1fe36432-40f8-4c53-ac2b-0f8e50e5743f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00602043_BT", "Secondary_id": "NCT01720602_BT", "Statement": "Several treatments in the secondary and primary trials are administered orally.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "3576f3e7-a1b9-4a75-934a-1ad2165b69dd_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01091454_BT", "Secondary_id": "NCT00054275_BT", "Statement": "There were more cases of anaemia and vomiting in the primary trial than in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "de71f285-4382-465f-9e7e-d163662f6d9c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01446159_BT", "Statement": "The primary trial included only 66 patients in both cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 13, 14]}, "406247fb-003a-47b7-8fe4-b6b963b98f08_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00281697_BT", "Statement": "The primary test does not record any pain-related adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "47553222-0aff-4394-bcfc-9f19c0863835_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02441946_BT", "Secondary_id": "NCT00325598_BT", "Statement": "The secondary test does not have a defined end date, whereas the primary test lasted 2 weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 3]}, "e4756896-55c2-46e1-be19-14697ad3b39f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201864_BT", "Statement": "One primary trial patient had levels of calcium in the blood well above normal.", "Label": "Entailment", "Primary_evidence_index": [5]}, "594c9a79-d601-46b4-ae30-0b48a1117693_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02447003_BT", "Secondary_id": "NCT00917735_BT", "Statement": "The difference in cohort size between cohort 2 in the secondary trial and cohort 2 in the primary trial makes it impossible to make meaningful comparisons.", "Label": "Entailment", "Primary_evidence_index": [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26], "Secondary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "99e8ee0e-d72d-4e19-9424-20e5891bb2b6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02447003_BT", "Secondary_id": "NCT00917735_BT", "Statement": "Clinical conclusions should be made comparing cohort 2 of the secondary trial and cohort 2 of the primary trial, despite the difference in size of the cohort.", "Label": "Contradiction", "Primary_evidence_index": [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26], "Secondary_evidence_index": [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]}, "f1b0653f-b5ce-4558-b325-56244940c0cd_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01273896_BT", "Statement": "There were twice as many cases of Dyspnea as of cardiac adverse events in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 8]}, "24b24d36-2500-4841-99a3-13cba905d77d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01234402_BT", "Statement": "At least 8 different types of heart-related adverse reactions were tested in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5, 6, 7, 8, 9, 10, 13, 17, 18, 19, 20, 21, 22, 23]}, "0797ff90-f847-4442-92fd-017c539bb38f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00546104_BT", "Statement": "A patient in the primary trial suffered from a blood clot blocking his trachea.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "6b595151-7e51-4062-b587-3207ea251677_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00606931_BT", "Statement": "The primary test tests positron emission tomography as a technique for guiding a medical procedure.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "e802b1f6-62fb-4759-b261-c69dbdc1d7ef_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04080297_BT", "Secondary_id": "NCT02780713_BT", "Statement": "The two cohorts in the primary trial receive higher doses of Q-122 than one of the cohorts in the secondary trial receive variants of AZD9496.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0a24a07e-2cb4-4591-aea4-a370f462cc49_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00593346_BT", "Secondary_id": "NCT00902330_BT", "Statement": "The duration of the primary test treatment is shorter than the duration of the secondary test treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "97d0bbf0-c2c5-409b-820b-6e14a6326b06_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02322814_BT", "Secondary_id": "NCT00356148_BT", "Statement": "A patient with positive breast cancer of epidermal growth factor 2, without known brain metastases and a history of histology-confirmed cardiac dysfunction, may be eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 22, 15, 33], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "bbb5ebc0-83c8-46cb-89b4-e1c67e042350_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00859651_BT", "Statement": "Helen had stage III ovarian cancer 7 years ago, but has not been ill for 5 years., she is excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [13, 14]}, "620106e8-2a7f-4078-80b6-d5f1840c66e1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00699491_BT", "Statement": "The primary test results show that the recommended dose for Phase II (Phase I) trials is 3 mg/k cixutumumab.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "94a7b007-0332-4d01-979e-9677e5da4316_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00513292_BT", "Statement": "In the primary trial, the FEC-75 group then Paclitaxel/Trastuzumab had more invasive tumours in the breast than the Paclitaxel/Trastuzumab group then Trastuzumab/FEC-75 group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2849d0ce-fed2-4c49-bec1-777c440caaeb_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00127205_BT", "Statement": "More patients in the primary trial suffer from dysfunction with ventricular contractions than the ventricular systole.", "Label": "Contradiction", "Primary_evidence_index": [10, 17, 18]}, "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00992225_BT", "Statement": "Only 2 of the 12 types of adverse events recorded during the primary trial occurred more than once.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "01a57096-0278-4c70-be43-acd57010cd6f_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01332630_BT", "Secondary_id": "NCT00121134_BT", "Statement": "There were more patients with significantly high blood pressure in cohort 1 of the primary trial than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "49213077-0a5b-4368-a48a-282d2ca9d77a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02953860_BT", "Statement": "Patients in the primary study receive more mg of Enzalutamide than Fulvestrant during the study.", "Label": "Entailment", "Primary_evidence_index": [3]}, "426d3ecd-73e3-4226-83c6-cfcb9212ed62_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00263588_BT", "Statement": "All subjects in the primary trial had a progressive disease, a complete objective CNS response rate, or a partial response rate.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26]}, "7c12676c-7973-4e9d-b1fc-3b14d241d0c8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00696072_BT", "Statement": "Twenty patients treated with Dasatinib and Letrozole in the primary trial had a disease-free interval (DFI) of more than 2 years.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "3419e901-5880-488d-912c-023e8d1b51c7_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01466972_BT", "Secondary_id": "NCT01446159_BT", "Statement": "The primary trial had one patient with congestive heart failure, and the secondary trial had more.", "Label": "Contradiction", "Primary_evidence_index": [0, 2], "Secondary_evidence_index": [0, 5, 13, 18]}, "cd645637-0a31-4f54-bc75-4a52349cf100_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00748553_BT", "Statement": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 every 5 days for each 4-week cycle.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "adfc79ba-2996-47ce-9986-7d287931df89_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02115984_BT", "Statement": "A total of 3 patients in the primary trial experienced an adverse event related to Herpes.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "414ae027-b420-4f01-afd5-164cd8146a30_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01129336_BT", "Secondary_id": "NCT01945775_BT", "Statement": "Sixteen primary trial participants are considered to be censored. The secondary trial used the same measure of results, but did not have censored patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "45b2b9ec-ba58-4323-810a-4baed9c84a0e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00470847_BT", "Statement": "The primary trial participants will not receive any post-WBRT Lapatinib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "72ffdfbf-aa72-4d44-814a-1d6ab8883898_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00971945_BT", "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "db613a72-e300-41a7-987f-788c306d94a4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00403130_BT", "Statement": "No cases of Leukopenia or Arrhythmia were observed in patients participating in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2667d301-2efb-4d92-bc12-ccfc869e4835_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02202252_BT", "Statement": "The difference between cohorts 1 and 2 in the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "60bff573-0251-4f05-b2b7-dec74c7363cc_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00934856_BT", "Statement": "In total, in both cohorts of the primary trial, there were at least 2 tired patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "f6f8a0d3-6288-44cf-9b34-27444110dd10_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01581619_BT", "Secondary_id": "NCT01008150_BT", "Statement": "A significant intraductal component of primary breast carcinoma, confirmed by histology, would result in the exclusion from the primary trial, but not from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43]}, "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00572728_BT", "Secondary_id": "NCT02472964_BT", "Statement": "Patients in the primary and secondary trials will take Herceptin?\u00a9 (trastuzumab) or paclitaxel intravenously.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "878dcfeb-c3db-4077-9a3e-8098efa80a99_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00836186_BT", "Statement": "Patients cannot be excluded from the primary trial because of their race or ethnicity.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "fc5dbfec-ba79-4c5d-9e38-3c97d0397570_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT04396665_BT", "Secondary_id": "NCT00493636_BT", "Statement": "Any patient may enter the primary or secondary trial; as long as he or she is willing to give his or her informed consent and is able to use the Internet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38]}, "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01234337_BT", "Secondary_id": "NCT00217672_BT", "Statement": "No cases of anaphylaxis occurred in the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "64411610-090b-42d2-a176-d2b13ffef591_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03210220_BT", "Secondary_id": "NCT00290745_BT", "Statement": "Unlike the primary test, the secondary test does not have a control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "82bd50ac-9407-413b-9eb8-653cef49706c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02364388_BT", "Secondary_id": "NCT01425268_BT", "Statement": "The hot saline solution is used in the primary test and in the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "470611af-16b2-4094-ae2a-c9c6155e2672_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02122796_BT", "Secondary_id": "NCT01575522_BT", "Statement": "The primary test intervention section does not specify the type or duration of the procedure, as opposed to the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4]}, "f3a03aec-194d-4538-9be3-cea8281d995c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00693719_BT", "Statement": "The primary test recorded less than 3 different adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "14a5e557-b223-4649-9867-0ff0e9001f5e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00911898_BT", "Secondary_id": "NCT02352779_BT", "Statement": "The primary and secondary trials do not explain their interventions in the intervention section.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "c8df3461-4063-4fb0-ae48-f57062eb0a68_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03329937_BT", "Statement": "Participants received niraparib 200 milligrams (mg) PO once daily for a 28-day cycle, for 3 cycles, after which all participants underwent neoadjuvant chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "1cd7cf90-bf66-480b-9227-2f7d2eccd647_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01539317_BT", "Secondary_id": "NCT01323530_BT", "Statement": "The primary test uses topical intervention and the secondary test uses only intravenous treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "15f9d033-ebf7-44b3-94e2-3b8ee90b862b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00370552_BT", "Statement": "There is more than 20% difference in the percentage of participants with the best tumour response of the partial response (PR) or complete response (CR) between the two cohorts in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00266799_BT", "Statement": "None of the patients in cohort 1 of the primary trial experienced acute coronary syndrome.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "51cf1333-78b1-410a-82fe-aabfaa00a840_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02995980_BT", "Statement": "A patient with a glomerular filtration rate of 63, a severe iodized contrast allergy and BI-RADS category c breast tissue would be eligilbic for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 4, 5, 6]}, "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00662025_BT", "Statement": "At the time of evaluation 0, participants in the primary trial had a confirmed disappearance of all target and non-target lesions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "aef2367d-78a5-4dc7-a6f7-d96415082362_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00570921_BT", "Secondary_id": "NCT00274456_BT", "Statement": "There is one case of cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [13, 14, 15, 3, 4, 5, 19, 20, 21, 22, 10, 11, 25]}, "29ae75a2-d8d2-4427-bba3-ab2c411d5718_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201851_BT", "Statement": "No cases of oesophageal spasming, diastolic dysfunction or thrombosis were observed in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "985c4cb3-2684-4a67-a479-998602044a0d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00475670_BT", "Statement": "Compared to cohort 1 in the primary trial, with the exception of sudden death, there are more cases of each adverse event observed in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00107276_BT", "Secondary_id": "NCT00232505_BT", "Statement": "Less than 5% of patients treated in the primary trial experienced adverse reactions, compared to almost 10% of patients in cohort 1 of the secondary trial experienced adverse reactions, and less than a third of those in cohort 2 of the secondary trial experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1, 8, 9]}, "d695120e-db68-481d-9023-881e48654e29_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00617539_BT", "Statement": "Patients with extracranial metastases are still allowed to enter the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "5319ac1a-07ae-4531-bf93-5fce83016c87_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00941330_BT", "Statement": "Patients in cohort 1 of the primary trial receive Exemestane more often than patients in cohort 2 receive Cytoxan.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "087aba29-40c6-4453-a44b-e63c3867e5b4_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00388726_BT", "Statement": "A 75-year-old patient with an ECOG of 3 years and an estimated life expectancy of more than one year would be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 11, 12, 13]}, "c66f3e9e-f232-4035-b705-2785946d1542_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03624972_BT", "Secondary_id": "NCT01216176_BT", "Statement": "A 72-year-old patient with dementia would be excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [4, 7], "Secondary_evidence_index": [56, 73]}, "c679f426-b235-4ae9-ad6c-4f1a46a494d2_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01390064_BT", "Secondary_id": "NCT00485953_BT", "Statement": "All primary and secondary trial cohorts are treated subcutaneously.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "122b1aef-4506-464d-9852-47caa508b047_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00879086_BT", "Statement": "While cohorts 1 and 2 in the primary trial had the same number of patients with anaemia and Neutropenia, Cohort 1 had 8 more cases of Leukopenia than cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 4, 5, 14, 17, 18, 19]}, "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00841828_BT", "Secondary_id": "NCT01959490_BT", "Statement": "All cohorts in the primary trial had a lower number of participants than in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9f7dc38b-1945-4035-a0ff-e08ead55145b_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00297596_BT", "Secondary_id": "NCT00580333_BT", "Statement": "Patients who have completed a trastuzumab regiment to treat breast cancer > 2 weeks prior to entry into the study are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8, 10], "Secondary_evidence_index": [8, 9]}, "b259774e-410a-49aa-b5d4-31b8d9505fc3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01525589_BT", "Statement": "People who inherit undamaged variants of the BREast Cancer 1 or 2 gene are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 13]}, "e09a11e4-afc8-4351-a5bc-d847424c79ce_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01565499_BT", "Secondary_id": "NCT01234402_BT", "Statement": "Some of the patients in the primary trial were reported to have heart-related adverse reactions, while many of the patients in the secondary trial had several breathing problems.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d22f01f0-b2be-45b9-8996-11727750b91e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01720602_BT", "Secondary_id": "NCT00082810_BT", "Statement": "The primary trial participants receive more anastrozole, Fulvestran and exemestane than the secondary trial patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2]}, "893d5684-03f8-4acd-86e4-6d38eea3ce16_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129935_BT", "Statement": "There were 80% more cases of embolism in cohort 2 of the primary trial than in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "4b46164d-a4c2-4738-be36-588ab231ceb1_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01596751_BT", "Secondary_id": "NCT00193050_BT", "Statement": "There were 0 patients with dysphagia or fever in the primary trial and in the secondary trial cohorts.", "Label": "Entailment", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "d9236874-7f3d-4402-9699-2889db9f5c61_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320541_BT", "Statement": "The primary trial cohort 2 recorded 10% more cases of Leukopenia than cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 13, 17]}, "e33825f1-45df-41f5-ba07-e9059636a146_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00057941_BT", "Secondary_id": "NCT01806259_BT", "Statement": "The occurrence of DLT, used as a measure of results in the secondary trial and the rate of clinical benefit, used in the primary trial are not synonymous and represent entirely different characteristics of the patient.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "5b0295e1-a322-40af-9acf-9cc1d55d3e64_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00295620_BT", "Secondary_id": "NCT03366428_BT", "Statement": "The secondary and primary trials use similar outcome measures, assessing the duration of patient survival after treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1]}, "3658f2f7-a497-4abb-badb-c877036456f2_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00077857_BT", "Statement": "Patients must be over 18 years of age, female, have three or more target lesions and more than one chemotherapy regiment to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 5]}, "37bc71d5-d9c0-4174-8da5-725d2d53a91b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00303108_BT", "Statement": "The cohort of the primary trial that received D+C and Taxane Na\u201a\u00e0\u00f6\u00f6ve produced slightly better results than those of the other cohort.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02781051_BT", "Secondary_id": "NCT01067976_BT", "Statement": "The primary trial procedure requires participants to exercise for 12 weeks while wearing clothing, and no physical activity is explicitly required for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2]}, "8bcc9fa3-0317-471a-a5b5-b115b5b72dea_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01302379_BT", "Statement": "Both cohorts of patients in the primary trial showed a median change in insulin from baseline of less than -15%.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "52610141-321d-4e3d-8660-ebc14b9f1696_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00082433_BT", "Statement": "The primary test results suggest that 40 mg/m2 administered as an intravenous infusion (IV) of 3 hours to day 1 of each cycle + Capecitabine triples the patient's SOS compared to Capecitabine alone.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "90203158-6477-4486-b8d9-09dcaca63617_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00570921_BT", "Secondary_id": "NCT00274456_BT", "Statement": "There is one case of cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "03334f23-49ab-47e5-b420-a6753ce6e832_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00574587_BT", "Secondary_id": "NCT00777049_BT", "Statement": "There were no cases of myocardial ischemia in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "a847cfc1-9556-4a55-9698-69c22696148f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02370238_BT", "Statement": "There were 2 cases of Angina in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "fcbb7e0f-d106-44bd-a252-9b57adc6f071_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01075100_BT", "Statement": "No mental health problems were observed in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "f82d94fe-c633-4bae-b28d-074196a08577_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03584009_BT", "Statement": "Participants in the primary trial administered with Fulvestant 500mg intramuscular injection had a higher percentage of clinical benefits than participants who received 160 mg additional Neratinib.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e5379a89-f880-44c1-bee0-a0d8ad2abfce_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00659373_BT", "Secondary_id": "NCT02202252_BT", "Statement": "The primary trial has a duration of intervention of 5 years, the duration of the secondary trial is not specified in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "d811aaec-b3bd-4376-a9d6-d14eacae875a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00717886_BT", "Statement": "\u2022 Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not allowed for entry into the primary trial, patients with high-dose chemotherapy may still enter if they meet all other inclusion criteria.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "99312d82-614c-4422-b6e6-104fe5a7fa54_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00050167_BT", "Statement": "Only patients with metastases in less than 9 infraclavicular lymph nodes are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "b02c99f3-70bd-4404-8d80-c57c6dfef7b7_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02049957_BT", "Secondary_id": "NCT01506609_BT", "Statement": "There is the same total number of patients in the primary trial as in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "3cbf2726-ddb0-460c-9dd2-082b8dda495d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454532_BT", "Statement": "Less than half of the patients in cohort 1 of the primary trial experienced adverse reactions, but more than 45% of patients in cohort 2 experienced adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "e7741151-2b2c-4e78-a4df-fe998c580714_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01912612_BT", "Secondary_id": "NCT02392611_BT", "Statement": "In the primary trial, only one cohort receives the intervention, while in the secondary trial, both cohorts receive the intervention, but cohort 2 receives more than double the dose of cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8cff36b0-a022-4469-8d14-7120be891cb1_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00376688_BT", "Statement": "Less than 1/10 of subjects in the primary trial had a complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "4ce24508-3d12-499f-ab7f-4b437ea51366_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00304096_BT", "Secondary_id": "NCT00876395_BT", "Statement": "A minimum body weight of 50 kg is required to participate in the primary or secondary test.", "Label": "Contradiction", "Primary_evidence_index": [14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "2514da19-b30a-44bb-8853-4545e97295da_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00633464_BT", "Statement": "The Ixabepilone 40 mg/m^2 group in the primary trial had worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "cb9f8a52-b88e-4b04-bb28-a0eabead1439_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00728949_BT", "Statement": "There were 6 categories of adverse reactions for cohort 1 of the primary trial that recorded at least one case.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02806544_BT", "Secondary_id": "NCT00605267_BT", "Statement": "A patient with positive breast cancer at stage 2B estrogen receptors, confirmed pathologically, is preventable for both the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3]}, "358a1d3c-9ccc-48fc-badc-1644e326c8cb_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02301988_BT", "Secondary_id": "NCT00728949_BT", "Statement": "The only type of adverse event recorded in the secondary and primary trials is diarrhoea and abdominal pain.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "60a86c87-7387-4eae-b5dd-6245f8bf541e_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00045032_BT", "Secondary_id": "NCT00416572_BT", "Statement": "WHOCBP which refuses to use contraception is excluded from the primary test, but may be eligible for the secondary test if it is a resident of the United Kingdom.", "Label": "Contradiction", "Primary_evidence_index": [18], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "bd3055c6-09aa-47f0-89ed-67ad3798a580_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00090857_BT", "Statement": "If the results of this study are greater than 2 standard deviations below normal, they should be excluded.", "Label": "Contradiction", "Primary_evidence_index": [7, 8]}, "21d7d726-8557-459f-a307-fae3e08f45d8_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00656019_BT", "Secondary_id": "NCT00328783_BT", "Statement": "Hyperparathyroid candidates are automatically excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9a8157a9-82fc-4d7e-9254-295123459430_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00054132_BT", "Statement": "The majority of patients in the primary trial had an EGFR expression rate of 0, and 0 patients had an EGFR of 3 or more.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "ff37494d-2c61-4c06-86c1-d6bcfbe9e360_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01856543_BT", "Secondary_id": "NCT00365599_BT", "Statement": "In all secondary and primary trial cohorts, there was only one recorded case of myocarditis and pericarditis.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "eb00b609-f17b-4595-87bd-d0843ec9e39a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01857882_BT", "Secondary_id": "NCT01439945_BT", "Statement": "The secondary trial gives 150 mg of magnesium oxide per day more to its patients than the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "8bc9ea31-b731-4799-a1cc-a5ba63da00c1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00904033_BT", "Secondary_id": "NCT03592121_BT", "Statement": "While patients are not required to be sexually active to receive the primary trial intervention, this is a requirement for the secondary trial where the intervention should be applied during sexual activity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "0864493d-9f64-49d1-a585-21be71704c59_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01684215_BT", "Statement": "In the primary trial, there was no difference in the number/percentage of participants with dose-limiting toxicity taking 100 mg vs 125 mg PD-0332991 orally, meaning that 0% of patients in the primary trial had Grade 4 or higher thrombocytopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "c49428a7-cc55-474e-a773-88ff2019de1b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02780713_BT", "Statement": "The two cohorts in the primary trial receive the same doses of their respective drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "78136809-c8de-4c40-9a7e-1d61d879ba27_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00611624_BT", "Secondary_id": "NCT00600340_BT", "Statement": "The primary and secondary trials administer their interventions at different frequencies.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b430ea52-fa55-4280-9e23-8a7392afca58_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00009945_BT", "Statement": "Patients with positive sentinel ganglia biopsy should undergo surgery to remove lymph nodes from the armpit (subarm or axilla) or will not be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "adfeff22-7bdd-4868-ab6e-90dd43d9621d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00038103_BT", "Statement": "There is no difference in the proportions of subjects with clinical benefit in the Exemestane + Celecoxib cohort and in the Exemestane only cohort of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00371345_BT", "Secondary_id": "NCT00475670_BT", "Statement": "There is only overlap between the adverse events observed in the primary and secondary trials, and Sepsis occurred in both trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "276f5523-f45b-45b0-ad30-b737f2c1b1d0_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00468585_BT", "Statement": "The primary trial recorded several skin infections in their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "884ba067-d3fe-4837-ad2a-a802b671b53c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00295867_BT", "Statement": "Patients with an ECOG score between 3 and 5 are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "6619c75a-4073-47e9-8586-5070be1b3d39_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02222337_BT", "Statement": "The primary test participants must be in a couple, a breast cancer survivor and a caregiver, both must be fluent in English or Spanish.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "d81fafa4-1196-407b-a8c2-27d7b5da2f4f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01816594_BT", "Secondary_id": "NCT02222337_BT", "Statement": "Patients with newly diagnosed stage 0 breast cancer may not participate in the primary or secondary trial unless they have a LVIF of less than 50%.", "Label": "Contradiction", "Primary_evidence_index": [11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "6d8b4720-e600-47d7-b6c5-3b8627f2358f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00320710_BT", "Statement": "There were no adverse events in cohort 2 of the primary trial in more than 0.5% of patients.", "Label": "Contradiction", "Primary_evidence_index": [13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "1b84007d-0002-4ab6-8e05-609e7de58684_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01646346_BT", "Secondary_id": "NCT03283553_BT", "Statement": "The secondary and primary trials do not use topical drugs in their studies.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00213980_BT", "Secondary_id": "NCT02536339_BT", "Statement": "While adequate haematological, renal and hepatic function is required to participate in the secondary and primary trials, patients with severe loss of cognitive function are still eligible.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]}, "dc7c4409-32e5-4211-83fe-0a97b6176ca0_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01007942_BT", "Statement": "In cohort 1 of the primary trial, febrile neutropenia was more than 5 times more common than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 12, 16]}, "73e7447b-a940-4126-a1d9-fffd7c56c900_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00337103_BT", "Statement": "Several patients in the Eribilin Mesylate group in the primary trial survived less than a year.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00629499_BT", "Statement": "Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 13]}, "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00129389_BT", "Secondary_id": "NCT00304096_BT", "Statement": "Patients with permanent sensory loss who interfere with daily activities are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [22, 30], "Secondary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53]}, "a7106a35-36da-423a-a6b3-3da62fc0eea8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01908101_BT", "Statement": "A prior exposure to taxane is mandatory for patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "f4f50a05-9d63-4006-9680-b7ef68dbb5fe_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00952731_BT", "Secondary_id": "NCT00956813_BT", "Statement": "Cohort 2 in primary and secondary trials, but receive daily doses of placebo PO.", "Label": "Contradiction", "Primary_evidence_index": [5, 6, 7, 8, 9], "Secondary_evidence_index": [3, 4, 5]}, "f34760f4-965e-4bbb-b88f-8b63a7045808_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00741260_BT", "Statement": "Patients with HER2 positive tumours are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "f4a33395-7e6b-46b9-b222-af3bbfff1591_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00866905_BT", "Statement": "Less than 2% of patients in the primary trial experienced an adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "e7d00591-381f-45e2-abdb-2ae1e568b193_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01421472_BT", "Statement": "More than 3 patients in the primary trial had side effects associated with a small number of white blood cells.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "59da1fb5-2636-4ca8-8970-6cb45dedbed3_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00885755_BT", "Secondary_id": "NCT01075100_BT", "Statement": "Patients' appetites were not affected during the primary or secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "f144c34b-9428-4836-bf01-5f7030eb579c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT04030104_BT", "Secondary_id": "NCT02525718_BT", "Statement": "Intervention 1 for the secondary and primary trials is for control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e7e87023-2227-4594-931a-0a3d89ec686e_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02073487_BT", "Secondary_id": "NCT03371732_BT", "Statement": "\u2022 Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opioid dependence are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36], "Secondary_evidence_index": [0, 1, 2]}, "ca4a190a-9007-4f8f-a199-b8fe4064e55b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02149524_BT", "Statement": "Several adverse events in the primary trial were not heart-related.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00711529_BT", "Secondary_id": "NCT02835625_BT", "Statement": "The primary trial participants are treated with cognitive behavioural therapy, which is not used at all in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "cb133915-dc40-4f93-a6a7-076e4d7f07a1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02685566_BT", "Secondary_id": "NCT03076190_BT", "Statement": "The primary and secondary trials have the same number of study groups but test different interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "1f0825b6-8e32-44ff-96b7-ab082e24b493_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00045032_BT", "Secondary_id": "NCT00416572_BT", "Statement": "WHOCBP, which refuses to use contraception, is excluded from the primary test, but may be eligible for the secondary test.", "Label": "Entailment", "Primary_evidence_index": [18], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "db96c4d6-ffcd-401a-8af3-807f665f16f7_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00375427_BT", "Secondary_id": "NCT00579826_BT", "Statement": "Patients with osteonecrosis are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [6, 7]}, "b74dc1bc-76c3-4ce6-9735-634e7a507ff5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00976989_BT", "Statement": "Patients with a LEVF of 53.5% are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "f078c722-b879-40f2-ac72-c733001b93dd_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01740323_BT", "Secondary_id": "NCT00127205_BT", "Statement": "The secondary trial and the primary trial only accept 18-year-olds.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16, 17]}, "c33d78e5-13be-4cde-b36e-7cc097f180a2_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02041429_BT", "Secondary_id": "NCT00068588_BT", "Statement": "The primary and secondary trials use the same outcome measures, the same drugs, and the same cohort size.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "58dbc33b-d32c-4e91-a940-ca1148bbdae4_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00075270_BT", "Secondary_id": "NCT01781299_BT", "Statement": "The primary trial is to test a chemotherapy treatment while the secondary trial is to test an implant.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00602043_BT", "Secondary_id": "NCT01720602_BT", "Statement": "Several treatments in the secondary trial are administered orally, none of the treatments in the primary trial are administered orally.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "2c462296-35f5-482a-9ece-3b4ed4c2f53a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01216176_BT", "Statement": "Urosepsis was the only adverse event recorded in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "16358be6-3895-48f7-8006-4effeb3f74b3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01196052_BT", "Statement": "The primary trial participants must be prepared to undergo cyclophosphamide-based chemotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 4]}, "6d4ecb16-6586-4ea8-a1dc-f825e951e060_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00703326_BT", "Secondary_id": "NCT00274768_BT", "Statement": "Participants with HER2- primary liver tumours, confirmed by in situ fluorescence hybridization, are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 5], "Secondary_evidence_index": [0, 1, 7, 8]}, "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01252290_BT", "Secondary_id": "NCT00479674_BT", "Statement": "Unlike the secondary trial, the primary trial does not record any cases of anaemia, dyspepsia, nausea or vomiting.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2731552d-195a-4f43-b6b5-02a3fbda81d9_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01323530_BT", "Secondary_id": "NCT01106040_BT", "Statement": "The results of the secondary and primary tests are not comparable.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "8fee5ce4-3e46-4731-842e-a5b1df451c7d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01231659_BT", "Statement": "Less than 40% of primary test participants received a complete (RC) or partial (PR) response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "def4199f-a22d-4939-b15d-66fd073fb280_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02518191_BT", "Statement": "The primary trial cohort 2 is the control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00871858_BT", "Statement": "One primary trial patient was diagnosed with clear cell renal carcinoma.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "d97c3981-50f9-4221-aec6-60661b831c8e_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03624972_BT", "Secondary_id": "NCT01216176_BT", "Statement": "A 56-year-old patient with occasional memory loss would be excluded from both the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [4, 7], "Secondary_evidence_index": [56, 73]}, "86c1430c-553b-4388-a034-b82f78afdc0d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01028352_BT", "Statement": "Patients with musculoskeletal symptoms associated with an aromatase inhibitor, such as grade 1 or higher musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5, 6]}, "b7cef0e1-7bd8-4c0e-a044-b11708cf927c_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01905592_BT", "Statement": "The two primary trial cohorts receive a selection of physicians from among 4 metastatic breast cancer chemotherapy standards.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00444587_BT", "Statement": "A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary Impairment or Diarrhoea.", "Label": "Contradiction", "Primary_evidence_index": [3, 6, 8]}, "225f95a5-7c22-4cb7-a463-1c57d5b69d7a_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01217385_BT", "Secondary_id": "NCT01202591_BT", "Statement": "Prior exposure to exemestane is not explicitly prohibited for patients in the secondary or primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [6, 7]}, "5464e8a7-159c-4e00-8710-45a44ceaeda3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03061175_BT", "Secondary_id": "NCT03098550_BT", "Statement": "The cohort 1 of the secondary trial did not receive the same doses of Daratumumab throughout the entire study, whereas cohort 1 of the primary trial had the same intervention for the full study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "98965d07-e2db-41bf-ac3e-a5c130513275_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00382018_BT", "Secondary_id": "NCT03012477_BT", "Statement": "Between primary and secondary trial patients, only 1.56% had sepsis.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [5]}, "784cc905-937f-43fd-96a6-34ea8dce9e8d_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00429104_BT", "Secondary_id": "NCT00878709_BT", "Statement": "Patients with terminal liver disease are excluded from the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [7, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "2e3f2fde-569e-46ef-958d-710599fec9a1_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00706030_BT", "Secondary_id": "NCT00171704_BT", "Statement": "Thus, the results of these two studies are not directly comparable.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "d1080199-2591-44bd-bdad-0dea3830e657_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00106002_BT", "Statement": "The primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until a complete response or progression of the disease.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "c37c21f5-19a0-4fcc-af92-89690fb64091_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02352779_BT", "Secondary_id": "NCT00263588_BT", "Statement": "The differences between the cohorts in the primary trial are once the cohort receives an omega-3 fatty acid at a low dose of 750 mg and the remaining 500 mg, while the difference in the secondary trial is the patient's characteristics.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bea7f10e-09d6-42c3-9e89-dfd1112a33d5_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01276041_BT", "Secondary_id": "NCT00688909_BT", "Statement": "0 patient in the primary trial or secondary trial died.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "3d41d86b-f53f-4bf9-a4dd-eae2412c485e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00545077_BT", "Statement": "Only cohort 2 of the primary trial receives letrozole, but both cohorts undergo endocrine therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "0159bfb3-231e-4711-b3ee-2798c66f5f6a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01015131_BT", "Secondary_id": "NCT00312208_BT", "Statement": "Both the primary and secondary trials recorded cases of rectal haemorrhage in their patient cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "9e7628cd-931e-4b1f-b4c1-f03f0449ac27_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00392392_BT", "Secondary_id": "NCT00503906_BT", "Statement": "The primary trial records two different types of pain in its adverse events, in the cranial zone and in the foot, the secondary trial does not record any type of pain in its participants.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "f1108cbc-db27-431d-9154-1a267278bda4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00312208_BT", "Statement": "There were only cases of cardiomyopathy and leukopenia in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "8eb69e3e-ac08-4e85-98be-211aecd4525d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT04396665_BT", "Statement": "Any patient may enter the primary trial as long as he or she is willing to give his or her informed consent and is able to use the Internet.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4]}, "baf7e338-91fd-47d0-b766-a4e039efc5d7_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01432886_BT", "Statement": "None of the patients in either cohort of the primary trial had DLT.", "Label": "Entailment", "Primary_evidence_index": [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9401b12d-3888-4a41-93a1-b2075930098b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00458237_BT", "Statement": "The patient who has undergone external radiation therapy and major surgery in the last two weeks is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 12, 21]}, "c7aa030a-6b76-4bd7-a934-f02a4638a1ac_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00908791_BT", "Secondary_id": "NCT00297596_BT", "Statement": "Patients over 60 years of age with histology-confirmed breast cancer and advanced Alzheimer's disease are not eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 21]}, "94f9a957-33bb-4409-8878-ba734d6b0d5c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01823107_BT", "Statement": "Several Patients implanted with a BioMatrix Acellular Meso Peritoneum Matrix suffered breast-related adverse reactions in both reconstructed breasts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "04fd88c2-cf92-468d-bbc4-567cae19948d_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00087152_BT", "Secondary_id": "NCT00203502_BT", "Statement": "The primary test recorded fewer nausea than the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 5]}, "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00499122_BT", "Secondary_id": "NCT00454805_BT", "Statement": "There were no cases of multi-organism failure in cohort 1 of the secondary trial and cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "8074c35f-b74c-4250-94f1-9ad22fa315d7_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00375427_BT", "Secondary_id": "NCT00579826_BT", "Statement": "Patients with osteoporosis are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [6, 7]}, "afc4a45b-6592-4ca8-b174-033fb6a0624a_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00580333_BT", "Secondary_id": "NCT00934856_BT", "Statement": "In order to participate in the primary and secondary trials, applicants must have a life expectancy of less than 12 weeks.", "Label": "Contradiction", "Primary_evidence_index": [8, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "2e1d4811-ae58-4b81-b53a-dbcb8c980a08_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00033514_BT", "Statement": "Elizabeth has positive HER2 breast cancer, she is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "d4f738c5-c99a-4d8d-b335-5821ce97fbd5_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00568022_BT", "Secondary_id": "NCT01120184_BT", "Statement": "Patients who are completely disabled, completely confined to bed or chair and unable to take care of themselves are eligible for the primary trial but excluded from the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 5]}, "f27b25bd-c28e-4aac-8ad6-951fd7381ce4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01262027_BT", "Statement": "More than one patient in the primary trial suffered from an adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "5311216c-94e0-4d04-acd2-b95b932ddc02_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00127933_BT", "Secondary_id": "NCT00191789_BT", "Statement": "In the primary trial, at least one patient was infected, while in the secondary trial, no patients were observed.", "Label": "Contradiction", "Primary_evidence_index": [12, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "01dfa37b-ce65-4e90-addc-395241c92f5f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00191451_BT", "Statement": "Patients in the primary trial experienced a variety of oesophageal and cardiac side effects.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "43588c50-7dc4-4d46-a53d-e94576e8ab55_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03197389_BT", "Statement": "Men and women of childbearing potential must use adequate contraceptive methods to qualify for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 16, 17, 18]}, "f419f810-ca53-4168-86fd-d1d9a9154d3a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02683083_BT", "Statement": "People with hyperthyroidism are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [11, 12, 13, 14, 15, 16]}, "630a8241-b776-4799-a7ca-b1fddf17686c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00206518_BT", "Statement": "The least common Chevalier grades in primary trial patients treated with Taxotere/Docetaxel were 1, 3D and 3C.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]}, "8f3fddf2-97ab-4456-bff7-8f83b27e3849_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00675259_BT", "Secondary_id": "NCT01875367_BT", "Statement": "Patients with an immuno-Historical test of 3+ are excluded from the primary trial but included in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [15, 18], "Secondary_evidence_index": [0, 3]}, "11617367-193f-4f6b-bc3e-e58ea76d1052_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00485953_BT", "Secondary_id": "NCT00068601_BT", "Statement": "The dose of cyclophosphamide in the secondary trial is 150 mg once every 4 weeks and the dose of Placebo in the primary trial is 12 mg QD.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "882f22f6-36d9-4c2f-8f49-52469d570977_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01840163_BT", "Secondary_id": "NCT02005549_BT", "Statement": "The primary and secondary trials do not exclude patients with non-melanoma skin cancer.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "8f5423c9-17b5-4f66-aa9f-1fc9763958b2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01250379_BT", "Statement": "None of the patients in the primary trial had thrombocytopenia, heart failure, pancytopenia, acute coronary syndrome or atrial fibrillation.", "Label": "Contradiction", "Primary_evidence_index": [0, 8, 5, 7, 9, 10, 11]}, "0c45a782-1a3d-4e9b-a258-136ab080dbb6_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00846027_BT", "Statement": "None of the adverse events recorded for the primary test occurred less than twice.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "4e42302d-2cd9-4a91-9338-8e3b0ffb9292_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00654836_BT", "Statement": "Patients with metastatic positive HER-2 adenocarcinoma in the breast may never be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 5]}, "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00270894_BT", "Statement": "60% of subjects in the primary trial were able to complete at least 85% of the dose set out in the schedule.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "da2ea2e9-3109-433e-9033-9ae322c30c4b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981812_BT", "Statement": "Women who have undergone breast enlargement in the last two years are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 8]}, "c77c8e02-7abb-4b63-8917-01babe5cd372_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00863655_BT", "Statement": "There were 5 other cases of anaemia and 1 other cases of intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 12, 13, 14, 15]}, "f2b14720-6ff2-4ff7-a5bc-3841b93f647e_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00911898_BT", "Statement": "The primary test does not explain its intervention in the intervention section.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "03e9368b-18a7-4643-a38b-a7b002403bf1_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00568022_BT", "Secondary_id": "NCT01120184_BT", "Statement": "\u2022 Patients who are completely disabled under the age of 20, who are completely confined to bed or chair and unable to take care of themselves, are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 5]}, "c5dbd52d-01d4-4919-bfe9-2b7885490d6a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00422903_BT", "Statement": "The percentage of participants who received an objective clinical response (ORC) in the breast, assessed by an independent radiological assessment monitoring committee, was highest in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "83115abd-1c07-4ee7-8ba5-b4575be2d50f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00630032_BT", "Secondary_id": "NCT00428922_BT", "Statement": "Patients with radiologically confirmed bone metatases are excluded from both the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [13, 14], "Secondary_evidence_index": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "784872db-8ccf-4ddc-a432-6ee00fd0b0cc_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01857882_BT", "Secondary_id": "NCT01439945_BT", "Statement": "The secondary trial administers magnesium oxide to its patients while the primary trial tests an educational intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 7, 14, 15]}, "adae7d81-bc8e-48e4-b966-27c2633eb72d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02131064_BT", "Statement": "More than 100 participants in the primary trial TCH + P group obtained the total pathological response (tpCR) from tumour samples.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "4ee4061e-a532-459e-8d03-3055bd92419c_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00082810_BT", "Statement": "During the entire duration of the primary test, paritiquants receive tipifarnib more often than Fulvestrant.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "4cbb7f8f-ea60-453d-b4ab-e967944426d3_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00992225_BT", "Statement": "Only 2 of the 16 types of adverse events recorded during the primary trial occurred more than once.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "47f11df7-6c82-4c50-9249-5085313a5064_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00209092_BT", "Secondary_id": "NCT00631852_BT", "Statement": "A patient with cytologically confirmed breast cancer with a diameter of 5 mm larger on imaging would be accepted for the primary trial, but not for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "3114ff0f-184c-48ba-b33d-631505cffeef_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01961544_BT", "Statement": "The primary trial revealed a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 7, 8, 9]}, "edf31a43-a774-4f2a-8a02-89b84de941bb_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02595372_BT", "Statement": "27.6% of patients with fatty acid synthase (FSFA) expression in the primary high-dose omeprazole trial did not receive a complete pathological response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01596751_BT", "Secondary_id": "NCT00193050_BT", "Statement": "There were at least 15 patients with dysphagia or fever between the primary trial and the secondary trial cohorts.", "Label": "Contradiction", "Primary_evidence_index": [6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00632489_BT", "Statement": "The primary trial uses a determined dose of 1000 mg PO per day of Lapatinib, while the dose of Capecitabine changes with patient body weight.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "5a076708-c8d4-4341-9c1d-3ee762f57be5_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03456427_BT", "Secondary_id": "NCT02685566_BT", "Statement": "There are no details of the types of imaging used in the intervention sections of the primary and secondary tests.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2]}, "98a946b0-2be1-474c-b373-043f329ba261_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02038010_BT", "Secondary_id": "NCT00764322_BT", "Statement": "Neither the primary nor the secondary trial measures the percentage of participants with an overall response rate after administration of Ispinesib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3]}, "b82e6861-3908-43e9-8e54-cf60c7d96a4e_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00721409_BT", "Secondary_id": "NCT02413320_BT", "Statement": "Patients with ER-positive tumours are eligible for the primary trial, but not for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "b8e5baf7-ddc5-407f-84d3-4c93224477cd_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02445586_BT", "Secondary_id": "NCT02115984_BT", "Statement": "More than half of the patients in the primary trial experienced adverse reactions, and there was no single patient in either cohort of the secondary trial who had no adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "79c34b71-a90f-4ddb-9aee-5f61f71f0846_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01277757_BT", "Statement": "The primary trial does not consist of testing a new physiotherapy or chemotherapy procedure.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02995980_BT", "Statement": "A patient with a glomerular filtration rate of 63 and a breast tissue category c BI-RADS would be eligilbe for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 3, 4]}, "02d5fe7a-60e2-422f-98c0-92461b8fa13f_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00438659_BT", "Secondary_id": "NCT01271725_BT", "Statement": "The primary test and the secondary test have a topical intervention, to be applied to the breast or face.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "869e413e-01c5-4a9e-8a4a-b6079f7ae300_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00996632_BT", "Secondary_id": "NCT01644890_BT", "Statement": "Emily has inoperable non-metastatic breast cancer and is eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c0b528ef-ae9f-4c01-8915-b47856f07c95_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01142661_BT", "Statement": "The primary trial accepts patients with grade 3 neuropathy.", "Label": "Contradiction", "Primary_evidence_index": [17, 19]}, "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01743560_BT", "Statement": "By week 48 of the primary trial, the majority of patients had a stable disease, none of them had a complete or partial response.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "da15fae6-7fa1-4fe0-b61c-e043df3e9e74_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01011946_BT", "Statement": "All patients in the primary trial should have bilateral breast MRI prior to entry into the study.", "Label": "Entailment", "Primary_evidence_index": [2, 7]}, "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02455453_BT", "Statement": "Patients with positive HER2, PR and ER tumours are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 10]}, "01236718-14da-450c-8051-0207d31743a5_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02555657_BT", "Statement": "The median time between randomization and death for any cause was one month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3419af1a-7923-419d-a673-2de96d41eabb_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03719677_BT", "Statement": "The potential participants will be considered regardless of the hormonal susceptibility of their breast cancer, unless they overexpress the ERBB2.", "Label": "Entailment", "Primary_evidence_index": [7]}, "2048912d-9e9f-4cbc-89cc-19020f20a976_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01966471_BT", "Secondary_id": "NCT00981812_BT", "Statement": "A patient who had a total bilateral mastectomy in the year prior to entering the study would be excluded from the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5], "Secondary_evidence_index": [5, 12]}, "f5907902-d4d1-4d73-a196-7fbe0dcb44ad_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00245219_BT", "Secondary_id": "NCT00038103_BT", "Statement": "Both the primary and secondary trials have control groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "93a8e018-ac25-48b2-81d2-fd5b01be8f37_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01463007_BT", "Secondary_id": "NCT00965523_BT", "Statement": "A higher number of patients in the secondary trial were infective compared to those in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "d72c45e5-6654-4afe-91a0-1f47b0c13dc0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00464646_BT", "Statement": "Anna is a 57-year-old woman with an ECOG of 0, diagnosed with a positive HER2 invasive adenocarcinoma of the breast, with pN2 ipsilateral lymph nodes. She is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 15, 16, 17, 18, 19, 10]}, "e68b5690-11fd-4567-8dcc-dec91d1e4bb8_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01033032_BT", "Statement": "The only adverse event recorded in the primary trial was a single case of spinal fracture.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "e1417a26-2f40-4dd6-b598-e66e57312595_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01931163_BT", "Secondary_id": "NCT00274469_BT", "Statement": "Less than 5% of patients in cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of patients in the secondary trial were registered as having LACRIMAL DISORDER.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "6ee89773-958b-4eb9-bc67-18fa98a70c2d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00365365_BT", "Statement": "The primary test recorded only one type of acute adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "4d776c28-8ed1-4f3f-9837-0821029d3775_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00063570_BT", "Statement": "None of the patients in cohort 1 of the primary trial had platelet deficiency and none of the patients in cohort 2 were constipated.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "50e54a67-9cfb-4259-b810-2e9bc0b09b4c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00611624_BT", "Secondary_id": "NCT00600340_BT", "Statement": "The primary and secondary trials require patients to undergo at least two weeks of mammositis treatment.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "9f23f617-b8ec-4665-ad0b-9a9bc8b19691_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00688740_BT", "Secondary_id": "NCT00191815_BT", "Statement": "The most common adverse reactions in the primary and secondary trials are Neutropenia, which has a total of 3 cases in all cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b76c9c21-64f7-487b-bf08-e232a9da0174_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01490892_BT", "Secondary_id": "NCT02364388_BT", "Statement": "The intervention in the primary trial requires one injection and two different imaging modalities, while the secondary trial requires consultation followed by intensive radiation therapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2]}, "66aaca41-f5f9-4ed4-b165-9510b7c64456_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03136367_BT", "Secondary_id": "NCT00129935_BT", "Statement": "Only patients who identify themselves as women are eligible for the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 6, 7], "Secondary_evidence_index": [18, 38]}, "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00206427_BT", "Statement": "One patient in the primary trial had a fungal infection of the mouth.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "d6b09c0f-979c-4151-87f9-830b964e275d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01216176_BT", "Statement": "Urosepsis was the most common adverse event in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "92da8d30-a7e9-4fb4-95e4-484b53279ad7_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01570036_BT", "Secondary_id": "NCT00021255_BT", "Statement": "The primary and secondary trials monitor the DSV of their patient cohorts, but the secondary trials indicate the percentage of patients with DSV >= 5 years, while the primary trials indicate the percentage of participants with DSV >= 2 years.", "Label": "Entailment", "Primary_evidence_index": [1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "762c3b23-547a-40cb-86c9-767294f4a142_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02165605_BT", "Statement": "A 56-year-old patient with a masectomy would not be eligible for the primary trial because of her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3]}, "95a509d6-2990-49ac-b36c-aedf842f17ee_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01111825_BT", "Statement": "No cases of Constipation, Diarrhoea, edema or febrile neutropenia were observed in cohorts 1 and 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00258960_BT", "Statement": "One patient in the primary trial had a Grade 4 adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "19c2c2d7-4c33-4842-9ed4-02cfae663ce2_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00066573_BT", "Secondary_id": "NCT01091454_BT", "Statement": "There were 1 cases of night blindness in the primary test and 0 in the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "1fdaafdc-766b-488e-9cc4-cbcad74ade97_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01818063_BT", "Secondary_id": "NCT00559507_BT", "Statement": "In both the primary and secondary trials, the only drugs administered orally are doxorubicin and v\u00e9liparib.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2]}, "2e591059-5a3b-4a69-84c5-59d9604394a8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02040857_BT", "Statement": "All sexes are eligible for the primary test.", "Label": "Entailment", "Primary_evidence_index": [2]}, "94a54cdf-4c1c-4994-929a-ced7a33f2b43_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00866905_BT", "Statement": "Less than 1% of patients in the primary trial became depressed.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "b217583e-2dbb-4951-8f73-cac08e365a7a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00562718_BT", "Statement": "Patients with heart pacemakers or stents may be allowed to participate in the primary trial at the discretion of their physician.", "Label": "Entailment", "Primary_evidence_index": [6]}, "42086f11-1fb1-4041-8d1e-e150d4cc09ea_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00304096_BT", "Statement": "A minimum body weight of 50 kg is required to participate in the primary test.", "Label": "Entailment", "Primary_evidence_index": [14]}, "0d75c493-58ce-4a45-8823-a9a1126751b3_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00916578_BT", "Statement": "The primary trial is to test a combination of chemotherapy and radiation therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "d0d4e184-0764-4c28-9af7-4535c7ed1aad_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00303108_BT", "Statement": "The primary trial cohort 2 produced slightly better results than the cohort 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e45886af-1edd-4987-a280-2609a86fd3dd_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02413320_BT", "Statement": "Women over 20 years of age who have received chemotherapy in the last 4 weeks are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5]}, "c207ff16-b7d0-49e4-9177-0597044f3008_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03374995_BT", "Statement": "Some subjects in the primary trial receiving keratin are administered topically twice a day for approximately 3 to 6 weeks, while others may administer it by subcutaneous injection.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "35234f08-cf01-478f-b739-600b5a6ea3d9_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00550771_BT", "Statement": "16/179 patients in the primary trial Experienced cardiac events, the majority of those from cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "87adb323-6f56-4e1a-a04d-8437ac571eab_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01805089_BT", "Statement": "Patients with lactate duct carcinomas are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "94410f2c-9c1c-4130-b479-738e343ba9f7_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00194779_BT", "Secondary_id": "NCT04080297_BT", "Statement": "There is at least one route of administration shared by the interventions used in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2]}, "b811e872-90ef-4649-9c8d-f5488f316ccc_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00671918_BT", "Secondary_id": "NCT00571987_BT", "Statement": "Patients with pure ductal carcinoma in situ (CDIS) are eligible for both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 12], "Secondary_evidence_index": [0, 9]}, "f66f4c30-2d39-4e29-876a-487bca9a8ccf_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02835625_BT", "Secondary_id": "NCT00486525_BT", "Statement": "The primary and secondary trials do not use chemotherapy or radiotherapy in their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00452673_BT", "Statement": "Seven patients in cohort 1 of the primary trial had dose-limiting toxicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "011991a5-724d-4b95-b9ab-9e1371d77368_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00086957_BT", "Statement": "All patients in cohort 1 of the primary trial had neutropenia of Leukopenia and Febrile.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "8421197a-3a35-4738-b1c8-83cce0ac4115_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02896855_BT", "Secondary_id": "NCT00171314_BT", "Statement": "The secondary trial recorded more total cardiac adverse events than the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "d09091f1-3fc5-498b-8c59-4678590c8464_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT03176238_BT", "Secondary_id": "NCT01498458_BT", "Statement": "While there is a much higher percentage of patients with enterocolitis in the secondary trial than in cohort 1 of the primary trial, no solid comparison can be made due to significant differences in cohort size.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "203a2e22-cae9-4bfe-b82d-6dc665a66ce6_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00821886_BT", "Statement": "Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [20, 33]}, "f4909215-5b14-42d9-bda4-4d112cf2a108_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02574455_BT", "Statement": "More than one third of patients in cohort 1 of the primary trial experienced an adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "9c27202c-7090-4be5-840e-351992aeb81c_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093808_BT", "Secondary_id": "NCT00394082_BT", "Statement": "The primary and secondary trials reported the same number of dehydrated patients in the studies.", "Label": "Entailment", "Primary_evidence_index": [11], "Secondary_evidence_index": [11]}, "fc7d8ffd-9896-4806-a095-d435cde83c88_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00528567_BT", "Secondary_id": "NCT01196052_BT", "Statement": "The total number of patients affected by adverse events in cohort 2 of the primary trial is greater than the size of the secondary trial cohort.", "Label": "Entailment", "Primary_evidence_index": [11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "23116aca-0064-4426-b147-7af688a82443_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00876395_BT", "Secondary_id": "NCT02287675_BT", "Statement": "Men with ulcerative colitis are excluded from the primary test but are eligible for the secondary test.", "Label": "Contradiction", "Primary_evidence_index": [9, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00005879_BT", "Secondary_id": "NCT01217385_BT", "Statement": "The only criterion for admission to the primary and secondary trials is that patients must be women over 21 years of age and British.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "98850daf-738c-4005-b476-8c5479ad3b79_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00033514_BT", "Statement": "Mark has a positive HER2 breast cancer, he is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00916578_BT", "Statement": "The primary test is to test a combination of capecitabine once daily and radiotherapy.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a4ed4cc0-9444-4a5d-863c-578fd42b8794_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425854_BT", "Statement": "The intervention in cohort B is described as Afatinib 50 mg taken orally twice a week.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a4dcb9b6-7b6f-4467-a159-d6e770f6762f_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01313039_BT", "Secondary_id": "NCT01031446_BT", "Statement": "\u2022 Nursing patients are not eligible for the primary or secondary trial because of the potential harm to the infant caused by the study interventions.", "Label": "Entailment", "Primary_evidence_index": [9], "Secondary_evidence_index": [19]}, "be1c82e6-200d-4bef-b723-c78655fa40e5_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00291694_BT", "Statement": "The primary test does not specify the route of administration of his intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "790047b1-43e3-486e-b41c-eaa89026eae7_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02447328_BT", "Statement": "In the primary trial, 11.1% of patients experienced serious adverse reactions, no patients experienced serious adverse reactions to the drug, and more than half of patients experienced unexpected adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "fc8ed290-e2b3-4eea-a837-d369dcd9b5da_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00875979_BT", "Statement": "None of the 3 patients in cohort 1 of the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "207b0895-91de-4238-8d50-e2b8b7420fb0_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559845_BT", "Secondary_id": "NCT00426556_BT", "Statement": "In total, there were more adverse reactions in the secondary trial than in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 14, 15]}, "1340769c-b55c-480c-a4c4-130034e128ce_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317720_BT", "Statement": "Patients must have received at least one prior treatment with trastuzumab to be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2]}, "a4d6e27f-737b-4597-86e1-79b3f064cbee_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02694029_BT", "Statement": "The primary test candidates should be able to hold their breath under water for 30 seconds.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00887575_BT", "Secondary_id": "NCT01610284_BT", "Statement": "The cohort 1 of the secondary trial was more than 3 times the size of cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "030eded8-6513-4028-b1fe-fefd6dd388ad_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02429427_BT", "Statement": "Patients with a platelet count of 50,000 x 109/l are not eligible for primary testing", "Label": "Contradiction", "Primary_evidence_index": [0, 7]}, "412d3ee2-bbfb-4e24-b159-684ae144e742_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00054275_BT", "Statement": "A patient with minimal symptoms but severe obstruction of the left main coronary artery would not be able to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [33, 35]}, "d1d77877-9c85-41c8-9eca-6fd75b254a15_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00768222_BT", "Statement": "Rachel is 19 years old and has skin ulcers and allergic reactions to triclosan, she cannot participate in the primary trial because of her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 4, 8, 9]}, "c32d1b74-07ab-4afb-9db6-878e20727661_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02279108_BT", "Statement": "Adult patients with HER2- histologically infiltrating breast cancer who have not undergone prior lumpectomy or breast reduction on the same side and have no indication to the contrary to surgery are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "ba0c0dc6-826b-426f-8738-eec23e47f6b0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03045653_BT", "Statement": "Sharone had a hip replacement 2 months before, it is not possible for the primary test.", "Label": "Contradiction", "Primary_evidence_index": [4, 6]}, "77982c81-d147-48d9-909c-18b9a98224e9_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01301729_BT", "Secondary_id": "NCT02129556_BT", "Statement": "Only one type of infection was recorded during the duration of the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00687440_BT", "Secondary_id": "NCT01307891_BT", "Statement": "The primary and secondary test results indicate that Abraxane + Tigatuzumab produces better ORR than Caelyx, Docetax and Trastuzumab.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2e03f6f1-0d4f-4ebf-8781-20918d70d78f_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02165605_BT", "Statement": "A 56-year-old patient with a masectomy would not be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 3]}, "57e74ef2-f170-47bd-a908-2a7b3cec150d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00482391_BT", "Statement": "Patients with no QT prolongation are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [29]}, "b5957a75-140f-445b-99dc-199b8182b8ed_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01805089_BT", "Statement": "Premenopausal patients with lactating duct carcinomas are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3]}, "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00486525_BT", "Statement": "The difference between the two cohorts in the primary trial was that cohort 1 received higher doses of IMGN853, while cohort 2 received lower doses more frequently.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f57350c2-ac90-47ea-92b4-d903509bf07a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03252431_BT", "Statement": "Patients in both arms of the primary trial had Grade 4 Neutropenia at the same time. There was no difference at all.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "77c61307-567d-4ac2-a7f7-85feffd30473_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00167414_BT", "Statement": "Patients do not need to have a known hormonal receptor status to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "35dd977f-53d8-4400-b5cb-34caaa938e78_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00764322_BT", "Statement": "The ultrafast Metabolizer group in the primary trial experienced an average increase in endoxifene concentration over 6 mg/m2 over 4 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "54554da5-e67f-4da5-819b-a85b7bc5d52c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00444535_BT", "Statement": "Less than one-third of primary trial participants achieved progression-free survival after 12 weeks of treatment.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "592edd64-7841-4c19-ba75-583066308137_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00343863_BT", "Statement": "On days 1-7 of the primary trial, cohort 1 received doxorubicin IV hydrochloride, oral cyclophosphamide, dexamethasone IV or orally, and ondansetron IV.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "a1d207c8-2d57-4c49-89fa-60ceacf65829_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00228943_BT", "Statement": "Clinically depressed patients are not able to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [8, 9]}, "4a8f0562-355b-4a68-8790-c283d93ce766_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00093808_BT", "Secondary_id": "NCT00394082_BT", "Statement": "The primary and secondary trials reported the same percentage of dehydrated patients in the studies.", "Label": "Contradiction", "Primary_evidence_index": [11], "Secondary_evidence_index": [11]}, "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02491892_BT", "Secondary_id": "NCT00887575_BT", "Statement": "In cohort 1 of the secondary trial, more cases of diarrhoea and dyspepsia were recorded than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 7, 8]}, "3cd353ed-af0d-4356-8f45-efc1e91a2a0d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02878057_BT", "Statement": "\u2022 Outpatients capable of self-care but unable to perform work activities are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "b8473ae8-11c9-4578-aab8-ee96e6287715_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00580333_BT", "Secondary_id": "NCT00934856_BT", "Statement": "\u2022 Applicants must have a life expectancy of more than 3 months to participate in the primary trial, there is no defined minimum life expectancy for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [8, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "4243dc45-5a64-486d-ae2a-11448db00dcf_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00246090_BT", "Secondary_id": "NCT00266799_BT", "Statement": "Cohort 1 of the primary trial 15% less total adverse reactions than cohort 2 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [15, 16]}, "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00073528_BT", "Secondary_id": "NCT00191152_BT", "Statement": "The secondary trial cohort 1 had a median PFS much longer than cohort 1 in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "f616e3d8-6c1a-4b99-ac79-ea87895e37b7_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00902330_BT", "Secondary_id": "NCT00952731_BT", "Statement": "The primary trial cohort 2 is the control group and cohort 1 is the secondary trial control group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "2f700407-8baf-4e5f-8fc0-378a294512f5_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01313039_BT", "Secondary_id": "NCT01031446_BT", "Statement": "\u2022 Nursing patients are not eligible for the primary or secondary trial because of potential harm to the father from the study interventions.", "Label": "Contradiction", "Primary_evidence_index": [9], "Secondary_evidence_index": [19]}, "cebee448-235d-49ff-8e87-56639399548b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02287675_BT", "Statement": "Informed consent is optional for entry into the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01073865_BT", "Statement": "Women over 18 years of age whose last period was 2 years prior to randomisation are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02187744_BT", "Statement": "Septicemia, due to the presence of an implanted device, was a common adverse event in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 7]}, "af677d94-a376-42ea-93fe-91963a071199_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00676793_BT", "Secondary_id": "NCT01931163_BT", "Statement": "Patients with dysphagia may not participate in the secondary trial but may be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 26]}, "6579e25e-8dcf-44b5-a50d-7c84672cba89_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00981305_BT", "Statement": "Only those who have already been diagnosed with cancer and are currently receiving treatment for their primary tumour are eligible for the primary trial as long as they are over 20 years of age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "1ac9c526-91e6-4e0d-8570-0a78e3ec78db_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00451555_BT", "Statement": "Cohorts 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse event.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "79c07f36-daf9-4844-ad8a-f362fbbaaf81_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00767520_BT", "Statement": "Both cohorts in the primary trial reported the same precentage of patients who vomited during the trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 13, 18]}, "bced9c90-5ce0-416c-a168-f9e74359b332_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01381874_BT", "Statement": "The Exemestane group in the primary trial had a better median response to tumours than the Abiraterone Acetate + Prednisone group, but the patient with maximum TR was in the Abiraterone Acetate + Prednisone group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "ce88c763-0062-48dc-b5e1-f81af32f2628_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00593827_BT", "Secondary_id": "NCT00478257_BT", "Statement": "Patients with B.C. HER2 are eligible for both the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "982469a3-2fc1-40b4-92a9-d531b6c0ab5d_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00296036_BT", "Statement": "The primary trial administered lactic acid-Urea/Creme topically twice daily, and placebo was administered orally once daily.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00334802_BT", "Secondary_id": "NCT00167414_BT", "Statement": "There is no age limit for secondary or primary testing.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1]}, "e6901a45-4c97-4618-bfcb-6f6dd046ef0c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00143390_BT", "Statement": "In the primary trial, there was a difference of less than 3 months between the maximum TTP and the minimum recorded TTP of the Exemestane group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e94ea1b1-1816-4bac-b1ca-f6d66b95702a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00004888_BT", "Statement": "Most primary trial participants experienced third-year or higher cardiotoxicity events after Cycle 8 of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "0e3c62f7-a152-4370-9d09-b69a715c0a21_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01216319_BT", "Secondary_id": "NCT03346161_BT", "Statement": "The secondary and primary trials evaluate surgical procedures for breast reconstruction of patients who have had mastectomies.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "7191b5e9-4f29-4261-8a64-51653ee151fe_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00410813_BT", "Statement": "In the primary trial, Dasatinib 70 mg twice daily gives a median PFS better than Dasatinib 100 mg daily.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "639ccada-370d-4709-bdd7-1b29bbcc8769_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01597193_BT", "Statement": "ECOG > 1 and life expectancy greater than 12 weeks are required to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 5]}, "8c6e6c06-c409-4c42-b195-e9d2a1065b97_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02069093_BT", "Statement": "All patients in the primary trial had tiny symptoms of stomatitis and a normal diet.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "b5183c1c-adb5-4877-b061-50a16d6a5b52_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00191815_BT", "Secondary_id": "NCT01301729_BT", "Statement": "None of the patients in the primary trial committed suicide, but there was one such case in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "69f57cdb-22e9-4a3a-8f19-6095c66c6497_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01855828_BT", "Secondary_id": "NCT00696072_BT", "Statement": "The secondary trial uses clinical benefit (CBR) as a measure of outcomes, which is different from the proportion of participants with a complete pathological response rate that is used for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "ea505463-c509-416e-ad88-11576764b734_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01771666_BT", "Secondary_id": "NCT01256567_BT", "Statement": "Japanese participants with an ECOG <=1 are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 7], "Secondary_evidence_index": [0, 1, 2]}, "81669281-db01-4493-a797-0d60f448f706_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00930930_BT", "Statement": "The most common adverse event in the primary trial was dehydration.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29]}, "40dbf023-ead5-45fc-bdce-bf40e1955578_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00382785_BT", "Secondary_id": "NCT00784849_BT", "Statement": "Neither the primary test nor the secondary test use low-dose magnesium oxide, high-dose magnesium oxide or mometasone in their intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "b64ae9c9-956a-421e-a41f-1886408fec2a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003782_BT", "Statement": "One of the cohorts in the primary trial had more than 5% of patients with side effects.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 11, 12]}, "e0980234-0611-44de-9165-54bdd086663d_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01539317_BT", "Secondary_id": "NCT01323530_BT", "Statement": "The primary trial uses topical intervention and the secondary trial uses a combination of oral and intravenous treatments.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "3366c10a-3d41-48ae-bfa8-26b9e655761e_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00005908_BT", "Statement": "There were 8 cases of pharyngitis in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "be29030a-98e8-40ad-9138-90076fdb50d3_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01572727_BT", "Statement": "In cohort 1 of the primary trial, more white blood cell-related adverse events were recorded than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "a31298d5-20ae-4a3d-a57b-e97288fff6c0_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01097460_BT", "Statement": "Each patient in the primary trial had at least one adverse event that occurred over a 2 year period.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "54e93334-0f21-4ea2-b0f2-34473385da53_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003830_BT", "Statement": "The most common adverse reaction in both cohorts of the primary trial was anaphylaxis, which affected less than 1% of patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "fbedd8fc-05e8-4438-b780-d7483aed3b45_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00404066_BT", "Statement": "When an abnormal EVAF, pregnancy or breast-feeding automatically eliminates patients from participating in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [22, 28, 29]}, "4bd9f061-6420-443d-8f84-b703733644ac_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01202591_BT", "Statement": "100% of patients in the primary trial experienced life-threatening adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e6d3354b-b36a-42b9-b406-61a9af594686_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00046891_BT", "Statement": "The primary trial cohort 1 receives 120 mg of Ginkgo Biloba twice daily.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "62b3d09e-6b2a-4827-8ceb-96ccafca18d4_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00896649_BT", "Statement": "A prior hormonal treatment(s) in a metastatic or adjuvant medium is not necessary for patients in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00317603_BT", "Statement": "The primary trial participants must be over 18 years of age, have a confirmed stage 3 histologically or above breast cancer, an ECOG < 2 and a life expectancy greater than 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 6, 7, 8]}, "85c315e5-7ae4-4764-8b02-87d36f67a159_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00278109_BT", "Secondary_id": "NCT01881230_BT", "Statement": "- Gemcitabine is not used in the primary test and is only used in one of the arms of the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "497188e0-9d88-406f-b163-c154516cb12c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01560416_BT", "Statement": "There were more than 10% more adverse event cases in cohort 2 than in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 12, 13]}, "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00438100_BT", "Secondary_id": "NCT00662025_BT", "Statement": "Patients with BUN < 20 mg/dL, platelet count < 90,000/mm3, leukocyte count 5,000/mm3 to 8,000/mm3 may be eligible for both the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "f26fb90b-a9a5-4614-9680-2e9f6f0ba649_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01828021_BT", "Secondary_id": "NCT01326481_BT", "Statement": "Patients in the primary and secondary trials did not have the same adverse reactions, with the exception of supraventricular extrasystoles that were most common in both trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "90dd042b-c16c-4ea7-b360-625bd5e64590_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00388726_BT", "Statement": "A 75-year-old patient with an ECG of 1 and an estimated life expectancy of more than one year would be eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 11, 12, 13]}, "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01271725_BT", "Statement": "In the primary trial, the percentage of participants with an objective response (OR) for Afatinib monotherapy was 13% lower than that for Afatinib and Paclitaxel or Vinorelbine Combine Therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "20cc98f8-a71a-466d-a39c-735899791613_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00915603_BT", "Secondary_id": "NCT02511730_BT", "Statement": "The INR equal to or greater than 1.5 is mandatory for participation in the primary test, it is not necessary for the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 24], "Secondary_evidence_index": [0, 1, 2, 3]}, "fa1c6f63-ae37-4c18-918b-7b9ba445fd81_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00391092_BT", "Statement": "In total, there were 32 cases of febrile neutropenia in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 12, 14]}, "6d0b2acc-11f4-479f-9a86-004e2f5f7599_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00194779_BT", "Secondary_id": "NCT04080297_BT", "Statement": "IA is used as a route of administration through interventions in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16], "Secondary_evidence_index": [0, 1, 2]}, "7e9c3980-9f12-40c7-920e-76594db26fd1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02352779_BT", "Secondary_id": "NCT00263588_BT", "Statement": "The differences between cohorts in the primary trial are once the cohort receives placebo and the other low-dose omega-3 fatty acid, unlike the difference in the secondary trial is the patient's characteristics.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c83e003d-d12d-4f72-ab1f-c39f3a13326b_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00499083_BT", "Secondary_id": "NCT03045653_BT", "Statement": "To be eligible for both the secondary and primary trials, patients must be women over 18 years of age, ECOG <2 and have negative breast cancer confirmed by HER2.", "Label": "Entailment", "Primary_evidence_index": [6, 10, 12], "Secondary_evidence_index": [0, 1]}, "cae58656-76e7-447a-940e-dfcc78159173_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00244933_BT", "Statement": "The primary trial monitors the onset of anaemia in its adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "94c4c3fc-7bcb-407b-86b5-6699305d3dbd_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02481050_BT", "Statement": "There are no adverse reactions in the primary trial that occurred more than once.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "103fbaa8-1852-402a-9368-36bbf6c747b2_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00022516_BT", "Statement": "At most 3 patients in the primary trial had Neutropenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "731dc36f-983d-4d4c-97ac-6e3eeee23a40_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00581256_BT", "Statement": "Patients with left-hand breast cancer and an ECOG of 3 are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 8, 14, 17]}, "b2883781-f4e9-405e-9231-7a07e46c35b0_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00429299_BT", "Statement": "Only one cohort in the primary trial is administered to trastuzumab at 4 milligrams per kilogram.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "932c2135-381a-4675-a782-e683eca8d935_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00791037_BT", "Secondary_id": "NCT00606931_BT", "Statement": "Both primary and secondary trials use vaccine-based interventions, but this is done at different intervals and for a different duration.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "6461007d-fc18-43e2-a797-11cb0a4512ce_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01648322_BT", "Secondary_id": "NCT00436566_BT", "Statement": "The primary test is shorter than the secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "819e85b0-2d4e-4535-b920-4e18868da883_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00630032_BT", "Secondary_id": "NCT00428922_BT", "Statement": "Patients with radiologically confirmed metatases in CNS are excluded from both the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [13, 14], "Secondary_evidence_index": [6, 7]}, "cc0d6fe8-69c4-49d3-b321-00e47c155db6_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03098550_BT", "Statement": "The results of cohort 3 of the primary trial were not conclusive.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0fbb4fb4-620b-4ee9-aaa8-956992026cef_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454532_BT", "Statement": "Less than half of the patients in cohorts 1 and 2 of the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "69b12ff4-6bb4-4207-b400-67795709c3c8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02679755_BT", "Statement": "Each patient of Palbociclib+L\u00e9trozole Australia Cohort in the primary trial experienced adverse events of therapeutic origin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 14, 15, 16, 17, 8, 19, 20, 21, 22, 23]}, "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00829166_BT", "Statement": "Women with Grade 3 or 4 peripheral neuropathy are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [9, 12]}, "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00464646_BT", "Statement": "Anna is a 57-year-old woman with an ECOG of 0, diagnosed with invasive adenocarcinoma of the breast, the IHC results were 1+. She is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 15, 16, 17, 18, 19, 10]}, "efc15257-5e19-4b7e-8b51-da94840784d8_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00623233_BT", "Secondary_id": "NCT01525589_BT", "Statement": "The primary trial recorded 1 patient with platelet deficiency in the blood, while a total of 6 patients with platelet deficiency were found in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01310231_BT", "Secondary_id": "NCT00093808_BT", "Statement": "19.57% of patients in the secondary trial developed a eating disorder, there were no cases of this in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02129556_BT", "Statement": "The cohort 1 of the primary trial had a much higher number of deaths than the cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 10, 13, 23]}, "e4961c1a-83e2-40ed-93ac-64d5cef1f84a_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01819233_BT", "Statement": "All participants in the primary trial should reduce the number of calories in their diet by a quarter throughout the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "9cb1c975-0d49-4437-af56-1a4f97e30aef_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01663727_BT", "Secondary_id": "NCT00072293_BT", "Statement": "There is no maximum or minimum age for participation in the primary or secondary test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18], "Secondary_evidence_index": [16, 17, 18]}, "51699ae8-d297-4635-95c1-4ed38c8706c3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02732119_BT", "Statement": "Mark has undergone refractory ventricular fibrillation twice in the last month, so he is excluded from the primary test.", "Label": "Entailment", "Primary_evidence_index": [8, 14]}, "c2c73b99-f89c-4dd3-8362-295f9a7965f3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02756364_BT", "Statement": "In order to meet the inclusion criteria for patients undergoing the primary trial, ineffective treatment with the aromatase inhibitor (AI) must be received prior to entry into the study.", "Label": "Entailment", "Primary_evidence_index": [0, 9]}, "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02129556_BT", "Statement": "The primary trial cohort 1 had a much higher mortality rate than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 10, 13, 23]}, "949ac54b-a871-4134-a507-c98a4de55720_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00394082_BT", "Secondary_id": "NCT01033032_BT", "Statement": "In the primary trial, cases of anaphylaxis and spinal compression fracture were recorded, none of which were observed in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "02407f87-235d-4240-98fe-498b352cce75_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00167414_BT", "Statement": "Patients should have overexpressive tumours of the human epidermal growth factor (HER2) receptor 2 to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "61a524d4-1697-4a10-b36a-a0c6cda79526_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00030823_BT", "Statement": "Patients with triple negative breast cancer of stage I, II, III or IV are not eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [12, 13]}, "304977b6-9742-4c3b-84fd-e5ef1737a143_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01597193_BT", "Statement": "ECOG < 2 and life expectancy greater than 12 weeks are required to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 4, 5]}, "87c65217-85d9-4f05-87aa-f4dfacd9f25a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01790932_BT", "Statement": "Patients with phosphoinositide 3-kinase inhibitor treatment are not eligible for primary testing.", "Label": "Entailment", "Primary_evidence_index": [5, 6]}, "19e89ebc-a417-47a8-bfa7-1778baead178_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01385137_BT", "Secondary_id": "NCT00593346_BT", "Statement": "While placebo treatment is used in the secondary trial, there is only one trial group in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3]}, "561a0631-1eb3-48d1-baa2-81eb3fa79b98_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00950300_BT", "Secondary_id": "NCT00615901_BT", "Statement": "The primary trial recorded one patient with chest pain, while the secondary trial observed one patient with abdominal pain.", "Label": "Entailment", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 3]}, "bc617e84-a0c1-400b-9ad5-88b56d1805e8_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01671319_BT", "Statement": "1/42 patients in cohort 1 of the primary trial passed out.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01097642_BT", "Statement": "Adult patients with histological confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 3, 4, 5]}, "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00354640_BT", "Statement": "Patients in primary trial 1 receive higher doses of anastrozole than simvastatin.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b059e44b-9830-4c45-858e-ebd007fbaf69_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00148668_BT", "Statement": "Cohorts 1 and 2 in the primary trial recorded the same number of patients with febrile neutropenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "fec065ca-fbde-476d-ab0d-7e7054e29858_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00436917_BT", "Statement": "Patients with scoliosis with a Cobb angle greater than 20 degrees to the lumbar spine, or with surgery prior to the lumbosacral spine, are excluded from the primary trial as they interfere with CT and MRI scans required for the study.", "Label": "Contradiction", "Primary_evidence_index": [39, 40, 41]}, "ea3bd229-001c-487f-9cda-edf2e699dbb2_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01153672_BT", "Secondary_id": "NCT01432145_BT", "Statement": "In the primary trial, patients receive vorinostat at the same frequency, dose and route of administration as in the secondary trial, 6-Mercaptopurine.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "576e519a-1ef3-43e5-a13c-6058ad71f388_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00297596_BT", "Secondary_id": "NCT00580333_BT", "Statement": "Patients who have already received radioactive treatment to treat current breast cancer in the last two weeks prior to entry into the study are eligible for the primary trial but excluded from the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 8, 10], "Secondary_evidence_index": [8, 9]}, "699d0cb5-1ebb-441d-aa7e-041a48923b00_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03374995_BT", "Statement": "Subjects in the primary trial receiving keratin are given topically twice daily for approximately 3 to 6 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01127373_BT", "Statement": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumours are eligrbs for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5]}, "6e882de6-e55f-40a4-95a1-bdb176e68a18_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00266799_BT", "Statement": "None of the patients in cohort 1 of the primary trial had acute coronary syndrome or VESTIBULAR ACUTE.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "525ed182-07e9-4548-87b3-c831e0b7389e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00834678_BT", "Statement": "Patients with lymphopenia may participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [18]}, "233d2ec1-1383-4088-90af-c5a948847631_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00110084_BT", "Secondary_id": "NCT01961544_BT", "Statement": "Both the primary and secondary trials reported cases of Pseudomonal septicaemia in their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 10], "Secondary_evidence_index": [0, 12]}, "8e3fe244-d47d-48ce-ab29-4a5226024aad_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00426556_BT", "Statement": "There was an equal number of cases of febrile neutropenia, leukopenia and neutropenia in the cohorts in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 14, 15, 16, 17, 18]}, "670443b0-89bf-4af4-a9ab-4cdff26d09a8_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00005957_BT", "Statement": "T4 N3 M0 breast adenocarcinoma are eligible for primary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "455748bf-8e12-4834-8126-ab77cab16200_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00332709_BT", "Secondary_id": "NCT00659373_BT", "Statement": "All participants in the primary trial receive the same dose of Letrozole, only some patients in the secondary trial are treated with Exemestane.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "d29bd9dd-b52e-4b18-82ea-e2914dfb9579_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01808573_BT", "Statement": "The primary trial Patients treated with Neratinib Plus Capecitabine had an average free survival (95% confidence interval) of more than 2 months compared to patients treated with Lapatinib Plus Capecitabine.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2649c857-f98d-4529-9a4a-4f8b17813cb8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00337103_BT", "Statement": "The median overall survival of patients in cohort 1 was 44 days longer than that of patients in cohort 2 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "0a6e8720-ea47-4520-bd02-e0eb8fcd880f_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00399802_BT", "Statement": "The single infusion IV in the ZA 4 mg group of the primary trial showed a lower percentage change from the baseline in the urinary N-telopeptide of collagen type I than in the Odanacatib 5 mg group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "ce6630d3-d3b7-4870-a486-9b6284a454f0_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02679755_BT", "Statement": "More patients in the Palbociclib+Letrozole Australia cohort of the primary trial experienced emerging adverse events compared to patients in the Palbociclib+Letrozole India cohort.", "Label": "Contradiction", "Primary_evidence_index": [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "27e31574-5a73-4a68-997d-daa84797a65a_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00054028_BT", "Secondary_id": "NCT02162719_BT", "Statement": "The primary and secondary trials administer at least partially their intravenous procedures.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "e21171de-ad49-4fc5-9c5d-aa362ca61c8a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00014222_BT", "Statement": "Cohort one of the primary trials reported 2,680 patients with eye-related adverse events, while cohort two reported 41.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02518191_BT", "Statement": "The primary trial cohort 2 is the control group, as eligible patients with breast cancer treated with GnRHA every 28 days.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "38f47a03-f71d-4072-a005-b954fb6069da_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00684983_BT", "Statement": "The median period during which a patient in the A arm of the primary trial lived with the disease without worsening was half a year.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "e41917b8-d921-4797-b845-0121a75104a4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00129376_BT", "Statement": "More than 2% of patients in the primary trial experienced clinically significant inflammation of the back of the throat.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02513472_BT", "Statement": "Cohort 1 patients in the primary trial survived almost twice as long as those in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02491892_BT", "Secondary_id": "NCT00887575_BT", "Statement": "In the secondary trial cohort 1 there were more cases of diarrhoea and dyspepsia than in the primary trial cohort 1, which is due to the significant difference in cohort size.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 6], "Secondary_evidence_index": [0, 7, 8]}, "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01881230_BT", "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier estimate of progression-free survival more than 83% lower than that of the Carboplatin group.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "6214280f-f665-48d3-b33f-9d798deff71f_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01855828_BT", "Secondary_id": "NCT00696072_BT", "Statement": "The secondary trial uses overall survival (SG) as a measure of results, which is different from the proportion of participants with a complete pathological response rate that is used for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "108b54a9-b5cc-4f31-956f-e4e2e653d756_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089999_BT", "Statement": "In total, more participants in the primary trial had no tumour response, than a partial response, and 0 participants had a complete response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "662f4992-0155-4a82-926f-b1821539aab7_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00723125_BT", "Secondary_id": "NCT00617942_BT", "Statement": "57% of patients in cohort 1 of the primary trial had complete pathological response rates to surgery, compared to 60% in cohort 1 of the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "398f744b-97cf-4f95-b162-99ec6652d327_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01091454_BT", "Secondary_id": "NCT00054275_BT", "Statement": "There were more cases of anaemia and leukopenia in the primary trial than in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "43421f19-878e-46f7-b456-8031835af649_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00632489_BT", "Statement": "The primary trial uses a determined dose of 1000 mg PO per day of Lapatinib, while the dose of Capecitabine changes with the body surface area.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "13fa44e7-38be-48fb-a0eb-6b212549f526_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02260531_BT", "Statement": "The percentage of participants with a complete (CR) or partial (PR) response was much lower in the HER2 positive group in the primary trial than in the ER+ and/or PR+ group.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "12ae2315-cc50-43ac-a595-762c85c1ec58_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02308020_BT", "Statement": "There were no participants in cohort 1 of the primary trial with a (CR) or a (PR) based on the assessment of response in the neuro-oncology (RANO-BM) brain metastasis response criteria.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "11403f92-661b-4334-8dfb-098586610ec6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02536339_BT", "Secondary_id": "NCT00371345_BT", "Statement": "In the primary and secondary trials, respiratory diseases were observed in most patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2823adfc-b3a4-4626-9690-0c292aa8da04_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01422408_BT", "Statement": "The primary trial is a Phase II trial in which all participants will receive topical fluoronide 0.05% facial cream twice daily for two weeks.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3]}, "1cda051f-27d0-4027-94cf-7b5340173ca2_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02504424_BT", "Secondary_id": "NCT03708393_BT", "Statement": "The primary and secondary trials do not have the same number of study groups.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00435409_BT", "Secondary_id": "NCT00319254_BT", "Statement": "The patient with the shortest PFS was in the secondary trial at only 5 days, and the longest PFS recorded was in the primary trial at 78 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "1e91c023-96e8-459b-9070-02df13339617_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00513292_BT", "Statement": "In the primary trial, the FEC-75 group then Paclitaxel/Trastuzumab produced better complete pathological response rates (pCR) than the Paclitaxel/Trastuzumab group then Trastuzumab/FEC-75.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "a15b4c0c-232b-4209-bf60-35d160e41d2c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT03012477_BT", "Statement": "One primary trial patient experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was anaemia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "795d634a-9f9c-49a2-a4e7-ec99bd3600f2_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02667626_BT", "Statement": "The primary trial is to test an educational tool online and the secondary trial is to test a medical device on menopausal women.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "e2d4c56c-a68f-4751-907d-9c2355c9528b_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01463007_BT", "Secondary_id": "NCT00965523_BT", "Statement": "A significantly higher proportion of patients in the secondary infection test than in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00193050_BT", "Secondary_id": "NCT00232479_BT", "Statement": "Patients must be over 18 years of age and have a life expectancy greater than 6 months to participate in the primary or secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 3, 11, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "9ad3444c-143d-4c28-a08a-e0c9cda44900_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00243503_BT", "Secondary_id": "NCT00448279_BT", "Statement": "The primary and secondary trials did not observe any of the same adverse events in their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 3], "Secondary_evidence_index": [0, 2]}, "43061a8b-c1b2-4b5e-b935-73733d674fb4_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01401959_BT", "Secondary_id": "NCT00852930_BT", "Statement": "The primary trial refers to specific interventions for its patients based on their tumour response, patients with a complete response go to cohort A and all other patients in cohort B, contrary to the secondary trial assigns random interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fc7369dc-0fc5-4823-a8eb-5ac85188fd60_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00416572_BT", "Statement": "Patients with ovarian or lung cancer are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [12, 13]}, "25ec56f0-e472-4423-92ae-8d4840b067b5_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03475992_BT", "Secondary_id": "NCT03106077_BT", "Statement": "The primary trial participants receive different interventions depending on their pre-diagnosis, while all patients in the secondary trial did the same intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2]}, "2c9e9407-e990-41bd-a87b-9d294c78f727_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02286843_BT", "Statement": "The primary test consists of testing a new radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "f3cebdf7-be0c-45ad-85bd-bde827524e20_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00693719_BT", "Statement": "The primary test recorded less than 5 different adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b5c7bfd2-d491-400c-8444-8bc424cd5dbf_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01705691_BT", "Statement": "One primary trial patient suffered from kidney stones.", "Label": "Entailment", "Primary_evidence_index": [9, 14]}, "53c62057-d6ea-4639-adaf-98cb1544a394_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425672_BT", "Statement": "Patients receiving Intervention 1 of the primary trial undergo a 21-day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer from an unacceptable disease progression or toxicity.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "599b37cd-f380-48ac-864d-e766a7af963e_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01570036_BT", "Secondary_id": "NCT00021255_BT", "Statement": "The primary and secondary trials monitor the percentage of their cohorts of patients with DSS below 6 years of age.", "Label": "Contradiction", "Primary_evidence_index": [1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c428ec76-4d22-4d2d-8c06-1675bd431d41_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02222337_BT", "Statement": "The primary test participants must be in a couple, a breast cancer survivor and a caregiver, both must be ethnically Hispanic.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT03283553_BT", "Statement": "The primary trial has two cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a9d5c664-896f-4bb1-95e7-1deaa88848ef_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00089479_BT", "Secondary_id": "NCT02964234_BT", "Statement": "Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, without any evidence of metastatic disease. Agatha is of white-British origin. she is eligible for the primary trial but not the secondary trial, due to her age.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2]}, "62b5fe62-470d-46e3-82a6-d57cd6cab452_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00471276_BT", "Secondary_id": "NCT00951665_BT", "Statement": "gastrointestinal haemorrhage was more common in patients in cohort 1 of the primary trial than in cohort 1 of the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "de349a2d-80ee-4c34-ab9f-38eb467c77d7_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01106040_BT", "Secondary_id": "NCT01441596_BT", "Statement": "The primary and secondary trials do not study the patient's PFS, RROs or DLTs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "0d37bf26-bc74-4a01-9bc9-61e2fa3051da_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00446030_BT", "Secondary_id": "NCT00975676_BT", "Statement": "The primary and secondary trials do not overlap with the drugs they use for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "69f7a93d-7134-40ec-aff3-50acd7119d2c_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02425891_BT", "Secondary_id": "NCT00593827_BT", "Statement": "The secondary and primary trials measure the PFS of their patient cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "8de31b0f-7127-4c8b-b5e0-060e7a83fae5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01299038_BT", "Statement": "Joe has a known history of hepatitis. However, as he is over 18 years of age is still eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "207a1d82-a61b-4b5f-bebf-0706def6729d_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01008150_BT", "Secondary_id": "NCT00375427_BT", "Statement": "In total, only 1 more cases of mucosal inflammation were recorded in the secondary trial than in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "968aeaf1-44b9-4454-8c99-e3c207037485_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01491737_BT", "Statement": "There were 4 cases of febrile neutropenia and heart failure in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 5]}, "2b79f9cc-4262-4353-ad28-91cda07a9b9a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02988986_BT", "Statement": "Patients should have an AST, an ALP and an ALT < 1.5 LSN to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 20]}, "d56ffd81-4007-477b-b3c3-0fdb89806931_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00723398_BT", "Statement": "Insipidusare diabetes patients are not suitable for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "f62e6c20-862b-4ce3-9121-0d93ff050839_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01373671_BT", "Secondary_id": "NCT00686127_BT", "Statement": "The Lidoderm products are used in response arm 1 of the secondary test, and an FFDM product is used in arm 1 of the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "833eeb4b-4921-468a-947d-bacfc7816ae6_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT02162719_BT", "Secondary_id": "NCT02131064_BT", "Statement": "The primary and secondary trials investigate the effects of their intervention on the patient's PRT.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1]}, "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00006110_BT", "Secondary_id": "NCT00464646_BT", "Statement": "The secondary trial has several gastrointestinal adverse events, while the primary trial has no gastrointestinal adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 7, 8, 9]}, "c317750d-6ef7-494d-8040-2c7fa3d777fb_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01129622_BT", "Secondary_id": "NCT01156987_BT", "Statement": "Both the secondary and primary trials used MRI for their interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "87eca8d2-72fe-4285-9884-6d2ec7bae6df_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00567190_BT", "Statement": "There was exactly the same proportion of anemic patnets in both cohorts of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 2, 12, 14]}, "7a87c605-fc41-4d0a-9291-85e88f6eb510_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01000662_BT", "Secondary_id": "NCT02413008_BT", "Statement": "The secondary test is to test a gel that is applied inside the vagina, and the primary test is to test an intervention that requires daily radiation from the breast(s).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "fbb853c9-bed4-4cde-a283-2d91b23d35bf_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01964924_BT", "Secondary_id": "NCT00524303_BT", "Statement": "Both the primary and secondary trials gave results on pathological evidence of invasive diseases with their patient cohorts after their interventions, using different measures of results.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00482391_BT", "Statement": "Patients with a QT interval greater than half a second are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [29]}, "84aa97cf-efce-484e-825e-5af509e5988f_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01441596_BT", "Statement": "Patients in cohort 1 of the primary trial may receive a progressive increase in Afatinib monotherapy doses, up to 160% of the initial dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "a40e172a-8839-499d-896d-be71a7ca4905_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03076190_BT", "Secondary_id": "NCT03196635_BT", "Statement": "While molecular breast imaging is not applied in either the primary trial or secondary trial interventions, all participants in these studies will be required to receive stem cell transplants.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "9e972e33-9ecd-4a8b-8337-7bee209f790b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT02202252_BT", "Statement": "The difference between cohorts 1 and 2 in the primary trial is assessed by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 5, 10, 5]}, "f29768ba-5d79-4528-839f-933ab13faaa1_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01943916_BT", "Secondary_id": "NCT01653964_BT", "Statement": "All subjects in the primary and secondary trials will be administered 4 mCi Tc-99m sestamibi and subjected to molecular breast imaging.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "343e0a32-aebe-4bbb-97c0-b2c597c36802_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00392392_BT", "Secondary_id": "NCT00503906_BT", "Statement": "The primary trial records two different types of pain in its adverse events, in the abdomen and chest, the secondary trial does not record any type of pain in its participants.", "Label": "Entailment", "Primary_evidence_index": [0, 6, 7], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "4d51608c-b0d8-4019-9b9a-34cf1c3d5087_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00558103_BT", "Statement": "All participants in the primary trial are treated with Lapatinib 1500 mg PO QD and Pazopanib 800 mg.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "7bb88699-1536-4fdc-9cb2-c5ef350d559b_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00331552_BT", "Secondary_id": "NCT01306942_BT", "Statement": "Trastuzumab was used for interventions in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "c86ef61b-7565-465a-82ba-25e7ac050ccc_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02139358_BT", "Secondary_id": "NCT02574455_BT", "Statement": "There was one case of haemorrhage in the primary trial, and no case was recorded in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "58dec898-e0af-41c1-96f9-7163d3e3e855_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02019277_BT", "Secondary_id": "NCT00863655_BT", "Statement": "The primary and secondary trials recorded three of the same types of adverse events.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "5cf74526-9f91-498d-a13a-6393dcd45b7b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02291913_BT", "Statement": "One patient in the primary trial suffered from inflammation of the liver.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "154caa20-3be1-4cee-a838-2d90b44566c4_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00191269_BT", "Statement": "The primary trial did not use the PFS to assess the performance of its interventions.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "c40d8532-4e66-4eef-9644-91f20a02066d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02001974_BT", "Statement": "No cases of esophageal adenocarcinoma were recorded in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "3d450be5-4587-48e5-ae2e-745623606631_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01289353_BT", "Secondary_id": "NCT00429182_BT", "Statement": "Both the primary and secondary trials administer biweekly oral carboplatin to their test groups.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2, 3]}, "fa28753a-aa3b-4642-9fd4-a2414fd8a472_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00943670_BT", "Statement": "The change from baseline in mean QTcF interval duration in primary trial patients was greatest on day 1 of the third cycle after intravenous infusion of T-DM1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "5e700303-cd26-4024-a260-62f6a1c297ed_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01000662_BT", "Secondary_id": "NCT02413008_BT", "Statement": "The secondary test is to test a gel that is applied to the breast, while the primary test is to test an intervention that requires daily radiation from the breast.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2]}, "4c4c191c-de68-44c8-a23c-2455acc43d46_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00371345_BT", "Secondary_id": "NCT00475670_BT", "Statement": "There is no overlap between the adverse events observed in the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "e5a4cb11-2a00-4144-93ba-f5462d7efbf0_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01818063_BT", "Secondary_id": "NCT00559507_BT", "Statement": "In both the primary and secondary trials, the only drugs administered orally are saracatinib and Veliparib.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14], "Secondary_evidence_index": [0, 1, 2]}, "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01720602_BT", "Secondary_id": "NCT00082810_BT", "Statement": "The primary trial participants receive more anastrozole, letrozole and exemestane than the secondary trial patients.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2]}, "27a4d1a8-185b-4483-85ce-0fbb3d323b99_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01945775_BT", "Statement": "In the Talazoparib group of the primary trial, the shortest PFS was more than one month higher than the duration of the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ff797dd4-0b4d-42fc-808d-27c439563ce2_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01743560_BT", "Statement": "At week 48 of the primary trial, none of the patients had a complete response, 7 had a partial response and 15 had a progressive disease.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "9f666667-0fde-4d79-b53c-33c0ffbbed90_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00494481_BT", "Statement": "Paula recently fell from a staircase and fractured her hip, she is excluded from the primary test.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "47084742-d031-4e59-865c-d8687282c782_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00494481_BT", "Statement": "Paula has recently had a heart attack, she is excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5]}, "ae583ea3-36a5-472c-acda-825cd7d513b6_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00454805_BT", "Statement": "In the primary trial, there were no cases of subendocardial myocardial infarction in cohort 1 or 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]}, "a18c447b-de08-48ef-8e65-0ecaa775c2b0_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00206427_BT", "Statement": "One primary trial patient had vaginal fungal infection.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "18b900fb-b071-43df-b37d-c68a89ef78c0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00050167_BT", "Statement": "Patients with metastases in four or more axillary lymph nodes are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 6]}, "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00932373_BT", "Statement": "Patients with peripheral neuropathy of grade III or more are eliminated from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 16]}, "d56745c3-ba0b-4b42-b3cf-ac060f658d83_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00670982_BT", "Statement": "Acute coronary syndrome was the most common adverse event in the primary trial, other than thrombocytopenia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8]}, "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01446159_BT", "Statement": "The primary trial included only a total of 6 patients in both cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 13, 14]}, "03c7f31f-788c-4edb-a885-b6cb0fca05da_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00375505_BT", "Statement": "In the primary trial, patients in the control group had a Z score of 0.037, higher than the control group score.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e43c01e9-20a2-4435-a32b-224d5f460d7c_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01997333_BT", "Statement": "The minimum progression-free survival for patients in cohort 1 of the primary trial was 1.6 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "c55f34ab-b883-465e-89dc-75bbeb8afa77_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00369655_BT", "Secondary_id": "NCT00091832_BT", "Statement": "One patient in the primary trial had a confirmed partial tumour response, No patients in the secondary trial were evaluated for tumour response.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3]}, "0ee36ceb-5790-440e-b6ad-10a0b7a23f43_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01925170_BT", "Secondary_id": "NCT00324259_BT", "Statement": "Participants in cohort 1 of the primary trial undergo mammography, while patients in cohort 1 of the secondary trial receive 6 mg estradiol and no mammography.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2]}, "2535da13-e0f7-44df-aa02-89765d8d51cb_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02419807_BT", "Secondary_id": "NCT00777101_BT", "Statement": "Patients with HER2+ breast cancer in stage 1-4 are eligible for both the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}, "94fc6e05-8a73-43d9-a48c-531d36dfbbcd_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00548184_BT", "Statement": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab had at least one almost complete or better pathological response after 12 weeks.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "0057172f-d019-401b-a516-993a7b46a67b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01306942_BT", "Statement": "Participants in cohort 1 of the primary trial received more Dasatinib than those in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "bb23e8b8-c7d6-4e58-80a2-0555db5645e9_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03096847_BT", "Secondary_id": "NCT01840163_BT", "Statement": "Recently prescribed Rapamycin patients are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a Stage 1 to 2 Ductal Carcinoma in situ and can speak English.", "Label": "Entailment", "Primary_evidence_index": [9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c4588d2c-b0d4-428d-a958-29787b9d4ec5_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00545077_BT", "Statement": "Only cohort 2 of the primary trial receives Bevacizumab, but both cohorts undergo endocrine therapy.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00364611_BT", "Statement": "Patients with clinically significant grade 3 DVP are eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [18]}, "00466f98-52b8-41f3-9bf1-2edaad950be9_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02504424_BT", "Secondary_id": "NCT03708393_BT", "Statement": "Both the primary and secondary trials require patients to activate remote control procedures.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "50a524ae-2135-45f7-ae9b-515fd4e2e404_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT02445586_BT", "Secondary_id": "NCT02115984_BT", "Statement": "More than half of patients in the primary study experienced adverse reactions and 100% of patients in the secondary study did not experience adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "b2062e01-0ea6-4ee8-94a1-b59dc40901d3_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01688609_BT", "Statement": "Patients should have histologically or cytologically confirmed invasive breast cancer ERBB2+ with a primary tumour greater than 2 cm in diameter to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3]}, "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00826267_BT", "Statement": "Cohorts 1 and 2 of the primary trial receive different amounts of different drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "43a9cc96-4020-459c-8fa4-4bbde7173f7a_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02447328_BT", "Statement": "In the primary trial, 11 patients experienced serious adverse reactions, no patients experienced serious adverse reactions to the drug, and more than half of patients died of unexpected adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]}, "ff319fa6-89b6-4f1a-871d-456edb91b69b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT03045653_BT", "Statement": "Sharone had a hip replacement 3 weeks before, it is not possible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [4, 6]}, "a321acf0-2296-4588-bf96-85b22bf1420f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274456_BT", "Statement": "There are a total of 14 cases of neutropenia-related adverse reactions in the primary trial in both cohorts.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "b841dfd8-4676-4d3c-a57d-6ba1055b8597_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02027376_BT", "Statement": "One patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to entry into the study and the patient fully recovered from the resulting side effects, so this patient is eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [10, 25]}, "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01042535_BT", "Statement": "The maximum tolerated dose (LMD) of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "48d40c7e-3514-43c3-a31a-7b391727f012_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01209195_BT", "Statement": "In both cohorts, lower doses of MM-121 are used in cohort 1 of the primary trial than in cohort 2, the doses of paclitaxel are the same.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "dd98fca1-27a7-41c2-ba0c-3ff90aceab54_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01305941_BT", "Statement": "Patients should submit IHC 3+ or FISH amplified results to participate in the primary trial, which means that their cancer is histologically confirmed as HER2-positive.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "b975dc12-757e-4ef5-af33-83dfce12e6cc_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01989676_BT", "Statement": "The primary test records only IG adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "2c4254c9-9c40-492f-aa45-2a9ab47579b3_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT02658734_BT", "Secondary_id": "NCT02073487_BT", "Statement": "Women Patients with FEVL > 50% who have already undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial.", "Label": "Entailment", "Primary_evidence_index": [8, 9, 10], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]}, "e140b055-b7fc-4802-a79b-9dfe7d136876_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01575522_BT", "Secondary_id": "NCT00181363_BT", "Statement": "The primary and secondary tests test completely different methods of intervention.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0a6418c8-63a6-4900-bfc9-1659acbe1ad7_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02581839_BT", "Statement": "At least 8 primary test participants had a central nervous system (CNS) progression-free survival >= 3 months.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "2db9e0c7-d94b-47d2-a61f-55a0896d714e_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00789581_BT", "Secondary_id": "NCT02445586_BT", "Statement": "The secondary trial reported more cases of Haemamesis, but the primary trial had more cases of Sinus tachycardia.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "3129e58d-0c16-42a5-90b4-f26e048dfe58_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01644890_BT", "Statement": "Throughout the primary trial, a cohort 1 patient developed vision problems.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "7be7cecb-d265-4098-9969-a40555702573_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00679211_BT", "Statement": "One patient in the primary trial was diangosed with influenza.", "Label": "Contradiction", "Primary_evidence_index": [0, 12]}, "5b0d3709-7879-4dea-96c3-29178cd9f162_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00767520_BT", "Statement": "The two cohorts in the primary trial reported the same number of patients who vomited during the trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 13, 18]}, "af70a3a9-d2d0-4d65-81fe-15a1becb5e95_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01420146_BT", "Secondary_id": "NCT00077376_BT", "Statement": "Both the primary and secondary tests have one control arm and several test arms.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3]}, "a378f448-eef0-465a-abc0-8b4dd1156bb5_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00372424_BT", "Secondary_id": "NCT00041067_BT", "Statement": "Patients with positive HER2 breast tumours are eligible for the primary and secondary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [3]}, "f30182a1-b82a-497c-885c-9bd2e805db62_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01487954_BT", "Statement": "All patients in the primary trial had to drink 237 ml of water, either alkaline water or distilled water, depending on the cohort in which they were located.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "ae87e5a3-fdd8-4003-ae80-4b370cade158_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01106898_BT", "Statement": "2% of patients in the primary trial had non-recidivism survival < 3 years.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "9f3062db-16fb-41b8-ac10-f205f66070c8_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00696072_BT", "Statement": "Most patients treated with Dasatinib and Letrozole in the primary trial had a disease-free interval (DFI) of more than 2 years.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "a1c5685a-8e6e-4733-aa8b-7040bac1a397_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00022672_BT", "Statement": "There were no patients in either cohort of the primary trial with PFS greater than 6 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "d58683e2-d276-4184-a8e9-c9df6ffd8047_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00559507_BT", "Statement": "The primary trial participants receive saracatinib PO for a maximum of 28 days.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "28d8f88a-e8cb-40c0-a12b-ef555f83ff59_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01904903_BT", "Secondary_id": "NCT01663727_BT", "Statement": "Patients must have a LEVF < 50% to be eligible for the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [3], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18]}, "0ee4c935-18bd-4807-a2af-041a3d84e125_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02721147_BT", "Statement": "Stephanie has been living with her boyfriend for 2 months, she is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5, 6]}, "355fb813-cbe0-44f5-b04a-87813e060d54_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00371254_BT", "Statement": "Patients should have an eceptorsestrogen (ER) receptor -, a progesterone receptor (PR) - and a human epidermal growth factor receptor 2 (HER2) - breast cancer, as well as the absence of Dysphagia.", "Label": "Entailment", "Primary_evidence_index": [0, 2, 8, 12]}, "274d9d2b-9227-4496-a525-d5477b0003ce_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00796978_BT", "Secondary_id": "NCT01276041_BT", "Statement": "A greater number of patients in cohort 1 of the secondary trial had oedema in their limbs, compared to patients in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]}, "3ab9c66c-06fc-4bc5-b504-d9193efa8701_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00290745_BT", "Statement": "In primary trials, participants from different ethnic groups receive different interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "d39078d9-9bc3-4b91-a012-e95f14813c9a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01252277_BT", "Statement": "The 34-year-old sister-in-law of Fiona has been diagnosed with channel carcinoma, so fiona may be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5]}, "02538194-97ac-4749-9301-83f108927478_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00041067_BT", "Secondary_id": "NCT01273896_BT", "Statement": "Patients with positive ER, RA or HER2 tumours may be eligible for the secondary or primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 14, 19, 20, 21, 22, 23, 24, 25, 26, 14, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 14, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]}, "6d9113b4-9d18-4a1b-bc78-cc3ac1150876_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01572038_BT", "Secondary_id": "NCT00826267_BT", "Statement": "Each patient in the primary trial receives 3 different drugs, while in the secondary trial, patients receive 1 of the 2 possible drugs.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "99599b71-85d7-4c15-8d23-4294732f87cf_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00558103_BT", "Statement": "All participants in the primary trial are treated with Lapatinib 1500 mg PO QD.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "adbc193f-ffd6-49ce-9acd-7b1675adf0c0_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00768222_BT", "Statement": "Rachel is 19 years old and has skin ulcers and allergic reactions to triclosan, she cannot participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 4, 8, 9]}, "c476f92a-a450-4e5c-9688-6557ff3d822b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01617668_BT", "Statement": "Patients must have healthy kidneys, liver and ovaries to participate in the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19]}, "39d685a4-b179-4687-a273-2a44e675f2c6_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00900627_BT", "Statement": "Both groups in the primary trial receive the same drug treatment, but group 2 receives twice the dose.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "c66963b9-19e0-4c0f-bb65-2fec15e60b8f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00965523_BT", "Statement": "The most common adverse events in the primary trial where infection and stomatitis affect a total of 14 patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "f541ce25-c43e-496b-98e6-8470fe23f840_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00559845_BT", "Secondary_id": "NCT00426556_BT", "Statement": "In total, there were more adverse reactions in cohort 1 of the secondary trial than in cohort 2 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10], "Secondary_evidence_index": [0, 1, 14, 15]}, "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01224678_BT", "Statement": "Intervention 2 of the primary test resulted in a lower percentage of mammographic density than intervention 1.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "24d81b18-ce9c-4927-9386-9ebef969a159_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00291135_BT", "Secondary_id": "NCT00291694_BT", "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "0046e113-8ac5-4725-a285-e78b8c26f825_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02756364_BT", "Statement": "To meet the inclusion criteria for patients in the primary trial, treatment with the aromatase inhibitor (AI) must be received prior to entry into the study, resulting in a complete tumour response.", "Label": "Contradiction", "Primary_evidence_index": [0, 9]}, "e90f7748-f4b4-4822-8768-586c3f2f9980_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00499083_BT", "Secondary_id": "NCT03045653_BT", "Statement": "To be eligible for both the secondary and primary trials, patients must be women over 18 years of age, ECOG < 2 years of age and have a HER2 + breast cancer confirmation.", "Label": "Contradiction", "Primary_evidence_index": [6, 10, 12], "Secondary_evidence_index": [0, 1]}, "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00429572_BT", "Secondary_id": "NCT02455453_BT", "Statement": "\u2022 Menopausal patients are excluded from the secondary trial but eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1]}, "3c3fb5e3-1994-455a-bae4-6d267c5c89d7_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00932373_BT", "Statement": "Patients with peripheral neuropathy of grade I or higher are eliminated from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 16]}, "2ecd62df-f5ea-417d-8783-2174a6d77087_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03573804_BT", "Secondary_id": "NCT02781051_BT", "Statement": "The primary trial participants must undergo at least one MRI during the procedure and a strict chemotherapy regiment, while in the secondary trial patients must use an adaptation device.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "b43c02bf-c4b0-495f-b7ba-879f409cb685_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT01781299_BT", "Statement": "All subjects in the primary trial must engage in a regular exercise program.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "fdff0cf1-a0a2-4516-bdf7-109ac7adb266_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT03136367_BT", "Secondary_id": "NCT00129935_BT", "Statement": "Only patients who have been assigned as women at birth are eligible for the secondary and primary trials.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 6, 7], "Secondary_evidence_index": [18, 38]}, "6babfc60-5043-4f2b-9605-3e44744265e9_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00398567_BT", "Statement": "80% of patients in the primary trial did not experience any adverse reactions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "5ca02204-6120-4b02-bf3b-fba94d6fac4f_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274469_BT", "Statement": "Not more than 1% of the two cohorts in the primary trial felt sick.", "Label": "Entailment", "Primary_evidence_index": [0, 12, 13, 25]}, "625c2690-ec9e-4ecc-85c0-9b5ca8467848_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00836186_BT", "Statement": "Patients cannot be excluded from the primary trial on the basis of sex or ethnicity.", "Label": "Contradiction", "Primary_evidence_index": [0, 6]}, "c28ad685-4c91-492a-85ab-180f37d9cef5_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00290758_BT", "Statement": "There was an adverse reaction GU and three GIs during the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "52e8d676-1744-4fdb-bab4-a553874329bd_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00829166_BT", "Statement": "Women with peripheral neuropathy > 0 are excluded from the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [9, 12]}, "beff8878-9405-412d-af3a-0f2720275bf3_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00068601_BT", "Secondary_id": "NCT01684215_BT", "Statement": "Both the primary and secondary trials use subcutaneous injections as the route of administration for their interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "96f41881-6ba5-4688-8471-9462fc727919_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00089661_BT", "Statement": "On average, cohort 1 participants in the primary trial had an increased mineral density of the lumbar spine, whereas cohort 2 participants had a lost mineral density.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "9dbf55d5-6af3-4250-b5cb-97799cdf778a_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02370238_BT", "Statement": "There were no cases of intracranial haemorrhage in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00338728_BT", "Statement": "While primary trial participants receive higher doses of imatinib mesylate than letrozole, letrozole is administered twice as often.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2]}, "d72709fd-e94e-4c27-bf56-3f028c0bbd3f_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01118624_BT", "Statement": "The majority of participants in the primary trial achieved either CR or PR.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00463788_BT", "Statement": "The best overall response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "49f44497-2382-4658-b716-38e66c5c52b7_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00425854_BT", "Statement": "The intervention in cohort B is described as Afatinib 50 mg taken orally for each day of the study.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2]}, "4a6dc84a-3afd-4060-b8c5-981895f31099_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00312208_BT", "Statement": "There were only cases of cardiomyopathy and coagulation disorders in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT02574455_BT", "Statement": "More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "f1f2e066-a016-422f-8627-d0e477933352_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00193063_BT", "Statement": "In the cohort of patients in the primary trial, three different types of infections are observed.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12]}, "efbd87d7-f8ac-42c6-ac9a-e3a35d354885_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00295867_BT", "Statement": "Patients with a Karnofsky status of 94% are eligible for the primary trial.", "Label": "Entailment", "Primary_evidence_index": [13, 16]}, "a604244f-789f-4c12-8c5a-96c86d1b976e_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00558272_BT", "Statement": "The greatest change from baseline in the collagen type I cross-link telopeptide (betaCTX) of beta-terminal serum at week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a change of -75.9% from baseline.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01565083_BT", "Statement": "Two different types of tachycardia occurred in patients in cohort 2 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [12, 22, 23]}, "987b1da5-0276-417d-a659-8e298529ccac_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01684215_BT", "Statement": "In the primary trial, there was no difference in the number/percentage of participants with dose limit toxicity taking 100 mg vs 125 mg PD-0332991.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "b9e8a0b3-574f-4079-9191-214af99e97a8_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01176916_BT", "Secondary_id": "NCT00186121_BT", "Statement": "\u2022 Postmenopausal women with T1-4N1-3M1 Early invasive breast cancer is eligible for primary testing, and premenopausal women with T4-4N1-3M1 Early invasive breast cancer is eligible for secondary testing.", "Label": "Contradiction", "Primary_evidence_index": [0, 3], "Secondary_evidence_index": [0, 2]}, "0151d1fa-05c8-45a0-b21e-f08478ea5110_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01697345_BT", "Secondary_id": "NCT00513292_BT", "Statement": "fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01075100_BT", "Secondary_id": "NCT00290758_BT", "Statement": "Several different mental health problems were observed in the primary and secondary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]}, "b838a265-99e4-42f0-bd72-b4f72d7eb16e_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT02027376_BT", "Statement": "One patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than a month before entering the study and the patient did not fully recover the resulting side effects, so this patient is eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [10, 25]}, "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00676793_BT", "Secondary_id": "NCT01931163_BT", "Statement": "Patients with vomiting are still eligible for both the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 26]}, "a1644573-fba8-4598-8353-a40d3ef1968c_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00428922_BT", "Secondary_id": "NCT00499083_BT", "Statement": "Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for the primary or secondary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [26]}, "ba533122-db9d-49e1-a2d1-936c8fdfdd00_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01298193_BT", "Statement": "More than 15 patients in cohort 1 of the primary trial experienced adverse reactions.", "Label": "Entailment", "Primary_evidence_index": [0, 1]}, "f20cd859-7159-457a-a1cb-56bdb01d521b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00274456_BT", "Statement": "There are a total of 7 cases of Gastritis in the primary trial in both cohorts.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]}, "d33df923-6c12-4135-b339-5cefdd240985_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00003782_BT", "Statement": "None of the primary trial cohorts had more than 5% of patients with side effects.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 11, 12]}, "0f49a1ec-ed73-465b-be20-b70fe990b1f0_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00333775_BT", "Secondary_id": "NCT00201864_BT", "Statement": "There are several coagulative adverse events recorded in the primary trial, but not one in the secondary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "7370c10d-f6e7-4153-9649-9d2598ce1ed7_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT03196635_BT", "Secondary_id": "NCT01943916_BT", "Statement": "The primary and secondary tests evaluate imaging techniques.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 1, 2]}, "3f89537a-479e-4314-b9de-4caf845850fc_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00558272_BT", "Statement": "The greatest change from baseline in collagen type I cross-link telopeptide (betaCTX) at week 4 observed in the primary trial was a zoledronic acid 4 mg patient with a change of -73.0% from baseline.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "8e9f417a-dc0f-4c20-9cf7-5f8586c23df2_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT01985971_BT", "Secondary_id": "NCT03273426_BT", "Statement": "Patients will have to undergo spinal MRI prior to entry for the secondary and primary trials, as patients in the primary trials will also have to have brain MR and PET imaging after entry into the study.", "Label": "Contradiction", "Primary_evidence_index": [0, 6, 2], "Secondary_evidence_index": [0, 6]}, "8ba451be-606a-4a57-a85e-82b5e5b286fc_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT03366428_BT", "Statement": "3/49 Primary Trial Participants with metastatic and/or non-resectable breast cancer with HER2 showed a maximum change of more than 30 ms from the initial QTcF test.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10]}, "46906361-5133-4db9-b9e5-b9b7f80a8666_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00721630_BT", "Secondary_id": "NCT00364611_BT", "Statement": "The primary and secondary trials recorded the same proportion of patients with nausea.", "Label": "Contradiction", "Primary_evidence_index": [0, 4], "Secondary_evidence_index": [0, 7]}, "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00121992_BT", "Statement": "To be eligible for the primary trial, patients must not have prior radiation therapy, systemic anthracycline or anticancer and must have breast cancer T1-3, N0 and M0.", "Label": "Entailment", "Primary_evidence_index": [12, 13, 14, 15, 19]}, "3320983d-55cb-49f9-9265-ca4e77acf62a_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01094184_BT", "Statement": "A patient who received a joint injection in the last month would not be eligible for the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "6c57e451-a706-4b32-ae71-254e9d0e04de_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01250379_BT", "Statement": "None of the patients in the primary trial experienced thrombocytopenia, congestive heart failure, pancytopenia, acute coronary syndrome or atrial fibrillation.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 7, 9, 10, 11]}, "73a5f715-6d4c-43f3-ace4-9f1217d3d0c4_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00383500_BT", "Statement": "The primary test is not a drug-based intervention test, it is a test of a medical device called Flexitouch.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "83883edd-ea16-4b20-8a97-2a545f957add_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00006110_BT", "Secondary_id": "NCT00464646_BT", "Statement": "The secondary trial records only gastrointestinal adverse events, while the primary trial does not record any gastrointestinal adverse events.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11]}, "ad0628ef-be51-4d54-a5c6-7608df258629_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00895414_BT", "Statement": "- Orange juice is prohibited for patients who undertake the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 8]}, "619d88fd-cef5-4f1a-83dc-3cc710c1c93d_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00203502_BT", "Statement": "Less than 30% of patients in the primary trial experienced at least one adverse reaction.", "Label": "Contradiction", "Primary_evidence_index": [0, 1]}, "42d6a15e-fa43-4ebc-b627-70f4dd0233f8_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00322374_BT", "Statement": "The primary trial cohort 2 received a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "fc60c272-ceeb-47b5-b25b-dca832a2a57e_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT02203565_BT", "Secondary_id": "NCT00194779_BT", "Statement": "The laboratory biomarker analysis and questionnaires are used in the secondary and primary trials.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]}, "dfe1236f-ac29-4c1c-a287-6f46abb7703d_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT00810797_BT", "Secondary_id": "NCT00828074_BT", "Statement": "Skin infections were more common in patients in cohort 2 of the secondary trial than in cohort 1 of the primary trial.", "Label": "Contradiction", "Primary_evidence_index": [0, 5], "Secondary_evidence_index": [13, 21]}, "b1060434-0f7c-4c4a-bcff-53c3124bb51e_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT02513472_BT", "Statement": "The primary trial cohort 1 produced better objective response results than the cohort 2.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "e2862bbf-562f-4c96-abf1-fc9f07655b46_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00627978_BT", "Statement": "Women with leptomenenic metastases are unfortunately excluded from the primary trial, as this would complicate the assessment of neurological and other adverse events.", "Label": "Entailment", "Primary_evidence_index": [18, 19]}, "aed75656-1594-4d99-be42-7097f7926c18_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00240071_BT", "Statement": "At least one primary trial participant died within 100 days.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "6ce5a9d7-5793-43b0-92ed-980cca3be02b_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01961544_BT", "Statement": "The primary trial revealed a combined total of 3 cases of pericardial effusion, asthenia, and gastritis in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 4, 8, 9]}, "b2a4f905-c6b5-4977-95de-5aa6424a5bb6_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00217399_BT", "Statement": "To be included in the primary trial, patients must have at least one measurable one-dimensional lesion, there are no size limits for eligibility.", "Label": "Contradiction", "Primary_evidence_index": [3, 4, 5, 8]}, "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00591851_BT", "Statement": "There were 4 different gastrointestinal adverse events in cohort 1 of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 5, 6, 7, 8]}, "4db02d9b-d96e-4ced-947c-71cebcccc933_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00847171_BT", "Secondary_id": "NCT01764022_BT", "Statement": "Patients with systemic lupus erythematosus are excluded from the primary trial, but may still be eligible for the secondary trial.", "Label": "Entailment", "Primary_evidence_index": [24, 32], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35]}, "cfb07772-e485-491c-8ae3-9009e3d04415_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00201864_BT", "Statement": "A primary test patient had a significantly lower BCE than normal.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6]}, "a283b69c-0f36-4773-a711-9e6088a8ee63_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT01712009_BT", "Secondary_id": "NCT00343382_BT", "Statement": "Cohort patients 2 in the primary trial receive naproxen at the same frequency as patients in cohort 2 in the secondary trial receive Pilocarpine.", "Label": "Entailment", "Primary_evidence_index": [3, 4, 5], "Secondary_evidence_index": [3, 4, 5]}, "8d90d538-3b56-48dd-bd58-007d266c923c_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT00915018_BT", "Statement": "The only cases of heart problems in the primary trial occurred in cohort 1.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421_BT": {"Type": "Comparison", "Section_id": "Intervention", "Primary_id": "NCT00904033_BT", "Secondary_id": "NCT03592121_BT", "Statement": "While patients are not required to be sexually active to receive primary trial intervention, this is a secondary trial requirement.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7]}, "8502cb9e-e382-41bc-b547-02d2d7beb381_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00620373_BT", "Statement": "The primary trial tests two different methods of breast imaging, i.e. X-ray and gamma-ray imaging.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "f6c64bb3-1836-4685-8541-8856f003524b_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT01105312_BT", "Statement": "Patients with non-measurable diseases are only eligible for Phase I of the primary trial.", "Label": "Entailment", "Primary_evidence_index": [5, 6]}, "79272218-91b9-4331-ba44-6a3709a13f62_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT00073528_BT", "Secondary_id": "NCT00191152_BT", "Statement": "In the secondary and primary studies of progression-free survival (PFS) of their participants, however, they use different units of measurement.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 8, 9], "Secondary_evidence_index": [0, 1, 9, 10]}, "97e3b0d7-3320-4eb5-bc42-5031db87692e_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01964924_BT", "Secondary_id": "NCT00524303_BT", "Statement": "Both the primary and secondary trials indicate the objective response rate (ORR) of their patients.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3], "Secondary_evidence_index": [0, 1, 2, 3]}, "83251670-803e-4fec-a5cf-50f052932752_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT00708214_BT", "Statement": "All participants with disease progression (after 16 weeks of treatment) in the primary trial were in the Afatinib 50 mg group with Letrozole.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15]}, "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de_BT": {"Type": "Single", "Section_id": "Adverse Events", "Primary_id": "NCT01610284_BT", "Statement": "One patient in the primary trial had a sudden loss of cardiac function.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]}, "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a_BT": {"Type": "Comparison", "Section_id": "Adverse Events", "Primary_id": "NCT01256567_BT", "Secondary_id": "NCT01926886_BT", "Statement": "The most common adverse reaction in the primary trial was febrile neutropenia (42.86%), while in the secondary trial it was a decrease in ejection fraction (4.95%).", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8], "Secondary_evidence_index": [0, 1, 2, 3, 4, 5]}, "97812fde-57f3-4299-be34-dd436757adde_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00093795_BT", "Statement": "Patients with cancer cells in the lymph nodes above the clavicle cannot enter the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 8]}, "f37774f4-db96-4aa6-b3a1-626953faeecf_BT": {"Type": "Comparison", "Section_id": "Eligibility", "Primary_id": "NCT00213980_BT", "Secondary_id": "NCT02536339_BT", "Statement": "The necessary blood, kidney and liver function are required to participate in the secondary trial, but this condition is not specified in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5], "Secondary_evidence_index": [0, 7]}, "4fef4cdf-53bf-4239-9d31-4710fd3edc6f_BT": {"Type": "Single", "Section_id": "Results", "Primary_id": "NCT01605396_BT", "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group in the primary trial had a median PFS of more than 38.43 months.", "Label": "Contradiction", "Primary_evidence_index": [0, 1, 2, 3, 4, 5, 6, 7, 8, 9]}, "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b_BT": {"Type": "Single", "Section_id": "Intervention", "Primary_id": "NCT00181363_BT", "Statement": "The only difference between the interventions used in the primary trial is the patient's position.", "Label": "Entailment", "Primary_evidence_index": [0, 1, 2, 3, 4, 5]}, "a577e819-c928-4217-8743-f4809e852919_BT": {"Type": "Single", "Section_id": "Eligibility", "Primary_id": "NCT00834678_BT", "Statement": "Patients should have a white blood cell count greater than 1500/mm\u00ac\u2032\u2022 to participate in the primary trial.", "Label": "Entailment", "Primary_evidence_index": [18]}, "bd073d05-3ba2-4898-9d86-a51951a7ad1f_BT": {"Type": "Comparison", "Section_id": "Results", "Primary_id": "NCT01004172_BT", "Secondary_id": "NCT00802945_BT", "Statement": "Both the primary and secondary trials use the objective response rate tumour to measure the effects of their different interventions.", "Label": "Contradiction", "Primary_evidence_index": [0, 1], "Secondary_evidence_index": [0, 1]}}